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Abstract 
The main aim of this research study was to develop methods to aid biologists and clinicians 
investigate the progression and evolution of tumours, through the analysis of microarray data. 
This thesis concentrates on the inference and analysis of Gene Regulatory Networks that 
represent different evolutionary and clinical stages of cancer cell line microarray data.  Three 
main areas of work were carried out.  
The first was the development and implementation of a network inference method specifically 
designed to infer Gene Regulatory Networks at differently defined classes from a single 
microarray dataset. Furthermore, this method was shown to be transferable across the 
different microarray datasets used in this work; and has been deployed on a local host version 
of a web-based bioinformatics tools server allowing easy access and use. 
The second was the investigation of appropriate graph theory metrics to quantitatively analyse 
the different defined stages of disease. Genes identified by the various metrics were scored for 
the particular disease of interest using a text-mining tool, allowing the graph theory metrics to 
be ranked against each other for the various GRNs. This enabled graph theory metrics to be 
scored for different categories of Gene Regulatory Networks inferred from different cancer 
microarray datasets, aiding in the identification of appropriate graph theory metrics to apply 
to Gene Regulatory Networks inferred for different stages of disease.   
The third was the comparison of Gene Regulatory Networks inferred for different disease 
stages across datasets for the same disease, neuroblastoma, from two different studies. Gene 
Regulatory Networks for common sample clinical disease stages across two different 
neuroblastoma microarray datasets were inferred using the novel network inference method, 
 
 
with a high number of common genes identified in the top 100 ranking genes in one of the 
disease stages, 4M, across both neuroblastoma microarray datasets, highlighting the 
transferability of the network inference method.   
It has been seen in this work that the application and analysis of Gene Regulatory Networks 
inferred using a method specif ically designed to infer multiple GRNs from a single 
microarray dataset has specifically identified genes involved in different disease or 
evolutionary stages of disease, and thereby has the potential to aid in the investigation of the 
progression and evolution of tumours.  
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Chapter 1 
Introduction 
1.1 Background 
In recent years, there has been an explosion in the availability of high throughput biological 
data. As a result of this, there has been a shift away from the traditional molecular biology 
divide-and-conquer reductionist approach, that complex problems are solvable by dividing 
them into smaller and simpler units [1]. Whilst this reductionist approach has been 
responsible for tremendous success in the field of medicine, and a great deal of our current 
understanding of biology, there are limits to the usefulness of this approach. In living 
organisms, a vast number of biological processes involve the interaction of different  
biological components, something that cannot be understood using the reductionist approach. 
As such, an alternative systems level perspective is required in order to complement it [2]. 
This alternative explanation, the systems perspective, has arisen from systems biology. The 
aim of systems biology is to understand biological systems at a systems level, by building 
models of biological systems from information about their components [3]. 
The interaction of biological components in an organism occurs through various pathways , 
such as Gene Regulatory Networks (GRNs) [4]. GRNs involve the interaction of different 
genes in an organism, providing a mechanism to control protein levels in cells. GRNs can be 
inferred from high throughput microarray data using a number of computational tools , and 
will be referred to as network inference methods for the rest of this work [5]. One particular 
systems biology approach has been to infer GRNs from cancer cell line microarray data, such 
as the studies by Bonnet et al [6], Jeong et al [7], and Horvath et al [8], and use graph theory 
2 
 
metrics such as the number of connections a gene has to identify particular genes of interest in 
these networks. These studies have grouped all the samples in the microarray dataset together, 
and have inferred a single GRN.  
In this thesis, the focus is on distinguishing the samples in cancer cell line microarray datasets 
into different evolutionary or clinical classes, and subsequently inferring and analysing GRNs 
for each of these distinct classes. Important information about the different evolutionary and 
clinical stages can be lost by grouping all the samples together, such as survival time, and 
inferring a single GRN. Furthermore, by inferring GRNs for different evolutionary and 
clinical stages, a picture of how the genetic interactions in a disease evolve can be formed. 
Current network inference methods have been predominantly developed with the goal of  
inferring a single GRN from microarray datasets, and are therefore not designed for multi-
class GRN inference from a single microarray dataset. A method specifically developed for 
this aim is presented, with application to a number of different cancer microarray datasets. 
Finally, this method is coded into a web-based platform, allowing simple and unrestricted use  
by biologists and clinicians, removing the need to learn specialist programming languages 
that have been a barrier to further adoption of GRN inference and analysis tools. 
1.2 Challenges 
Three major challenges are identified in the inference and analysis of GRNs from cancer cell 
line microarray data. These are listed below; from which the objectives of the thesis, set out in 
section 1.3, are derived.  
1. Whilst there is a large amount of existing tumour microarray data from a vast number 
of cancer cell lines, issues exist in inferring relevant evolutionary information from 
tumour microarray datasets using GRN inference and analysis methods. Most 
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microarray datasets include additional information, such as disease class or survival 
time, by which to categorise the samples. However, current methods are focused on 
the inference of a single GRN from a microarray dataset. This potentially leads to 
important evolutionary or clinical stage information being lost as a result; a gene 
involved in the regulation of a number of other genes at one particular clinical stage, 
may not be involved in the regulation of the same genes at a different clinical stage. 
By capturing gene interactions at a number of different stages, a more complete 
picture of the gene interactions across the evolution of the disease can be formed. As 
existing GRN inference methods have been developed to infer a single GRN from a 
microarray dataset, they are not suited to infer multiple GRNs, and do not exhibit the 
same level of performance across different microarray datasets; performance tends to 
be heavily biased towards the dataset used to develop the method. GRN inference and 
analysis methods also require specialist programming skills, that whilst not posing an 
issue for researchers accustomed to working with computer programming languages, 
does cause a problem for biologists and clinicians without these specialist skills that 
wish to make use of these tools. Due to these specialist programming skills required, 
current methods for GRN inference and analysis are not being fully exploited [9]. It is 
preferable for biologists and clinicians to be able to directly utilise network inference 
and analysis tools as they possess the specialist biological and clinical knowledge to 
be able to interpret the results, rather than computer scientists and engineers. 
2. Due to the current focus on inferring a single GRN from a microarray dataset, 
appropriate graph theory metrics that can be used to quantitatively analyse different 
evolutionary categories of GRNs have not been defined. Whilst certain graph theory 
metrics, such as degree centrality and betweenness centrality, have been applied to 
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single GRNs inferred from a microarray dataset to identify genes of interest, the 
application of appropriate graph theory metrics to identify genes of interest from 
different GRNS from a single microarray dataset has yet to be studied. As disease 
evolves, the ability of the same metric to identify important genes for the disease may 
alter. An objective overview of which graph theory metrics perform better in the 
different GRNs inferred for the different stages of disease is therefore required in 
order to aid researchers interested in inferring and analysing GRNs for different stages 
of disease.  It is likely that a metric that performs well and is able to identify genes 
already associated with a certain disease, will be a good choice of metric to identify 
new genes of interest for that same disease. 
3. As the focus to date has been on inferring a single GRN from a microarray dataset, the 
comparison of GRNs inferred for common disease stages from different microarray 
datasets for the same disease has not been investigated. Comparing the same disease 
stage GRN across different microarray datasets may be a better indicator to highlight 
genes that are involved in that disease stage, rather than simply considering one 
tumour microarray dataset in isolation. If the same genes are identified across multiple 
datasets, there is likely to be greater confidence in the results, than if genes are 
identified from one dataset. Therefore, comparing and analysing GRNs for the same 
disease stage across different microarray datasets could act as an important guide to 
genes that are important to that disease stage. 
1.3 Research Aims and Objectives 
The aim of this thesis is to aid biologists and clinicians investigate the progression and 
evolution of tumours, through the inference and analysis of  GRNs that represent different 
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evolutionary and clinical stages of cancer cell line microarray data. In order to do this, the 
following three objectives have been implemented.  
1. Implement a transferable network inference method specifically designed for the 
inference of different GRNs from a single microarray dataset. Additionally, this 
method should be easily accessible for biologists and clinicians to carry out gene 
regulatory network inference and analysis themselves, without needing specialist 
programming skills and expertise. 
2. Investigate appropriate graph theory metrics to quantitatively analyse the GRNs 
inferred for the different defined stages of disease. 
3. Compare GRNs inferred for different stages of disease across microarray datasets 
from different studies for the same disease. 
1.4 Contributions 
The thesis offers a number of novel contributions to the analysis of cancer cell line microarray 
data using GRNs. The first is the implementation of a network inference method specifically 
designed to infer GRNs at differently defined classes from a single microarray dataset. This 
method is transferable across different microarray datasets; in this thesis it has been applied to 
four different microarray datasets, and the application of graph theory metrics to the GRNs 
inferred has been able to identify unique genes of interest for the different categories of GRN 
within each microarray dataset. 
Furthermore, all network inference methods used in this thesis, including the novel network 
inference method developed, have been implemented on a local host version of the Galaxy 
[10] bioinformatics tools web-based server. This implementation allows users to easily access 
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and use GRN inference and analysis tools that previously required specialist computer 
programming language skills.  
The second contribution is the investigation of appropriate graph theory metrics to 
quantitatively analyse the different defined stages of disease. Genes that various graph theory 
metrics have identified have been scored using Génie [11], a text mining tool that scores 
genes for particular biological topics, allowing the graph theory metrics to be ranked against 
each other for the various GRNs. This has allowed graph theory metrics to be scored for 
different categories of GRN inferred from different cancer microarray datasets, aiding in the 
identification of appropriate graph theory metrics to apply to GRNs inferred for different 
stages of disease.   
Building on the second contribution of the work, the third contribution is the comparison of 
GRNs inferred for different stages of disease across datasets for the same disease from 
different studies. GRNs for common sample clinical disease stages across two different 
neuroblastoma microarray datasets have been inferred using the novel network inference 
method, with a high number of common genes identified in the top 100 ranking genes in 
disease stage 4M across both neuroblastoma microarray datasets, highlighting the 
transferability of the network inference method.    
1.5 Thesis Structure 
The thesis is set out as follows. Chapter 2 gives an overview of the research area. This begins 
with an introduction to graph theory; in this section various network metrics are discussed, 
and existing examples of the use of graph theory to model data are shown. Biological 
networks are also introduced.  
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Chapter 3 provides a summary of GRNs, and different network inference methods that can be 
used to construct GRNs from microarray data are explained. Finally, an overview of the 
proposed approach for this work is presented.  
Chapter 4 details the application of an existing network inference method, WGCNA, to the 
problem of inferring different classes of GRNs from a single microarray dataset. Five 
different classes of GRNs are inferred from a glioblastoma dataset, using survival time as the 
class discriminator. Some of the issues that can result from applying existing techniques for 
inferring GRNs from microarray data are evident in the results, such as the identification of 
common genes of interest across markedly different survival categories. This  arises primarily 
due to the network inference technique being designed for inferring a single GRN from a 
microarray dataset, and not distinguishing between the different survival categories.    
Chapter 5 details the application of a different network inference method; a novel z-score 
based approach, to the glioblastoma dataset introduced in chapter 4.  The purpose of this 
chapter is to highlight the application of a network inference method specifically developed 
for inferring multiple GRNs from a single microarray dataset that addresses the first objective.  
Chapter 6 details the application of the novel z-score based approach to two neuroblastoma 
datasets from different studies. The work in this chapter addresses the second and third 
objectives, graph theory metrics are scored based on the genes they identify and GRNs that 
represent different disease stages from the two neuroblastoma studies are compared. 
Chapter 7 details the application of a further refined version of the novel z-score based 
approach to a proprietary retinoblastoma microarray dataset. Samples from normal retinal 
data are contained in this dataset, and as such, a sample reference network for normal retinal 
data is also constructed to compare to the retinoblastoma networks. 
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Chapter 8 details the implementation of GRN inference and analysis tools on a web-based 
server, including the WGCNA and novel z-score method presented in this work. This further 
addresses the first objective, by providing an easy-to-use and easily accessible means for 
biologists and clinicians to infer and analyse GRNs from microarray data.  
Chapter 9 provides a summary of the work in the thesis. This includes a discussion on how 
well the original objectives have been addressed, limitations of the work, and speculates on 
how the work presented in this thesis could be developed in the future.  
There are a number of tables and figures referred to in this work. Where possible, these have 
been placed in the appendix to improve the readability. 
1.6  Summary 
The aim of this thesis is to aid biologists and clinic ians in the understanding of the evolution 
and progression of tumours. This can be achieved through the application of the network 
inference method initially presented in chapter 5 that infers different GRNs from a single 
microarray dataset, allowing GRNs that represent either different evolutionary or clinical 
stages to be inferred from a single microarray dataset. Appropriate graph theory metrics for 
the analysis of these GRNs is then investigated in Chapter 6, along with the comparison of 
GRNs representing different clinical disease stages for the same disease, neuroblastoma, from 
two different microarray studies. Chapter 7 presents refined version of the network inference 
method, and chapter 8 then details the implementation of a number of network inference and 
analysis tools, including all those used in this work, on a web-based server allowing clinicians 
and biologists easy-to-use and easily accessible means to investigate microarray data using 
GRN inference and analysis tools. 
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Chapter 2 
Systems Biology, Biological Networks, and Graph 
Theory 
In this chapter, a brief introduction to systems biology is presented. Following on from this, 
the concept of biological networks is introduced. GRNs, introduced briefly in the previous 
chapter, are further expanded on, along with other types of biological network. Relevant areas 
of graph theory are then finally introduced that can be used to model and analyse these 
biological networks, with a particular focus on graph theory concepts that are applicable to 
GRNs. 
2.1 Systems Biology 
In recent years, there has been a realisation that there are limits to be usefulness of the 
reductionist approach traditionally advocated in biology. This divide-and-conquer approach, 
that complex problems are solvable by dividing them into smaller and simpler units, studied 
the properties of the cell on an individual molecular basis. This traditional approach of 
reductionism has been responsible for successfully identifying most of the cellular 
interactions and components, and thus heralded a huge number of key breakthroughs in the 
history of biology, such as the existence of genes and the discovery of DNA. However, the 
reductionist approach does not offer any methods to understand how system properties 
emerge [1], and therefore an alternative approach is required in order to complement it [2]. 
This has caused a shift in the approach used in recent years, with the realisation that emergent 
properties can be discovered and better understood by taking a systematic view of biological 
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processes, through observation, using quantitative measures, of multiple components and also 
data integration with mathematical models. A key reason for this is that within a cell, 
biological functions rarely arise due to individual molecules; instead they take place because 
of interactions between many different molecules. Therefore, biological functions are 
controlled by ‘modules’, consisting of many types of molecules [12]. 
The notion of each module is that it is responsible for a separate, discrete function. The 
functions that these modules undertake cannot be easily predicted by studying the properties 
of the individual molecules that they are comprised of, thereby supporting the ‘overall’ view, 
as opposed to the individual molecular-basis one. However, identification of these modules is 
not always straight-forward, it is not always apparent what molecules they are made up of.  
The idea that biological functions are carried out by various molecules is one of the reasons 
that there has been a shift away from reductionism towards systems biology. Due to the 
isolated approach of reductionism, dynamic interactions between parts are disregarded. 
Instead the human body is depicted as a collection of static biological components, with the 
emphasis placed on static stability, as oppose to dynamic  stability. If we consider that 
biological functions are carried out by a number of molecules by modules, then it is clear that 
taking a systems approach over a reductionist approach is beneficial. The table below 
highlights the differences between the two approaches [2].  
TABLE 2.1 DIFFERENCES BETWEEN REDUCTIONIST AND SYSTEMS APPROACH 
 
CHARACTERISTIC REDUCTIONIST APPROACH SYSTEMS APPROACH 
PRINCIPLE BEHAVIOUR OF A BIOLOGICAL 
SYSTEM CAN BE EXPLAINED 
BY THE PROPERTIES OF ITS 
CONSTITUENT PARTS 
BIOLOGICAL SYSTEMS 
POSSESS EMERGENT 
PROPERTIES THAT ARE ONLY 
POSSESSED BY THE SYSTEM AS 
A WHOLE, AND NOT BY ANY 
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ISOLATED PART OF THE 
SYSTEM 
METAPHOR MACHINE, MAGIC BULLET NETWORK 
APPROACH ONE FACTOR IS SINGLED OUT 
FOR ATTENTION AND IS GIVEN 
EXPLANATORY WEIGHT ON ITS 
OWN 
MANY FACTORS ARE 
SIMULTANEOUSLY 
EVALUATED TO ASSESS THE 
DYNAMICS OF THE SYSTEM 
CRITICAL FACTORS PREDICTORS/ASSOCIATED 
FACTORS 
TIME, SPACE, CONTEXT 
MODEL CHARACTERISTICS LINEAR, PREDICTABLE, 
FREQUENTLY DETERMINISTIC 
NON-LINEAR, SENSITIVE TO 
INITIAL CONDITIONS, 
PROBABILISTIC 
MEDICAL CONCEPTS HEALTH IS NORMALITY, RISK 
REDUCTION AND 
HOMEOSTASIS 
HEALTH IS ROBUSTNESS, 
ADAPTION AND 
HOMEODYNAMICS 
 
One of the most revolutionary developments in recent biology has been the Human Genome 
Project. A fundamental idea emerged from this, the view of biology as an informational 
science [13]. Other sciences such as chemistry, physics, and geology, are measured through 
observations based on analogue results; at the heart of biology lies the genome, a digital code. 
The nature of digital codes, being discrete rather than continuous data, means that biology 
lends itself particularly well to disciplines such as computer science and engineering.  
2.2 Biological Networks 
High-throughput data techniques have been developed, such as the use of yeast two-hybrid 
screens and protein chips, that allow for integration of the components of the cell, and provide 
information about the status of molecular interactions within the cell [14]. One of the key 
concepts in systems biology related to this is the use of biological networks [15]. Biological 
networks are abstract representations of biological systems that capture a number of the 
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essential characteristics that make up that system; the nodes represent molecules, and links 
represent interactions between the molecules. These networks provide a first inkling of the 
overall structure of molecular interaction networks of biological systems. Whilst the focus of 
this thesis concerns GRNs, it is worth introducing protein-protein interaction (PPI) and 
metabolic networks at this point.  
PPI networks model protein binding interactions in an organism, and in humans provide a 
valuable tool to better understand the functional organisation of the proteome [16]. The first 
PPIs were generated using two-hybrid studies in the yeast organism Saccharomyces 
Cerevisiae [17]. Other organisms, such as humans [18] and Drosophila [19], have been the 
subject of protein interaction studies using large-scale two-hybrid studies. More recently, Xu 
and Li [20] used topological properties to discover hereditary disease genes in a human PPI 
network, highlighting the application of graph theory metrics, introduced in a later section, to 
PPI networks. 
Inside an organism, chains of reactions, known as metabolic pathways [21], combine to 
perform particular functions, such as the process of glycolysis, extracting energy from food. 
Nodes represent compounds, and edges represent reactions in a metabolic pathway. The 
system of connected metabolic pathways is the metabolic network of the organism [22]. There 
are a number of repositories that detail metabolic pathway information for an organism, such 
as KEGG [23], facilitating the construction of metabolic networks for organisms. As with PPI 
networks and GRNs, metabolic networks can be analysed using graph theory concepts. These 
graph theory concepts are introduced in a later section of the thesis.  
GRNs are the main biological network used in this thesis, and are used to model the 
interactions between genes in an organism. In a GRN, RNA transcripts of genes are 
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represented as nodes, and relationships between these are represented as links [24]. These 
edges represent presumptive relationships between the RNAs; the amount of one RNA affects 
the amount of the other RNA. These relationships can be simple, where RNA C encodes a 
transcription factor that promotes the transcription of RNA D, or complex where multiple 
metabolites or protein signalling is involved. Whilst these metabolites and proteins are not 
explicitly shown in the GRN, they may be involved in the relationship shown in the link 
between two genes.  
In this thesis, GRNs are constructed from microarray data from cancer cell lines; GRNs can 
also be constructed from other types of data, such as RNAseq experiments. To date, a number 
of GRNs have been constructed for various types of cancer; these include prostate cancer [6], 
breast cancer [7], and brain cancer [7]. Microarrays, and GRN inference methods, will be 
explained and discussed in detail in the next chapter. 
Despite the huge amount of data available, very few biological networks are complete in their 
structure [25]. This incomplete structure has given rise to the prevalence of mathematical 
models that represent the different biological networks. Historically, the process of evolution 
has been viewed by some, such as François Jacob [26], as being somewhat haphazard, with 
parts being added or taken away until a working solution is found. However, recent advances 
in the understanding of biological networks, using engineering concepts, have found that the 
solutions created by evolution share a number of  features with good engineering design [27], 
a perhaps somewhat surprising result. Three main engineering principles have been identified 
in biological networks; modularity, robustness to component tolerances, and the use of 
recurring circuit elements.  
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The idea of modularity has already been noted in the previous section, that biological 
functions are controlled by ‘modules’ of molecules that work together. This is further 
illustrated by the example of proteins that function in co-regulated overlapping groups such as 
pathways [28]. Modules are apparent in engineered systems; such as subroutines in software 
[29]. Robustness to component tolerances is a well-known and observed feature of engineered 
systems; the system should function under all conceivable conditions that may arise due to the 
components and the surrounding environment. This has also been observed in biological 
network, recent studies have shown how particular gene circuits are robust in bacterial 
chemotaxis [30] and fruit-fly development [31].  
The third observed principle is the use of recurring circuit elements. Electronic devices, such 
as computers, include thousands of circuit elements such as memory registers. This same 
principle is apparent in biological design; key wiring patterns are repeated throughout a 
network. One such example of this is the presence of recurring ‘network motifs’ circuit 
elements observed in the transcriptional network of E.Coli [32]. In order to analyse biological 
networks, and more specifically GRNs, tools and concepts from the field of graph theory can 
be used. Graphs can be used as representations of real world systems. These tools can identify 
important genes in the GRN based on topological properties. Relevant graph theory tools and 
concepts are introduced in the following section.  
2.3 Undirected Unweighted Graph 
In the field of mathematics, the graph, G, consists of vertices, V, that represent points, and 
edges, E, that represent links between the points and can be defined as (V,E) [33]. In essence, 
a graph is a series of points connected by a series of links. A connection between nodes i and j 
is defined as E = {(i, j)| i, j Î V}. As there is an edge between nodes i and j, they are said to be 
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neighbours. It is possible for more than one edge to exist between nodes. The simplest graph 
model is the undirected unweighted graph, no direction is assigned to the edges, and no 
weighting either, so all edges in this type of graph have the same strength. A graph can be 
represented mathematically using an adjacency matrix. The graph containing n vertices would 
be represented by an n x n matrix A = (ai,j); with the entry ai,j =1 to indicate an edge 
connecting vertex i to vertex j, and ai,j =0 if there is no connection from vertex i to vertex j 
[34]. Note that for undirected graphs, the adjacency matrix is symmetrical, as no distinction is 
made between the origin and destination of the edge. An example of an undirected graph and 
corresponding adjacency matrix is shown in figure 2.1 below: 
FIGURE 2.1 UNDIRECTED UNWEIGHTED GRAPH AND CORRESPONDING ADJACENCY MATRIX 
 
2.4 Directed Unweighted Graph 
In a directed graph, the edges have directionality. This builds upon the previous model, and 
directionality is assigned to the edges.  This captures the directionality that exists in certain 
real world situations; such as communications networks, where there is a sender and a 
recipient of a message. In this case, an edge originating at i, representing the sender of the 
message, and finishing at j, the recipient of the message, would be represented as E = (i, j), 
and not E = (j, i) [33]. As with the undirected graph, an adjacency matrix can be used to 
represent it mathematically; with a 1 indicating an edge, and a 0 representing no edge. Note 
that this matrix is not symmetrical due to the directionality of the edges.  This can be seen on 
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the example of a directed graph and corresponding adjacency matrix is shown in figure 2.2 
below, there is an edge from vertex A to vertex B, not from vertex B to vertex A.  
FIGURE 2.2 DIRECTED UNWEIGHTED GRAPH AND CORRESPONDING ADJACENCY MATRIX 
 
2.5 Undirected Weighted Graph 
Another extension to the first model introduced is the assignment of weights to the links that 
connect the nodes. The weighted graph differs from the unweighted graph in that edges 
between nodes are not discrete in nature, either 1 or 0, but instead edges have respective 
weights that show the strength of the edge in relation to the other edges in the network. There 
are a number of scenarios where an edge weight is useful for providing additional 
information. One such example of this is a map represented as a graph; the nodes represent 
cities, the edges routes between cities, and the edge weight distances.  Weighted networks can 
be represented mathematically by an adjacency matrix, as is the case with unweighted 
networks, but instead of having entries that are binary, 1 or 0, instead these entries are equal 
to the relative weights of the edges [35]. The adjacency matrix A therefore has elements: 
Aij = (weight of connection from i to j) 
This can be further seen in the example undirected weighted graph along with corresponding 
adjacency matrix in figure 2.3 below: 
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FIGURE 2.3 UNDIRECTED WEIGHTED GRAPH AND CORRESPONDING ADJACENCY MATRIX 
 
2.6 Directed Weighted Graph 
The fourth model adds directionality to the weighted graph, so that edges are  both directed 
and weighted. As with the previous three types of graphs, it can be represented using an 
adjacency matrix. Figure 2.4 shows an example of a directed weighted graph with 
corresponding adjacency matrix: 
FIGURE 2.4 DIRECTED WEIGHTED GRAPH AND CORRESPONDING ADJACENCY MATRIX 
 
2.7 Graph Models 
The use of graphs as a mathematical modelling technique for real world systems is not a new 
phenomenon, and can be traced back to the 1730s. Leonard Euler, a Swiss mathematician, 
used it to solve the bridges of Konigsberg problem [36]; was it possible to walk across all 
seven bridges of the city, and never cross the same bridge twice? By modelling the bridges of 
the city as graph, Euler was able to prove that such a path did not exist due to four of the 
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nodes have an odd number of edges. When a new bridge was built in 1875, such a walk 
finally became possible. 
The number of edges that a node has can be thought of as perhaps the most basic quantitative 
property of a graph, and is termed the degree. The degree of a node is the number of edges 
that are connected to that node [37]. The distribution of the number of connections each edge 
has is therefore the degree distribution. In 1957, the first serious attempt to construct a model 
for large and apparently random networks, the random graph, was proposed by Rapoport et al 
[38], and rediscovered independently a few years later by Erdős and Rényi [39]. Extremely 
simple models of networks were proposed; take n number of vertices and connect each pair 
with probability p or 1-p, resulting in the model having a clear Poisson degree distribution. 
This model demonstrated the most important property of the random graph, the transition 
from low-density, low p-state to high density, high p-state.  
However, these early models had two major shortcomings. Firstly, they did not capture the 
property of clustering. This property, also known as network transitivity, is the observation 
that two vertices that are both neighbours of a separate third vertex have an increased 
probability of also being neighbours themselves [40]. It is more likely that two of your friends 
will also themselves be friends with each other, than if they were not friends with you. This 
property can be quantified by the clustering coefficient:  
 [2.1] 
On a fully connected graph, this number is 1, in real-world networks the value tends to be 
between 0.1 and 0.5 [40]. Due to the random and independent probability of two nodes being 
connected in a random graph, random graphs exhibit a low clustering coefficient.  
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Watts and Strogatz [41] proposed the small-world model as a graph generation model that 
generated graphs with a high clustering coefficient. By taking a standard ring lattice, 
containing n nodes each with k edges, and rewiring the edges with probability p, they 
observed how altering this value of p affected the clustering coefficient. This is the foundation 
of the small-world model, a network built on a low-dimensional regular lattice with edges 
added or moved to create low density shortcuts that join remote parts of the lattice to each 
other. As well as generating graphs with a high clustering coefficient, the graphs also have a 
small average path length, both small-world properties.  
Arguably the most famous discovery in the study of networks, popularised by science books 
and social networking experiments, was the small-world effect; that most pairs of people are 
connected by at least one, and probably many, short chains of acquaintances. Whilst 
originally this applied to social networks, as highlighted by Milgram [42], it is not just 
confined to these, and seems to apply to many other networks. The connectivity of the 
Internet, gene networks, the power grid of the western United States, and the neural network 
of the worm C.Elegans all display small-world behaviour [41].  
The average path length in the small-world model has received a lot of attention. No exact 
solution exists for this metric, denoted ℓ, however a number of partial exact results are 
known, as well as a number of approximate solutions for its behaviour. Small average path 
lengths have been observed in real-world scenarios; the average mean path length for 
academic co-authorship with Erdős is 4.65 [43]; whilst in Milgram’s original study it was 4.4, 
5.4, and 5.7 for the three groups of participants [42].    
Despite generating graphs that encapsulate a high clustering coefficient and small average 
path length, the model proposed by Watts and Strogatz has one major flaw. The degree 
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distribution generated by the model is not realistic; it does not match the degree distribution 
observed in real networks. This is also a shortcoming of the random graph model. Real-world 
networks do not have a Poisson degree distribution; Barabási and Albert observed that the 
world wide web was scale-free, that it followed a power-law degree distribution [44].  This 
power law states that the fraction of nodes in the network, P(k), that have k  connections to 
other nodes in the network is: 
      [2.2] 
with c being a normalisation constant, and the parameter y typically having a value between 2 
and 3 [45]. Scale-free networks are dominated by a small number of highly-connected nodes, 
referred to as hubs. A number of studies have noted that biological networks display this 
scale-free topology, such as those by Jeong et al [46] ,on the topology of metabolic networks, 
with authors of other studies proposing that the scale-free topology of biological networks is 
more conserved than content during evolution [47]. Zhang and Horvath [48] are even more 
explicit, stating that a number of biologists would be wary of gene correlation networks that 
did not display scale-free behaviour. 
One of the properties that arises due to power-law degree distributions is the high resilience to 
uniform random removal of nodes; when nodes are removed from a network with a power-
law degree distribution uniformly at random, the network typically remains connected and 
functional regardless of the number of nodes removed [49]. However, whilst scale-free 
networks are incredibly resilient against the random removal or failure of nodes, they are 
highly susceptible to targeted removal of the highest-degree nodes. It has been suggested that 
regardless of the power-law exponent, no more than 3 % of these nodes need to be removed 
before the entire network is disconnected [50], meaning the average probability of there being 
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a path connecting any two nodes disappears. 
2.8 Network Metrics 
A number of metrics can be used to analyse the networks modelled by graphs. The most basic 
of these, the previously introduced degree, is simply the number of connections that a node 
has. In the case of weighted networks, where all the nodes in the network are connected to all 
the other nodes in the network, a ll nodes have the same degree. Therefore, the degree 
centrality property can be extended for weighted networks, by taking the edge weights into 
consideration. The sum of the edge weights of a node is of interest, and is referred to as the 
weighted degree centrality. The greater the strength of a connection, i.e. the weight of an edge  
between two nodes, the more informative this connection is likely to be. This is especially 
relevant in the case of GRNs; higher edge weights are indicative of a stronger regulatory 
relationship between two genes [51]. 
In addition to the number and strength of connections a node in a network has, it can be useful 
to monitor communications between all nodes in the network. More specifically, it is of 
interest to measure the effect that a particular node has on these communications. This can be 
measured using the betweenness centrality; it measures how many shortest paths between all 
the node pairs in a network pass through a specific node [52]. The shortest path in a network 
is defined as the path that requires the least amount of intermediary nodes between a pair of 
nodes, and can be defined formally as [53] : 
 [2.3] 
h=intermediary nodes on path between nodes i and j 
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Each node that is part of the shortest path between a pair of nodes is able to control the 
information that flows between these nodes.  As such, a node that is part of many shortest 
paths is important in the network as it controls the communications between many nodes in 
the network [54].The formal definition of betweenness centrality, as given by Freeman, is 
[55]: 
    [2.4] 
=number of shortest paths between two nodes, and  number of those paths that pass 
through node i 
A node with a high betweenness centrality in a network is crucial to maintaining certain 
connections, and its removal can result in the network becoming disconnected; there no 
longer is a path in the network between certain nodes, resulting in the nodes no longer being 
able to communicate with each other. In a biological context, Scardoni states that the 
betweenness of a node in a protein signalling network gives an indication of the relevance of 
the protein as capable of holding together communicating protein [56]. A study by Potapov et 
al [57] on mammalian transcriptional networks identified the betweenness centrality as 
probably being the most biologically significant topological property, indicating that a gene 
with high betweenness is more likely to be involved in regulatory mechanisms.  
However, in the case of a weighted network where, all nodes are connected to other nodes, the 
above implementation of betweenness centrality is not applicable. As such, a modified 
implementation taking into account the edge weights is required. There have been a number 
of different approaches to the area of identifying shortest paths in a weighted network. 
Dijkstra [58] suggested an approach based on the path of least resistance, i.e. prioritising paths 
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that involved lower edge weights. This approach is suited to networks where the edge weight 
represents a cost, such as time or money; as would be the case for a network representing a 
city metro system, where edges weights are the costs of travelling between stations. However, 
in a number of networks, the edge weight represents a measure of optimality, and as such, 
paths with higher edge weights should be prioritised over paths with lower edge weights. 
Both Newman [59] and Brandes [60] inverted the edge weights in order to achieve this. The 
formal definition of their implementation of the shortest path algorithm is then: 
 [2.5] 
Another well-studied network metric is that of closeness centrality. It is of interest to be able 
to measure how quickly a node can reach all the other nodes in the network. The closeness 
centrality is the inverse of the average length of the shortest paths to/from all the other 
vertices in the graph, and is defined as [55]: 
[2.6] 
A node with a high closeness centrality will have a small average distance to all other nodes 
in the network. Scardoni [56] states that in a protein-signalling network, a protein with high 
closeness will be central to the regulation of other proteins; but that some of the proteins will 
not influenced by its activity. It might therefore be expected a gene with high closeness in a 
GRN is likely to be involved in some regulatory mechanisms, but will not have any influence 
on others; although this has not explicitly shown.  
As was the case with betweenness centrality, we are interested in extending this metric to 
weighted networks. Newman extended closeness centrality to weighted networks using a 
similar approach adopted for extending betweenness to weighted networks detailed previously 
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[59]. The edge weights in the network were inverted, and the least costly paths for all pairs of 
nodes were found. This cost of the path indicated how far a node was from another, and as 
such, the higher the cost, the further away a node was. In order to then create the closeness 
measure, this cost was inverted, so that high costs were transformed into  a low closeness 
centrality, and low costs were transformed into high closeness centrality [53]. 
Another network metric of interest is the eigenvector centrality. This metric, initially 
proposed by Bonacich [61], can be thought of as an extended version of degree centrality. 
Scores are assigned to nodes based on the sum of the degree of the nodes they are connected 
to; therefore a node can have a high eigenvector centrality either by being connected to lots of 
others nodes, or being connected to nodes that themselves have a high degree. The famous 
PageRank algorithm used by the Google search engine is a variation of the eigenvector 
centrality metric. The eigenvector centrality can be formally defined as [62]: 
 [2.7] 
= score of the vth node,  
M(v)=  set of nodes v connected to, 
 = adjacency matrix of the network i.e.  = 1 if v is connected to t, 
λ = constant 
Re-writing this in matrix notation, we get:  
λx = Ax              [2.8]                                   
as a result we can see that x is an eigenvector of the adjacency matrix. Extending the 
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eigenvector centrality to a weighted network, we can take into account the edge weights. This 
means that if node B was connected to node A with double the edge weight of the edge from 
node A to node C, node B would contribute twice as much as node C to the eigenvector 
centrality of node A.   
As noted earlier, typical network connections are far from random. One indicator of this is the 
correlation between degrees of different nodes; are highly connected nodes connected to each 
other? To formally measure this, the assortative mixing coefficient of the network can be 
calculated. This is the Pearson correlation coefficient of nodes that are connected. Newman  
[63] defines this for an undirected network as: 
 [2.9] 
j,k=excess degree of the specific edge  
= joint probability distribution of excess degrees of the nodes at either end of a randomly 
chosen edge,  
 = standard deviation of the excess degree distribution of the network q(k) 
Where r = 1, there is perfect assortative mixing, where r = -1, there is perfect diassortative 
mixing. In social networks, there are positive correlations, r has been observed to be positive, 
meaning that the highly social party animals tend to know and socialise with each other. 
However, most non-social networks, including biological networks, have negative correlation. 
These degree correlations have a strong effect on the structure of networks. Networks with a 
positive correlation have a core-periphery structure; a highly interconnected core surrounded 
by periphery lower degree nodes, networks with a negative correlation have high-degree 
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nodes scattered more broadly over the network. These structural differences also affect the 
way a network behaves, for example a disease can persist more easily in a network with 
positive correlation by circulating in the dense core where there are opportunities for it to 
spread, in a network with negative correlation it is harder for the disease to persist, but if it 
manages to do so, it will typically spread to the whole of the network.  
The greatest distance between any pair of nodes in a graph is the diameter. It is relatively 
straightforward to calculate; calculate all the shortest paths in the graph as per the 
betweenness centrality, the largest length of these paths is the diameter. The diameter can give 
an initial insight into how compact a graph is; it is possible that two nodes are far away from 
each other in a graph giving a high diameter, yet the graph itself is quite compact. This should 
be taken into consideration before making conclusions about how compact a graph is based 
on diameter. Low diameter values have been observed generally in biological networks [64], a 
low diameter in a GRN can indicate that the genes are able to communicate with each other 
relatively easily.  
Cliques are another area of interest. The clique, also called the complete graph, is a complete 
subset, S, of a graph in which each pair of nodes is connected. In particular, the maximum 
clique is of interest; this is the largest clique that exists in the graph. The maximum clique can 
be informative in a GRN as it highlights gene co-expression relationships, i.e. genes up-
regulated or down-regulated together. It has been shown that genes that form part of this 
maximum clique are likely to be functionally related, and this can give an insight into cellular 
processes [65].  
The maximum clique containing a specific set of nodes can also be informative. The 
maximum clique containing nodes F, D, and L,  shown in green in figure 2.5, also includes 
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node E. This indicates that node E is more likely to be part of cellular processes that nodes F, 
D, and L, are involved in [65]. The clique coloured red in figure 2.5 is the largest clique in the 
graph. 
FIGURE 2.5 CLIQUES IN A NETWORK 
 
2.9 Summary 
This chapter has introduced a number of theoretical concepts that are central to the thesis. An 
introductory overview of systems biology was presented, along with the notion of biological 
networks. GRNs in particular were detailed, with examples of their application to cancer cell 
line data sets. Relevant concepts of graph theory relating to the thesis were outlined; different 
types of graphs, mathematical models of graphs, and a number of properties of graphs. In 
particular, graph theory metrics were presented that can be used to analyse GRNs, and the 
context of their application to GRNs. In the next chapter, the specific data type that will be  
used for the thesis is briefly explained, along with a number of potential GRN network 
inference methods, and a proposed methodology for the thesis.  
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Chapter 3 
Gene Regulatory Network Inference Methods and 
Proposed Methodology 
In this chapter, a brief introduction to microarrays is presented, along with a description and 
discussion of various GRN inference methods. Finally, the proposed method for this thesis is 
presented. 
3.1 Microarray Data 
For the purposes of this project, GRNs will be inferred from microarray data. Before different 
GRN inference methods are detailed, microarray data will be introduced. In order to 
understand microarray data, the underlying biology has to be first understood. Almost all of 
the cells in the body contain a set of chromosomes and identical genes, with only a small 
portion of these genes turned on. It is this small fraction of genes that are expressed and that 
are responsible for the unique properties of each cell. The term gene expression refers to the 
transcription of information contained in the DNA into messenger RNA, mRNA, then 
translated into proteins responsible for the critical functions of most cells. By studying the 
type and amount of mRNA produced by a cell, we can get an insight into how the cell 
behaves. The process of gene expression is highly complicated, and allows a cell to respond to 
the environment and its own needs. As well as genes turning on and off, the level of 
expression can be increased or decreased. The correct expression of a number of genes is 
required for normal growth and development; changes to these expression levels are the cause 
of a great deal of diseases. 
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A microarray enables the gene expression levels of thousands of genes to be measured in one 
experiment. It works by exploiting the ability of a mRNA to bind to the DNA template it 
originated from; the mRNA is fluorescently labelled and the fluorescence is measured by a 
scanner generating the gene expression level [66]. It is these gene expression levels that then 
make up the array which is used for the inference of the GRNs. 
It is necessary for a number of procedures to be carried out on an array before GRNs can be 
inferred from it. Essentially, three steps have to be carried out on a microarray before it can be 
used; background correction to remove background signal, normalisation to correct for 
systematic biases such as different dye absorption, and a summarisation of the values of all 
the probes representing one gene [67]. RMA, Robust Multichip Analysis, is the most common 
pre-processing method applied to microarray data, as it is performs all three steps [68]. 
Additionally, in studies such as those by Freudenberg [69] and Hill et al [70], RMA has been 
shown to outperform other pre-processing methods, including the Affymetrix MAS5 
algorithm. 
3.2 GRN Inference Methods 
In order to infer a GRN from microarray data, a number of different approaches can be used. 
We will focus on four techniques that can be used; mutual information based methods, 
correlation based methods, Bayesian networks, and a discretised approach.  
3.2.1 Mutual Information Networks 
The first category of network inference model that will be introduced is the mutual 
information based approach. Mutual information is  an indicator of being able to predict the 
value of one variable, knowing the value of the other variable, and is defined mathematically 
as [71]: 
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                                                                                                       [3.1] 
 
where p(x,y) is the joint probability of variables X and Y, 
p(x) is marginal probability distribution function of X, 
p(y) is marginal probability distribution function of Y 
An illustrative way to display mutual information is on a Venn diagram, shown in figure 3.1: 
FIGURE 3.1 VENN DIAGRAM DISPLAYING MUTUAL INFORMATION 
 
 
The mutual information network inference approach uses mutual information to determine if a 
link exists between two nodes in a network. There are two steps involved in the inference of a 
network using mutual information. The first step is the calculation of the mutual information 
matrix. This is a square matrix, where: 
MIMij = I(Xi:Xj)   [3.2] 
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represents the mutual information between Xi and Xj [72]. Having calculated the mutual 
information matrix, the next step is to then use an inference algorithm to calculate an edge 
score for each pair of nodes in the network, using the mutual information matrix. One of the 
advantages of mutual information methods should be highlighted here; they are able to deal 
with thousands of variables with only a limited number of samples, making them ideally 
suited to microarray data. It should be noted that as the mutual information is a symmetrical 
measure, edge directionality cannot be inferred using this method.  
A number of inference algorithms for calculating the edge scores from the mutual information 
matrix have been developed. Amongst the most promising for use with microarray data to 
infer GRNs are ARACNE [73] and MRNET [71]. ARACNE in particular has received a lot of 
attention. It is an inference algorithm based on the Data Processing Inequality; if gene 
XA interacts with gene XC through gene XB, then [74]: 
I(XA; XC) ≤ min (I(XA; XB), I(XB; XC))        [3.3] 
Each pair of nodes is initially assigned a weight equal to the mutual information matrix by 
ARACNE. A threshold I0 is set, and all edges which are below that threshold, i.e. I(Xi; Xj) <I0, 
are removed. ARACNE interprets the weakest edge of each triplet as an indirect interaction, 
and this is removed if the different between the two lowest weights is greater than another 
threshold, W0. In the study outlining its use, ARACNE was shown to perform better than 
relevance networks and Bayesian networks on a number of network inference tasks [73]. 
MRNET is a network inference algorithm that uses the maximum relevance/minimum 
redundancy (MRMR) feature selection method [75]. This approach scores the set of inputs, V, 
based on the difference between the mutual information and the output, Y, the maximum 
relevance, and the minimum redundancy, which is the average mutual information of the 
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previously ranked variables. The idea is that this approach will highly rank direct interactions, 
whereas indirect interactions will be given a low ranking. MRNET performs similarly to 
ARACNE, and outperforms it for precision recall from simulated datasets [76]. 
3.2.2 Correlation Networks 
Another network inference approach is to use correlation networks. Correlation networks are 
used in a wide variety of applications such as finance [77] , ecology [78], gene expression 
analysis [79], and metabolomics [80]. A correlation network displays the correlation that 
exists between two elements, with 1 representing a perfect positive correlation, and -1 a 
perfect negative correlation. The creation of a correlation network is in itself a relatively easy 
process consisting of two steps; the calculation of all pairwise correlations, and the 
application of a threshold to identify significant correlations that hence form edges in a 
network [81].  
Gene correlation networks are a tool used to explore the role of genes in a system context. 
The concept of gene correlation networks is fundamentally simple; nodes represent genes, and 
edges represent interactions between these genes. A gene co-expression matrix can be 
defined:  
S =[ij]     [3.4] 
where ij is the correlation between the genes i and j,  
S is the matrix of correlations.  
A common approach is to use the Pearson Correlation coefficient between pairs of genes; and 
to then assign either an edge be ing present, or absent, based on a threshold value, resulting in 
an unweighted adjacency matrix that can be used to construct a network [82]. A variation on 
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this is to represent all the correlations between pairs of genes using a weighted adjacency 
matrix, although this results in a much more computationally demanding matrix.  
A number of previous studies have used correlation based methods successfully for dealing 
with biological data, such as those by Stuart et al [83] , Li et al [84], and Horvath et al [7]. 
These results from these previous studies show the practical usefulness of the correlation 
based approach for dealing with microarray data. In particular, the weighted correlation 
network analysis (WGCNA) approach proposed by Horvath et al [85] has provided a number 
of interesting results, in particular when the method was applied to a glioblastoma dataset.  
3.2.3 Bayesian Networks 
Bayesian networks are another type of network inference method. Think of a situation where 
two events have an effect on a third event; for our example, a car is clean depends on whether 
it has been raining or whether someone has washed it. Whether the car is washed also depends 
on the rain; the car is not washed when it is raining. In such a scenario, we can use a Bayesian 
network to model this. Bayesian networks are probabilistic graphical models that represent 
probabilistic dependencies between a set of entities, and in doing so combine two areas of 
mathematics; graph theory and probability. The Bayesian network is a directed acyclic graph, 
G(X, E), where gene expression levels are represented by random variables that are the nodes, 
xi ∈ X, and the dependencies between these nodes are represented as edges [86]. The variables 
representing the nodes are derived from conditional probability distributions, P(xi|Pa(xi)), 
where Pa(xi) is each node’s set of parents. The Markov Assumption, that each variable is 
independent of its non-descendants given its parents, is implicitly encoded by the Bayesian 
network.  Building on this assumption, the joint probability distribution over all the variables 
down to the conditional distribution of the nodes can be defined as [24]: 
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P(x1, x2... xn) = (xi|Pa(xi))    [3.5] 
As well as the set of dependencies implied, that children nodes are dependent on their parent 
nodes, a set of independencies are also implied.   
The Bayesian network is appealing for modelling deterministic relationships, such as GRNs, 
as the joint probability distribution for the probabilities of events, represented by the nodes, 
given other events can be queried. Inferences can be made from the joint distribution and 
likely causal relationships can be made. The probability based nature of Bayesian networks 
also makes them suited to handling noise that is inherent in microarray data.  
In order to use a probabilistic framework for a GRN, the aim is to learn a Bayesian network 
that is a good fit for the microarray data. There are two steps to learning a Bayesian network 
from the data; the first is the selection of the model, and the second is the parameter fitting 
[87].  The model selection consists of finding the best graph, G, to represent the relationship 
between the variables of the data. The second step then consists of finding the best conditional 
probabilities for each node of this model.  A number of methods have been proposed for 
learning Bayesian networks from genomic data, such as those proposed by Werhli et al [88], 
and Chen et al [89], have proved promising for inferring GRNs from microarray data using a 
Bayesian approach. 
3.2.4 Discretised Networks 
A fourth conceptually much simpler network inference method is the discretised approach. 
Vass et al [90] proposed such an approach for inferring a GRN from microarray data. In their 
work, firstly the gene expression levels for all the genes are converted to z scores; and are 
then dicretised into 3 values based on a threshold value. The 3 discretised values are 1, which 
represents an up regulated gene, -1 which represents a down regulated gene, and 0 which 
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represents neither, and are stored in a matrix. This matrix of discretised values is used to 
derive two matrices, P and M, which hold the 1 and -1 values in positive form. These matrices 
are then used to calculate PP, the positive – positive network, i.e. where up regulation in one 
gene occurs with up regulation with another gene, negative – negative, where down regulation 
in one gene occurs with down regulation of another gene, and positive – negative, where up 
regulation of one gene occurs with down regulation of another gene.  
In order to filter out relationships that may be as a result of chance, a ll the scores for these 
matrices are evaluated against an expectation, P = 0.005, using Monte Carlo sampling.   
Monte Carlo methods can be used to solve various types of computational problems through 
the use of random numbers [91]; Vass et al estimated the distribution of scores for 
randomised vectors of all possible densities, and repeated this test 1000 times. Values which 
exceeded 99.5% of the random scores were accepted, resulting in 5% of original edges 
remaining.  
This simple discretised approach captures whether genes are up and down regulated for 
certain samples compared to others, which is often what biologists are interested in. It was 
shown that this method identified most of the defined relationships in the synthetic microarray 
dataset created using SynTReN [92], as well as identifying a great number of gene-gene 
relationships in observational microarrays across different mRNA platforms. 
3.3 Comparison of GRN Inference Methods 
In the previous section, a number of inference methods that can be used to infer GRNs from 
microarray data were introduced. However, a great many more network inference methods 
exist, and it would be impossible to introduce them all. Accurately reconstructing GRNs from 
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microarray data is still a big challenge, despite the huge range of different network inference 
methods available.  
Such is the challenge, that a project specifically dedicated to this problem exists; the dialogue 
on reverse engineering Assessment and methods (dreAm) project. This consortium meets 
annually to assess different network inference methods that have been proposed. At the 2010 
conference [93], over 30 network inference methods were assessed, without one inference 
method identified as performing optimally across all of the datasets. From experience with the 
network inference methods used so far, all perform significantly better on their training set 
data than they do on other datasets, an observation that is in concordance with those from the 
2010 dreAm conference.  
Due to this large number of different inference methods, it is both impossible to use all of 
them, and also, to form a conclusive opinion as to which is the best-suited for the project. 
With this in mind, a number of network inference method review papers that have compared 
the respective performance of a number of different network inference methods have been 
referred to for initial guidance. These papers compared the performance of mutual 
information, correlation-based, and Bayesian network approaches. The discretisation 
approach proposed by Vass et al did not feature in any of the network inference review papers 
consulted.  
The Bayesian network and discretisation approach potentially offer advantages over the two 
other approaches in that they have the potential to assign directionality to the interactions.  
However, in a number of studies, including that by Hurley et al [9], it was reported that the 
inferred directionality from a number of network inference methods, including Bayesian 
networks, was incorrect. Reasons for this could be due to the complexity of gene regulation; 
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gene A may regulate gene B, but both genes A and B are regulated by gene C and so on, and 
also there is limited directional information available in the microarray dataset for the method 
to infer the correct directionality. Whilst direct ionality offers a number of benefits to 
identifying genes of interest, if the inferred directionality is not correct, as the studies suggest, 
then this potential advantage of directionality is negated. As such, the networks that will be 
inferred will not be directed. 
Another GRN inference methods study, by Allen et al [94], suggested that Bayesian networks 
are not suited to large scale microarray data due to computational and memory requirements.  
Learning the structure of a Bayesian network is NP-hard [95]. Considering that the datasets 
that will be used for this study consist of several thousand genes, Bayesian networks are not a 
feasible choice of network inference method for large-scale gene regulatory networks [96]. 
There is also high variability in the learning of the Bayesian networks; a slight difference in 
the parameter fitting and choice of model results in the inference of a completely different 
GRN. Taking these two negative aspects into account, Bayesian networks will not be used in 
this project, despite the potential advantages that they offer over other network inference 
methods.   
It is worth noting that in the study by Allen et al, both WGCNA and ARACNE were 
identified as being a good choice of inference model for constructing the global network. 
These two methods also out-performed the other network inference methods when using the 
E.coli dataset, suggesting that they are also more robust than the other methods and also 
perform better with real datasets. The importance of the number of samples should be 
mentioned here. As with most other cases, increasing the number of samples will result in 
more meaningful results. This is especially pertinent in the inference of the GRNs from the 
data; a minimum number of samples are required for certain network inference methods. In 
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the Allen el al paper, it was observed that as the number of samples increased, the 
performance of the network inference methods improved. Of particular interest was the 
performance of the network inference methods for the 20-50 samples category, in which 
WGCNA out-performed the others. This is of interest as the typical datasets that will be used 
contain this number of samples. 
Finally, when considering the area of inferring a model that approximates a GRN from a 
microarray dataset, the words of David Edwards should be heeded: ‘Any method (or 
statistician) that takes a complex multivariate dataset and, from it, claims to identify one true 
model, is both naive and misleading’ [97]. 
3.4 Software Tools  
A number of software tools will be used in this work; the main tool that will be used is the R 
programming language [98]. R is a language specifically developed for statistical computing 
and graphics, and builds on the S language developed at Bell laboratories. It has been widely 
adopted by bioinformaticians in recent years due to the wide range of bioinformatics libraries 
available; in particular the Bioconductor project [99]. Bioconductor project is an open source 
collaborative development project for the creation of software libraries in R for computational 
biology, and contains a wide range of software libraries with useful functions for applying to 
microarray data.  
R will be heavily used in this work; the network inference methods to infer the GRNs from 
the samples will be implemented using R, as will the calculation of a number of different 
metrics for the GRNs and the identification of the largest unique cliques in the networks using 
the igraph [100] package in R. Igraph is package of functions specifically designed for 
complex network analysis. Filtering of the results will also be carried out in R, so that lists of 
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highly ranked genes based on the metric scores, and the genes that comprise the largest 
unique cliques, are output for further analysis.  
In order to counter the problem of assigning biological meaning to the lists of genes produced, 
there are a number of tools that are able to ascertain whether these lists have biological 
meaning. These tools highlight whether the genes identified are enriched for certain biological 
significance. Examples of widely used tools for this purpose include DAVID; Database for 
Annotation, Visualization and Integrated Discovery [101], a website with a number of tools 
for interrogation of the results, GATHER; Gene Annotation Tool to Help Explain 
Relationships [102], which is able to display annotations that distinguish the input list of 
genes from other genes in the genone, and GeneSetDB [103]; which can be thought of as an 
extended version of GATHER by using a greater number of databases, thereby ensuring 
greater coverage of the results. 
The web-based tool Génie [11] will be used to score the genes identified. This tool scores 
genes for a selected biomedical topic based on a text-mining search of scientific abstracts. 
This thereby provides an objective means by which to scores genes for particular biological 
topics, rather than the subjective interpretation of GenesetDB that requires expert knowledge.  
For the purposes of this work, it provides a means to rank the metrics based on the scores of 
the genes they identify. For each microarray dataset, Génie will be used to generate a list of 
scored genes for the particular microarray disease. 
3.5 Proposed Approach  
Having reviewed the areas of interest that are applicable to this work, a proposed approach 
can now be presented to specifically address the aim and objectives outlined in chapter 1. The 
flowchart in figure 3.2 below shows the proposed approach that will be adopted.  
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FIGURE 3.2 OVERVIEW OF PROPOSED APPROACH 
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As can be seen from the flowchart above, there are seven steps to the proposed approach. The 
first thing to note is the role of the biologists and clinicians in the proposed approach in figure 
3.2; initial input from these specialists will guide the selection and categorisation of  
microarray datasets that will be analysed; and once the network inference and analysis is 
complete they will be presented with the output lists of the genes and the enrichment resu lts 
that will allow the results to be evaluated.  
The first step of the proposed approach, the initial input from biologists and clinicians, will 
guide in ensuring that both the microarray datasets and classification criteria used are both 
relevant and of use to them, particularly as many biologists and clinicians are interested in 
certain diseases and subtypes of these diseases. 
The second step is the application of a network inference method to infer the GRNs for the 
categorised samples. It is the intention of this work to explore the use of a number of GRN 
inference methods that can be used on microarray data; particularly to compare the use of an 
existing network inference method to infer a number of GRNs from a single microarray 
dataset, to the use of a novel network inference method to infer a number of GRNs from a 
single microarray dataset. Specifically, the performance of the WGCNA method, described in 
greater detail in the next chapter, will be compared to a novel network inference method, 
described in chapter 5, using a glioblastoma microarray dataset. This inference of GRNs from 
the different categories of samples directly addresses the first objective set out in chapter 1. 
The third step is to analyse the GRNs inferred for the different categories. This directly relates 
to the second and third objectives set out in the first chapter. Metrics will be calculated for the 
networks using the igraph package in R, enabling genes to be identified for the networks 
42 
 
based on these metric scores. The fourth step is to filter the results using R so that these genes 
are output for further analysis.  
The fifth step is to interpret this list of genes using enrichment and gene scoring tools. For this 
work, the GenesetDB [103] tool will be used for enrichment. By using this tool, it is hoped 
that some biological insight into the results can be achieved.  For the purposes of this work, 
the intention is to only use the top ten enrichment results returned by GenesetDB for each 
gene set. The analysis of the results is presented partly in this work to provide a 
demonstration of the ability of the network inference methods to derive results that are 
biologically meaningful for the microarray datasets they have been used on.  
It should be noted that the output results of GenesetDB and the other enrichment tools detail 
specific biological processes that are hard for the casual user to interpret, thereby requiring 
specialists with expert knowledge to fully make sense of these. By presenting only the top ten 
enrichment results, this subjective need for expert biological knowledge is removed. In 
exceptional cases, other results outside of the top ten will be presented, but only when it is 
clear that they are related to the biological area of interest. Interpretation of the top ten 
enrichment results returned that will be presented in this work will be carried out using 
literature searches of the topics detailed. It should also be noted here that whilst GenesetDB 
has been chosen as the enrichment tool for this work, the biologists and clinicians may have 
their own enrichment tools that they feel are better suited to the purpose of interpreting the 
results. Again, this highlights the necessity for their expert interpretation and analysis of the 
results. Génie will be used to score the genes identified, providing an objective means by 
which to scores genes for particular biological topics, rather than the subjective interpretation 
of GenesetDB that requires expert knowledge.   
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The penultimate step is to present the results to the biologists and clinicians. A number of the 
tools that will be used to interpret the lists of genes make reference to the need for manual 
validation of the results, and it can be seen why this is the case. It should be remembered that 
the overall aim of this work is to aid biologists and clinicians in the interrogation of 
microarray data; whilst some analysis and interpretation is presented here, the full expert 
interpretation of these results is best suited to biologists and clinicians.  
Related to this is the final step of the evaluation of the results that are obtained. It is important 
that the biologists and clinicians have confidence in the results, and also that the results make 
sense from a biological perspective. If the results do not follow basic biological principles, 
then in essence, they are not of use. By involving experts in the final evaluation, it is more 
likely that results will be produced that are meaningful.   
3.6 Summary 
This chapter has introduced a further number of concepts central to the thesis. A brief 
introduction to microarray datasets has been presented, from which the GRNs are inferred. A 
number of network inference methods for inferring GRNs have been outlined, along with a 
comparison of these different inference methods. Finally, the proposed approach that will be 
used in this work to address the objectives outlined in the first chapter has been outlined; 
including the introduction of the tool Génie for scoring lists of genes, and the tool GeneSetDB 
for biological interpretation of lists of genes. In the next chapter, an existing network 
inference method will be applied to a glioblastoma microarray dataset to infer a number of 
GRNs.  
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Chapter 4  
Inference of Glioblastoma Survival Category GRNs 
using WGCNA 
4.1 Introduction 
In this chapter, an existing GRN network inference method, WGCNA, will be used to infer 
five different survival categories, based on survival time data, from a glioblastoma microarray 
dataset. These five GRNs will be analysed using the different graph theory metrics introduced 
in chapter 2. The text-mining tool Génie will be used to score the genes identified by the 
various metrics, and GenesetDB will be used to check for biological enrichment for the genes 
identified by each metric. This chapter will refer to a number of previous results from a study 
by Upton and Arvanitis [104]. 
The work in this chapter addresses the first two objectives outlined in the introductory 
chapter. The first of these concerns the implementation of a transferable GRN inference 
method to infer a number of GRNs from a single microarray dataset. The existing GRN 
inference method WGCNA is used here to investigate the feasibility of implementing an 
existing GRN inference method for this purpose. Some of the issues that arise from the 
application of an existing GRN inference method to infer multiple GRNs from a single 
microarray dataset are highlighted here. In the previous chapter, it was noted that in the study 
by Allen et al [94], WGCNA was the best performing GRN inference method when 20-50 
samples were available. The number of samples available for GRN inference for each 
category of network for the dataset that will be used in this chapter roughly falls into this.   
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The second objective concerns the investigation of appropriate metrics to quantitatively 
analyse and compare GRNs constructed for different stages of disease, namely glioblastoma, 
in this chapter. The various graph theory metrics will identify genes of interest in each of the 
GRNs inferred, and these genes will be scored for their relevance to glioblastoma using the 
text-mining tool Génie. This allows an objective scoring of the genes that each of the metrics 
identifies in each category of glioblastoma GRN, and also allows the different categories of 
GRN to be compared. Génie does not rely on expert knowledge to interpret the results, 
something that is required when using the gene set enrichment tool GeneSetDB. Another 
possible approach to scoring the genes is based on their biological enrichment using 
GeneSetDB; however this requires expert biological knowledge to interpret the results. As 
such, the GeneSetDB tool will be used to check for biological enrichment, but will not be 
used in the process of scoring the genes. Furthermore, whilst references to the biological 
enrichment for the gene identified by the metrics will be made in this chapter and throughout 
the thesis, all GeneSetDB biological enrichment results will be presented in the appendix and 
not in main body so as not to overwhelm the thesis with tables, and the reader with specialist 
biological data that may not be relevant.  
4.2 WGCNA GRN Inference Method 
In this chapter, GRNs are inferred from a glioblastoma dataset of 120 samples from a 
previous study by Horvath et al [8]. The approach used by Horvath et al was to infer a single 
GRN from this dataset, using the WGCNA correlation-based network inference method. The 
main advantage of the WGCNA network inference method is that it is able to approximate the 
scale-free topology that is exhibited by biological networks [48]. Zhang and Horvath go 
further, and state that a number of biologists would be wary of gene correlation networks that 
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did not display this scale-free behaviour [48]. Therefore, gene regulation networks inferred 
from microarray data should also observe this scale-free phenomenon.   
Scale-free networks are approximated in WGCNA as a result of the method used to construct 
the weighted adjacency matrix. The weighted adjacency matrix used for WGCNA is 
constructed using two principal steps [85]. The first of these steps is to take the absolute value 
of the correlation between the nodes in question, in this case i and j, and define this quantity 
as the co-expression similarity as such: 
sij = |cor(xi, xj)|    [4.1] 
The weighted adjacency is subsequently created by raising the co-expression similarity by a 
soft threshold power, β, which is greater than or equal to 1, as such: 
aij =  sij
β     [4.2] 
This then allows the relevant power of β to be selected that allows scale-free topology to be 
exhibited by the network. As previously mentioned, the frequency distribution in a scale -free 
network is of the form . Inspection of whether a network fits the scale-free 
topology is achieved by plotting log10(p(k)) versus log10(k). If this plot is a straight line, it 
indicates that the network has a scale-free topology. Following on from this, the square of the 
correlation, , between log10(k) and log10(p(k)), can be used to indicate the relationship; if 
this value approaches 1, then there is a straight line relationship between log10(k) and 
log10(p(k)).   A range of candidate values for the soft threshold power β can then be plotted, 
with the first value greater than 0.8 past the saturation point of the curve selected as the value 
of β. An example of this is shown in figure 4.1 below: 
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FIGURE 4.1 EXAMPLE PLOT OF SOFT THRESHOLD POWER β   
 
 
From the plot above, it can be seen that a value of β= 8 satisfies the conditions to approximate 
scale-free topology, i.e. it is the first value greater than 0.8 past the saturation point of the 
curve. 
4.3 Glioblastoma Microarray Dataset Categories 
Glioblastoma is the most common primary malignant brain tumour in adults and also one of 
the most lethal forms of cancer, with a median survival time of only 14 months from the time 
of first diagnosis [105]. There are a number of previous glioblastoma studies, such as that by 
Verhaak et al [106], which have identified four glioblastoma subtypes, and a number of 
signature genes that correspond to each of these subtypes. This particular study found that the 
four subtypes had a narrow median survival range, from 11.3 months for the most lethal 
subtype, to 13.1 months for the least lethal subtype. Whilst identifying genes that 
corresponded to each subtype, this study did not identify genes that are specifically associated 
with glioblastoma prognosis, i.e. survival time.  Therefore,  in this chapter, the focus is on 
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identifying genes that are associated with different survival times in glioblastoma cell lines, 
and can therefore be used as potential prognostic biomarkers of the disease. 
The glioblastoma dataset consists of two independent sets of clinical tumour samples, 55 and 
65 samples, respectively, obtained at the time of surgery at UCLA. Gene expression profiling 
of these samples was carried out using Affymetrix high-density oligonucleotide microarrays 
[107]. This dataset contains survival information, allowing the samples to be categorized 
based on survival time. A number of statistics based on this information can be calculated. 
The dataset as a whole has a mean survival time of 447.29 days, which correlates closely to 
the previously mentioned 14 month median survival time of glioblastoma. Median survival 
time of 336 days for this dataset is approximately 3 months less however. The standard 
deviation is 426.15 days.  
These statistics highlight two observations; that the close correlation of mean and median 
survival time of the dataset with the clinical median survival time of 14 months indicates that 
this is a typically representative glioblastoma dataset, and also the high standard deviation 
value, which is very close to the mean, shows how survival time in the dataset greatly varies. 
In fact, the dataset has a range of 2800 days, with the lowest survival time of 7 days, and the 
highest of 2807. This gives an idea that potentially there are prognostic differences in the 
samples in the dataset, and that grouping all the data together into one single network to 
model the gene regulatory interactions in the dataset could lead to a great deal of information 
being lost about how the cancer evolves.  
Five categories of samples were created from the glioblastoma dataset, using survival time as 
the class discriminator. Table 4.1 shows the five categories, along with the number of samples 
in each category and the mean, median and standard deviation.  
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TABLE 4.1 CATEGORIES, NUMBER OF SAMPLES AND STATISTICAL INFORMATION OF 
GLIOBLASTOMA MICROARRAY DATASET 
 
Category Number 
of 
Samples 
Mean 
(days) 
Median 
(days) 
Standard 
Deviation 
(days) 
200 days 
or fewer 37 112.11 112 54.37 
201 to 
400 days 35 298.66 302 59.25 
401 to 
600 days 18 500.22 500 72.05 
601 to 
800 days 15 677.98 667 53.57 
800+ 
days 15 1326.73 1098 538.42 
 
The first observation to be made is about how well spread out the samples are across the 
categories. It can be seen that the first two categories have a significantly higher number of 
samples than the other three. Initially, five categories were created with 24 samples each, 
although this approach was abandoned as the samples in each category were not so evenly 
spread out in terms of survival time. As can be seen, the 1
st
, 2
nd
 and 3
rd
 categories split well, 
as shown by mean and median being very close to the mid-point of each category. The next 
two categories are not so evenly spread out, and perhaps ideally could be further split; 
however from observations of the WGCNA algorithm, a minimum number of 15 samples are 
required for network construction. It is worth remembering the constraints that number of 
samples put on network inference, as previously mentioned, the greater the number of 
samples, the better the network inference method performs.  
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One analysis that highlights the value of the network inference method on the categories of 
data is to rank the mean expression for each gene in the five categories, and see how well 
these rankings correlate across the five categories. This gives an idea of how homogenous the 
data is across the five categories before the networks are constructed. Table 4.2 below shows 
the correlations.  
TABLE 4.2 CORRELATION SCORES OF AVERAGE GENE EXPRESSION RANKINGS IN 
GLIOBLASTOMA CATEGORIES 
 
Category 200 
days 
or 
fewer 
201 
to 
400 
days 
401 
to 
600 
days 
601 
to 
800 
days 
801 
days 
and 
more  
200 days 
or fewer 1 0.989 0.982 0.975 0.968 
201 to 
400 days 0.989 1 0.982 0.980 0.970 
401 to 
600 days 0.982 0.982 1 0.962 0.958 
601 to 
800 days 0.975 0.980 0.962 1 0.966 
801 days 
and 
more 0.968 0.970 0.958 0.966 1 
 
As can be seen, all the correlations are both positive and extremely strong. The strength of the 
correlations is perhaps surprising, and the issue of data preparation should be noted here. If a 
significant proportion of genes in a microarray are either expressed at very low levels, thereby 
effectively silent, or are expressed at a very high level, throughout all the samples, then this 
could be a factor for the strong correlations observed here. This is something that can arise to 
the methods involved in the normalisation of the microarray. The correlations in table 4.2 
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above show that by simply looking at gene expression in each category, it would be difficult 
to distinguish the categories, and gain meaningful information about them.   
4.4 Glioblastoma GRN Construction and Analysis 
For the five categories identified in the previous section, GRNs are constructed from the 
samples belonging to each group. The WGCNA library of functions for R is used to construct 
a weighted gene correlation network for each category. Having constructed the weighted 
networks, only the top 0.5% of edges based on edge weight are retained, with all other edges 
deleted. There are two reasons for this. The first reason is that keeping only the top 0.5% of 
edges minimizes the effect of noisy data, making it more likely that biologically meaningful 
interactions are maintained.  Secondly, it is computationally very intensive to work with large 
networks; an example in point is the calculation of betweenness centrality for each of the 
original ten networks. Using a 64-bit version of R running on a Windows 7 computer with an 
Intel Core 2 2.67 GHz processor with 4 GB of RAM, this takes around 30 hours each, in the 
network with the top 0.5% of edges it takes around 20 seconds.  
In order to analyse the networks inferred, the network metrics of weighted betweenness, 
weighted closeness, weighted degree, degree, and eigenvector centrality, are calculated using 
the igraph [108] library of functions in R. As well as these node level metrics, a number of 
network level metrics are calculated; these include assortativity, clustering coefficient, and 
diameter. The igraph library in R will also be used for the identification of cliques in the 
networks. 
In the previously mentioned study by Upton and Arvanitis, rankings were assigned to each 
node in the five networks for each of the metrics of weighted degree, weighted betweenness, 
and closeness centrality, which were then added together, and each gene re-ranked based on 
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the total of these scores. This gave a combined metric ranking score for each gene in each 
category of GRN. Here, we will present these results in tables; and additionally, will also 
calculate the individual node rankings for the metrics of betweenness, closeness, weighted 
degree, degree, and eigenvector centrality.  
By scoring the top ranked genes identified by each metric, it is possible to quantitatively 
compare the performance of the metrics in each category of GRN. This addresses the second 
objective set out in this work; to investigate and identify appropriate graph theory metrics to 
analyse and compare the GRNs. The text-mining tool Génie is used with a p-value for abstract 
selection of 0.01 and FDR 0.01, to generate a list of 299 ranked genes for glioblastoma. This 
list of genes is included as table A.1 in the appendix. A score is assigned to each gene by 
subtracting its rank from 300; the top ranking gene of IDH1 is therefore assigned as score of 
299, and the 299
th
 ranked gene of ESR2 assigned a score of 1.  
4.5 Network Level Metrics 
Prior to looking at the individual metrics in the five categories of network, the network level 
metrics for these five networks will be calculated and compared. Note that weighted 
assortativity is a slight modification on the previously defined assortativity definition, and 
simply uses the weighted degree value of the node instead of the degree value. It is possible to 
use other node values such as weighted betweenness, and weighted closeness for modified 
assortativity scores.  
As well as these network level metrics, the largest unique cliques in each network will be 
calculated and analysed. Table 4.3 below shows the scores for weighted degree assortativity, 
degree assortativity, diameter, and clustering in the five networks. 
53 
 
TABLE 4.3 NETWORK LEVEL SCORES ACROSS ALL THE GLIOBLASTOMA GRNS INFERRED 
USING WGCNA 
 
Metric 200 or less 
category 
201 - 400 
category 
401 - 600 
category 
601 - 800 
category 
800+ 
category 
Weighted 
Degree 
Assortativity 
-0.341 -0.335 0.032 -0.307 -0.126 
Degree 
Assortativity 
-0.338 -0.320 0.029 -0.294 -0.151 
Diameter 1.287 1.107 2.152 1.520 2.167 
Network 
Clustering 
0.530 0.563 0.617 0.611 0.568 
Largest Clique 
Size 
242 genes 251 genes 249 genes 276 genes 147 genes 
 
From the above network level scores, a number of observations can be made. Firstly, there is 
no clear correlation between any of the metrics and survival category, suggesting that survival 
time cannot be associated with any metric behaviour. The diameter might be expected to 
follow a trend as diameter can be indicative of how easily the genes in the network can 
communicate with each other, but this is not the case. Whilst the diameter value is highest in 
the highest survival category, there is no correlation in the other categories. The network 
clustering does not offer any insights either due to the similar values across the categories, nor 
does either of the assortativity scores. Perhaps the most important observations to be made are 
regarding the size and composition of the largest unique cliques in the networks. This is 
examined in depth in the following section.  
 
 
54 
 
4.6 Largest Clique Identification and Analysis 
Another analysis of interest on a network wide level is to investigate the largest unique 
cliques in each network. It is of interest to see both the size of these cliques, and also the 
genes that comprise them. A large number of common genes in the cliques across all the 
networks would suggest that the same genes are involved in important cellular processes 
across the glioblastoma life cycle. As well as identifying common and unique genes in these 
cliques, it is also of interest to see whether these genes have been previously identified as 
being either glioblastoma subtype signature genes or  are present in the list of ranked 
glioblastoma genes generated by Génie. Finally, the list of genes that comprise the largest 
unique clique in each network can be checked for enrichment using the GenesetDB website. 
Table 4.4 below shows whether genes in each cliques have been identified as glioblastoma 
subtype signature genes, or glioblastoma candidate genes. Later on in the section, the Venn 
diagram shows the number of unique genes in each category, and how many genes are 
common to two or more categories. 
 
TABLE 4.4 GLIOBLASTOMA GENES OF INTEREST IN THE LARGEST UNIQUE CLIQUES 
 
 Proneural 
Subtype 
Genes 
Mesenchymal 
Subtype 
Genes 
Neural 
Subtype 
Genes 
Classical 
Subtype 
Genes 
Number of 
Génie genes 
and score 
200 or less 
category 
clique 
8 0 14 1 1, score of 
165 
201 – 400 
survival days 
category 
clique 
4 0 15 0 1, score of 
178 
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401- 600 
survival days 
category 
clique 
6 0 15 1 0 
601-800 
survival days 
category 
clique 
9 0 19 1 1, score of 
165 
More than 
800 survival 
days category 
clique 
1 0 10 0 0 
 
Looking at the cliques in the network categories in turn, some interesting results can be seen. 
Starting with the 200 or less category, 24 previously identified glioblastoma genes of interest 
are present in the clique of 242 genes; 9.91% of the genes in this category have been 
previously identified as being of interest for glioblastoma.  Of interest is the large number of 
subtype signature genes identified, 23, out of a total of 242 genes, almost 10%. The top ten 
gene set enrichment results from GeneSetDB for the genes that comprise this clique are shown 
in table A.2 of the appendix.  
In the 201 - 400 category, 20 previously identified glioblastoma genes of interest are present in 
the clique of 251 genes; 7.97% of the genes in this category have been previously identified as 
being of interest for glioblastoma.  As with the previous category, the most glioblastoma 
subtype genes are identified in the neural subtype. In total, there are 19 subtype signature genes 
present in this category. The top ten gene set enrichment results from GeneSetDB for the genes 
that comprise this clique are shown in table A.3 of the appendix.  
In the 401 - 600 category, 22 previously identified glioblastoma genes of interest are present in 
the clique of 249 genes; 8.84% of the genes in this category have been previously identified as 
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being of interest for glioblastoma. Once again, there are more signature genes associated with 
the neural subtype than any other subtype; 6 signature genes associated with the neural subtype 
are identified in this clique, and one gene associated with the classical subtype. In total, there 
are 22 subtype signature genes present in this category. The top ten gene set enrichment results 
from GeneSetDB for the genes that comprise this clique are shown in table A.4 of the 
appendix. 
In the 601 - 800 category, 30 previously identified glioblastoma genes of interest are present in 
the clique of 276 genes; 10.87% of the genes in this category have been previously identified 
as being of interest for glioblastoma. This is the largest sized unique cliques of any of the 
categories. As might be expected due to this, this clique contains more subtype signature genes 
than any other, 29, and also the highest number of proneural subtype signature genes, 19. The 
top ten gene set enrichment results from GeneSetDB for the genes that comprise th is clique are 
shown in table A.5 of the appendix.  
In the more than 800 category, 11 previously identified glioblastoma genes of interest are 
present in the clique of 147 genes; 7.48% of the genes in this category have been previously 
identified as being of interest for glioblastoma.  This is a noticeably smaller largest unique 
clique than for any of the other categories, and also a noticeably smaller amount of previously 
identified glioblastoma genes of interest present in this clique. It is interesting to note that the 
smallest sized clique, and the smallest number of previously identified glioblastoma genes of 
interest are in the GRN for the longest survival category. Once again, there are more signature 
genes associated with the neural subtype than any other subtype. 10 signature genes associated 
with the neural subtype are identified in this clique, and one gene associated with the proneural 
subtype. In total, there are 11 subtype signature genes present in this category. The top ten 
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gene set enrichment results from GeneSetDB for the genes that comprise this clique are shown 
in table A.6 of the appendix. 
The results in table 4.4 suggest quite a high degree of biological significance; a significant 
amount of genes previously identified with glioblastoma have been identified in all of the 
cliques. As noted, a  noticeably smaller amount of these genes have been identified in the 
largest unique clique in the highest survival category, 11, compared to 24, 20, 22, and 30 in the 
other categories, suggesting that certain genes associated with glioblastoma are not as involved 
in cellular processes for this category as they are in the others. This result could suggest that 
the previously identified genes are not involved in glioblastoma cellular processes until a later 
stage of the glioblastoma life cycle.  In contrast, a large number of neural subtype signature 
genes have been identified in the largest cliques in all of the networks. This would indicate that 
neural signature genes are involved right across the glioblastoma life cycle, and perhaps are not 
a good indicator of glioblastoma progression due to being ubiquitous throughout the 
glioblastoma life cycle.  
Looking at the distribution of unique and common genes in the cliques, it can be seen that 
there are 79 genes common to all five cliques, and 144 genes that are unique to one category. 
Across all five categories there are 1165 genes, of which 431 are unique.  This means that only 
12.36% of genes appear in one category, and that of the 431 unique genes that are in the 
cliques, 18.33% appear in all five of the cliques. This suggest that a large number of genes are 
common to cellular processes across all five categories of the network, and therefore would 
suggest as a result that these genes are common to cellular processes across the glioblastoma 
life cycle. There are two ways then to regard these genes; either that they are of interest due to 
appearing across the glioblastoma life cycle, or to disregard them as it is of interest to identify 
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genes that are unique to specific evolutionary stages. Figure B.1 in the appendix displays the 
distribution of common and unique genes in the cliques. 
5 of these 79 genes have been identified as being neural subtype signature genes although no 
other subtype signature genes have been identified in this list of 79 genes. It is perhaps not 
surprising to find a large number of common genes being responsible for cellular processes 
across the whole glioblastoma life cycle; referring to table 4.2 in a previous section, the very 
strong positive correlation between the gene expression level rankings across all the five 
categories can be seen. As such, it could be derived from this that there are a number of 
common genes involved in cellular processes across all five categories.  
4.7 Node Level Metrics 
Having looked at the network level metrics, the next step is to focus on the node level metrics.  
A number of metrics for each node are calculated; weighted degree, degree, weighted 
betweenness, weighted closeness, and eigenvector centrality. Additionally, a combined metric 
ranking based on weighted degree, weighted closeness, and weighted betweenness is also 
calculated, as was the case in the previously highlighted study by Upton and Arvanitis. For 
each category of GRN, a table of the top 20 ranked genes for each of these metrics is 
presented, detailing also whether have been previously identified as a glioblastoma subtype 
signature gene or in the ranked glioblastoma gene list generated by Génie.  
The list of ranked glioblastoma genes from the text-mining tool Génie, used previously in this 
chapter, is used to assign scores to the genes identified by the different metrics. This provides 
an objective means to score the genes that the different metrics identify. The subjective nature 
of interpreting the results from GeneSetDB was outlined earlier in the chapter, making it 
difficult to use these as a basis for scoring the genes identified by the metrics. The enrichment 
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results in this work are used as a guide to the presence of potentially biologically significant 
results; in order to correctly and meaningfully interpret them, expert biological knowledge is 
necessary. The scores from the glioblastoma gene list generated by Génie of the top 20, 100, 
and 500 ranking genes for each metric will be used to compare the performance of the metrics 
in each category of glioblastoma GRN.  
It should be noted that many of the metrics identify the same genes in the GRNs; this can also 
be seen in the high Spearman correlation scores between the metrics. Due to this repetition in 
the genes identified by the different metrics, for the basis of comparing the top ranking genes 
identified in each category, the combined metric ranking based on the metrics of weighted 
betweenness, weighted closeness, and weighted degree centrality will be used.  
4.7.1 200 or fewer Survival Days Category 
Table 4.5 below shows the top 20 ranked genes identified by each of the metrics. 
Additionally, the table also details whether the gene has previously been identified as either a 
glioblastoma subtype signature gene or is present of the ranked list of glioblastoma genes 
generated by the text-mining tool Génie. 
TABLE 4.5 TOP 20 RANKED GENES IDENTIFIED BY EACH M ETRIC IN 0 – 200 SURVIVAL DAYS 
CATEGORY GRN 
 
Degree 
Rank 
Gene Previously 
Identified 
Weighted 
Degree  
Rank 
Gene Previously 
Identified 
Weighted 
Betweenness 
Rank 
Gene Previously 
Identified 
1 SYN1 No 1 SYN1 No 1 RAB40B No 
2 AK5 No 2 SULT4A1 No 2 DNAJC6 No 
3 SULT4A1 No 3 AK5 No 3 ATP8A1 No 
4 SLC17A7 No 4 SLC17A7 No 4 MAST3 No 
5 HSPA12A No 5 PAK6 No 5 TUBB4 No 
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6 PAK6 No 6 HSPA12A No 6 ATP2B2 No 
7 SH3GL2 Yes, c 7 KIAA0513 No 7 ANK3 No 
8 NAP1L2 No 8 STXBP1 No 8 PAK3 Yes, a  
9 STXBP1 No 9 SH3GL2 Yes, c 9 NCF4 Yes, b 
10 GRM5 No 10 NAP1L2 No 10 SLC25A4 No 
11 KIAA0513 No 11 GRM5 No 11 SEC14L5 No 
12 SV2B No 12 SV2B No 12 KIF5A No 
13 MOAP1 No 13 GLS2 No 13 SYT1 No 
14 GLS2 No 14 SLC12A5 No 14 PRKCZ No 
15 SCN2A No 15 PHYHIP No 15 NEUROD2 No 
16 CDH18 No 16 SNAP91 Yes, a 16 GNAO1 No 
17 SNAP91 Yes, a 17 SCN2A No 17 MAP1A No 
18 SLC12A5 No 18 CDH18 No 18 SCN2A No 
19 EPB41L1 No 19 MOAP1 No 19 AATK No 
20 NSF No 20 EPB41L1 No 20 C1orf38 Yes, b 
         
Weighted 
Closeness 
Rank 
Gene Previously 
Identified 
Eigenvector 
Centrality 
Rank 
Gene Previously 
Identified 
Combined 
Metric 
 Rank 
Gene Previously 
Identified 
1 AK5 No 1 SYN1 No 1 AK5 No 
2 HSPA12A No 2 SULT4A1 No 2 SYT1 No 
3 SYT1 No 3 SLC17A7 No 3 MAP1A No 
4 SYN1 No 4 PAK6 No 4 HSPA12A No 
5 MAP1A No 5 KIAA0513 No 5 SNAP91 Yes, a 
6 SLC17A7 No 6 AK5 No 6 SULT4A1 No 
7 STXBP1 No 7 HSPA12A No 7 EPB41L1 No 
8 PRKCZ No 8 STXBP1 No 8 SCN2A No 
9 EPB41L1 No 9 GLS2 No 9 PRKCZ No 
10 MAST3 No 10 NAP1L2 No 10 STXBP1 No 
11 SNAP91 Yes, a 11 SH3GL2 Yes, c 11 SLC17A7 No 
12 NRGN No 12 PHYHIP No 12 MAST3 No 
13 SULT4A1 No 13 SLC12A5 No 13 SYN1 No 
14 DYNC1I1 Yes, c 14 GRM5 No 14 PAK6 No 
15 RGS7 No 15 SV2B No 15 VAMP2 No 
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16 ANK3 No 16 SNAP91 Yes, a 16 RGS7 No 
17 VAMP2 No 17 CDH18 No 17 MOAP1 No 
18 RAB6B No 18 NSF No 18 NAP1L2 No 
19 KIF3C No 19 SCN2A No 19 NRGN No 
20 CYFIP2 No 20 OLFM1 No 20 RAB6B No 
 
a = proneural signature gene, b = Mesenchymal signature gene, c = neural signature gene, d = classical signature gene 
 
A number of glioblastoma subtype signature genes are identified by the metrics, as can be 
seen in table 4.5 above. Note that a number of common genes are identified by the metrics, as 
shown by the Spearman rank correlation scores for the genes identified by the metrics, shown 
in table 4.6 below, and the Venn diagram of common and unique genes ide ntified by the 
metrics, figure B.2 of the appendix.  
TABLE 4.6 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN 0 – 200 SURVIVAL DAYS CATEGORY GRN 
 
 Degree 
Centrality 
Weighted 
Degree 
Weighted 
Betweenness 
Weighted 
Closeness 
Eigenvector 
Centrality 
Degree 
Centrality 
1 0.998 0.534 0.740 0.764 
Weighted 
Degree 
0.998 1 0.537 0.726 0.755 
Weighted 
Betweenness 
0.534 0.537 1 0.177 0.199 
Weighted 
Closeness 
0.740 0.726 0.177 1 0.892 
Eigenvector 
Centrality 
0.764 0.755 0.199 0.892 1 
 
All of the metrics apart from weighted betweenness centrality correlate strongly, greater than 
+0.7, and identify similar genes, something that is borne out by only 48 unique genes being 
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identified out of 100.  The extremely strong correlation between degree and weighted degree 
is expected due to the method of only keeping the top 0.5% of edges, and also the strong 
correlations between degree, weighted degree, and eigenvector centrality. There is also a 
strong correlation between weighted closeness and eigenvector centrality, implying that they 
identify the same genes as being of high rank.  
If the betweenness centrality metric is removed, only 34 unique genes are identified out of 80 
genes. This shows that the betweenness centrality identified 14 genes that the other metrics 
did not. It should be noted as well that 7 genes were identified by four of the network metrics; 
all but weighted betweenness centrality.  A visual representation of this is shown in the Venn 
diagram in figure B.2 of the appendix, showing 14 unique genes are identified using weighted 
betweenness, 7 using weighted closeness, and 2 using eigenvector centrality.  
For the purposes of this chapter, and the work as a whole, presenting the genes identified as 
table 4.5 does not help to address the objectives. It does not provide an objective means by 
which to score the metrics, as scoring a gene based on whether it is a glioblastoma subtype 
signature genes adds subjectivity requiring specialist biological knowledge. Additionally, a 
table with a large number of genes detailed may provide the reader with a lot of unnecessary 
information. As such, the same approach adopted in our previous study will be used; the top 
20 ranked genes for the combined metric will solely be presented for each category of GRN 
for the rest of this chapter, and the rest of the thesis.  
One of the main reasons for using various metrics was to investigate whether certain metrics 
performed better than others in giving biologically significant results. Therefore, a better 
approach is to score the top 20, top 100, and top 500 ranked genes for each metric using the 
list generated by Génie. This directly addresses the second objective; it gives a means by 
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which to score the metrics for the genes that they identify in the GRNs for the different 
categories of glioblastoma, allowing the performance of the metric in each category to be 
compared based on their ability to identify genes in the Génie list. Starting with the top 20 
ranked genes by each metric, table 4.7 below shows the scores that are obtained.  
TABLE 4.7 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 0 0 1
st
 
Weighted Degree 0 0 1
st
 
Weighted Betweenness 0 0 1
st
 
Weighted Closeness 0 0 1
st
 
Eigenvector Centrality 0 0 1
st
 
Combined Metric 0 0 1
st
 
 
None of the metrics identify a single Génie glioblastoma gene of interest.  Applying the 
scoring system to the top 100 ranked genes for each metric, the results in table 4.8 below are 
given. 
TABLE 4.8 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 1 165 1
st
 
Weighted Degree 1 165 1
st
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Weighted Betweenness 1 165 1
st
 
Weighted Closeness 1 165 1
st
 
Eigenvector Centrality 1 165 1
st
 
Combined Metric 1 165 1
st
 
 
All of the metrics identify the same glioblastoma gene of interest, LGI1, ranked as the 135
th
 
most important gene for glioblastoma. Finally, extending the scoring system to the top 500 
genes, the following results shown in table 4.9 below are given.  
TABLE 4.9 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 9 1107 1
st
 
Eigenvector Centrality 5 364 2
nd
 
Weighted Closeness 3 295 3
rd
 
Degree Centrality 5 281 4
th
 
Weighted Degree 5 281 4
th
 
Combined Metric 4 238 6
th
 
  
The weighted betweenness is the best performing metric, followed by the eigenvector 
centrality. The degree and weighted degree centrality both identify the same 5 genes, and the 
weighted closeness centrality identifies 3 genes. The combined metric ranking performs the 
worst; although it identifies one more gene than the weighted closeness, the genes it identifies 
are lower scoring. Only one of the 9 genes identified by the weighted betweenness centrality 
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is in the top 50 Génie ranked genes for glioblastoma. In total, 33 out of the 299 Génie 
glioblastoma ranked genes are present in this network.  
These results might suggest that using the combined metric ranking will not lead to the 
identification of biologically significant genes. It should be taken into account that this is 
solely for one network, and that the different metrics will perform different ly across the 
different networks. The main purpose of using different metrics is to objectively score them 
based on their ability to identify genes from a ranked list; it is of interest to identify high 
ranking genes for the metrics that have been identified as glioblastoma subtype signature 
genes or have been identified in previous glioblastoma studies, but it does not specifically 
address the objectives laid out in the first chapter. Furthermore, presenting only one list of 20 
genes for each category allows the interrogation to be much more thorough, and in addition to 
the use of GenseSetDB, The Cancer Genome Atlas [109] , the IntOGen browser [110], and 
CGPrio [111], will be used to aid in the biological interpretation of the results returned for the 
glioblastoma GRNs.     
The enrichment results for the top 20 ranked genes for the combined metric are shown in table 
A.7 of the appendix. Nothing of note for glioblastoma stands out from these results. The most 
notable gene in the top 20 combined metric ranking for this category is SNAP91, which has 
been identified in a number of studies as a signature gene of the proneural glioblastoma 
subtype, such as the study by Brennan et al [112]. This is the only signature gene of any 
glioblastoma subtype that occurs in the top 20 ranking. The 2
nd
 ranked gene in this list, SYT1, 
is highly ranked as an oncogene by CGPrio, and is also identified in a glioblastoma study by 
Dong et al [113] as being a candidate gene for the disease.  The 9
th
 ranked gene, PRKCZ, has 
been identified in 3 glioblastoma gene lists by the cancer genome atlas gene checker. PRKCZ 
was also been shown in a study by Donson et al [114] to be crucial to proliferation in 
66 
 
glioblastoma cell lines. 9 of the top 20 ranked genes in this category do not appear in the top 
20 rankings for any of the other categories, including the top 4 ranked genes. This suggests 
that these genes identified as being important in this category do not have such an important 
role in the other categories of network.  
Of the 11 genes in the top 20 combined metric list that appear in top 20 combined metric lists 
for other categories; 3 genes, SNAP91, SYN1, and RGS7, appear in three of the five top 20 
lists, including this category. SNAP91 has already been highlighted; however the two other 
genes have not previously been identified as candidate glioblastoma genes, and this suggests 
that they may play a role across various stages of the glioblastoma life cycle. The other two 
genes, SYN1 and RGS7, also appear in all five of the largest unique cliques across the 
different categories, which would also suggest that they are involved in cellular processes 
across the whole glioblastoma life cycle. The top ten enrichment results for this list of genes 
are shown in table XVII. Despite a number of enrichment results yielded, none of the results in 
the top ten relate to glioblastoma.  
4.7.2 201-400 Survival Days Category  
Table 4.10 on the following page shows the top 20 ranked genes for the combined metric in 
the 201-400 survival days category GRN. Looking at the top 20 ranked genes for the 
combined metric, the presence of SNAP91 amongst the top 20 ranked genes once again stands 
out. The second result of note is that the two top ranked genes for the combined metric are 
both solute carriers; SLC9A6 is a sodium/hydrogen exchanger, and SLC8A2 is involved in 
sodium/calcium exchange. This result would suggest that the exchange of sodium plays a role 
in glioblastomas within the 201-400 survival days category, and potentially is an area of 
interest for glioblastoma studies. 10 of the top 20 ranked genes for the combined metric in this 
67 
 
category do not appear in the top 20 combined metric rankings for any of the other categories, 
including the top 2 ranked genes previously discussed. This potentially suggests that the 
importance of sodium exchange is limited to glioblastomas within this category, and that, as 
before, there are a number of genes identified as being important in this category that do not 
have such an important role in other categories. 
Of the 10 genes that do appear in top 20 combined metric ranked lists in other categories, 
there are again 3 genes that appear in three of the five top 20 lists, including this category. As 
well as SNAP91, these include PPP1R16B, and CAMKV. Whilst these two genes have not 
been specifically identified as candidate glioblastoma genes, it should be noted that CAMKV 
has been identified as potential cancer gene target by the Broad Institute research group [115]. 
These two genes, PPP1R16B and CAMKV, are also part of the list of genes that appear in all 
of the largest cliques across all of the categories in the network, suggesting that they are 
involved in cellular processes across the glioblastoma life cycle. 
The top 10 results for this list of genes from GenesetDB are shown in table A.8 in the 
appendix. The 8
th
 result, relating to ERBB1 pathway, should be noted; ERBB1 has been 
identified as being over expressed in high grade glioma, in a 2003 study by Gilbertson et al 
[116]. 
TABLE 4.10 TOP 20 RANKED GENES FOR COMBINED METRIC IN 201 – 400 SURVIVAL DAYS 
CATEGORY GRN 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
SLC9A6 1 CAMKV 11 
SLC8A2 2 DYNC1I1 12 
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INA 3 PHYHIP 13 
SNAP91 4 KCNAB2 14 
PPP1R16B 5 NAP1L2 15 
MEF2C 6 MAST3 16 
WDR7 7 TAGLN3 17 
CYFIP2 8 FBXO41 18 
KIAA0513 9 STXBP1 19 
PDE2A 10 MOAP1 20 
 
Table 4.11 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the 201-400 survival days category GRN inferred using WGCNA. 
TABLE 4.11 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN THE 201-400  SURVIVAL DAYS CATEGORY GRN 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.790 0.831 0.664 
Weighted 
Degree 0.998 1 0.772 0.814 0.673 
Eigenvector 
Centrality 0.790 0.772 1 0.962 0.374 
Closeness 
Centrality 0.831 0.814 0.962 1 0.395 
Betweenness 
Centrality 0.664 0.673 0.374 0.395 1 
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As was the case with the previous category, all of the metrics apart from weighted 
betweenness centrality correlate strongly, > +0.75, and as such identify similar genes. The 
correlations are even stronger this time compared to the last category, and the weighted 
betweenness has a stronger correlation with the other metrics as well compared to the last 
category. Using the scoring system for the metrics used in the previous category, the 
following rankings for the metrics based on their top 20 ranked genes are shown in table 4.12 
below. 
TABLE 4.12 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 0 0 1st 
Weighted Degree 0 0 1st 
Weighted Betweenness 0 0 1st 
Weighted Closeness 0 0 1st 
Eigenvector Centrality 0 0 1st 
Combined Metric 0 0 1st 
 
None of the metrics identify a single Génie glioblastoma gene of interest.  Applying the 
scoring system to the top 100 ranked genes for each metric, the results in the table 4.13 below 
are given. 
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TABLE 4.13 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 0 0 1st 
Weighted Degree 0 0 1st 
Weighted Betweenness 0 0 1st 
Weighted Closeness 0 0 1st 
Eigenvector Centrality 0 0 1st 
Combined Metric 0 0 1st 
 
Again, none of the metrics identify a single Génie glioblastoma gene of interest. Despite the 
enrichment result pertaining to ERBB1, the metrics do not identify any glioblastoma genes of 
interest. Applying the scoring system to the top 500 ranked genes for each metric, the results 
in table 4.14 below are given. 
TABLE 4.14 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 6 944 1
st
 
Eigenvector Centrality 5 499 2
nd
 
Weighted Closeness 4 412 3
rd
 
Degree Centrality 5 370 4
th
 
Weighted Degree 5 370 4
th
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Combined Metric 5 370 4
th
 
 
The weighted betweenness is the best performing metric, followed by the eigenvector 
centrality, as was the case with the last glioblastoma category. The degree, weighted degree 
and combined metric each identify the same 5 genes. Again, only one of the 9 genes identified 
by the weighted betweenness centrality is in the top 50 Génie ranked genes for glioblastoma, 
the gene TERT. In total, 33 out of the 299 Génie glioblastoma ranked genes are present in this 
network. It should be noted that this category and the previous category have the same 
number of Génie glioblastoma ranked genes in their networks, although they are not the same 
genes. 
4.7.3 401-600 Survival Days Category 
Table 4.15 below shows the top 20 ranked genes for the combined metric in the 401-600 
survival days category GRN. The previously mentioned genes CAMKV, SYN1 and RGS7 
appear in this list, and are again the only genes that appear in two other top 20 ranked lists, as 
well as this one. The presence of gene EPHB6 is interesting; as well as being identified in one 
glioblastoma specific gene list, it has also been identified as being on six other cancer gene 
lists, such as ovarian cancer and breast cancer, by the cancer genome atlas. SH3GL2 is 
another glioblastoma gene of interest identified in the glioblastoma study by Dong et al, and 
also a 2008 study by Chang [117]. It is also a signature gene of the neural glioblastoma 
subtype, as are the genes CPNE6, and HPCAL4. It is worth noting the presence of 3 neural 
subtype signature genes in the top 20 ranked genes for this category.  
13 of the 20 genes that appear in this list do not appear on any of the other top 20 genes lists. 
This is a greater number of unique genes than the previous two lists, suggesting increasingly 
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different network behaviour as the survival time increases. It also suggests that genes that are 
important for the behaviour of the network in the two previous categories are not as important 
for the function of the network in this category, and that different processes are taking place 
that these genes are not involved in. None of the top 10 results for this list of genes from 
GenesetDB, shown in table A.9 in the appendix stand out as being of interest to glioblastoma. 
TABLE 4.15 TOP 20 RANKED GENES FOR COMBINED METRIC IN 401 – 600 SURVIVAL DAYS 
CATEGORY GRN 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
RIMS3 1 BZRAP1 11 
CAMKV 2 SH3GL2 12 
CA11 3 PCSK2 13 
CHGB 4 PRKAR1B 14 
GLS2 5 HPCAL4 15 
NELL2 6 MYRIP 16 
EPHB6 7 CPNE6 17 
INA 8 SYN1 18 
GAD2 9 PAK6 19 
KIAA1107 10 RGS7 20 
 
Table 4.16 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the 401-600 survival days category GRN inferred using WGCNA. 
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TABLE 4.16 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN THE 401-600  SURVIVAL CATEGORY GRN 
 
 
Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.704 0.698 0.715 
Weighted 
Degree 0.998 1 0.695 0.684 0.705 
Eigenvector 
Centrality 0.704 0.695 1 0.904 0.416 
Closeness 
Centrality 0.698 0.684 0.904 1 0.494 
Betweenness 
Centrality 0.715 0.705 0.416 0.494 1 
 
Compared to the last category, the correlations are weaker between all of the metrics. As 
before, weighted closeness and eigenvector centrality have a very strong correlation, >0.9, but 
the other correlations are noticeably weaker. Whilst before the correlations between all of the 
metrics apart from weighted betweenness was at least >0.75, this time they are  >0.68. This 
implies that for this category there is a greater diversity in the genes that the metrics identify.  
Applying the scoring metrics used in the previous category to the top 20 ranked genes for 
each metric, the rankings shown in table 4.17 are obtained. 
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TABLE 4.17 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 1 273 1
st
 
Degree Centrality 0 0 2
nd
 
Weighted Degree 0 0 2
nd
 
Weighted Closeness 0 0 2
nd
 
Eigenvector Centrality 0 0 2
nd
 
Combined Metric 0 0 2
nd
 
 
Weighted betweenness is the only metric to identify a glioblastoma gene of interest, the 27
th
 
ranked PLAUR. Applying the scoring system to the top 100 ranked genes for each metric, the 
results in table 4.18 below are given.  
TABLE 4.18 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 610 1
st
 
Degree Centrality 0 0 2
nd
 
Weighted Degree 0 0 2
nd
 
Weighted Closeness 0 0 2
nd
 
Eigenvector Centrality 0 0 2
nd
 
Combined Metric 0 0 2
nd
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Weighted betweenness centrality is again the only metric that identifies any glioblastoma 
genes of interest, and in addition this time also identifies the genes RAC2, ranked 164
th
 most 
important gene for glioblastoma, and EZH2, ranked 99
th
 most important gene for 
glioblastoma. Finally, applying the scoring system to the top 500 ranked genes for each 
metric, the results in table 4.19 below are given.  
TABLE 4.19 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 10 1895 1
st
 
Weighted Degree 5 830 2
nd
 
Degree Centrality 4 617 3
rd
 
Weighted Closeness 4 302 4
th
 
Eigenvector Centrality 4 302 4
th
 
Combined Metric 3 215 6
th
 
  
The weighted betweenness is the best performing metric, followed by the weighted degree, 
and degree centrality. The combined metric is the worst performing metric, identifying 3 
genes.  Of the 10 genes identified by the weighted betweenness centrality, 3 are in the top 50 
Génie ranked genes for glioblastoma. This suggests that the weighted betweenness centrality 
performs better at identifying glioblastoma genes of interest in this glioblastoma category than 
the previous two. In total, 44 out of the 299 Génie glioblastoma ranked genes are present in 
this network, 11 more than the previous two categories. This might seem surprising; it might 
be expected that the networks inferred for the previous two glioblastoma stages would contain 
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more glioblastoma genes due to their shorter survival time, however Génie does not 
distinguish the genes based on glioblastoma evolution.   
4.7.4 601-800 Survival Days Category  
Table 4.20 below shows the top 20 ranked genes for the combined metric in the 601-800 
survival days category GRN. The 2
nd
 ranked gene, VAMP2, which is the 15
th
 ranked gene in 
the lowest survival category network, is ranked by IntOGen as having a high probability of 
being an oncogene, as is the 5
th
 ranked gene SCAMP5. This would suggest that these genes 
are highly likely to be involved in interactions with other genes, and the high ranking results 
here concur with that prediction. The gene PRKCZ is the 20
th
 ranked gene in this list, having 
previously been highlighted as being fundamental in glioblastoma proliferation in human cell 
lines.  
There are again 13 unique entries on the top 20 ranking list for this category of network, 
suggesting, as was the case with the last network category, that there is markedly different 
behaviour in the network, compared to the other categories of network. The three genes in this 
list that also occur in two other lists are PPP1R16B, RGS7, and the proneural signature gene 
SNAP91.  Once again, despite a number of enrichment results yielded for this list of genes, 
shown in table A.10 of the appendix, none of the top ten results specifically relate to 
glioblastoma. 
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TABLE 4.20 TOP 20 RANKED GENES FOR COMBINED METRIC IN 601 – 800 SURVIVAL DAYS 
CATEGORY GRN 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
TUBB 1 SNAP91 11 
VAMP2 2 ATP6V1G2 12 
HLF 3 RGS7 13 
ARHGEF9 4 GFOD1 14 
SCAMP5 5 PDE2A 15 
PPP3CB 6 ATP2B2 16 
SNPH 7 CHGA 17 
PPP1R16B 8 EPB49 18 
GOT1 9 S100A1 19 
IQSEC3 10 PRKCZ 20 
 
Table 4.21 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the 601-800 survival days category GRN inferred using WGCNA. 
 
TABLE 4.21 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN THE 601-800  SURVIVAL CATEGORY GRN 
 
 
Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.824 0.864 0.754 
Weighted 
Degree 0.999 1 0.811 0.852 0.757 
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Eigenvector 
Centrality 0.824 0.811 1 0.976 0.524 
Closeness 
Centrality 0.864 0.852 0.976 1 0.565 
Betweenness 
Centrality 0.754 0.757 0.524 0.565 1 
 
For this category, as was the case with 201-400 category, all of the metrics apart from 
weighted betweenness centrality correlate strongly, > +0.80, and as such identify similar 
genes. The correlations are even stronger than for the 201-400 category, and the weighted 
betweenness has a stronger correlation with the other metrics as well. Note the extremely 
strong correlations between eigenvector centrality and closeness centrality, >0.97.  
Applying the Génie scoring system to the top 20 ranked genes for each metric, the following 
metric rankings shown in table 4.22 below are obtained.  
TABLE 4.22 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 2 268 1
st
 
Degree Centrality 0 0 2
nd
 
Weighted Degree 0 0 2
nd
 
Weighted Closeness 0 0 2
nd
 
Eigenvector Centrality 0 0 2
nd
 
Combined Metric 0 0 2
nd
 
 
79 
 
All of the metrics apart from the weighted betweenness centrality fail to identify any ranked 
glioblastoma genes of interest. Weighted betweenness centrality identifies two glioblastoma 
genes of interest; FPR1 ranked 168
th
 for glioblastoma, and RAC2 ranked 164
th
 for 
glioblastoma. Applying the scoring system to the top 100 ranked genes for each metric, the 
results in table 4.23 below are given.  
TABLE 4.23 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 488 1
st
 
Degree Centrality 0 0 2
nd
 
Weighted Degree 0 0 2
nd
 
Weighted Closeness 0 0 2
nd
 
Eigenvector Centrality 0 0 2
nd
 
Combined Metric 0 0 2
nd
 
 
Weighted betweenness centrality again is the only metric that identifies any glioblastoma 
genes of interest; this time, in addition to the genes FPR1 and RAC2, the 80
th
 ranked gene 
SOX10 is identified. Applying the scoring system to the top 500 ranked genes for each 
metric, the results in table 4.24 below are given.  
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TABLE 4.24 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 6 1036 1
st
 
Weighted Closeness 3 575 2
nd
 
Combined Metric 3 563 3
rd
 
Weighted Degree 4 397 4
th
 
Degree Centrality 2 343 5
th
 
Eigenvector Centrality 2 343 5
th
 
  
The weighted betweenness is the best performing metric, followed by the weighted closeness, 
and the combined metric. Degree and eigenvector centrality are the worst performing metrics, 
identifying 2 genes.  None of the 6 genes identified by the weighted betweenness centrality 
are in the top 50 Génie ranked genes for glioblastoma. In total, 37 out of the 299 Génie 
glioblastoma ranked genes are present in this network, 7 fewer than the previous category, but 
3 more than the first two categories. 
4.7.5 More than 800 Survival Days Category 
Table 4.25 below shows the top 20 ranked genes in the 801+ survival days category. The 
presence of GABRD and GABRA1 as the top two ranked genes is immediately noticeable, 
suggesting that the GABR area is of interest. In fact, whilst these two genes are not signature 
genes of any glioblastoma subtype, the gene GABR2 is a proneural signature gene, as 
identified by Verhaak et al [106]. The 9
th
 ranked gene, KALRN, appears in 3 glioblastoma 
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gene lists in the cancer genome atlas gene ranker, as well as appearing in 3 other cancer gene 
related lists. The enrichment results  
As with the two previous categories, there are 13 unique entries on the top 20 ranking list for 
this network. There are also 3 genes in the list below that also appear on two other lists, these 
genes are CAMKV, SYN1, and PPP1R16B. The enrichment results for this list of genes are 
shown in table A.11 of the appendix, however none of the top ten results specifically relate to 
glioblastoma. 
TABLE 4.25 TOP 20 RANKED GENES FOR COMBINED METRIC IN MORE THAN 800 SURVIVAL DAYS 
CATEGORY GRN 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
GABRD 1 GLS2 11 
GABRA1 2 CACNG3 12 
EPB41L1 3 SLC12A5 13 
BSN 4 KIAA1107 14 
CAMKV 5 PNOC 15 
CALY 6 NUAK1 16 
FAM153A 7 SYN2 17 
SYN1 8 CABP1 18 
KALRN 9 GOT1 19 
PPP1R16B 10 SNCB 20 
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Table 4.26 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the more than 800 survival days category GRN inferred using 
WGCNA. 
TABLE 4.26 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
DIFFERENT METRICS TO THE GENES IN MORE THAN 800  SURVIVAL CATEGORY GRN 
 
 
Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.995 0.692 0.766 0.703 
Weighted 
Degree 0.995 1 0.676 0.744 0.695 
Eigenvector 
Centrality 0.692 0.676 1 0.638 0.445 
Closeness 
Centrality 0.766 0.744 0.638 1 0.647 
Betweenness 
Centrality 0.703 0.695 0.445 0.647 1 
 
The correlations between the metrics are not as strong as the last category. Only the 
correlation between degree and weighted degree is stronger than 0.8 this time. However, the 
correlations between the weighted betweenness and the other metrics are stronger this time 
compared to the previous categories, with only the correlation between weighted betweenness 
and eigenvector centrality less than 0.64. This implies that the weighted betweenness will 
identify more genes in common with the other metrics, compared to the other categories. 
Using the scoring system for the metrics, the following rankings shown in table 4.27 based on 
the top 20 ranked genes for each metric are obtained.  
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TABLE 4.27 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 0 0 1st 
Weighted Degree 0 0 1st 
Weighted Betweenness 0 0 1st 
Weighted Closeness 0 0 1st 
Eigenvector Centrality 0 0 1st 
Combined Metric 0 0 1st 
 
None of the metrics identify a single Génie glioblastoma gene of interest.  Applying the 
scoring system to the top 100 ranked genes for each metric, the results in table 4.28 below are 
given. 
TABLE 4.28 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 1 68 1
st
 
Degree Centrality 2 54 2
nd
 
Weighted Degree 2 54 2
nd
 
Weighted Closeness 0 0 4
th
 
Eigenvector Centrality 0 0 4
th
 
Combined Metric 0 0 4
th
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Weighted betweenness is the best performing metric, identifying one ranked glioblastoma 
gene, the 232
nd
 ranked ALOX2. Weighted degree and degree centrality are the next best 
performing metrics, both identifying the same two genes; ING4 ranked 296
th
 most important 
gene for glioblastoma, and CSF2 ranked 250
th
 most important gene for glioblastoma. The 
other metrics do not identify any ranked glioblastoma genes. Applying the scoring system to 
the top 500 ranked genes for each metric, the results in the table be low are given.  
TABLE 4.29 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 10 804 1
st
 
Weighted Closeness 6 626 2
nd
 
Eigenvector Centrality 6 626 2
nd
 
Degree Centrality 5 522 4
th
 
Weighted Degree 5 522 4
th
 
Combined Metric 5 450 6
th
 
  
The weighted betweenness is the best performing metric, followed by the weighted closeness 
eigenvector centrality. The combined metric is the worst performing metric; despite 
identifying the same number of genes as degree and weighted degree, the genes identified are 
lower scoring. None of the 10 genes identified by the weighted betweenness centrality, the 
best performing metric, are in the top 50 Génie ranked genes for glioblastoma. In total, 34 out 
of the 299 Génie glioblastoma ranked genes are present in this network, the same number as 
in the first two categories. 
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4.8 Overall Metric Scores 
Previously, each of the metrics was ranked based on the top 20, top 100 and top 500 genes 
they identified for each glioblastoma GRN category. This ranking is based on the score of the 
identified genes in the Génie glioblastoma gene list.  
The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 4.30 below are given.  
TABLE 4.30 OVERALL METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN 
INFERRED USING WGCNA 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More 
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Betweenness 1st  1st  1st  1st  1st  5 1st 
Weighted 
Closeness 3rd  3rd  4th  2nd  3rd  15 2nd 
Eigenvector 
Centrality 2nd  2nd  4th  5th  3rd  16 3rd 
Weighted 
Degree 4th  4th  2nd  4th  3rd  17 4th 
Degree 
Centrality 4th  4th  3rd  5th  3rd  19 5th 
Combined 
Metric 6th  4th  6th  3rd  6th  25 6th 
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From table 4.30 above it can be seen that weighted betweenness is clearly the best performing 
metric overall, followed by weighted closeness and eigenvector centrality. This is not 
surprising, considering that weighted betweenness was the only metric to identify 
glioblastoma genes of interest a number of times.  
Taking just the scores for the top 20 genes identified by each metric in each category, the 
following rankings shown in table 4.31 are obtained.  
TABLE 4.31 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN 
INFERRED USING WGCNA BASED ON TOP 20 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More 
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Betweenness 1st  1st  1st  1st  1st  5 1st  
Degree 
Centrality 1st  1st  2nd  2nd  1st  7 2nd  
Weighted 
Degree 1st  1st  2nd  2nd  1st  7 2nd  
Weighted 
Closeness 1st  1st  2nd  2nd  1st  7 2nd  
Eigenvector 
Centrality  1st  1st  2nd  2nd  1st  7 2nd  
Combined 
Metric 1st  1st  2nd  2nd  1st  7 2nd  
 
Whilst the weighted betweenness is the best performing metric, followed by the other metrics, 
it should be noted though that solely using the top 20 genes identified by each metric is not 
very informative. In a number of the categories, no glioblastoma genes were identified by any 
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of the metrics, giving all the metrics the same ranking. Taking just the scores for the top 100 
genes identified by each metric in each category, the ranks in table 4.32 are obtained.  
TABLE 4.32 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN 
INFERRED USING WGCNA BASED ON TOP 100 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More 
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Betweenness 1st  1st  1st  1st  1st  5 1st  
Degree 
Centrality 1st  1st  2nd  2st  2nd  8 2nd  
Weighted 
Degree 1st  1st  2nd 2nd  2nd  8 2nd  
Weighted 
Closeness 1st  1st  2nd  2nd  4th  10 4th  
Eigenvector 
Centrality 1st  1st  2nd  2nd  4th  10 4th  
Combined 
Metric 1st  1st  2nd  2nd  4th  10 4th  
 
Weighted betweenness is again the best performing metric, followed by degree and weighted 
degree.  A similar situation to that of using just the top 20 genes identified by each metric 
occurs; some of the metrics do not identify any genes, thus having the same ranks for some of 
the glioblastoma categories. Finally, taking just the scores for the top 500 genes identified by 
each metric in each category, the ranks in table 4.33 are obtained. 
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TABLE 4.33 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN 
INFERRED USING WGCNA BASED ON TOP 500 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More 
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Betweenness 1st  1st  1st  1st  1st  5 1st  
Weighted 
Closeness 3rd  3rd  4th  2nd  2nd  14 2nd  
Eigenvector 
Centrality 2nd  2nd  4th  5th  2nd  15 3rd  
Weighted 
Degree 4th  4th  2nd  4th  4th  18 4th  
Degree 
Centrality 4th  4th  3rd  5th  4th  20 5th  
Combined 
Metric 6th  4th  6th  3rd  6th  25 6th  
 
Whilst the weighted betweenness centrality is the best performing metric again, there are clear 
differences between the performance of the metrics. Weighted closeness is the second best 
performing metric, just out-performing the eigenvector centrality. The combined metric is the 
worst performing metric overall.  
From these results, the weighted betweenness is the metric best suited to identifying 
glioblastoma genes of interest in the GRNs inferred for the different categories of 
glioblastoma.  
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4.9 Discussion 
There are a number of areas in this chapter that merit discussion. The first of these is the 
combined metric gene rankings in each category. There are 57 unique entries in the five  
combined metric top 20 ranked gene lists. This represents quite a high proportion of genes 
being unique to one evolutionary category, and also that there are more unique entries in the 
top 20 ranked lists than common ones. This high number of unique genes suggests that the 
five categories of network are very different. This is especially relevant if previous static 
studies are considered that grouped all the samples in a data set together and constructed one 
network to represent their behaviour, it is quite clear from this study how different the 
behaviour of sample at different evolutionary stages is.   
There are 14 genes that appear in two lists. 9 of these appear in the first two categories, 
suggesting that these two categories are the most similar based on the top ranking genes. 
These two categories are the two with the lowest survival days, so a reasonable presumption 
would be to suggest that these 9 genes play a role in the later stages of glioblastoma. It is also 
worth noting the very high correlation that these two categories have for common genes, 0.75, 
which is the highest correlation for any two categories. This again suggests that these two 
categories are similar. 5 genes appear in three lists, including SNAP91. Their presence in lists 
across the evolutionary stages would suggest they are involved in processes that are common 
throughout the glioblastoma life cycle, and that they do not play such an important role in the 
specific processes related to the evolution of glioblastoma.  
The second area of focus is the biological relevance of these results. The identification of 
genes previously identified in a number of publications using a solely graph theory approach 
shows the biological relevance of this approach. Genes such as SNAP91, EPHB6, PRKCZ, 
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CPNE6, HPCAL4 and SH3GL2 have been identified without any prior biological knowledge 
or bias. A number of glioblastoma signature genes were identified across the evolutionary 
categories using the metrics; however there was no correlation between the identification of 
these as being high ranking and the evolutionary category. This corresponds to the study by 
Verhaak et al that showed the four glioblastoma subtypes had a narrow survival range, as 
from this study, it cannot be concluded that one glioblastoma subtype can be significantly 
associated with any of the categories of network. The findings of this study suggest that high 
network centrality scores for specific genes may be a better indicator of glioblastoma survival 
time, than subtype classification.  
The performance of a number of graph theory metrics was compared, based on their ability to 
identify genes in the different categories of GRN ranked by the text-mining tool Génie. 
Across all of the different categories of GRN, weighted betweenness centrality was shown to 
be the best performing metric at identifying these ranked genes. This might be a slightly 
surprising result; degree centrality is the commonly applied graph theory metric for analysis, 
and the number of connections that a node has is often thought of as being an indicator of the 
importance of a node. However, the concept of nodes that have a high betweenness acting as 
broker nodes has been noted, and in the context of a GRN where gene regulatory processes 
are likely to involve a number of genes, this perhaps should not be considered such a surprise.  
The results in this chapter highlight some of the problems of applying an existing network 
inference to infer different categories of GRN from a microarray dataset. Whilst WGCNA has 
been shown to perform well at inferring one GRN from a microarray dataset, there are some 
issues with applying it to infer different categories of network from the same dataset. Firstly, 
whilst 57 out of the 100 genes in the five top 20 ranked gene lists are unique, there are 43 
genes that are common to two or more glioblastoma categories. This represents quite a deal of 
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overlap, and is not in concordance with the biology; such a high overlap amongst the 
categories is not expected. Email PC1 in the appendix from Dr Carmel McConville, Senior 
Lecturer in Cancer Sciences, notes this issue when applied to a different dataset, the 
underlying problem is the same here. Furthermore, looking at the composition of the largest 
unique cliques, there are 76 genes that are common to the largest unique cliques in all f ive 
networks, this again goes against the biology. Additionally, the identification of a number of 
genes being common to multiple survival categories implies that they are involved in 
processes common to the glioblastoma life cycle, and are not involved in processes specific to 
one survival category. This does not provide much assistance to biologists and clinicians 
wishing to interrogate microarray data to identify genes that are of interest in specific disease 
stages. 
Secondly, the gene expression levels of the genes that are identified as being high ranking in 
the categories do not vary a great deal between the different categories of samples that they 
are taken from. This can be attributed to the method that WGCNA employs to assign the 
correlation scores to the networks; essentially it is looking for the greatest variability in 
expression level within the categories of the samples, and is not taking the expression level of 
the gene in the other categories of the samples into account. This is something that was noted 
by biologists, see email PC1, who immediately noticed this lack of variability in the 
expression levels of the highly ranked genes, across the categories.  Leading on from this, a 
network inference method that takes into account the different gene expression levels of the 
genes across the different categories is of use; in the following chapter, a method that 
specifically addresses this is introduced and applied to this glioblastoma dataset.  
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4.10 Conclusions 
To conclude, the work in this chapter has addressed the first two objectives of the work laid 
out in the introductory chapter. Firstly, an existing network inference technique , WGCNA, 
has been applied to a glioblastoma microarray dataset to infer GRNs representing different 
survival categories based on survival time; this was done in order to investigate the feasibility 
of using an existing network inference method for the purpose of inferring GRNs for different 
categories from a single microarray dataset. One of the issues of using an existing network 
inference approach is highlighted, namely that gene expression levels across the categories are 
not taken into account. Secondly, different metrics were used to identify genes of interest in 
the GRNs, and the performance of these metrics was scored and then compared, thus allowing 
a comparison of the ability of different metrics to identify glioblastoma genes of interest.  
However, two main problems were identified with the results. A number of genes were 
identified as being common to both the cliques, and the highly ranked genes across the 
different glioblastoma categories. Additionally, the gene expression levels of the top ranked 
genes did not show much variance across the survival categories. These two findings are an 
issue as they do not agree with the feedback from biologists; it would be expected that 
different genes would be important in the different survival categories, and the genes of 
interest are those whose expression levels vary significantly across the survival categories. In 
the next chapter, a novel Z score based method based on the discretisation inference method 
developed by Vass et al [90] will be introduced, with the aim of resolving these issues by 
implementing a network inference that takes into account gene expression levels across 
different categories. 
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Chapter 5  
Construction of Glioblastoma Survival Category 
GRNs using Novel Inference Method 
In this chapter, an alternative novel network inference method that takes into account gene 
expression levels in different categories in a microarray dataset is developed, and applied to 
the glioblastoma dataset used in the previous chapter. It was noted in the previous chapter that 
the correlation-based WGCNA method used only identified genes with a high variance in 
their values within the categories. Whilst this is suited to the purpose of inferring a single 
GRN across a whole dataset, it does not seem as well suited to the purpose of inferring GRNs 
for different categories within a microarray dataset, and the subsequent identification of genes 
of interest in these different categories of GRN.  
An approach that is capable of distinguishing whether genes are significantly expressed in one 
category of disease compared to their values in the other categories, is better suited for the 
purposes of this work, as suggested in email PC2 from Dr Andrew Peet, Reader in Paediatric 
Oncology; and more explicitly, in addressing the aim of this thesis which is to aid in the 
investigation of progression and evolution of tumours. Identifying genes in particular 
categories of disease, namely different types of cancer, has the potential to allow a better 
understanding of how a tumour evolves and progresses.   
5.1 Novel GRN Inference Method 
Some of the issues with using an existing network inference method for the inference of 
multiple GRNs from a single microarray dataset were highlighted in the previous chapter. 
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With this in mind, a novel absolute Z score network inference method is now introduced and 
applied to the glioblastoma dataset. This specifically addresses the first objective of the work; 
to design and implement a transferable method for inference of multiple GRNs from a single 
microarray dataset.  
This method introduced here builds on the discretised approach by Vass et al detailed in 
chapter 3. As with the discretised method, the gene expression array levels are transformed 
into Z scores. However, unlike the discretised approach, these Z scores are not discretised into 
either a 0 or 1, and instead the Z score is transformed into an absolute value. The array of 
these absolute values is multiplied by the transpose of this array, resulting in a matrix of n by 
n dimensions, where n is the number of genes in the microarray dataset. This matrix is then 
scaled, by dividing all entries by the highest entry, resulting in a weighted adjacency matrix 
with values between 0 and 1. A weighted graph is inferred from this matrix; only the top 0.5% 
edges based on edge weight are then retained. Keeping only the top 0.5% of edges has two 
benefits; it results in a network with a scale-free topology, and keeping only the top 0.5% of 
edges based on edge weight minimises the effect of noise in the microarray data making it 
more probable that biologically meaningful interactions are maintained.  
This network inference approach has two specific advantages over existing network inference 
techniques that are directly applicable to this work. Firstly, there is no minimum number of 
samples required in order to infer a network. This is an important consideration, as a number 
of microarray datasets only have a limited number of samples per category. Using the 
example of the WGCNA network inference technique applied in the last chapter, this method 
requires a minimum of 12 samples in order to infer a network. The proprietary retinoblastoma 
dataset that is introduced in chapter 6 has two categories where the number of samples are 
less than 12, highlighting this constraint. Secondly; the discretised approach developed by 
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Vass is also highly influenced by the number of samples. The discretised 0 or 1 nature of the 
scores means that the value of network metrics such as weighted degree centrality can only be 
one of a finite selection of values. In practice, this results in a great deal of genes having the 
same scores for particular metrics, and in fact means that these metrics cannot be used to 
discriminate between genes.     
In this chapter, one GRN will be constructed for each evolutionary category detailed in the 
previous chapter, using the absolute Z score based network inference technique. This mirrors 
the WGCNA method in the networks that are constructed, and allows direct comparisons 
between an established method, WGCNA, and the novel method introduced and applied here. 
5.2 Network Level Metrics 
As was the case in the last chapter, before looking at the individual genes in the networks, the 
network level metrics will be calculated and analysed. The same metrics will be used again; 
weighted degree assortativity, degree asssortativity, diameter, and network clustering. The 
largest unique cliques will again be calculated for each of the networks, and the genes that 
comprise these cliques will be investigated for both enrichment and the presence of 
glioblastoma genes of interest using Génie and the lis t of glioblastoma subtype genes. The 
network level metric scores for the GRN categories are shown in table 5.1 below. 
TABLE 5.1 NETWORK LEVEL SCORES GLIOBLASTOMA GRNS INFERRED USING THE NOVEL 
INFERENCE METHOD 
 
Metric 200 or less 
category 
201 - 400 
category 
401 - 600 
category 
601 - 800 
category 
801+ category 
Weighted 
Degree 
Assortativity 
-0.123 -0.147 -0.360 -0.323 -0.364 
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Degree 
Assortativity 
-0.130 -0.134 -0.358 -0.319 -0.363 
Diameter 2.030 1.889 1.143 1.638 0.934 
Network 
Clustering 
0.359 0.400 0.326 0.468 0.237 
Largest 
Clique Size 
94 144 118 217 122 
 
There again appears to be no clear pattern between any of the network level scores and the 
evolutionary category. This is again suggestive that survival time cannot be associated with 
any network level metric behaviour. The value of the diameter should be noted here for two 
reasons; in the correlation based approach it was greatest in the highest survival category 
whilst here the exact opposite is the case, secondly it is also highest here in the lowest survival 
category. The diameter can be an indicator of how easily genes are able to communicate in a 
network; the low relative value here might be indicate genes in the highest survival category 
are able to communicate with each other much easier than in the lowest survival category. The 
network clustering is also smallest in the highest evolutionary category, as are the weighted 
degree and degree assortativity values. The most important observations to be made about the 
networks on a network level could possibly be made about the size and composition of the 
largest unique cliques in the networks. This is examined in depth in the following section.  
5.3 Largest Clique Calculation and Analysis 
As noted above, the size and composition of the largest unique cliques in the different 
categories can be informative. A large number of common genes in the cliques across all the 
networks would suggest that the same genes are involved in important cellular processes 
across the glioblastoma life cycle. As well as identifying common and unique genes in these 
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cliques, it is informative to see whether these genes have been previously identified as being 
either glioblastoma subtype signature genes or appear on the list of Génie glioblastoma genes. 
Finally, the list of genes that comprise the largest unique clique in each network can be 
checked for enrichment using the GenesetDB website. Table 5.2 below shows whether genes 
in each cliques have been identified as glioblastoma subtype signature genes, or in the ranked 
Génie glioblastoma gene list. On the following page, the Venn diagram shows the number of 
unique genes in each category, and how many genes are common to two or more categories.  
TABLE 5.2 GLIOBLASTOMA GENES OF INTEREST IN LARGEST UNIQUE CLIQUES IN THE 
GLIOBLASTOMA GRNS INFERRED USING THE NOVEL INFERENCE METHOD 
 
Category Size of 
clique 
Proneural 
Subtype 
Genes 
Mesenchymal 
Subtype 
Genes 
Neural 
Subtype 
Genes 
Classical 
Subtype 
Genes 
Number 
of Génie 
genes and 
score 
200 or less 94 1 0 12 1 5, score of 
582 
201 – 400  144 2 8 0 8 1, score of 
122 
401- 600  118 0 0 13 1 3, score of 
418 
601-800  217 1 17 3 7 1, score of 
51 
More than 
800  
122 4 1 3 6 5, score of 
920 
 
The first observation is the presence of fewer proneural subtype genes in these cliques 
compared to those in the last chapter. In contrast to those cliques in the last chapter, there are 
Mesenchymal subtype genes in these cliques, and also a far greater abundance of classical 
subtype genes as well. This clearly suggests that these two methods vary in terms of the cliques 
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they identify. Another observation to make is the subtype ‘profile’ of these cliques, the cliques 
in the last chapter all had a strong neural presence; this is not the case here. Whilst the cliques 
in the 0-200 and 401-600 categories have a strong neural profile, this is not the case with the 
other cliques. The 201-400 category clique has a joint Mesenchymal/classical profile, the 601-
800 clique a strong Mesenchymal/medium classical subtype profile, and the 801 and more 
clique a weak mixed subtype profile.  
Marginally fewer glioblastoma genes of interest are identified overall in the cliques above, 
104 in total in table 5.2, compared to those in the last chapter, 106 in total in table 4.4. 
However, more genes in the cliques in table 5.2 are present in the glioblastoma list generated 
by Génie; 15 genes compared to only 3 genes in the cliques in table 4.4. As noted before, the 
Génie list is of more interest as it allows genes to be scored based on their relevance to 
glioblastoma. It should also be remembered that there is a high degree of repetition in the 
genes that comprise the cliques shown in table 4.4.  
Starting with the clique in the GRN for the 200 or fewer survival days glioblastoma category, 
19 out of the 94 genes, 20.21%, have been previously identified as being of interest for 
glioblastoma; 14 subtype genes, and 5 genes identified by Génie. The top ten enrichment 
results for the genes that comprise this clique are shown in table A.12 of the appendix. The 6
th
 
result should be noted; SMAD7 has been suggested as being involved in glioblastoma cell 
proliferation, and is noted in a recent study by Eichhorn et al [118] as being involved in TGF-
B signalling in glioblastoma. 
19 out of the 144 genes, 20.21%, in the clique in the GRN for the 201-400 survival days 
glioblastoma category have been previously identified as being of interest for glioblastoma; 18 
subtype genes, and 1 gene identified by Génie. Table A.13 of the appendix shows the top 10 
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results for the enrichment of the genes that comprise this clique. The 2
nd
 result detailing ErbB1 
is of note; the pathway of this gene was the 8
th
 enrichment result for the list of top ranked 
genes in the 201-400 network inferred using WGCNA, and is the subject of the previously 
mentioned study by Gilbertson et al [116].    
17 out of the 118 genes, 14.41%, in the clique in the GRN for the 401-600 survival days 
glioblastoma category have been previously identified as being of interest for glioblastoma; 14 
subtype genes, and 3 genes identified by Génie. Table A.14 of the appendix shows the top 10 
results for the enrichment of the genes that comprise this clique. Unlike the previous two 
categories, none of the enrichment results stand out.    
29 out of the 217 genes, 13.36%, in the in the GRN for the 601-800 survival days glioblastoma  
category have been previously identified as being of interest for glioblastoma; 28 subtype 
genes, and 1 gene identified by Génie. Table A.15 of the appendix shows the top 10 results for 
the enrichment of the genes that comprise this clique. As was the case with the previous 
category, none of the enrichment results stand out.    
19 out of the 122 genes, 15.57%, in the 801 or more clique have been previously identified as 
being of interest for glioblastoma; 14 subtype genes, and 5 genes identified by Génie. Only 
three results are returned by GeneSetDB for this combination of genes, suggest that this  
combination of genes is either not associated with any particular biological feature, or is a 
novel finding. The three results returned are shown in table A.16 of the appendix.  
In contrast to the distribution of genes in the largest unique cliques in the last chapter, there are 
no genes common to all five cliques. The 200 or less, 401-600, and 801 categories are 
comprised of unique genes. Of the total 695 genes in all of the cliques, 650 are unique, with 
only 45 shared genes that belong to the 201-400 and 601-800 categories.  This high proportion 
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of unique genes and very few shared genes suggests that the cellular processes are very 
different in the cliques in the different categories. It might be expected that different cellular 
processes and genes are associated with different survival times; this result may be of more use 
in understanding the evolution and progression of tumours than the results in the last chapter 
that implied there were a high number of cellular processes common to the different categories. 
The Venn diagram in figure B.3 in the appendix shows the distribution of unique and shared 
genes in the largest cliques 
Having focused on the network level metrics and cliques, in the following sections the focus is 
on the node-level metrics in each category. 
5.4 Node Level Metrics 
As before, a number of metrics for each node are calculated; weighted degree, degree, 
weighted betweenness, weighted closeness, eigenvector centrality, and the combined metric 
ranking based on weighted degree, weighted closeness, and weighted betweenness. For each 
category of GRN, a table of the top 20 ranked genes for the combined metric is presented. 
Gene set enrichment and the presence of subtype signature and glioblastoma candidate genes 
will be investigated for the combined list, and also whether these genes have been identified in 
previous glioblastoma studies. 
The list of ranked glioblastoma genes from the text-mining tool Génie is used again to assign 
scores to the genes identified by the different metrics. The scores from the glioblastoma gene 
list generated by Génie of the top 20, 100, and 500 ranking genes for each metric will be used 
to compare the performance of the metrics in each category of glioblastoma GRN.  
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5.4.1 200 or Fewer Survival Days  Category 
Table 5.3 below shows the top 20 ranked genes for the combined metric in the GRN for the 0-
200 survival days glioblastoma category. None of these genes in the table appear in the list of 
299 glioblastoma genes generated by Génie. Four of the genes in the list are glioblastoma 
subtype signature genes. The genes P4HA2 and LOXL1 are neural subtype signature genes, 
the gene FHOD3 is a proneural subtype signature gene, and the gene SH3BP5 is a 
Mesenchymal subtype signature gene. None of the genes that appear in the top 20 ranked list 
appear in any of the top 20 ranked for the other categories. As was the case with the largest 
unique cliques, this suggests that there are clearly distinguishable differences between the 
survival categories in terms of the genes that are playing important roles in cellular processes.  
Only one result is returned for this set of genes by GeneSetDB, shown in table A.17 of the 
appendix. This implies that either this combination of genes has not been identified as being 
involved in significant biological processes, or that this is a novel finding.  
TABLE 5.3 TOP 20 RANKED GENES FOR COMBINED METRIC IN 0 – 200 SURVIVAL DAYS 
CATEGORY GRN INFERRED USING NOVEL INFERENCE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
ERLIN1 1 LOXL1 11 
IGF2R 2 FZD2 12 
HMX1 3 SH3BP5 13 
SLC22A17 4 TCF3 14 
P4HA2 5 ZNRF4 15 
SPAG4 6 FHOD3 16 
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TXNDC9 7 DNASE1L1 17 
TIMM23 8 STAR 18 
AMBP 9 RCC1 19 
ANXA2P2 10 ZNF187 20 
 
Table 5.4 below shows the Spearman Rank correlation scores for the rankings assigned to the 
genes by each metric in the 0 – 200 survival days GRN inferred using the novel method.  
TABLE 5.4 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN 0 – 200 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
INFERENCE METHOD 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.853 0.869 0.857 
Weighted 
Degree 0.999 1 0.850 0.862 0.853 
Eigenvector 
Centrality 0.853 0.850 1 0.853 0.694 
Closeness 
Centrality 0.869 0.862 0.853 1 0.831 
Betweenness 
Centrality 0.857 0.853 0.694 0.831 1 
 
From the table above, it can be seen that all of metrics have a positive correlation greater than 
0.69; if the correlation between eigenvector centrality and betweenness centrality is 
discounted then all the other correlations have positive correlation strength of at least 0.83. 
These very strong correlations imply that there is a substantial overlap in the genes that the 
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metrics rank highly, as was the case for a lot of the metrics in the last chapter. Therefore, we 
would expect that there will be quite a lot of overlap in the genes that these metrics identify. 
In the last chapter, a scoring system was used to compare the performance of the different 
metrics in identifying glioblastoma genes of interest from a ranked list. The same scoring 
system will be used in this chapter to compare the performance of the metrics. Using the same 
scoring system will allow comparisons between the performance of the metrics in identifying 
glioblastoma genes of interest in the networks inferred using the WGCNA  network inference 
technique, and the performance of the metrics in this chapter using the novel Z score method. 
Starting with the top 20 ranked genes by each metric, table 5.5 below shows the scores that 
are obtained. 
TABLE 5.5 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 1 6 1
st
 
Weighted Degree 1 6 1
st
 
Eigenvector Centrality 1 6 1
st
 
Weighted Betweenness 0 0 4
th
 
Weighted Closeness 0 0 4
th
 
Combined Metric 0 0 4
th
 
 
Weighted degree, degree, and eigenvector centrality each identify the same glioblastoma 
genes of interest, CTGF, on the list generated by Génie. The other metrics do not identify any 
if the genes on this list. Previously, the network metrics were scored using the top 20, top 500, 
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and the whole network. This approach will be modified as well; the top 20, top 100, and top 
500 genes ranked by each metric will be used to score the metrics. Applying the scoring 
system to the top 100 ranked genes for each metric, the results in table 5.6 below are given.  
TABLE 5.6 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 2 426 1
st
 
Eigenvector Centrality 3 421 2
nd
 
Degree Centrality 2 240 3
rd
 
Weighted Degree 2 240 3
rd
 
Weighted Closeness 2 240 3
rd
 
Combined Metric 2 240 3
rd
 
 
Applying the scoring system to the top 100 genes identified by the metrics, weighted 
betweenness centrality is the best performing metric, followed by eigenvector centrality. 
Although eigenvector centrality identifies more genes, weighted betweenness centrality 
identifies genes with a higher score. Weighted betweenness centrality was identified as being 
the best performing metric overall in the last chapter for the correlation based network 
inference method. Finally, extending the scoring system to the top 500 genes, the following 
results shown in table 5.7 below are given.  
 
 
105 
 
TABLE 5.7 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 0 – 200 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Degree 24 4170 1
st
 
Degree Centrality 23 4133 2
nd
 
Eigenvector Centrality 22 3366 3
rd
 
Weighted Betweenness 19 2850 4
th
 
Combined Metric 17 2391 5
th
 
Weighted Closeness 14 1565 6
th
 
 
In terms of the individual metrics, there are discernable differences in the performance of the 
metrics depending on the number of genes used. The performance of the degree centrality 
metric improves from 5
th
 to 1
st
 as the number of genes increases from 100 to 500, and the 
weighted betweenness centrality performance decreases from 1
st
 to 4
th
. Interestingly, the 
performance of all the other metrics is the same for 100 genes, as it is for 500 genes.  
Across the whole network, 149 out of the 299 glioblastoma genes generated by Génie are 
present. Whilst this represents just under half of these genes being present, 49.83%, only 24 
are identified by the best performing metric, weighted degree centrality. In addition, in the top 
500 ranked genes by weighted degree, only 7 out of the top 50 Génie ranked glioblastoma 
genes are present. This shows that the genes that Génie highlights as being important for 
glioblastoma are not identified by the network metrics in this category. This could be due to 
two reasons. Either the network inference method and metrics are not accurate in re-
constructing and identifying the gene regulatory processes that take place, or these genes 
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identified by Génie do not in fact play an important role in this evolutionary category. It 
should be noted that there is no survival information present with the genes identified by 
Génie, i.e. specific genes are not associated with specific survival time. 
5.4.2 201-400 Survival Days Category 
Table 5.8 shows the top 20 ranked genes for the combined metric in the GRN for the 201-400 
survival days glioblastoma category. One of the genes, MAPK3, in the table appears in the list 
of 299 glioblastoma genes generated by Génie, ranked as the 122
nd
 most important gene for 
glioblastoma. Three of the genes in the table are glioblastoma subtype signature genes. MMD 
and DMWD are classical subtype signature genes, and CRYZL1 is a signature gene of the 
Mesenchymal glioblastoma subtype. Again, none of the genes that appear in the top 20 ranked 
list appear in any of the top 20 ranked for the other categories. As was the case with the 
previous category, this suggests that different genes are playing important roles in the 
different survival categories.   
Looking at the top 10 results for this list of genes from GenesetDB, shown in table A.18 of 
the appendix, the 3
rd
 and 10
th
 results stand out. IL-4 has been highlighted in a number of 
glioblastoma studies, such as that by Rahaman et al [119], and therefore suggests that this list 
of genes might be biologically significant.  
TABLE 5.8 TOP 20 RANKED GENES FOR COMBINED METRIC IN 201 – 400 SURVIVAL DAYS 
CATEGORY GRN INFERRED USING NOVEL INFERENCE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
STX12 1 ELF2 11 
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PHIP 2 SLC5A6 12 
C1orf27 3 MMD 13 
BCAT2 4 GOLGB1 14 
IKBKB 5 ITFG1 15 
GRB2 6 RALGAPB 16 
HNRNPH2 7 DMWD 17 
GTPBP3 8 FAM32A 18 
MAPK3 9 PAFAH1B1 19 
CRYZL1 10 MICU1 20 
 
Table 5.9 below shows the Spearman Rank correlation scores for the rankings assigned to the 
genes by each metric in the 201 – 400 survival days GRN inferred using the novel method.  
TABLE 5.9 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN 201 – 400 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
INFERENCE METHOD 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.844 0.842 0.838 
Weighted 
Degree 0.998 1 0.835 0.831 0.836 
Eigenvector 
Centrality 0.844 0.835 1 0.853 0.643 
Closeness 
Centrality 0.842 0.831 0.853 1 0.777 
Betweenness 
Centrality 0.838 0.836 0.643 0.777 1 
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The correlations between the metric are strong, if the correlation between eigenvector 
centrality and betweenness centrality is discounted then all the other correlations have 
positive correlation strength of at least 0.77.  Whilst these correlations are strong, they are not 
as strong as those in the last category, and as such, we would not expect there to be as much 
overlap as there was before in the genes that the metrics identify.  
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 5.10 below. 
TABLE 5.10 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 1 178 1
st
 
Weighted Degree 1 178 1
st
 
Weighted Betweenness 1 178 1
st
 
Eigenvector Centrality 1 178 1
st
 
Combined Metric 1 178 1
st
 
Weighted Closeness 0 0 6
th
 
 
All of the metrics apart from the weighted closeness identify the gene MAPK3. Applying the 
scoring system to the top 100 ranked genes for each metric, the results in table 5.11 below are 
given. 
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TABLE 5.11 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 568 1
st
 
Degree Centrality 2 271 2
nd
 
Weighted Degree 2 271 2
nd
 
Weighted Closeness 2 271 2
nd
 
Combined Metric 2 271 2
nd
 
Eigenvector Centrality 1 178 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the weighted 
betweenness centrality is the best performing metric. Three genes; MAPK3, MAPK1, and 
EGFR, are identified. It is worth noting that EGFR is the 3
rd
 ranked gene by Génie for 
glioblastoma. Finally, extending the scoring system to the top 500 genes, the following results 
shown in table 5.12 below are given.  
TABLE 5.12 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 201 – 400 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 11 1805 1
st
 
Combined Metric 10 1443 2
nd
 
Weighted Closeness 9 1308 3
rd
 
Degree Centrality 8 1186 4
th
 
110 
 
Weighted Degree 8 1186 4
th
 
Eigenvector Centrality 3 358 6
th
 
 
The weighted betweenness centrality out-performs the other metrics when the scoring is 
applied to the top 500 genes identified by each metric.  2 of the top 20 ranked genes by Génie 
for glioblastoma, EGFR ranked 3
rd
 and IL13RA2 ranked 17
th
 are amongst the top 500 genes 
ranked by weighted betweenness centrality. This is quite a significant result in terms of the 
biology, and implies that weighted betweenness centrality is a good metric to use for 
identifying biologically significant results. The combined metric performs well due to the 
strong performance of the weighted betweenness centrality. Apart from eigenvector centrality, 
the other metrics perform reasonably well.  
Across the whole network, 115 out of the 299 glioblastoma genes generated by Génie are 
present, 38.46%. This represents fewer genes identified than in the last category; as the 
survival time increases it might be expected that fewer of the genes identified by Génie might 
be present, a trend that fits in with the result observed.  
5.4.3 401-600 Survival Days Category 
Table 5.13 below shows the top 20 ranked genes for the combined metric in the GRN for the 
401-600 survival days glioblastoma category. Three of the genes in the table, FOXM1, 
TNFRSF10B, and CDKN1A, appear in the list of 299 glioblastoma genes generated by Génie. 
There is only one glioblastoma subtype signature gene in the list, KCNF1, associated with the 
classical glioblastoma subtype. As with the two previous categories, none of the genes that 
appear in the table are present in the top 20 rankings for any of the other categories. 
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24 results are returned by GeneSetDB for this set of genes, of which 17 relate to the 
drug/chemical class. If these 17 results are excluded as they are not relevant to the purposes of 
the work, 7 results are left which are shown in table A.19 of the appendix. Of interest are the 
two results identifying TP53 and p53. These two genes have been highlighted in glioblastoma 
studies, such as those by Rasheed et al [120], and Zheng et al [121]. 
TABLE 5.13 TOP 20 RANKED GENES FOR COMBINED METRIC IN 401 – 600 SURVIVAL DAYS 
CATEGORY GRN INFERRED USING NOVEL INFERENCE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
FOXM1 1 POLDIP2 11 
HMGB3 2 TNFRSF10B 12 
BSDC1 3 CDKN1A 13 
APOC2 4 DDB2 14 
MRPL4 5 SAP130 15 
GM2A 6 BOK 16 
PKN2 7 ORC5 17 
TAC3 8 SRR 18 
LILRB1 9 KCNF1 19 
TMEM177 10 TULP3 20 
 
Table 5.14 below shows the Spearman Rank correlation scores for the rankings assigned to the 
genes by each metric in the 401 – 600 survival days GRN inferred using the novel method.  
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TABLE 5.14 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
DIFFERENT METRICS TO THE GENES IN 401 – 600 SURVIVAL DAYS CATEGORY GRN INFERRED 
USING NOVEL INFERENCE METHOD 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.961 0.906 0.836 
Weighted 
Degree 0.998 1 0.956 0.898 0.832 
Eigenvector 
Centrality 0.961 0.956 1 0.934 0.796 
Closeness 
Centrality 0.906 0.898 0.934 1 0.833 
Betweenness 
Centrality 0.836 0.832 0.796 0.833 1 
 
There is a positive correlation strength of at least 0.79 between all of the metrics. This implies 
that there is significant overlap in the genes ranked highly by the different metrics.  Applying 
the scoring system to the top 20, top 100, and top 500 genes identified by each of metrics, the 
metrics can be ranked. The scores for the top 20 genes identified by each metric are shown in 
table 5.15 below. 
TABLE 5.15 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 3 469 1
st
 
Weighted Closeness 3 469 1
st
 
Eigenvector Centrality 3 469 1
st
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Combined Metric 3 469 1
st
 
Weighted Degree 2 313 5
th
 
Weighted Betweenness 1 193 6
th
 
 
Four of the metrics; weighted closeness, degree, eigenvector centrality and the combined 
metric, both identify three genes, FOXM1, TNFRSF10B, and CDKN1A, which appear on the 
glioblastoma genes of interest list generated by Génie. Weighted degree identifies two of 
these genes, FOXM1 and CDKN1A, and weighted betweenness identifies FOXM1. Applying 
the scoring system to the top 100 ranked genes for each metric, the results in table 5.16 below 
are given. 
TABLE 5.16 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 6 1310 1
st
 
Degree Centrality 6 1152 2
nd
 
Weighted Degree 6 1152 2
nd
 
Weighted Betweenness 4 764 4
th
 
Combined Metric 4 764 4
th
 
Eigenvector Centrality 4 611 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the weighted 
closeness centrality metric is the best performing, identifying 6 genes. Degree and weighted 
degree also identify six genes, but these are lower ranked. The other three metrics each 
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identify four genes.  Finally, extending the scoring system to the top 500 genes, the following 
results shown in table 5.17 below are given.  
TABLE 5.17 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 401 – 600 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 23 3979 1
st
 
Weighted Degree 23 3979 1
st
 
Combined Metric 20 3457 3
rd
 
Weighted Betweenness 18 3404 4
th
 
Weighted Closeness 17 3162 5
th
 
Eigenvector Centrality 18 2957 6
th
 
 
The degree and weighted degree metrics are the joint best performing metrics, each 
identifying the same 23 glioblastoma genes. Previously the performance of the weighted 
betweenness centrality, the 4
th
 best performing metric, at identifying highly ranked 
glioblastoma genes was noted. This time, the weighted closeness centrality, the 5
th
 best 
performing gene this time, performs impressively. This metric identifies 3 of the top 15 
ranked genes by Génie for glioblastoma amongst its top 500 ranked genes; MGMT ranked 
2
nd
, PTEN ranked 5
th
, and BIRC5 ranked 13
th
. This result implies that weighted closeness 
centrality is a good metric to use for identifying biologically significant genes. In general the 
metrics perform strongly for this category; and identify a number of glioblastoma genes.  
Across the whole network, 126 out of the 299 glioblastoma genes generated by Génie are 
present, 42.14%. This represents more genes identified than in the last category; as is contrary 
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to the observation for the last category, we might expect fewer genes to be identified as the 
survival time increases, instead of more genes compared to the last category.  
5.4.4 601-800 Survival Days Category  
Table 5.18 below shows the top 20 ranked genes for the combined metric in the GRN for the 
601-800 survival days glioblastoma category. The 7
th
 ranked gene, PTK2B, appears in the list 
of 299 glioblastoma genes generated by Génie. One glioblastoma subtype gene is present in 
the table, EPS15, which is Mesenchymal subtype signature gene. As before, none of the genes 
that appear in the top 20 ranked list appear in any of the top 20 ranked for the other 
categories.  
No results are returned for this set of genes by GeneSetDB. This implies that either this 
combination of genes has not been identified as being involved in signif icant biological 
processes, or that this is a novel finding.  
TABLE 5.18 TOP 20 RANKED GENES FOR COMBINED METRIC IN 601 – 800 SURVIVAL DAYS 
CATEGORY GRN INFERRED USING NOVEL INFERENCE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
CLSTN3 1 PEX16 11 
NPY1R 2 FRY 12 
CBFB 3 MDN1 13 
PTK2B 4 EML4 14 
HMG20A 5 ARHGEF9 15 
EPS15 6 GLRB 16 
ZDHHC11 7 CDK5R2 17 
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CAMKK2 8 FAM190B 18 
HNRPDL 9 CIT 19 
GFRA2 10 FGF14 20 
 
Table 5.19 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the 601 – 800 survival days GRN inferred using the novel 
method. 
TABLE 5.19 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN 601 – 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
INFERENCE METHOD 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.997 0.872 0.844 0.746 
Weighted 
Degree 0.997 1 0.870 0.835 0.743 
Eigenvector 
Centrality 0.872 0.870 1 0.941 0.615 
Closeness 
Centrality 0.844 0.835 0.941 1 0.693 
Betweenness 
Centrality 0.746 0.743 0.615 0.693 1 
 
The correlation scores between the metrics are weaker this time. Whilst some of the 
correlations are strong and as a result there will still be some overlap between the genes 
identified by the metrics, we would not expect there to be as much overlap as previously when 
the correlations were stronger. 
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Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 5.20 below. 
TABLE 5.20 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 2 333 1
st
 
Weighted Closeness 2 333 1
st
 
Degree Centrality 1 51 3
rd
 
Weighted Degree 1 51 3
rd
 
Eigenvector Centrality 1 51 3
rd
 
Combined Metric 1 51 3
rd
 
 
The weighted closeness and weighted betweenness both identify the same two genes, TNC 
ranked 18
th
 and the previously mentioned PTK2B ranked 249
th
 by Génie. The other metrics 
all identify one gene, PTK2B.  Applying the scoring system to the top 100 ranked genes for 
each metric, the results in table 5.21 below are given.  
TABLE 5.21 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 4 677 1
st
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Degree Centrality 2 333 2
nd
 
Weighted Betweenness 2 333 2
nd
 
Combined Metric 2 333 2
nd
 
Weighted Degree 1 51 5
th
 
Eigenvector Centrality 1 51 5
th
 
 
The weighted closeness is the best performing metric, identifying four glioblastoma genes, 
TNC and PTK2B identified before, and CTNNB1 and PEG3. The weighted degree and 
eigenvector centrality metrics perform badly, only identifying the same gene that they 
identified before in their top 20 rankings. Finally, extending the scoring system to the top 500 
genes, the following results shown in table 5.22 below are given.  
TABLE 5.22 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN 601 – 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 15 2698 1
st
 
Weighted Closeness 13 2148 2
nd
 
Combined Metric 10 1745 3
rd
 
Degree Centrality 7 1361 4
th
 
Weighted Degree 7 1361 4
th
 
Eigenvector Centrality 6 731 6
th
 
 
Applying the scoring to the top 500 genes identified by each metric, weighted betweenness is 
the best performing metric, followed by the weighted closeness centrality. Whilst all of the 
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metrics perform worse than in the previous category, weighted betweenness, weighted degree 
and degree identify 2 of the top 20 ranked genes by Génie for glioblastoma. TNC ranked 18
th
, 
and PTGS2 ranked 20th, are amongst the respective top 500 genes ranked by these metrics. 
This is still quite a significant result in terms of the biology, and implies that these metrics are 
able to identify biologically significant genes. 
Across the whole network, 102 out of the 299 glioblastoma genes generated by Génie are 
present, 30.43%. This is the lowest amount of genes identified any of the categories; whilst 
this was not the case with the previous category, as the survival time increases it might be 
expected that fewer of the genes identified by Génie might be present.   
5.4.5 More than 800 Survival Days Category 
Table 5.23 below shows the top 20 ranked genes for the combined metric in the GRN for the 
more than 800 survival days glioblastoma category. Two genes, NR2E1 and NBN, appear in 
the list of 299 glioblastoma genes generated by Génie. There is only one glioblastoma subtype 
gene in the table; as well being ranked as the 220
th
 most important glioblastoma gene by 
Génie, the 15
th
 ranked gene NR2E1 is also a proneural subtype signature gene. Again, none of 
the genes that appear in the top 20 ranked list appear in any of the top 20 ranked for the other 
categories.  
49 results are returned GenesetDB for this set of genes, of which 34 relate to the 
drug/chemical class, which are not informative for our purposes. This leaves 15 results, the 
top 10 of which are shown in table A.20 of the appendix. The 6
th
 result should be noted, as 
RAC1 has been highlighted in a study by Chan et al [122] investigating glioblastoma cell 
invasion. 
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TABLE 5.23 TOP 20 RANKED GENES FOR COMBINED METRIC IN MORE THAN 800 SURVIVAL 
DAYS CATEGORY GRN INFERRED USING NOVEL INFERENCE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
ABI1 1 TIAM1 11 
AKR1C3 2 RASSF4 12 
AKR1C1 3 JAK1 13 
OSBPL11 4 NR2E1 14 
ADCYAP1R1 5 RABL3 15 
CALHM2 6 ARPC1A 16 
PARD3 7 NBN 17 
PLAC8 8 ARHGAP12 18 
ABLIM3 9 PACSIN3 19 
TJP2 10 UPF1 20 
 
Table 5.24 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the more than 800 survival days GRN inferred using the novel 
method. 
TABLE 5.24 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING 
NOVEL INFERENCE METHOD 
 
 
Degree 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 1 0.998514131 0.969827884 0.851143211 0.815157589 
Weighted 
Degree 0.998514131 1 0.968143263 0.843257684 0.809975183 
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Eigenvector 
Centrality 0.969827884 0.968143263 1 0.867907565 0.783339875 
Closeness 
Centrality 0.851143211 0.843257684 0.867907565 1 0.758443262 
Betweenness 
Centrality 0.815157589 0.809975183 0.783339875 0.758443262 1 
 
The correlations between the metrics in this category are strong, with the weakest correlation 
between weighted betweenness centrality and weighted closeness centrality have a strength of 
0.75. The next weakest correlation is 0.78. We would expect to see substantial overlap in the 
genes identified by the metrics due to these strong correlations.  
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 5.25 below. 
TABLE 5.25 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR 
EACH METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Degree 1 267 1
st
 
Eigenvector Centrality 1 267 1
st
 
Combined Metric 2 262 3
rd
 
Weighted Closeness 1 182 4
th
 
Weighted Betweenness 1 80 5
th
 
Degree Centrality 0 0 6
th
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The weighted degree and eigenvector centrality are the joint best performing metrics, despite 
identifying one gene less than the combined metric, which identifies the genes NR2E1 and 
NBN. This is due to the weighted degree and eigenvector centrality identifying EPHA2, the 
33
rd
 ranked gene by Génie. Applying the scoring system to the top 100 ranked genes for each 
metric, the results in table 5.26 below are given.  
TABLE 5.26 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 9 1104 1
st
 
Weighted Betweenness 6 964 2
nd
 
Degree Centrality 6 879 3
rd
 
Weighted Degree 4 813 4
th
 
Weighted Closeness 8 808 5
th
 
Eigenvector Centrality 4 800 6
th
 
 
The combined metric again identifies the most genes, and is the best performing metric this 
time. The weighted betweenness is the next best performing, followed by the degree 
centrality. Finally, extending the scoring system to the top 500 genes, the following results 
shown in table 5.27 below are given.  
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TABLE 5.27 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN MORE THAN 800 SURVIVAL DAYS CATEGORY GRN INFERRED USING NOVEL 
METHOD 
 
Metric Number of Génie 
glioblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 22 2517 1
st
 
Weighted Degree 22 2517 1
st
 
Eigenvector Centrality 19 2326 3
rd
 
Weighted Betweenness 20 2195 4
th
 
Combined Metric 17 1899 5
th
 
Weighted Closeness 18 1733 6
th
 
 
Compared to the last category, the metrics identify quite a few glioblastoma genes, with the 
degree and weighted degree the best performing metrics. However, only 1 of the top 30 
glioblastoma genes ranked by Génie are identified by any of the metrics; the gene AKT1, 
ranked 16
th
. It might be expected that as this is the longest survival category time, genes that 
have been identified as being highly ranked for glioblastoma might not be as prominent in the 
network, something that this result would suggest.   
Across the whole network, 139 out of the 299 glioblastoma genes generated by Génie are 
present, 42.81%. This is the 2
nd
 highest amount of genes identified in any of the categories, 
only fewer than the 200 or less category. It might be expected that the lowest amount of Génie 
genes would be present in this category, however it has been noted that highly ranked Génie 
genes do not figure prominently in terms of their network metrics. This suggests that those 
genes most associated with glioblastoma cellular processes are not as active in the network in 
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this category, something that would be expected considering the survival time of this 
category.  
5.5 Metric Performance 
Previously, each of the metrics was ranked based on the top 20, top 100 and top 500 genes 
they identified for each glioblastoma GRN category. This ranking is based on the score of the 
identified genes in the Génie glioblastoma gene list.  
The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 5.28 below are given.  
TABLE 5.28 OVERALL METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN 
INFERRED USING NOVEL INFERENCE METHOD 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More   
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Degree 
Centrality 2nd  3rd  1st  4th  3rd  13 1st  
Weighted 
Degree 1st  3rd  3rd  5th  1st  13 1st  
Combined 
Metric 5th  2nd  3rd  3rd  2nd  15 3rd  
Weighted 
Betweenness 4th  1st  6th  1st  5th  17 4th  
Weighted 
Closeness 6th  5th  2nd  1st  6th  20 5th  
Eigenvector 
Centrality 2nd  6th  5th  6th  3rd  22 6th  
125 
 
Overall, degree and weighted degree are the best performing metrics for this dataset using the 
Z score network inference approach. The degree is the most widely studied and applied 
network metric for analysis, and it appears that for this dataset, it is the most informative 
overall.  If the rankings for just the top 20 genes in each category are taken into consideration, 
the ranks shown in table 5.29 are obtained.  
TABLE 5.29 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN INFERRED 
USING NOVEL INFERENCE METHOD BASED ON TOP 20 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More   
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Eigenvector 
Centrality 1st 1st 1st 3rd 1st 7 1st 
Weighted 
Degree 1st 1st 5th 3rd 1st 11 2nd 
Combined 
Metric 4th 1st 1st 3rd 3rd 12 3rd 
Degree 
Centrality 1st 1st 1st 3rd 6th 12 3rd 
Weighted 
Closeness 4th 6th 1st 1st 4th 16 5th 
Weighted 
Betweenness 4th 1st 6th 1st 5th 17 6th 
 
The degree and weighted degree metrics perform strongly again, but this time their 
performance is bettered by the eigenvector centrality. The popular Google search engine uses 
a variant of the eigenvector centrality, Pagerank, and for this dataset it appears that a metric 
that takes into account the properties of the links of a node as well as the number of links, 
performs better than metrics that simply take into account the number or strength of links. The 
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combined metric also performs well, matching the performance of the degree centrality. 
Taking the ranking for just the top 100 genes into account, the following ranks shown in table 
5.30 obtained. 
TABLE 5.30 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN INFERRED 
USING NOVEL INFERENCE METHOD BASED ON TOP 100 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More 
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Betweenness 1st 1st 4th 2nd 2nd 10 1st 
Weighted 
Closeness 3rd 2nd 1st 1st 5th 12 2nd 
Combined 
Metric 3rd 2nd 4th 2nd 1st 12 2nd 
Degree 
Centrality 3rd 2nd 2nd 2nd 3rd 12 2nd 
Weighted 
Degree 3rd 2nd 2nd 5th 4th 16 5th 
Eigenvector 
Centrality 2nd 6th 6th 5th 6th 25 6th 
 
Weighted betweenness is the best performing metric again, jointly followed by weighted 
closeness and degree centrality. The eigenvector centrality is the worst performing metric this 
time, perhaps somewhat surprising to see the performance decrease by so much as the number 
of genes is increased. Finally, solely taking the network rankings for the top 500 genes into 
account, the following rankings shown in table 5.31 are obtained. 
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TABLE 5.31 METRIC RANKS IN THE DIFFERENT CATEGORIES OF GLIOBLASTOMA GRN INFERRED 
USING NOVEL INFERENCE METHOD BASED ON TOP 500 GENES IDENTIFIED BY EACH METRIC 
 
  
200 or 
fewer 
category 
rank 
201-400 
category 
rank 
401-600 
category 
rank 
601-800 
category 
rank 
More    
than 800 
category 
rank 
Ranking 
totals 
Overall 
rank 
Weighted 
Degree 1st 4th 1st 4th 1st 11 1st 
Degree 
Centrality 2nd 4th 1st 4th 1st 12 2nd 
Weighted 
Betweenness 4th 1st 4th 1st 4th 14 3rd 
Combined 
Metric 5th 2nd 3rd 3rd 5th 18 4th 
Weighted 
Closeness 6th 3rd 5th 2nd 6th 22 5th 
Eigenvector 
Centrality 3rd 6th 6th 6th 3rd 24 6th 
 
Weighted degree is the best performing metric, followed by the degree centrality. The 
weighted betweenness still performs relatively well, but not as well as for the top 100 genes. 
The eigenvector centrality is again the worst performing metric.  
5.6 Distribution of Genes in the Combined Metric Rankings List 
As noted previously, none of the genes that appear in the top 20 combined metric rankings list 
for any category appear in any other. This can be seen on the Venn diagram in figure B.4 of 
the appendix below, showing the distribution of genes in the top 20 combined metric rankings 
list in the categories. Furthermore, extending this to look at the top 100 combined  metric  
rankings lists, shown in figure B.5 of the appendix, this is also the case. This suggests that this 
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approach is suited to identifying specific genes associated with the different glioblastoma 
survival times. 
5.7 Comparison of Glioblastoma Results from different Network Inference Methods 
Having inferred networks for the same survival categories in the glioblastoma dataset using 
both the WGCNA network inference method in the previous chapter, and the Z score based 
network inference method in this chapter, the results can be compared. More specifically, the 
number of ranked glioblastoma genes identified in each of the five categories of network can 
be compared for both network inference methods. In this section, the number and scores of 
the ranked glioblastoma genes identif ied by both the combined metric, and also the best 
performing metric, for the networks inferred using both of the network inference methods for 
each survival category are compared. Table 5.32 below shows the number and scores of 
ranked Génie glioblastoma genes identified in the networks inferred for the 200 or less 
survival days glioblastoma category. 
TABLE 5.32 RANKED GLIOBLASTOMA GENES IDENTIFIED IN 200 OR LESS SURVIVAL DAYS 
CATEGORY GRNS INFERRED USING WGCNA AND NOVEL INFERENCE METHOD 
 
200 or less category Top 20 ranked genes Top 100 ranked genes Top 500 ranked genes 
WGCNA combined 
metric 0 1, score of 165 4, score of 238 
Z Score combined 
metric 0 2, score of 240 17, score of 2391 
WGCNA best 
performing metric 0 1, score of 165 9, score of 1107 
Z Score best 
performing metric 1, score of 6 2, score of 426 24, score of 4170 
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For the 200 or less survival days category, the combined metric in the GRN inferred using the 
Z score approach identifies more ranked glioblastoma genes 2 out of the 3 times. The other 
time, the combined metric fails to identify any ranked glioblastoma genes in either the 
network inferred using WGCNA, or the Z score approach. The best performing metric in the 
network inferred using the Z score approach outperforms the best performing metric in the 
network inferred using WGCNA all three times. Table 5.33 below shows the number and 
scores of ranked Génie glioblastoma genes identified in the networks inferred for the 201-400 
survival days glioblastoma category. 
TABLE 5.33 RANKED GLIOBLASTOMA GENES IDENTIFIED IN 201 - 400 SURVIVAL DAYS 
CATEGORY GRNS INFERRED USING WGCNA AND NOVEL INFERENCE METHOD 
 
201 - 400 category Top 20 ranked genes Top 100 ranked genes Top 500 ranked genes 
WGCNA combined 
metric 0 0 5, score of 370 
Z Score combined 
metric 1, score of 178 2, score of 271 10, score of 1443 
WGCNA best 
performing metric 0 0 6, score of 944 
Z Score best 
performing metric 1, score of 178 3, score of 568 11, score of 1805 
 
This time, the combined metric in the network inferred using the Z score approach identifies 
more ranked glioblastoma genes all 3 times. This is also the case for the best performing 
metric in the network inferred using the Z score approach which outperforms the best 
performing metric in the network inferred using WGCNA all three times. Table 5.34 below 
shows the number and scores of ranked Génie glioblastoma genes identified in the network 
inferred for the 401-600 survival days glioblastoma category. 
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TABLE 5.34 RANKED GLIOBLASTOMA GENES IDENTIFIED IN 401 - 600 SURVIVAL DAYS 
CATEGORY GRNS INFERRED USING WGCNA AND NOVEL INFERENCE METHOD 
 
401 - 600 category Top 20 ranked genes Top 100 ranked genes Top 500 ranked genes 
WGCNA combined 
metric 0 0 3, score of 215 
Z Score combined 
metric 3, score of 469 4, score of 764 20, score of 3457 
WGCNA best 
performing metric 1, score of 273 3, score of 610 10, score of 1895 
Z Score best 
performing metric 3, score of 469 6, score of 1310 23, score of 3979 
 
Again, the combined metric and best performing metrics in the network inferred using the Z 
score approach identify more ranked glioblastoma genes all 3 times.  Table 5.35 below shows 
the number and scores of ranked Génie glioblastoma genes identified in the GRNs inferred for 
the 601-800 survival days glioblastoma category. 
TABLE 5.35 RANKED GLIOBLASTOMA GENES IDENTIFIED IN 601 - 800 SURVIVAL DAYS 
CATEGORY GRNS INFERRED USING WGCNA AND NOVEL INFERENCE METHOD 
 
601 - 800 category Top 20 ranked genes Top 100 ranked genes Top 500 ranked genes 
WGCNA combined 
metric 0 0 3, score of 563 
Z Score combined 
metric 1, score of 51 2, score of 333 10, score of 1745 
WGCNA best 
performing metric 2, score of 268 3, score of 488 6, score of 1036 
Z Score best 
performing metric 2, score of 333 4, score of 677 15, score of 2698 
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As before, the combined metric and best performing metrics in the network inferred using the 
Z score approach identify more ranked glioblastoma genes all 3 times.  Finally, table 5.36 
below shows the number and scores of ranked Génie glioblastoma genes identified in the 
GRNs inferred for the more than 800 survival days glioblastoma category.  
TABLE 5.36 RANKED GLIOBLASTOMA GENES IDENTIFIED IN MORE THAN 800 SURVIVAL 
DAYS CATEGORY GRNS INFERRED USING WGCNA AND NOVEL INFERENCE M ETHOD 
 
More than 800 
category Top 20 ranked genes Top 100 ranked genes Top 500 ranked genes 
WGCNA combined 
metric 0 0 5, score of 450 
Z Score combined 
metric 2, score of 262 9, score of 1104 17, score of 1899 
WGCNA best 
performing metric 0 1, score of 68  10, score of 804 
Z Score best 
performing metric 1, score of 267 9, score of 1104 22, score of 2517 
 
The combined metric and best performing metrics in the network inferred using the Z score 
approach identify more ranked glioblastoma genes all 3 times for this survival category. 
Overall, the combined metric in the networks inferred using the Z score approach outperform 
the combined metric in the networks inferred using the WGCNA method 14 out of 15 times. 
The other time, the combined metric fails to identify any ranked glioblastoma genes. The best 
performing metrics in the networks inferred using the Z score approach outperf orm the best 
performing metrics in the networks inferred using the WGCNA method all 15 times. This 
suggests that as the same metrics were used to identify genes in all of the networks, based on 
the presence of ranked glioblastoma genes, the Z score network inference method outperforms 
the WGCNA network inference method at identifying glioblastoma genes of interest across 
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different survival categories in the glioblastoma dataset. This result could also suggest that 
highly ranked genes identified by the Z score approach that have not been previously 
identified as being of interest for glioblastoma might be worth investigating as potential new 
glioblastoma genes of interest.  
5.8 Discussion 
Having inferred networks for the different survival categories using the Z score absolute value 
approach, and subsequently analysed the results, a number of concluding observations can be 
made. Firstly, unique genes were identified as being prominent in the networks for each of the 
survival categories, using the combined metric. This is a result that is in concordance with 
biological principles; it would be expected that different genes would be involved in cellular 
processes associated with different survival times. It is also a result that biologically could be 
informative, as it specifically highlights different genes associated with specific survival time. 
This was not the case with the correlation based approach, where there was a substantial 
overlap amongst the 100 genes in total identified from the 5 categories, 43 in fact, suggesting 
that the previous approach was not the best suited to identifying specific genes associated 
with specific survival times. Extending the number of genes to the top 100 in each category 
based on the combined metric, there is still no overlap of genes, with only completely unique 
genes in each category.  
Secondly, those genes identified as being of interest show significant variability in their gene 
expression levels across the different survival categories. As was the case with the 
identification of unique genes being prominent in the different survival categories, this is a 
result that observes the biological principles, differences in gene expression levels would be 
expected to be responsible for different gene behaviour in the different survival categories. 
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Furthermore, the biologists believe these results to be a much better representation of the gene 
regulatory processes in the different survival categories than was the case with the results 
presented in the last chapter. 
The identification of genes previously identified in a number of publications, using a solely 
graph theory approach shows the biological relevance of a graph theoretical approach to 
microarray data. The enrichment results of these genes that relate to glioblastoma cellular  
processes also show the biological significance of this approach, with a number of biological 
processes associated with glioblastoma present in the enrichment results. Genes such as 
MAPK3, FOXM1, PTK2B, and NR2E1, have been identified without any prior biological 
knowledge or bias. As was the case with the WGCNA network inference approach, a number 
of glioblastoma subtype signature genes were identified across the evolutionary categories 
using the metrics; however there was no correlation between the ident ification of these as 
being high ranking and the evolutionary category. This is in concordance with the study by 
Verhaak et al that showed the glioblastoma subtypes had a narrow survival range. The results 
in this chapter show that glioblastoma subtype cannot be significantly associated with any of 
the survival categories of network, thereby suggesting that glioblastoma subtype cannot be 
significantly associated with survival time for this dataset. Again, the findings of the Z score 
network inference approach suggest that high network centrality scores for specific genes may 
be a better indicator of glioblastoma survival time, than subtype classification.  
The distribution of the genes in the largest unique cliques is also very different to that in the 
last chapter. In the last chapter, there were 79 genes that were common to all five of the 
cliques. Using the Z score approach, no genes are common to all five cliques; three of the 
largest unique cliques for the categories are comprised of unique genes and the only overlap 
of genes between cliques are the 45 genes that appear in both the 201-400 and 601-800 
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categories. As was the case with the genes ident ified using the combined metric, it would be 
expected that different genes would be involved in the different cellular processes associated 
with different survival times, something that is largely the case with the largest unique 
cliques. The enrichment results for the cliques suggest that particular processes involved in 
glioblastoma occur for different surviva l categories, a result that also highlights the 
differences between the networks of the different categories. 
5.9 Conclusions 
To conclude, in this chapter a network inference method to address the first objective was 
proposed. This method takes into account some of the constraints of using existing network 
inference methods to infer multiple GRNs from a single microarray dataset highlighted in the 
previous chapter, and addresses these. In the next chapter, this method will be applied to two 
neuroblastoma microarray datasets in an attempt to gauge whether it is transferable to other 
cancer microarray datasets.  
The second objective was also addressed; various metrics were used to identify different 
genes in the different categories of glioblastoma GRNs, and the performance of the metrics 
was compared and analysed. Unique genes were identified based on their metric scores for 
each glioblastoma GRN category. Additionally, these genes identified have significant 
variability in their expression levels across the survival categories, two results that are in 
keeping with observed biological phenomena. A greater number of ranked glioblastoma genes 
of interest were identified using the novel approach introduced in this chapter than with the 
WGCNA approach used in the last chapter. 
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Chapter 6 
Analysis of Disease Stage GRNs in Two 
Neuroblastoma Microarray Datasets 
In the previous chapter, a novel network inference method was introduced; this method was 
used to infer a number of GRNs for different survival categories of glioblastoma from a single 
microarray dataset, and graph theory metrics were applied to identify genes of interest in the 
different categories of GRN. In this chapter, the same novel network inference method is 
applied to two neuroblastoma datasets, from well-cited studies by Molenaar et al [123], and 
Wang et al [124]. These two datasets will be referred to as the Molenaar dataset, and the 
Wang dataset, respectively.  
The work in this chapter addresses all three objectives specif ied for this work. Firstly, the 
novel network inference method is used to infer multiple GRNs from two different microarray 
datasets of the same disease; thereby investigating the transferability of the method, by 
applying it to two different microarray datasets of the same disease. A different type of 
disease microarray dataset is used than in the last chapter.  
Secondly, different graph theory metrics are applied to the GRNs to identify high ranking 
genes. In the previous two chapters, a number of genes previously highlighted in various 
studies as being relevant to glioblastoma were identified through the application of graph 
theory metrics to the GRNs inferred. This approach is repeated here; to investigate whether 
this approach is also valid for other disease type microarray datasets, in this case 
neuroblastoma. 
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Thirdly, the GRN networks inferred for the disease stages that are common to both  the 
Molenaar and Wang neuroblastoma microarray datasets are compared. This is carried out with 
the aim of investigating whether repeatable results are obtained across different microarrays 
for the same disease, and whether as a result common genes are identified with the same 
disease stage across both datasets. 
6.1 Neuroblastoma Microarray Datasets 
Having applied the Z score network inference technique to a glioblastoma dataset, in this 
chapter it is applied to neuroblastoma. Neuroblastoma is the most commonly diagnosed 
extracranial cancer in infancy; it is an embryonal tumour of the autonomic nervous system, 
with an incidence of 10.2 cases per million in children under 15 years of age [125]. It is 
highly variable; a staging system previously developed to classify neuroblastoma between 
1986 and 1988, the International Neuroblastoma Staging System, INSS, has been further 
refined recently based on the correlation between MYCN amplification and survival [126]. 
Whilst the two previous chapters detailed the analysis of one dataset, in this chapter two 
datasets from two independent well-cited neuroblastoma studies will be used. The rationale 
for using two datasets is to investigate whether results can be replicated across datasets from 
different studies. Due to the use of greatly varying training datasets for the creation and 
validation of network inference techniques, replicating results using network inference 
techniques across different datasets is something of an issue. With the aim of investigating 
whether results can be replicated using the Z score network inference, the two datasets from 
the well-cited Molenaar et al [123], and Wang et al [124], studies will be used.  
In order to apply the same inference and analysis to both datasets, the genes that are common 
to both of the datasets can be used. There are 4829 genes common to the Molenaar and Wang 
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datasets. The Molenaar dataset consists of 88 samples, and the Wang dataset comprises 101 
samples. Four categories of samples were used from both of these neuroblastoma datasets, 
following input from biologists. INSS stage was used as an initial class discriminator; stage 4 
samples were then further classified based on whether the gene MYCN was amplified or not. 
The amplification of the gene MYCN in stage 4 neuroblastoma is an area of particular interest 
for many biologists researching neuroblastoma [127], following feedback from biologists this 
was used as part of the criteria for categorisation. Those with significant MYCN amplification 
were labelled stage 4M, and those without significant amplification labelled stage 4. Due to 
the absence of INSS stage 2 samples in the Wang dataset, all stage 2 samples in the Molenaar 
dataset were discarded. Likewise, all stage4S samples were also discarded from the Molenaar 
dataset. This left 61 samples in the Molenaar dataset, and 101 samples in the Wang dataset. 
Table 6.1 shows the number of samples in each category for the Verbeeg and Wang datasets.  
TABLE 6.1 NUMBER OF SAMPLES IN THE COMMON NEUROBLASTOMA CATEGORIES IN THE 
TWO DATASETS 
 
Category Number of 
Samples 
Molenaar 
Dataset 
Number of 
Samples 
Wang 
Dataset 
Stage 1 8 28 
Stage 3 13 23 
Stage 4 20 30 
Stage 4M 20 20 
 
From table 6.1 above, it can be seen that the samples are spread out quite well across the 
categories. As with the glioblastoma dataset used previously, one analysis that highlights the 
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value of the network inference method on the categories of data is to rank the mean 
expression for each gene in the categories, and see how well these rankings correlate across 
the four categories. This gives an idea of how homogenous the data is across the categories 
before the networks are constructed. This analysis also allows an initial comparison of the two 
datasets, to see how similar they are in terms of the expression levels of the common genes.  
Table 6.2 below shows the correlations for the Molenaar dataset, and table 6.3 shows the 
correlations for the Wang dataset. Table 6.4 shows the correlations between the common 
categories between both neuroblastoma datasets. 
TABLE 6.2 CORRELATION SCORES OF AVERAGE GENE EXPRESSION RANKINGS MOLENAAR 
DATASET  
 
Category Stage 1 Stage 3 Stage 4 Stage 4M 
Stage 1 1 0.976 0.981 0.963 
Stage 3 0.976 1 0.979 0.969 
Stage 4 0.981 0.979 1 0.983 
Stage 4M 0.963 0.969 0.983 1 
 
TABLE 6.3 CORRELATION SCORES OF AVERAGE GENE EXPRESSION RANKINGS WANG 
DATASET 
 
Category Stage 1 Stage 3 Stage 4 Stage 4M 
Stage 1 1 0.976 0.976 0.939 
Stage 3 0.976 1 0.971 0.934 
Stage 4 0.976 0.971 1 0.958 
Stage 4M 0.939 0.934 0.958 1 
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TABLE 6.4 CORRELATION SCORES OF AVERAGE GENE EXPRESSION RANKINGS BETWEEN 
MOLENAAR   AND WANG DATASETS 
 
Category Wang 
Stage 1 
Wang 
Stage 3 
Wang 
Stage 4 
Wang 
Stage 4M 
Molenaar 
Stage 1 0.631 0.608 0.604 0.591 
Molenaar 
Stage 3 0.616 0.588 0.588 0.590 
Molenaar 
Stage 4 0.631 0.608 0.621 0.621 
Molenaar 
Stage 4M 0.610 0.592 0.602 0.630 
 
The correlations for the first two tables, table 6.2 and table 6.3, inter-dataset, are both positive 
and extremely strong, again showing that by simply looking at gene expression in each 
category it is difficult to distinguish the categories, and gain meaningful information about 
them. However, the correlations across the two datasets are weaker, table 6.4, showing that 
the datasets are somewhat different from each other. This result would suggest that the gene 
expression levels of the common genes are significantly different from each other, and t hat as 
a result of this, different results might be expected from the two datasets. This is in keeping 
with the earlier observation about repeatability of results across different datasets; differences 
in the datasets used leads to a lack of repeatable observations. This is something that might be 
also expected to be the case here.   
6.2 Network Level Metrics in the Neuroblastoma GRNs 
As was the case in the last chapter, before looking at the individual genes in the networks, the 
network level metrics will be calculated and analysed. These are shown in table 6.5 for the 
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Molenaar dataset, and table 6.6 for the Wang dataset. The same metrics will be used again; 
weighted degree assortativity, degree asssortativity, diameter, and network clustering. The 
largest unique cliques will again be calculated for each of the networks for the two different 
datasets, and the genes that comprise these cliques will be investigated for both enrichment 
and the presence of neuroblastoma genes of interest using Génie. The list generated by Génie 
for neuroblastoma is also much larger than for glioblastoma, in fact only the top 500 ranked 
genes for neuroblastoma will be used. The Génie list of the scoring genes for neuroblastoma 
is shown in table A.21 of the appendix. Unlike with glioblastoma, there are no neuroblastoma 
subtype gene lists to use.  
TABLE 6.5 NETWORK LEVEL SCORES FOR THE DISEASE STAGE GRNS INFERRED FROM THE 
MOLENAAR DATASET USING NOVEL INFERENCE M ETHOD 
 
Metric Stage 1 Stage 3 Stage 4 Stage 4M 
Weighted Degree 
Assortativity 
-0.449 -0.295 -0.288 -0.284 
Degree Assortativity -0.476 -0.312 -0.300 -0.278 
Diameter 0.608 1.760 1.545 1.859 
Network Clustering 0.292 0.482 0.399 0.347 
Largest Clique Size 84 134 105 72 
 
TABLE 6.6 NETWORK LEVEL SCORES FOR THE NEUROBLASTOMA DISEASE STAGE GRNS 
INFERRED FROM THE WANG DATASET USING NOVEL INFERENCE METHOD 
 
Metric Class 1 Class 3 Class 4 Class 4M 
Weighted Degree 
Assortativity 
-0.276 -0.077 -0.289 -0.419 
Degree Assortativity -0.265 -0.069 -0.280 -0.424 
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Diameter 1.654 2.227 2.093 2.545 
Network Clustering 0.328 0.546 0.330 0.455 
Largest Clique Size 63 122 76 114 
 
Looking at the network level metric scores for the two neuroblastoma datasets, some patterns 
emerge between metric level score and neuroblastoma category. As the neuroblastoma stage 
increases from stage 1 to stage 4M, the weighted degree assortativity and degree assortativity 
values both increase for the Molenaar dataset, although this is not the case with the Wang 
dataset. For both datasets, the value of the diameter is greatest in the stage 4M category 
networks. As noted before, diameter can be indicative of how easily genes are able to 
communicate in a network; a low relative value might indicate genes are able to communicate 
with each other much easier than when there is a high relative diameter value. As the most 
advanced neuroblastoma stage, stage 4M, has the highest diameter for both datasets, this could 
be an indication that genes involved in certain cellular processes are not able to communicate 
easily with each other, contributing to the more advanced stage of neuroblastoma. Between the 
two datasets, only the diameter values correlate perfectly, again indicating that the two datasets 
are somewhat different. As noted before, the most important observations to be made about the 
networks on a network level could possibly be made about the size and composition of the 
largest unique cliques in the networks. This is examined in depth in the following section.  
6.3 Largest Clique Calculation and Analysis 
The size and composition of the largest unique cliques in the GRNs for the different 
categories can be informative. It is also of interest to compare the largest unique cliques for 
the categories in the networks inferred from both datasets. A large number of common genes 
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in the same category cliques across both datasets would be indicative of the same genes being 
involved in important cellular processes for specific neuroblastoma stages.  
As well as identifying common and unique genes in these cliques, it is informative to see 
whether these genes have been previously identified as being neuroblastoma genes of interest 
and appear on the list of Génie neuroblastoma genes. The list of genes that comprise the 
largest unique clique in each network can also be checked for enrichment using the 
genesetDB website. The table below for the networks inferred from the Molenaar dataset 
shows the number of unique genes in each clique, whether these genes are present in the 
largest unique cliques in the other dataset, and also whether any of the genes in the clique 
appear on the Génie neuroblastoma gene list.   
TABLE 6.7 NEUROBLASTOMA GENES OF INTEREST IN THE LARGEST UNIQUE CLIQUES OF THE 
NEUROBLASTOMA DISEASE STAGE GRNS INFERRED FROM THE MOLENAAR DATASET 
 
 Clique 
Size 
Genes 
present 
in other 
Molenaar 
cliques 
Genes 
present 
in Wang 
Stage 1 
clique 
Genes 
present 
in Wang 
Stage 3 
clique 
Genes 
present 
in Wang 
Stage 4 
clique 
Genes 
present 
in Wang 
Stage 
4M 
clique 
Number of 
Génie 
genes and 
score 
Molenaar 
Stage 1  
84 4 0 12 1 1 13, score 
of 3618 
Molenaar 
Stage 3  
134 1 0 1 4 0 12, score 
of 3000 
Molenaar 
Stage 4  
105 5 0 26 2 0 21, score 
of 5211 
Molenaar 
Stage 4M  
72 6 0 15 1 0 6, score of 
1484 
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Across the cliques, a number of neuroblastoma genes that appear the list generated by Génie 
are present. Stage 4 has both the highest number of Génie genes, and also the highest score of 
genes identified. Stage 4M has the lowest number of genes identified, and the lowest score. 52 
genes that appear on the list generated by Génie for neuroblastoma are present in the cliques, 
which represents just over 10% of the complete list used. This is quite a significant 
proportion, and is suggestive that the genes in the cliques are important neuroblastoma genes. 
A number of genes in these cliques are also present in the cliques in the Wang dataset, most 
notably the largest unique clique for stage 4 that has 33 genes in cliques in the Wang dataset. 
However, there are only 3 genes common to the same category clique in both datasets, 
another indicator of how different the two datasets are. The Venn diagram in figure B.6 of the 
appendix shows the distribution of the genes in the largest unique cliques in the GRNs 
inferred from the Molenaar dataset.   
There are 395 genes in total in the four cliques, with 379 being unique to one clique. There are 
no genes common to either all four cliques, or three cliques. However, none of the cliques are 
comprised entirely of unique genes. The high proportion of unique genes and very few shared 
genes suggests that the cellular processes are very different in the cliques in the different 
neuroblastoma categories. This result corresponds to the biology, that suggests that the 
neuroblastoma stages are different from each other and as such different cellular processes are 
involved in the different stages.  
Table 6.8 below details the number of unique genes in each clique inferred for the networks 
from the Wang dataset, whether these genes are present in the largest unique cliques in the 
other dataset, and also whether any of the genes in the clique appear on the Génie 
neuroblastoma gene list.   
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TABLE 6.8 NEUROBLASTOMA GENES OF INTEREST IN THE LARGEST UNIQUE CLIQUES OF THE 
NEUROBLASTOMA DISEASE STAGE GRNS INFERRED FROM THE WANG DATASET 
 
 Clique 
Size 
Genes 
present 
in other 
Wang 
cliques 
Genes 
present in 
Molenaar 
Stage 1 
clique 
Genes 
present 
in 
Molenaar 
Stage 3 
clique 
Genes 
present in 
Molenaar 
Stage 4 
clique 
Genes 
present in 
Molenaar 
Stage 4M 
clique 
Number 
of Génie 
genes 
and score 
Wang 
Stage 1 
Clique 
63 0 0 0 0 0 3, score 
of 525 
Wang 
Stage 3 
Clique 
122 0 12 1 26 12 16, score 
of 4791 
Wang 
Stage 4 
Clique 
76 0 1 4 2 1 4, score 
of 1237 
Wang 
Stage 4M 
Clique 
114 0 1 0 1 0 4, score 
of 1580 
 
As was the case with the cliques in the networks inferred from the Molenaar dataset, across 
these cliques a number of neuroblastoma genes that appear the list generated by Génie are 
present. Stage 3 has both the highest number of Génie genes, and also the highest score of 
genes identified. Stage 1 has the lowest number of genes identified, and the lowest score.  A 
substantially lower number of genes that appear on the list generated by Génie for 
neuroblastoma are present in the cliques, 27, compared to the Molenaar dataset, 52. This 
could suggest that the cliques inferred for the networks in the Molenaar dataset are more 
biologically relevant for neuroblastoma, although this is based on the implication that 
presence of genes in the Génie neuroblastoma list is indicative of biological relevance. A 
number of genes in these cliques are also present in the cliques in the Molenaar dataset, most 
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notably the largest unique clique for stage 3 that has 51 genes in cliques in the Wang dataset. 
However, there are only 3 genes common to the same category clique in both datasets, 
another indicator of how different the two datasets are. The Venn diagram in figure B.7 of the 
appendix shows the distribution of the genes in the largest unique cliques in the GRNs 
inferred from the Wang dataset.   
There are 375 genes in total in the four cliques. Unlike the cliques in the Molenaar dataset, 
there are no genes common to either two, three or four cliques, with each gene only appearing 
in one clique.  This result is even more indicative that the cellular processes are very different 
in the cliques in the different neuroblastoma categories than for the Molenaar dataset. Again, 
this result corresponds to the biology, that suggests that the neuroblastoma stages are different 
from each other and as such different cellular processes are involved in the different stages.  
6.4 Enrichment Results for the Largest Unique Cliques in the GRNs Inferred from the 
Molenaar Dataset 
Having investigated the distribution of genes in the cliques in the two datasets, the next step is 
to investigate the enrichment of these genes using GenesetDB.  In this section, the enrichment 
results for the genes that comprise the largest unique cliques in the GRNs inferred from the 
Molenaar dataset will be analysed. Table A.22 in the appendix shows the top 10 results for the  
genes that comprise the largest unique clique in the GRN inferred for stage 1 in the Molenaar 
dataset. Of interest is the presence of enrichment results related to immune function. As noted 
by De Preter et al in a 2006 study [128], neuroblastomas are characterised by an over-
representation of genes involved in immune response, cell growth, and cell cycle. 
Table A.23 in the appendix shows the top 10 results for enrichment of the genes that comprise 
the stage 3 largest unique clique. The 10
th
 result detailing Interferon alpha/beta signaling is of 
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note; a 2010 study by Dedoni et al [129] detailed how Interferon-β induces apoptosis in human 
SH-SY5Y neuroblastoma cells. 
Table A.24 of the appendix shows the top 10 results for enrichment of the genes that comprise 
the stage 4 largest unique clique. Unlike the enrichment results for the two previous cliques, 
there are no results that immediately stand out for neuroblastoma. 
The enrichment results for the genes that comprise the largest unique clique in stage4M 
network inferred from the Molenaar dataset are shown in table A.25 of the appendix. The 10
th
 
result, detailing negative regulation of transforming growth factor beta (TGF-β) receptor 
signaling pathway, is of particularly note for this clique; a 2000 study by Iolascon et al [130] 
specifically highlighted reduced expression of TGF-β in high stage neuroblastomas. That it 
appears in the top ten enrichment results for stage 4M, the highest stage neuroblastoma, 
corresponds with this study.  
6.5 Enrichment Results for the Largest Unique Cliques in the GRNs Inferred from the 
Wang Dataset 
In this section, the enrichment results for the genes that comprise the largest unique cliques in 
the GRNs inferred from the Wang dataset will be analysed.  For the list of genes that 
comprise the largest unique clique in the GRN inferred for stage 1, only one result is returned 
from GenesetDB, shown in table A.26 of the appendix. This implies that this combination of 
genes has not been identified as being involved in biological processes. 
Table A.27 of the appendix shows the top 10 results for the enrichment of the genes that 
comprise the stage 3 largest unique clique. The 2
nd
 result in the table, detailing SP1 gene 
regulation, should be noted as a 2003 study by Tuthill et al [131] highlighted the role that SP1 
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plays in terms of MYCN amplification. As MYCN is not amplified in the stage 3 samples in 
the Wang dataset, this result would suggest that SP1 might play a role in this. 
For the list of genes that comprise the largest unique clique in stage 4, no enrichment results 
are returned from GenesetDB. This would imply that this combination of genes has not been 
identified as being involved in biological processes.  
The top 10 enrichment results for the genes that comprise the stage 4M largest unique clique  
are shown in table A.28 of the appendix. There are no results that immediately stand out for 
neuroblastoma. 
6.6 Node Level Metrics of the GRNs Inferred from the  Molenaar Dataset 
Having investigated the network level metrics, and the largest unique cliques in the networks, 
the focus is now the node level metrics. As before, a combined metric comprised of weighted 
degree, weighted betweenness and weighted closeness, is used to infer a list of top 20 ranked 
genes for this survival category, and all subsequent categories. Enrichment and the presence 
of previously identified neuroblastoma genes will be investigated for the combined list.  
Correlations will be calculated for the metrics, and the metrics will be scored using the 500 
top ranked genes for neuroblastoma returned by Génie.  
6.6.1 Stage 1 Molenaar Dataset 
Table 6.9 shows the top 20 ranked genes for the combined metric in the GRN for the stage 1 
category inferred from the Molenaar dataset. Four of these genes in the table appear in the list 
of 500 neuroblastoma genes generated by Génie; AKR1B1, NGFR, NOV, and CCL2. This 
represents quite a high proportion of genes having been previously identified as interest for 
neuroblastoma. None of the genes that appear in the top 20 ranked list appear in any of the top 
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20 ranked for the other categories. As was the case with the largest unique cliques, this 
suggests clearly distinguishable differences between the neuroblastoma categories in terms of 
the genes that are playing important roles in cellular processes.  
A number of interesting enrichment results are returned for this list of genes, shown in table 
A.29. As well as the previously mentioned SP1 regulation, the 8
th
 result in relation to TNFR2 
is worth highlighting as TNFR2 is proposed as a novel target to modulate cell responses to 
nerve growth factor by Takei et al [132], a process involved in neuroblastoma. 
TABLE 6.9 TOP 20 RANKED GENES FOR COMBINED METRIC IN NEUROBLASTOMA STAGE 1 
GRN INFERRED FROM MOLENAAR DATASET  
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
SLC22A4 1 SMPDL3A 11 
DOCK2 2 NGFR 12 
MEOX2 3 FCER1A 13 
CLEC10A 4 NOV 14 
IKBKAP 5 SLC26A2 15 
ASB4 6 SH3BP5 16 
PDE4DIP 7 TNFAIP3 17 
AKR1B1 8 BTG2 18 
TM7SF2 9 CCL2 19 
ABCB9 10 ARHGAP25 20 
 
Table 6.10 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 1 GRN inferred from the Molenaar dataset.  
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TABLE 6.10 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN  STAGE 1 GRN INFERRED FROM MOLENAAR DATASET  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.926 0.835 0.756 
Weighted 
Degree 0.998 1 0.929 0.826 0.747 
Eigenvector 
Centrality 0.926 0.929 1 0.773 0.670 
Closeness 
Centrality 0.835 0.826 0.773 1 0.747 
Betweenness 
Centrality 0.756 0.747 0.670 0.747 1 
 
From table 6.10 above, it can be seen that all of metrics have a positive correlation greater 
than 0.67. These strong correlations imply that there is a substantial overlap in the genes that 
the metrics rank highly, as was the case for a lot of the metrics in the last chapters. Therefore, 
we would expect that there will be quite a lot of overlap in the genes that these metrics 
identify. 
The list of genes generated by Génie for neuroblastoma will be used to score the metrics, 
limited to the top 500 ranking genes. This is due to a great deal of genes returned, and some 
specificity of results is desired. Starting with the top 20 ranked genes by each metric, table 
6.11 below shows the scores that are obtained.  
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TABLE 6.11 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 1 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 4 1106 1
st
 
Weighted Betweenness 3 720 2
nd
 
Eigenvector Centrality 3 707 3
rd
 
Weighted Closeness 3 634 4
th
 
Degree Centrality 2 589 5
th
 
Weighted Degree 2 589 5
th
 
 
The combined metric performs best, followed by weighted betweenness and e igenvector. The 
combined metric identifies four genes, as noted earlier; the weighted betweenness and 
eigenvector centrality identify three genes. Applying the scoring system to the top 100 ranked 
genes for each metric, the results in table 6.12 below are given.  
TABLE 6.12 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 1 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 14 3924 1
st
 
Weighted Degree 14 3924 1
st
 
Combined Metric 14 3749 3
rd
 
Weighted Betweenness 8 2410 4
th
 
Weighted Closeness 11 2384 5
th
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Eigenvector Centrality 6 1919 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the weighted 
degree and degree centrality are the joint best performing metrics, identifying the same 14 
genes. The combined metric also identifies 14 genes, but these are not as high scoring.  The 
weighted betweenness and eigenvector centrality metrics perform relatively poorly. Finally, 
extending the scoring system to the top 500 genes, the following results shown in table 6.13 
below are given.  
TABLE 6.13 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 1 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 41 10823 1
st
 
Degree Centrality 39 10717 2
nd
 
Weighted Degree 39 10717 2
nd
 
Eigenvector Centrality 37 10360 4
th
 
Weighted Closeness 40 10032 5
th
 
Weighted Betweenness 35 9464 6
th
 
 
The combined metric performs best, followed by weighted degree and degree centrality. Four 
of the top 25 ranked genes by Génie for neuroblastoma are identified by these metrics; AKT1 
ranked 3
rd
, NFKB1 ranked 14
th
, STAT3 ranked 17
th
, and PLAU ranked 21
st
.  This result 
suggests that these metrics are able to identify biologically relevant genes of interest in the 
network inferred from the stage 1 samples in the Molenaar dataset.  
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Across the whole network, 142 out of the 500 neuroblastoma genes generated by  Génie are 
present, with 41 of these identified by the combined metric. However, only 4 out of the top 50 
Génie ranked neuroblastoma genes are present in the top 500 ranked neuroblastoma genes for 
any of the metrics. This shows that many of the genes that Génie highlights as being 
important for neuroblastoma are not identified by the network metrics in this category. This 
could be due to two reasons. Either the network inference method and metrics are not accurate 
in re-constructing and identifying the gene regulatory processes that take place, or these genes 
identified by Génie do not in fact play an important role in this neuroblastoma. It should also 
be noted that there is no stage specific information present with the genes identified by Génie, 
i.e. specific genes are not associated with specific neuroblastoma stages. 
6.6.2 Stage 3 Molenaar Dataset 
Table 6.14 shows the top 20 ranked genes for the combined metric in the GRN inferred for 
the stage 3 category from the Molenaar dataset. One of the genes in the table, , ADCYAP1, 
appears in the list of 500 neuroblastoma genes generated by Génie, ranked as the 330
th
 most 
important gene for neuroblastoma. Again, none of the genes that appear in the top 20 ranked 
list appear in any of the top 20 ranked for the other categories. As was the case with the  
previous category, this suggests that different genes are playing important roles in the 
different neuroblastoma stages.   
No enrichment results are returned for the list of top 20 ranked genes, implying that this 
particular combination of genes has not been identified as being involved in any significant 
biological processes. The presence of only one gene in the top 500 list returned by Génie also 
suggests that this list of genes might not be as biologically relevant as the previous list.   
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TABLE 6.14 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 3 GRN INFERRED FROM 
MOLENAAR DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
LSAMP 1 CETN2 11 
CD59 2 ADCYAP1 12 
GHITM 3 ATP6V1D 13 
PSMD10 4 ARL1 14 
SNCG 5 HIPK3 15 
CRYGC 6 PEA15 16 
CHUK 7 NEBL 17 
ANAPC13 8 PDE8B 18 
RIT2 9 TOR1AIP1 19 
ZNF365 10 UBE2V2 20 
 
Table 6.15 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 3 GRN inferred from the Molenaar dataset.  
TABLE 6.15 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN STAGE 3 GRN INFERRED FROM MOLENAAR DATASET  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.905 0.877 0.771 
Weighted 
Degree 0.998 1 0.902 0.870 0.765 
Eigenvector 
Centrality 0.905 0.902 1 0.889 0.643 
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Closeness 
Centrality 0.877 0.870 0.889 1 0.734 
Betweenness 
Centrality 0.771 0.765 0.643 0.734 1 
 
From table 6.15 above, it can be seen that all of metrics have a positive correlation greater 
than 0.64. The correlation scores are very similar to the scores for the previous neuroblastoma 
stage. These strong correlations again imply that there is a substantial overlap in the genes 
that the metrics rank highly, as was the case for a lot of the metrics in the last chapters.  
Therefore, we would expect that there will be quite a lot of overlap in the genes that these 
metrics identify. 
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.16 below. 
TABLE 6.16 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 3 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 1 171 1
st
 
Weighted Closeness 1 171 1
st
 
Combined Metric 1 171 1
st
 
Degree Centrality 0 0 4
th
 
Weighted Degree 0 0 4
th
 
Eigenvector Centrality 0 0 4
th
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As noted previously, only one gene on the top 500 ranked list is identified by the combined 
rank, and this is also the case for both the weighted degree and degree centrality, which are 
the best performing metrics along with the combined metric. Applying the scoring system to 
the top 100 ranked genes for each metric, the results in table 6.17 below are given. 
TABLE 6.17 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 3 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 10 2272 1
st
 
Degree Centrality 6 1236 2
nd
 
Weighted Degree 6 1236 2
nd
 
Weighted Closeness 4 752 4
th
 
Combined Metric 5 585 5
th
 
Weighted Betweenness 3 365 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the eigenvector 
centrality is the best performing metric, identifying ten genes. One of these genes identified, 
FGF2, is the 30
th
 ranked gene for neuroblastoma. Fewer genes are identified by the metrics 
than for the last neuroblastoma stage. Finally, extending the scoring system to the top 500 
genes, the following results shown in table 6.18 below are given. 
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TABLE 6.18 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 3 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 38 10478 1
st
 
Degree Centrality 30 8225 2
nd
 
Weighted Degree 30 8225 2
nd
 
Combined Metric 26 6517 4
th
 
Weighted Closeness 25 6509 5
th
 
Weighted Betweenness 23 5979 6
th
 
 
The eigenvector centrality out-performs the other metrics when the scoring is applied to the 
top 500 genes identified by each metric. However, only one of the top 25 ranked genes for 
neuroblastoma is identified by eigenvector centrality, compared to 4 of t he top 25 by the best 
performing metric for the previous neuroblastoma stage. Extending this, only 3 of the top 50 
ranked genes are identified, again worse than the best performing metric for the last category.  
All of the metrics perform worse than for the previous category.  This is also shown across the 
whole network. 78 out of the 500 neuroblastoma genes generated by Génie are present, fewer 
genes identified than in the last category.  
6.6.3 Stage 4 Molenaar Dataset 
Table 6.19 shows the top 20 ranked genes for the combined metric in the stage 4 GRN for the 
Molenaar dataset. None of the genes in the table appear in the list of 500 neuroblastoma genes 
generated by Génie. As with the two previous categories, none of the genes that appear in the 
table are present in the top 20 rankings for any of the other categories.  
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Entering this list of genes into GenesetDB with a FDR of 0.05, 2 results are returned, shown 
in table A.30 of the appendix. This follows on from the previous category, where no 
enrichment results were returned. This suggests that checking the top ranked genes for 
neuroblastoma category might not be particularly informative.  
TABLE 6.19 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 4 GRN INFERRED FROM 
MOLENAAR DATASET  
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
TRIP12 1 ZNF337 11 
MIPEP 2 CAPNS1 12 
CHGA 3 WFDC2 13 
SLC8A2 4 PDCD6 14 
INS 5 UBE2M 15 
LYPLA2 6 CDH4 16 
RPS6KB1 7 MPV17 17 
CELSR1 8 PAK4 18 
PSMC4 9 SLC35A2 19 
PNMT 10 DPF1 20 
 
Table 6.20 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 4 GRN inferred from the Molenaar dataset.  
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TABLE 6.20 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN STAGE 4 GRN INFERRED FROM MOLENAAR DATASET  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.896 0.847 0.813 
Weighted 
Degree 0.998 1 0.893 0.841 0.806 
Eigenvector 
Centrality 0.896 0.893 1 0.811 0.691 
Closeness 
Centrality 0.847 0.841 0.811 1 0.829 
Betweenness 
Centrality 0.813 0.806 0.691 0.829 1 
 
There are again strong correlation scores between the metrics, with the minimum correlation 
score being 0.69. As before, this implies significant overlap in the genes ranked highly by the 
different metrics.  Applying the scoring system to the top 20, top 100, and top 500 genes 
identified by each of metrics, the metrics can be ranked. The scores for the top 20 genes 
identified by each metric are shown in table 6.21 below. 
TABLE 6.21 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 4 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 6 1479 1
st
 
Weighted Degree 5 1276 2
nd
 
Degree Centrality 3 676 3
rd
 
159 
 
Weighted Betweenness 1 461 4
th
 
Weighted Closeness 0 0 5
th
 
Combined Metric 0 0 5
th
 
 
The eigenvector and weighted degree centrality metrics perform strongly, identifying six and 
five genes, respectively, from the top 500 ranked neuroblastoma genes. Both these metrics 
identify the 8
th
 ranked gene MMP2 in their respective top 20 rankings. The weighted 
closeness and combined metric do not identify any genes. Applying the scoring system to the 
top 100 ranked genes for each metric, the results in table 6.22 below are given.  
TABLE 6.22 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 4 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 22 5676 1
st
 
Degree Centrality 16 4557 2
nd
 
Weighted Degree 17 4469 3
rd
 
Combined Metric 10 3124 4
th
 
Weighted Betweenness 9 2845 5
th
 
Weighted Closeness 5 1625 6
th
 
 
The eigenvector centrality again is the best performing metric, followed by the degree and 
weighted degree centrality metrics. Four of the top 50 ranked genes for neuroblastoma; 
MMP2, MMP14, ADAM17, and MUC1, are identified by eigenvector centrality from the 22 
genes it identifies.  The metrics perform better than in the previous two neuroblastoma 
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categories. Finally, extending the scoring system to the top 500 genes, the following results 
shown in table 6.23 below are given.  
TABLE 6.23 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 4 GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 64 17763 1
st
 
Degree Centrality 54 15091 2
nd
 
Weighted Degree 54 15091 2
nd
 
Weighted Closeness 50 14366 4
th
 
Combined Metric 48 13480 5
th
 
Weighted Betweenness 47 13380 6
th
 
 
Overall, the metrics perform better for this category than for the two previous Molenaar 
neuroblastoma categories, identifying a significant number of top 500 ranked neuroblastoma 
genes. The eigenvector centrality again is the best performing metric, 9 of the 64 ranked genes 
it identifies are in the top 50.  The degree and weighted degree metrics are the next best 
performing metrics, each identifying the same 54 neuroblastoma genes. Even the worst 
performing metric, weighted betweenness, for this neuroblastoma identifies 47 genes and 
performs better than the best performing metrics for the two previous neuroblastoma 
categories. These results suggest that for this neuroblastoma category, the metrics perform 
much better at identifying neuroblastoma genes of interest. The stronger performance of the 
metrics is reinforced by the identification of 156 out of the 500 neuroblastoma genes 
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generated by Génie across the whole network, more than for the two previous neuroblastoma 
categories.   
6.6.4 Stage 4M Molenaar Dataset 
Table 6.24 shows the top 20 ranked genes for the combined in the stage 4M GRN for the 
Molenaar dataset. Four of the genes in the table appear in the list of 500 neuroblastoma genes 
generated by Génie; MYCN ranked 1
st
, SMAD3 ranked 197
th
, PDGFRA ranked 223
rd
, and 
PFKFB3 ranked 383
rd
.  Bearing in mind that the criteria for the stage 4M neuroblastoma 
category is MYCN amplification, this result corresponds with the underlying biology. As 
before, none of the genes that appear in the top 20 ranked list appear in any of the top 20 
ranked for the other categories.  
Looking at the enrichment results returned for this list of genes, shown in table A.31 of the 
appendix, the 9
th
 result is most if interest. The genes MYCN, FES, and PDGFRA, are 
identified by the Cancer Genes database [133]. Although it should be noted that this is a 
database for identifying genes that are generally of interest for cancer genomics, and is not 
specific to neuroblastoma.  
TABLE 6.24 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 4M GRN INFERRED 
FROM MOLENAAR DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
MYCN 1 INPP4B 11 
FES 2 PFAS 12 
TGIF2 3 RAB32 13 
GPR125 4 HDAC9 14 
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SOCS2 5 STC2 15 
HS3ST1 6 RSL1D1 16 
SMAD3 7 PFKFB3 17 
FBL 8 NFIX 18 
PDGFRA 9 MGP 19 
DDX10 10 APEX1 20 
 
Table 6.25 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 4M GRN inferred from the Molenaar dataset.  
TABLE 6.25 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
DIFFERENT METRICS TO THE GENES IN STAGE 4M GRN INFERRED FROM MOLENAAR DATASET  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.99818175 0.960905689 0.834491125 0.871084923 
Weighted 
Degree 0.99818175 1 0.95895602 0.827033544 0.868246578 
Eigenvector 
Centrality 0.960905689 0.95895602 1 0.899516798 0.822331147 
Closeness 
Centrality 0.834491125 0.827033544 0.899516798 1 0.775013763 
Betweenness 
Centrality 0.871084923 0.868246578 0.822331147 0.775013763 1 
 
The correlation scores between the metrics are again strong, with the weakest correlation 
having a score of 0.77. Again there will still be substantial overlap between the genes 
identified by the metrics. 
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Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.26 below. 
TABLE 6.26 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 4M GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 4 1200 1
st
 
Combined Metric 4 1200 1
st
 
Eigenvector Centrality 3 1125 3
rd
 
Degree Centrality 3 1082 4
th
 
Weighted Degree 3 1082 4
th
 
Weighted Closeness 3 1082 4
th
 
 
The weighted betweenness is the best performing metric. In addition to identifying the genes 
MYCN, PDGFRA, and SMAD3, that the other metrics all identify, it also identifies PFKFB3 
ranked 383
rd
 by Génie. Applying the scoring system to the top 100 ranked genes for each 
metric, the results in table 6.27 below are given. 
TABLE 6.27 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 4M GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 12 2828 1
st
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Weighted Betweenness 8 2645 2
nd
 
Degree Centrality 9 2535 3
rd
 
Weighted Degree 9 2425 4
th
 
Eigenvector Centrality 10 2220 5
th
 
Combined Metric 8 2159 6
th
 
 
The weighted closeness is the best performing metric, identifying 12 neuroblastoma Génie 
genes. TNC and PTK2B identified before, and CTNNB1 and PEG3. The weighted degree and 
eigenvector centrality metrics perform badly, only identifying the same gene that they 
identified before in their top 20 rankings. Finally, e xtending the scoring system to the top 500 
genes, the following results shown in table 6.28 below are given.  
TABLE 6.28 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 4M GRN INFERRED FROM MOLENAAR DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 52 14837 1
st
 
Weighted Degree 48 13465 2
nd
 
Degree Centrality 47 13104 3
rd
 
Combined Metric 40 11011 4
th
 
Weighted Betweenness 41 10956 5
th
 
Weighted Closeness 38 10316 6
th
 
 
Applying the scoring to the top 500 genes identified by each metric, eigenvector centrality is 
the best performing metric, followed by the weighted degree centrality. Whilst all of the 
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metrics perform slightly worse at identifying genes than in the previous category, they all 
identify 3 of the top 20 ranked genes by Génie for neuroblastoma. MYCN ranked 1
st
, TGFB1 
ranked 7
th
, and HIF1A ranked 19
th
, are amongst the respective top 500 genes ranked by all the 
metrics. Although not as good a result as for the previous neuroblastoma category, this still 
implies that these metrics are able to identify a number of biologically significant genes.  
Across the whole network, 150 out of the 500 neuroblastoma genes generated by Génie are 
present, a similar number to the last category. This again suggest that there are a number of 
genes previously identified as being important for neuroblastoma present in the network for 
this category, and that these genes are involved in cellular processes in the network for this 
category.  
6.7 Metric Performance GRNs Inferred from Molenaar Dataset 
Previously, each metric was ranked based on the top 20, top 100 and top 500 genes they 
identified from each neuroblastoma disease stage GRN for the Molenaar dataset. This ranking 
is based on the score of the identified genes in the Génie neuroblastoma gene list.  
The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 6.29 below are given.  
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TABLE 6.29 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE GRNS 
INFERRED USING NOVEL ABSOLUTE Z SCORE NETWORK INFERENCE METHOD FROM THE 
MOLENAAR DATASET  
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 2nd 2nd 2nd 3rd 9 1st 
Weighted 
Degree 2nd 2nd 2nd 3rd 9 1st 
Eigenvector 
Centrality 5th 1st 1st 2nd 9 1st 
Combined 
Metric 1st 4th 4th 5th 14 4th 
Weighted 
Betweenness 4th 6th 5th 1st 16 5th 
Weighted 
Closeness 6th 4th 5th 5th 20 6th 
 
Weighted degree, degree, and eigenvector centrality are the joint best performing metrics 
overall. The number of connections a node has in a network is the most often applied property 
for determining its importance in a network, so it should perhaps not be surprising to see the 
degree metrics performing well. If the rankings for just the top 20 genes in each category  are 
taken into consideration, the following scores in table 6.30 are obtained. 
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TABLE 6.30 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE 
STAGE GRNS INFERRED USING NOVEL ABSOLUTE Z SCORE NETWORK INFERENCE METHOD FROM 
THE MOLENAAR DATASET BASED ON TOP 20 GENES IDENTIFIED BY EACH METRIC 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Weighted 
Betweenness 2nd 1st 4th 1st 8 1st 
Combined 
Metric 1st 1st 5th 1st 8 1st 
Eigenvector 
Centrality 3rd 4th 1st 3rd 11 3rd 
Weighted 
Closeness 4th 1st 5th 4th 14 4th 
Weighted 
Degree 5th 4th 2nd 4th 15 5th 
Degree 
Centrality 5th 4th 3rd 4th 16 6th 
 
Weighted betweenness and the combined metric are the joint best performing metrics. The 
degree based metrics perform poorly this time, perhaps surprising considering the 
phenomenon of scale-free network where a few number of nodes have a high degree, and a 
large number of nodes have a low degree. If we take the ranking for the top 100 genes into 
account, the following results shown in table 6.31 are obtained.  
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TABLE 6.31 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE 
GRNS INFERRED USING NOVEL ABSOLUTE Z SCORE NETWORK INFERENCE METHOD FROM THE 
MOLENAAR DATASET BASED ON TOP 100 GENES IDENTIFIED 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 1st 2nd 2nd 3rd 8 1st 
Weighted 
Degree 1st 2nd 3rd 4th 10 2nd 
Eigenvector 
Centrality 6th 1st 1st 5th 13 3rd 
Weighted 
Closeness 5th 4th 6th 1st 16 4th 
Weighted 
Betweenness 4th 6th 5th 2nd 17 5th 
Combined 
Metric 3rd 5th 4th 6th 18 6th 
 
Degree centrality is the best performing metric again, followed by weighted degree centrality 
and the combined metric. Finally, taking the top 500 genes into account, the following results 
shown in table 6.32 are obtained.  
TABLE 6.32 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE 
GRNS INFERRED USING NOVEL ABSOLUTE Z SCORE NETWORK INFERENCE METHOD FROM THE 
MOLENAAR DATASET BASED ON TOP 500 GENES IDENTIFIED 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Eigenvector 
Centrality 4th 1st 1st 1st 7 1st 
Weighted 
Degree 2nd 2nd 2nd 2nd 8 2nd 
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Degree 
Centrality 2nd 2nd 2nd 3rd 9 3rd 
Combined 
Metric 1st 4th 5th 4th 14 4th 
Weighted 
Closeness 5th 5th 4th 6th 20 5th 
Weighted 
Betweenness 6th 6th 6th 5th 23 6th 
 
This time eigenvector centrality just out-performs weighted degree and degree centrality, with 
these three metrics showing similar performance. The combined metric is the 4
th
 best 
performing metric. Weighted closeness centrality, the 5
th
 ranked metric, and weighted 
betweenness centrality, the 6
th
 ranked metric, perform poorly compared to the other metrics. 
6.8 Distribution of Genes in Combined Metric Top 20 Rankings List across the GRNs 
Inferred from Molenaar Dataset 
As noted in the category sections, none of the genes that appear in the top 20 ranked genes for 
the combined metric for any category appear in any other. This can be seen on the Venn 
diagram in figure B.8 of the appendix showing the distribution of genes in the top 20 
combined metric rankings list in the categories. Furthermore, extending this to look at the top 
100 combined metric rankings lists, shown in figure B.9 of the appendix, this is also the case 
and suggests that this approach is suited to identifying specific genes associated with the 
different survival time 
6.9 Node Level Metrics Wang Dataset 
Having investigated the network level metrics, and the largest unique cliques in the networks, 
the focus is now the node level metrics. As before, a combined metric comprised of weighted 
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degree, weighted betweenness and weighted closeness, is used to infer a list of top 20 ranked 
genes for this survival category, and all subsequent categories. Enrichment and the presence 
of previously identified neuroblastoma genes will be investigated for the combined list.  
Correlations will be calculated for the metrics, and the metrics will be scored using the 500 
top ranked genes for neuroblastoma returned by Génie.  
6.9.1 Stage 1 Wang Dataset 
Table 6.33 shows the top 20 ranked genes for the combined metric in the GRN inferred for 
neuroblastoma stage 1 in the Wang dataset. One of the genes, PIK3R1, in the table appears in 
the list of 500 neuroblastoma genes generated by Génie, ranked as the 327
th
 most important 
gene for neuroblastoma. None of the genes that appear in the top 20 ranked list appear in any 
of the top 20 ranked for the other categories. As was the case with all the categories in the 
Molenaar dataset, this suggests that different genes are playing important roles in the different 
neuroblastoma stages.   
Entering this list of genes into GenesetDB, only six results are returned. This implies that this 
combination of genes has not been identified as being involved in significant biological 
processes, and could suggest that this is a novel finding. The six results returned are presented 
in table A.32 of the appendix.  
TABLE 6.33 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 1 GRN INFERRED FROM 
WANG DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
MAP3K4 1 RAP2A 11 
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HMX1 2 SOX4 12 
ERCC5 3 ADCY7 13 
UBE2J1 4 SEC63 14 
PHF3 5 RAB5B 15 
UPF3A 6 CLASP1 16 
PIK3R1 7 DDX17 17 
APC 8 CAMTA1 18 
CNR1 9 MCFD2 19 
ELAVL2 10 TNNT2 20 
 
Table 6.34 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 1 GRN inferred from the Wang dataset.  
TABLE 6.34 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN STAGE 1 GRN INFERRED FROM WANG DATASET  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.887 0.866 0.860 
Weighted 
Degree 0.998 1 0.880 0.857 0.856 
Eigenvector 
Centrality 0.887 0.880 1 0.965 0.769 
Closeness 
Centrality 0.866 0.857 0.965 1 0.811 
Betweenness 
Centrality 0.860 0.856 0.769 0.811 1 
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The correlation scores between the metrics are again strong, with the weakest correlation 
having a score of 0.76. Again there will still be substantial overlap between the genes 
identified by the metrics. 
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.35 below. 
TABLE 6.35 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 1 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 1 174 1
st
 
Weighted Betweenness 1 174 1
st
 
Weighted Closeness 1 174 1
st
 
Combined Metric 1 174 1
st
 
Weighted Degree 0 0 5
th
 
Eigenvector Centrality 0 0 5
th
 
 
Degree, weighted betweenness, weighted closeness, and the combined metric all identify the 
same neuroblastoma genes of interest, PIK3R1, on the list generated by Génie. The other 
metrics do not identify any genes on this list. Applying the scoring system to the top 100 
ranked genes for each metric, the results in table 6.36 below are given.  
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TABLE 6.36 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 1 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Degree 5 1224 1
st
 
Degree Centrality 4 1083 2
nd
 
Eigenvector Centrality 7 1022 3
rd
 
Combined Metric 4 797 4
th
 
Weighted Closeness 4 775 5
th
 
Weighted Betweenness 1 174 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, weighted degree 
centrality is the best performing metric, followed by degree centrality. Although eigenvector 
centrality identifies the most genes, weighted degree and degree centrality identify genes with 
a higher score. Finally, extending the scoring system to the top 500 genes, the following 
results shown in table 6.37 below are given.  
TABLE 6.37 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 1 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Degree 31 7284 1
st
 
Combined Metric 28 7241 2
nd
 
Weighted Betweenness 28 7209 3
rd
 
Degree Centrality 30 7130 4
th
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Weighted Closeness 25 6855 5
th
 
Eigenvector Centrality 25 5999 6
th
 
 
Applying the scoring to the top 500 genes identified by each metric, weighted degree 
centrality is the best performing metric, followed by the combined metric. The metrics 
perform poorly at identifying top 20 ranked genes by Génie for neuroblastoma. Only 
weighted closeness and weighted betweenness identify one gene, TNF ranked 15
th
, in their 
respective top 500 ranked genes.  These results imply that the metrics are not able to identify 
many biologically significant genes for this category of network.  
Across the whole network, 134 out of the 500 neuroblastoma genes generated by Génie are 
present, compared to 142 in the stage 1 network for the Molenaar dataset. As was the case 
with the stage 1 network in the Molenaar dataset, only 4 out of the top 50 Génie ranked 
neuroblastoma genes are present in the top 500 ranked neuroblastoma genes for any of the 
metrics. This shows that many of the genes that Génie highlights as being important for 
neuroblastoma are not identified by the network metrics in this category. This is again 
suggestive that genes Génie identifies as being important for neuroblastoma might not be 
involved in cellular processes in this neuroblastoma stage, due to the similar results for the 
same stage in the Molenaar dataset. This is something that biologically could be the case, as it 
is more likely that the genes Génie identifies as being important are involved in higher stage 
neuroblastomas.  
6.9.2 Stage 3 Wang Dataset 
Table 6.38 shows the top 20 ranked genes for the combined metric in the GRN inferred for 
neuroblastoma stage 3 in the Wang dataset. Two genes, LGALS1 ranked 406
th
, and ITGA5 
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ranked 155
th
, appear in the list of 500 neuroblastoma genes generated by Génie. As before, 
none of the genes that appear in the top 20 ranked list  for the combined metric appear in any 
of the top 20 ranked list for the combined metric for the other neuroblastoma disease stage 
categories. As was the case with the previous category, this suggests that different genes are 
playing important roles in the different neuroblastoma stages.   
No enrichment results are returned for the list of top 20 ranked genes, implying that this 
particular combination of genes has not been identified as being involved in any significant 
biological processes. This was also the case with the list of top ranked genes for stage 3 of the 
Molenaar dataset.  
TABLE 6.38 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 3 GRN INFERRED FROM 
WANG DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
PON2 1 PPM1F 11 
GNG11 2 TIE1 12 
MVP 3 MITF 13 
TBC1D22A 4 PDLIM7 14 
LGALS1 5 FLNA 15 
ARPC1B 6 GFPT2 16 
TPP1 7 LRP10 17 
POLD4 8 IFITM2 18 
CIB1 9 NPTX1 19 
ITGA5 10 GPC5 20 
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Table 6.39 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 3 GRN inferred from the Wang dataset. 
TABLE 6.39 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
DIFFERENT METRICS TO THE GENES IN STAGE 3 GRN INFERRED FROM WANG DATASET 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.997598864 0.921212167 0.919433584 0.831541994 
Weighted 
Degree 0.997598864 1 0.912415326 0.907864861 0.830431065 
Eigenvector 
Centrality 0.921212167 0.912415326 1 0.924316126 0.693070954 
Closeness 
Centrality 0.919433584 0.907864861 0.924316126 1 0.773817133 
Betweenness 
Centrality 0.831541994 0.830431065 0.693070954 0.773817133 1 
 
The correlation scores between the metrics are again strong, with the weakest correlation 
having a score of 0.69. Again there will still be substantial overlap between the genes 
identified by the metrics. 
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.40 below. 
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TABLE 6.40 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 3 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 4 1415 1
st
 
Weighted Degree 4 1415 1
st
 
Eigenvector Centrality 4 1395 3
rd
 
Weighted Closeness 4 1281 4
th
 
Combined Metric 2 441 5
th
 
Weighted Betweenness 1 95 6
th
 
 
Degree, weighted degree, and weighted closeness all identify four genes; however degree and 
weighted degree are the best performing due to indentifying higher scoring genes.  Applying 
the scoring system to the top 100 ranked genes for each metric, the results in table 6.41 below 
are given. 
TABLE 6.41 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 3 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 14 4310 1
st
 
Degree Centrality 11 3572 2
nd
 
Eigenvector Centrality 12 3571 3
rd
 
Weighted Degree 12 3553 4
th
 
Weighted Closeness 12 3506 5
th
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Weighted Betweenness 8 2157 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the combined 
metric is the best performing metric, identifying 14 genes. Four of the other metrics each 
identify 12 genes. The performance of the weighted betweenness is noticeably worse than the 
other metrics, only identifying 8 genes. It is worth noting that the 7
th
 ranked gene for 
neuroblastoma, TGFB1, is identified by all of the metrics apart from weighted betweenness in 
their respective top 100 rankings. Finally, e xtending the scoring system to the top 500 genes, 
the following results shown in table 6.42 below are given.  
TABLE 6.42 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 3 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 68 18595 1
st
 
Degree Centrality 68 18078 2
nd
 
Weighted Degree 68 18078 2
nd
 
Combined Metric 60 16522 4
th
 
Weighted Closeness 59 16222 5
th
 
Weighted Betweenness 48 13218 6
th
 
 
The eigenvector centrality out-performs the other metrics when the scoring is applied to the 
top 500 genes identified by each metric.  8 of the top 50 ranked genes by Génie for 
neuroblastoma are amongst the top 500 genes ranked by weighted betweenness centrality. 
This is quite a significant result in terms of the biology, and implies that weighted 
179 
 
betweenness centrality is a good metric to use for identifying biologically significant results. 
All of the metrics identify substantially more genes in this stage than for the equivalent stage 
in the Molenaar dataset. Eigenvector is also the best performing metric for stage 3 in the 
Molenaar dataset identifying 38 genes, compared to 68 genes this time. Across the whole 
network, 140 out of the 500 neuroblastoma genes generated by Génie are present. This 
compares to 78 present in the stage 3 network in the Molenaar dataset.  
6.9.3 Stage 4 Wang Dataset 
Table 6.43 shows the top 20 ranked genes for the combined metric in the GRN inferred for 
neuroblastoma stage 4 in the Wang dataset. One of the genes in the table appears in the list of 
500 neuroblastoma genes generated by Génie, AKT1 ranked as the 3
rd
 most important gene 
for neuroblastoma. As with the two previous categories, none of the genes that appear in the 
table are present in the top 20 combined metric rankings for any of the GRNs for the other 
neuroblastoma disease stage categories. 
Table A.33 in the appendix shows the top ten enrichment results for these genes from 
GenesetDB. The 2
nd
 result is worth noting; the role of TNF-α in neuroblastoma apoptosis has 
been highlighted in a 2011 study by Álvarez et al [134]. 
TABLE 6.43 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 4 GRN INFERRED FROM 
WANG DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
MTERF 1 PPP1CA 11 
PPFIA1 2 IRS1 12 
ADIPOR2 3 CDH4 13 
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POLR2G 4 AKT1 14 
AP1G2 5 AMOT 15 
TSNAX 6 SF3B2 16 
IDH3B 7 BNIP1 17 
PVR 8 PPP6C 18 
COX8A 9 FBXW11 19 
ZNF410 10 GLT8D1 20 
 
Table 6.44 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 4 GRN inferred from the Wang dataset. 
TABLE 6.44 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
DIFFERENT METRICS TO THE GENES IN STAGE 4 GRN INFERRED FROM WANG DATASET 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.940 0.866 0.869 
Weighted 
Degree 0.998 1 0.936 0.858 0.865 
Eigenvector 
Centrality 0.940 0.936 1 0.922 0.803 
Closeness 
Centrality 0.866 0.858 0.922 1 0.835 
Betweenness 
Centrality 0.869 0.865 0.803 0.835 1 
 
The correlation scores between the metrics are very strong, with the weakest correlation 
having a score of 0.8. As a result, there will be substantial overlap between the genes 
identified by the metrics. 
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Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.45 below. 
TABLE 6.45 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 4 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 2 768 1
st
 
Degree Centrality 1 498 2
nd
 
Weighted Degree 1 498 2
nd
 
Weighted Betweenness 1 498 2
nd
 
Combined Metric 1 498 2
nd
 
Eigenvector Centrality 0 0 6
th
 
 
Weighted closeness is the best performing metric, identifying two genes. As well as the 
previously mentioned AKT1, the 231
st
 ranked gene for neuroblastoma ENPP2 is also 
identified. Degree, weighted degree, weighted betweenness and the combined metric all 
identify AKT1. Applying the scoring system to the top 100 ranked genes for each metric, the 
results in table 6.46 below are given. 
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TABLE 6.46 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 4 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 8 2422 1
st
 
Weighted Degree 7 2166 2
nd
 
Weighted Betweenness 6 2098 3
rd
 
Eigenvector Centrality 7 2047 4
th
 
Combined Metric 5 1553 5
th
 
Weighted Closeness 3 1120 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, degree centrality 
is the best performing metric, identifying 8 genes. The weighted closeness centrality performs 
badly compared to the other metrics, only identifying 3 genes. Finally, extending the scoring 
system to the top 500 genes, the following results shown in table 6.47 below are given.  
TABLE 6.47 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 4 GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 29 9047 1
st
 
Degree Centrality 25 8196 2
nd
 
Weighted Degree 24 7804 3
rd
 
Eigenvector Centrality 24 7451 4
th
 
Combined Metric 25 7434 5
th
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Weighted Closeness 22 6440 6
th
 
 
The weighted betweenness is the best performing metric, followed by the degree centrality. 
Compared to the stage 4 category of the Molenaar dataset, the metrics identify substantially 
fewer genes. The best performing metric for the Molenaar stage 4 dataset identifies 9 out of 
the top ranked genes by Génie for neuroblastoma; here the weighted betweenness only 
identifies 4. Across the whole network, 149 out of the 500 neuroblastoma genes generated by 
Génie are present, representing a similar figure to the 156 present in the Molenaar stage 4 
network.  
6.9.4 Stage 4M Wang Dataset 
Table 6.48 shows the top 20 ranked genes for the combined metric in the GRN inferred for 
neuroblastoma stage 4M in the Wang dataset.  As with the previous category, one of the genes 
in the table appears in the list of 500 neuroblastoma genes generated by Génie. Additionally, 
as was the case with the previous category, this gene is very highly ranked by Génie. T his 
time the top ranked gene for neuroblastoma, MYCN, is present. As with all the categories for 
both of the datasets, none of the genes that appear in the table are present in the top 20 
combined metric rankings for any of the other neuroblastoma disease stage categories. 
Looking at the enrichment results for this list of genes shown in table A.34 of the appendix, 
the presence of results detailing purine nucleotide metabolism is of note. In a 1985 study, 
Kaplinsky et al [135] noted that purine pathway activity was 2-3 times higher in metastatic 
neuroblastoma cell lines. Metastasis is associated with the final stages of cancer, so it is 
biologically significant that this enrichment result appears in this neuroblastoma category.  
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TABLE 6.48 TOP 20 RANKED GENES FOR COMBINED METRIC IN STAGE 4M GRN INFERRED 
FROM WANG DATASET 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
MYCN 1 RSL1D1 11 
PAICS 2 RPL14 12 
DDX1 3 TFAP4 13 
HSPD1 4 FBL 14 
TGIF2 5 GMPS 15 
NPM1 6 GPR125 16 
EXOSC7 7 BAZ1A 17 
TRAP1 8 PRDX6 18 
TKT 9 PFAS 19 
IMPDH2 10 DDX10 20 
 
Table 6.49 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the stage 4M GRN inferred from the Wang dataset.  
TABLE 6.49 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN STAGE 4M GRN INFERRED FROM WANG DATASET 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.996 0.979 0.936 0.842 
Weighted 
Degree 0.996 1 0.975 0.929 0.840 
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Eigenvector 
Centrality 0.979 0.975 1 0.959 0.801 
Closeness 
Centrality 0.936 0.929 0.959 1 0.779 
Betweenness 
Centrality 0.842 0.840 0.801 0.779 1 
 
The correlation scores between the metrics are strong, with the weakest correlation having a 
score of 0.78. As a result, there will be substantial overlap between the genes identified by the 
metrics. 
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 6.50 below. 
TABLE 6.50 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN STAGE 4M GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 1178 1
st
 
Degree Centrality 1 500 2
nd
 
Weighted Degree 1 500 2
nd
 
Weighted Closeness 1 500 2
nd
 
Eigenvector Centrality 1 500 2
nd
 
Combined Metric 1 500 2
nd
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The weighted betweenness is the best performing metric, identifying three genes; MYCN 
ranked 1
st
, ODC1 ranked 301
st
, and HGF ranked 23
rd
. All of the other metrics identify 
MYCN. Applying the scoring system to the top 100 ranked genes for each metric, the results 
in table 6.51 below are given. 
TABLE 6.51 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN STAGE 4M GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 1178 1
st
 
Degree Centrality 2 953 2
nd
 
Weighted Degree 2 953 2
nd
 
Weighted Closeness 2 953 2
nd
 
Eigenvector Centrality 2 953 2
nd
 
Combined Metric 2 953 2
nd
 
 
Again the weighted betweenness is the best performing metric, but does not identify any 
additional genes. All of the other metrics identify one more gene this time, NME1, ranked 
48
th
. The performance of the metric is relatively poor, as can be seen by the very small 
number of genes that they identify. Finally, extending the scoring system to the top 500 genes, 
the following results shown in table 6.52 below are given.  
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TABLE 6.52 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN STAGE 4M GRN INFERRED FROM WANG DATASET 
 
Metric Number of Génie 
neuroblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 21 6078 1
st
 
Combined Metric 21 6077 2
nd
 
Degree Centrality 21 5825 3
rd
 
Weighted Degree 20 5600 4
th
 
Eigenvector Centrality 20 5600 4
th
 
Weighted Closeness 19 5587 6
th
 
 
Applying the scoring to the top 500 genes identified by each metric, weighted betweenness is 
again the best performing metric, followed by the combined metric. Compared to the stage 
4M network in the Molenaar dataset, the metrics identify fewer Génie neuroblastoma genes. 
Across the whole network, 89 out of the 500 neuroblastoma genes generated by Génie are 
present, compared to 150 in the stage 4M Molenaar network. Across all of the categories in 
both datasets, more Génie genes are present in three of the Molenaar category networks, and 
only one of the Wang category networks.  
6.10 Metric Performance GRNs Inferred from Wang Dataset  
Previously, each metric was ranked based on the top 20, top 100 and top 500 genes they 
identified from each neuroblastoma disease stage GRN for the Wang dataset. This ranking is 
based on the score of the identified genes in the Génie neuroblastoma gene list.  
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The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 6.53 below are given.  
TABLE 6.53 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE GRNS 
INFERRED USING NOVEL INFERENCE METHOD FROM THE WANG DATASET  
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 1st 1st 1st 3rd 6 1st 
Weighted 
Degree 1st 2nd 3rd 4th 10 2nd 
Combined 
Metric 1st 4th 4th 2nd 11 3rd 
Weighted 
Betweenness 4th 6th 2nd 1st 13 4th 
Eigenvector 
Centrality 6th 2nd 6th 4th 18 5th 
Weighted 
Closeness 5th 5th 5th 6th 21 6th 
 
As can be seen from the table above, degree centrality is the best performing metric overall, 
followed by weighted degree and the combined metric. It should be noted that degree 
centrality was the joint best performing metric for the Molenaar dataset, as was weighted 
degree centrality. There is a positive correlation of 0.61 between the overall metric ranks in 
both the datasets. If the rankings for just the top 20 genes in each category are taken into 
consideration, the following scores shown in table 6.54 are obtained. 
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TABLE 6.54 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE GRNS 
INFERRED USING NOVEL INFERENCE METHOD FROM THE WANG DATASET BASED ON TOP 20 
GENES IDENTIFIED BY EACH METRIC 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 1st 1st 2nd 2nd 6 1st 
Weighted 
Closeness 1st 4th 1st 2nd 8 2nd 
Weighted 
Degree 5th 1st 2nd 2nd 10 3rd 
Weighted 
Betweenness 1st 6th 2nd 1st 10 3rd 
Combined 
Metric 1st 5th 2nd 2nd 10 3rd 
Eigenvector 
Centrality 5th 3rd 6th 2nd 16 6th 
 
Degree centrality is again the best performing metric, followed by weighted closeness 
centrality.  There is a negative correlation of 0.4 with the metric ranks for the top 20 genes in 
the Molenaar dataset. If we take the ranking for the top 100 genes into account, the following 
results are obtained. 
TABLE 6.55 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE 
GRNS INFERRED USING NOVEL INFERENCE METHOD FROM THE WANG DATASET BASED ON TOP 
100 GENES IDENTIFIED BY EACH METRIC 
 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 2nd 2nd 1st 2nd 7 1st 
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Weighted 
Degree 1st 4th 2nd 2nd 9 2nd 
Eigenvector 
Centrality 3rd 3rd 4th 2nd 12 3rd 
Combined 
Metric 4th 1st 5th 2nd 12 3rd 
Weighted 
Betweenness 6th 6th 3rd 1st 16 5th 
Weighted 
Closeness 5th 5th 6th 2nd 18 6th 
 
Once again, degree centrality is the best performing metric. Weighted degree centrality is the 
second best performing metric. These two metrics also rank in the exact same position, first 
and second respectively, for the top 100 in the Molenaar dataset, and there is a positive 
correlation of 0.63 between the metric ranks across the two datasets for the top 100. Finally, 
taking just the top 500 rankings into account, the following results  shown in table 6.56 are 
obtained. 
TABLE 6.56 OVERALL METRIC RANKS IN THE DIFFERENT NEUROBLASTOMA DISEASE STAGE 
GRNS INFERRED USING NOVEL INFERENCE METHOD FROM THE WANG DATASET BASED ON TOP 
500 GENES IDENTIFIED BY EACH METRIC 
 
  
Stage 1 
Rank 
Stage 3 
Rank 
Stage 4 
Rank 
Stage 4M 
Rank 
Ranking 
Totals 
Overall 
Rank 
Weighted 
Degree 1st 2nd 3rd 4th 10 1st 
Degree 
Centrality 4th 2nd 2nd 3rd 11 2nd 
Weighted 
Betweenness 3rd 6th 1st 1st 11 2nd 
Combined 
Metric 2nd 4th 5th 2nd 13 4th 
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Eigenvector 
Centrality 6th 1st 4th 4th 15 5th 
Weighted 
Closeness 5th 5th 6th 6th 22 6th 
 
Weighted degree centrality just out-performs degree centrality, with both metrics showing 
similar performance. The eigenvector centrality is the best performing metric for the top 500 
in the Molenaar dataset; here it is the 5
th
 best performing metric. Between the top 500 in both 
datasets, there is a very weak positive correlation of 0.05.  
6.11 Distribution of Genes in Combined Metric Top 20 Rankings List across the GRNs 
Inferred from Wang Datasets 
As noted in the category sections, none of the genes that appear in the top 20 combined metric  
rankings list for any category appear in any other. This can be seen on the Venn diagram in 
figure B.10 of the appendix, showing the distribution of genes in the top 20 combined metric  
rankings list in the categories. Furthermore, extending this to look at the top 100 combined  
metric rankings lists, shown in the Venn diagram in figure B.11 of the appendix, this is also 
the case and suggests that this approach is suited to identifying specific genes associated with 
the different survival time 
6.12 Overlap of Combined Metric Top 20 and Top 100 Ranked Genes in Common 
Categories 
The final comparison between the two datasets is to see whether there is any overlap in the 
genes that are identified as being important in the neuroblastoma categories across the two 
datasets. It has been noted before that these two datasets are quite different, and as such, it 
might be expected that significant overlap does not occur. Two comparisons will be made; 
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firstly the top 20 combined metric ranking genes for the same category identified in the two 
datasets will be plotted on a Venn diagram, figures B.12 – B.15 in the appendix, and secondly 
the top 100 combined metric ranking genes will be plotted against each other, figures B.16 – 
B.19 in the appendix.  
As can be seen from figures B.12 and B.13, there are no genes in common for either stage 1, 
or stage 3, across both datasets. There is one gene common to the stage 4 categories in both 
categories, CDH4. Whilst not specifically identified in previous neuroblastoma studies, in a 
2003 study by Charrasse et al [136] it was shown to be up-regulated in the paediatric solid 
tumour Rhabdomyosarcoma. 
There is quite a significant overlap in the stage 4M categories across both datasets, shown in 
figure B.15. 7 out of the top 20 ranked genes for the stage 4M category network in each 
dataset are also ranked in the top 20 in the other dataset. Amongst these seven genes in 
common, the presence of MYCN should be highlighted. The high number of genes in 
common across the same neuroblastoma category is perhaps also a surprising finding, 
considering the differences in the datasets already noted.  
Extending the number of genes to the top 100 ranked genes in each stage, there are more 
genes in common across the stages in the two datasets. There are 4 genes common to stage 1; 
TGDS, EPN2, EPB41L3, and DLG4. None of these genes appear on the top 500 genes 
returned by Génie for neuroblastoma. There is only one gene common to stage 3 across the 
Wang and Molenaar datasets, GPC5, which has been the subject of lung cancer studies, but 
none relating specifically to neuroblastoma.  
There are eight genes in common to both stage 4 categories; PDCD6, GGA3, CHGA, CDH4, 
BZRAP1, ARFIP2, APOBEC3B, and AP1G2. None of these eight genes appear on the top 
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500 genes returned by Génie for neuroblastoma. Finally, there are 23 genes common to both 
stage 4M categories; TRAP1, TKT, TGIF2, SNRPA, RUVBL1, RSL1D1, PFAS, PES1, 
PAICS, NMU, MYCN, LAPTM4B, GPR125, GMPS, FBL, DDX10, DDX1, CBS, CAD, 
BYSL, BAZ1A, BAMBI, and APEX1. Of these genes, only the number 1 ranked MYCN 
appears on the top 500 genes returned by Génie for neuroblastoma.  
6.13 Discussion 
Having used the Z score method to infer networks for different categories in the two datasets, 
a number of concluding observations can be made. Firstly, as suggested by the initial 
correlation of the gene expression level rankings, the datasets differ substantially. This is 
highlighted in both the genes that are highly ranked for each neuroblastoma stage in the 
datasets, and also in the genes that comprise the largest unique genes in the cliques. It is 
important to take the different array platforms used in the different studies int o account; the 
Wang study used the relatively old Affymetrix U95 microarray design with approximately 
10,000 genes represented, whilst the Molenaar study used the far more recent Affymetrix 
EXON ST 1.0 design with approximately 20,000 genes represented. There are also a number 
of technical differences in relation to how the arrays are constructed, and how background is 
calculated.  
There are also differences in the network level metrics, with only the diameter values 
correlating exactly. However, there were a number of common genes identified in the stage 
4M categories for both datasets. This is a promising finding, although perhaps it should be 
remembered that this was the only category specifically classed based on a genomic property, 
high MYCN amplification, which might go some way to explaining why this is the case. 
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Looking at the cliques, there are a number of enrichment results of note for the genes that 
make up the largest unique cliques in the network inferred from the Molenaar dataset. In 
particular, the 10
th
 enrichment result for both stage 2 and stage 4M are of particular interest, 
relating to specific biological processes previously observed in neuroblastoma, and also 
corresponding to the neuroblastoma stage. Three out of the four largest unique cliques 
inferred for the Molenaar dataset had results relating to neuroblastoma in their respective top 
ten enrichment results, suggestive of biological relevance and significance.  
For the list of genes that make up the largest unique cliques in the networks inferred from the 
Wang dataset, there is only one result of note, detailing SP1 gene regulation. The list of genes 
that comprise the largest unique clique in the stage 4 network did not return any enrichment 
results, and the list of genes that comprise the largest unique clique in the stage 1 network 
returned one enrichment result. This would suggest that the cliques in the networks in the 
Wang dataset are not involved in significant biological processes, and in particular, are not 
involved in biological processes associated with neuroblastoma. Comparing the cliques in the 
networks inferred from the two datasets, it would appear that the cliques in the networks 
inferred from the Molenaar dataset are biologically of greater interest. This is based on the 
greater number of enrichment results returned specifically relating to neuroblastoma. 
Of particular note is the top ranking of the gene MYCN in both the GRN inferred from the 
stage 4M samples in the Wang dataset, and also the Molenaar dataset. The feedback from 
biologists relating to the top ranked genes in the glioblastoma survival categories has been 
previously noted. Prior to constructing the GRNs for the neuroblastoma disease stages, one 
biologist specifically indicated that she would expect to see the gene MYCN as the top rated 
gene for the 4M stage networks.  The fact that this is the case for the networks in both of the 
datasets not only suggests that the network inference method is capable of inferring networks 
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that are biologically meaningful, but also are capable of inferring networks that biologists 
have confidence in. This was not the case with the networks inferred from the glioblastoma 
dataset using the WGCNA method.  It is important to note however that the distribution of  
MYCN expression values is somewhat different from the majority of other genes. It tends to 
be either very high due to gene amplification, or quite low. In contrast, most other genes are 
either consistently high or consistently low in all samples, or have a much broader distribution 
from low to high.  As a result, MYCN will have a much greater discriminatory power than 
most other genes; particularly since it is also strongly associated with a specific clinical sub-
type implying biological significance, in this case neuroblastoma stage 4M.  
Overall, the results from this chapter give an insight into some of the issues that exist in 
replicating results across different datasets. There have been a number of proposed 
approaches to deal with this problem, such as different normalisation techniques, however this 
is still an area without an adequate solution. Another problem is the use of non-genomic 
criteria for categorising microarray data. Despite all this, there are a number of promising 
results. As well as MYCN being the top ranked genes in both GRNs inferred from the stage 
4M samples in both datasets, there are a number of common genes in the top ranking genes in 
these two networks. If the Spearman rank score of 0.63 between the ranking of the common 
gene average expression values is taken into account as well between the stage 4M samples in 
both datasets, this illustrates that this method has been able to identify common top ranking 
genes in the stage 4M categories across both datasets despite the obvious differences in the 
gene expression values. Whilst on the whole this chapter has shown the problems that exist 
replicating results across microarray datasets, there is a significant overlap in the stage 4M 
results, and demonstrates that using a genomic criteria for classifying data can result in some 
degree of replication across different datasets.  
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6.14 Conclusions 
To conclude, in this chapter the novel inference method introduced in the last chapter was 
applied to two different neuroblastoma microarray datasets from two different studies. All 
three objectives were addressed in this chapter. Firstly, the transferability of the novel 
inference method proposed in the previous chapter was demonstrated through applying it to 
two neuroblastoma microarray datasets. Secondly, various metrics were used to identify 
different genes in the different disease stage neuroblastoma GRNs across both datasets, and 
the performance of the metrics was compared and analysed. Thirdly, the different disease 
stage neuroblastoma GRNs across both datasets were compared, and genes common to the 
same disease stage GRN across both neuroblastoma microarray datasets were identified. In 
the next chapter, a further refinement of the novel network inference method is presented, and 
it is applied to a retinoblastoma microarray dataset. In the next chapter, a further refinement of 
the novel inference method is applied to a proprietary retinoblastoma microarray dataset. 
Samples from normal retinal data are contained in this dataset, and as such, a sample 
reference network for normal retinal data is also constructed to compare to the retinoblastoma 
networks.  
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Chapter 7 
Application of Refined Novel Network Inference 
Method to retinoblastoma dataset 
In this chapter, a further refined version of the novel network inference method used in 
chapters 5 and 6 is presented. This is done with the purpose of implementing a GRN inference 
method that is able to distinguish between genes that are amplified or under-expressed 
together, following feedback from biologists. All of the datasets analysed so far in the work 
have been taken from previously published studies containing samples from different stages 
of disease that do not contain healthy reference data for comparison. In this chapter, the 
analysis of a proprietary retinoblastoma microarray dataset is carried out  that also has normal 
samples allowing a reference normal GRN to be inferred. This dataset is from a very recent 
2013 study by Kapatai et al [137].  
7.1 Retinoblastoma Microarray Dataset 
Retinoblastoma is an aggressive cancer of the retina that arises due to a mutation on the RB1 
gene at chromosome 13 [138, 139]. The retinoblastoma dataset consists of 21 samples from 
Birmingham Children’s Hospital, BCH, analysed using the Affymetrix HuGene Array 
platform. The samples have been classified into three groups by researchers at BCH; blue, 
red, and green. Two of the samples were found to be similar to normal retina, and 
subsequently lead to the assumption that normal rather than tumour tissue was supplied. As 
such, these two samples are taken as normal samples from which the normal reference GRN 
will be inferred. For the rest of the samples, standard analysis methods including SAM and 
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PCA were used to detect two different retinoblastoma groups, red, and blue. There were some 
clinical associations relating to tumour aggressiveness that suggested the blue category of 
samples is a more advanced and aggressive retinoblastoma category than the red category. It 
should be noted that both these groups contain high stage retinoblastoma samples, as the only 
retinoblastoma tissue available for investigation is from high stage tumours due to these being 
the the only ones which are removed surgically. There are 13 samples in the blue category, six 
in the red category, and two in the green category. For the rest of the chapter, the categories 
will be referred to as RB Blue for the category containing the blue samples, RB Red for the 
category containing the red samples, and RB Green for the category containing the green 
samples.   
As before, prior to inferring networks from the different categories in the microarray dataset, 
an idea of how similar the categories are can be gauged from how well the gene expression 
levels correlate.  Table 7.1 below shows the correlation scores between the rankings of the 
gene expression levels.  
TABLE 7.1 CORRELATION SCORES OF AVERAGE GENE EXPRESSION RANKINGS IN 
RETINOBLASTOMA MICROARRAY DATASET 
 
Category RB Blue RB Red RB Green 
RB Blue 1 0.9277262 0.8775253 
RB Red 0.9277262 1 0.9285888 
RB Green 0.8775253 0.9285888 1 
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From the table above, it can be seen that the greatest discrepancy between the gene expression 
rankings occurs between the RB Blue and RB Green categories. This corresponds to the 
biology; RB Blue is the most advanced retinoblastoma category, and RB Green containing 
samples from normal retinal data. It would therefore be expected that the gene expression 
levels between these two categories would be those with the greatest difference. 
Instead of the absolute value Z score approach used in the two previous chapters, a further 
modified network inference technique will be used in this chapter. It is beneficial to be able to 
further understand the relationship between gene expression levels by identifying which genes 
are amplified together, and which genes are under-expressed together. In order to ascertain 
this, two additional approaches will be implemented. A positive-positive variant of the Z 
score approach, where only positive Z scores greater than 0 are retained, and a negative-
negative variant of the Z score approach where only negative Z scores less than 0 are retained. 
The positive-positive variant will be referred to as the positive Z score method, and the 
negative-negative variant will be referred to as the negative Z score method. 
7.2 Network Level Metrics in the Retinoblastoma GRNs Inferred using the Positive Z 
Score Method 
As was the case in the last chapter, prior to identifying individual genes in the networks using 
node level metrics, the network level metrics will be calculated and analysed. The scores for 
these are shown in table 7.2. The same metrics will be used again; weighted degree 
assortativity, degree asssortativity, diameter, and network clustering. The largest unique 
cliques will again be calculated for each of the networks for the two different datasets, and the 
genes that comprise these cliques will be investigated for both enrichment and the presence of 
retinoblastoma genes of interest using Génie. As was the case with neuroblastoma, the list 
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generated by Génie is extensive, and only the top 500 ranked genes for retinoblastoma will be 
used. The Génie list of scoring genes for retinoblastoma is shown in table A.35 of the 
appendix. 
TABLE 7.2 NETWORK LEVEL SCORES ACROSS THE CATEGORIES FOR THE RETINOBLASTOMA 
GRNS INFERRED USING THE POSITIVE Z SCORE METHOD 
 
Metric RB Blue RB Red RB Green 
Weighted Degree 
Assortativity 
0.068 -0.268 -0.257 
Degree Assortativity 0.103 -0.262 -0.248 
Diameter 4.352 3.959 3.263 
Network Clustering 0.652 0.437 0.844 
Largest Clique Size 132 96 238 
 
Looking at the network level scores, the value of the diameter is of interest. In the previous 
chapter, it was noted that in both the neuroblastoma datasets that the value of the diameter 
was greatest in the most advanced neuroblastoma category. Here, in the most advanced 
retinoblastoma category, the diameter value is also greatest. This could again be an indication 
that the diameter is a network level property that is associated with disease stage, and more 
specifically, one could hypothesise that this could be due to genes involved in certain cellular 
processes not being able to easily communicate with each other, thereby contributing to the 
more advanced stage of disease. The size and composition of the largest unique cliques in the 
different categories can be informative; this is looked at in the next section.  
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7.3 Largest Clique Calculation and Analysis  in Retinoblastoma GRNs Inferred using 
Positive Z Score Method 
As well as identifying common and unique genes in the cliques for the different categories, it 
is informative to see whether these genes have been previously identified as being 
retinoblastoma genes of interest and appear on the list of Génie retinoblastoma genes. The list 
of genes that comprise the largest unique c lique in each network category can also be checked 
for enrichment using the GenesetDB website. Table 7.3 below shows the size of the cliques in 
each category, whether any of the genes that comprise this clique are present in any other 
cliques, and finally whether any of the genes in the clique appear on the Génie retinoblastoma 
gene list.   
TABLE 7.3 RETINOBLASTOMA GENES OF INTEREST IN THE LARGEST UNIQUE CLIQUES IN THE 
RETINOBLASTOMA GRNS INFERRED USING POSITIVE Z SCORE METHOD 
 
 Clique 
Size 
Genes 
present in 
other RB 
cliques 
Number of 
Génie genes 
and score 
RB Blue 132 0 7, score of 
1909 
RB Red 96 0 3, score of 
1323 
RB Green 238 0 11, score of 
3207 
 
Across the cliques, a number of retinoblastoma genes that appear on the list generated by 
Génie are present. The RB Green category has both the highest number of Génie genes, and 
also the highest score of genes identified. This might appear to be a surprising result, 
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considering that the RB Green category network has been inferred from healthy retinal 
samples. One possible explanation for this is that genes identified by Génie for a disease 
might also be responsible for regulation of healthy cellular processes. Also, unfortunately 
Génie does not allow a distinction to be made as to whether genes that are present of the list 
have been identified in the studies as being significantly over or under-expressed, another 
potential explanation. The RB Red category has the lowest number of genes identified, and 
the lowest score. Only 21 genes that appear on the list generated by Génie for retinoblastoma 
are present in the cliques, which represents just 4.2 % of the complete list used. This lower 
proportion though can be attributed to the more specific network inference method used; it 
will be of interest to compare the cliques that are identified in the two different network 
inference techniques to see the composition of the cliques for the negative Z score method. 
The Venn diagram in figure B.20 of the appendix shows the distribution of the genes in the 
largest unique cliques in the networks inferred using the positive Z score method.  
There are 466 genes in total across the three cliques. There are no genes common to either two 
or three cliques, with each gene only appearing in one clique.  This result is indicative that the 
cellular processes are very different in the cliques in the different retinoblastoma categories. It 
would be expected that different genes are over-expressed in different retinoblastoma stages 
and healthy cellular processes; the distribution of genes in the cliques corresponds with this.  
Having investigated the distribution of genes in the cliques, the next step is to investigate the 
enrichment of these genes using GenesetDB. Once again, these tables will be presented in the 
appendix. For the genes that comprise the largest unique clique in the RB Blue category, only 
seven results are returned from GenesetDB. This would imply that this combination of genes 
has not been identified as being involved in biological processes. The seven results returned 
are shown in table A.36 of the appendix.  
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The genes that comprise the largest unique clique in the RB Red category do return any 
enrichment results. As was the case with the RB Blue category, this would imply that this 
combination of genes has not been identified as being involved in biological processes. 
Unlike the previous two categories, the genes that comprise the largest unique clique in the RB 
Green category return a number of enrichment results. The top ten results are shown in table 
A.37 of the appendix. As noted before, it might be surprising that the network inferred from 
healthy retinal data returns the most biologically relevant results. However, it should be 
remembered that normal tissues are highly specialized to carry out specific functions, and as a 
result have a gene expression profile which reflects this. This can be seen in the results; there 
are a number of results that relate to eye function and degradation. As noted with Génie, the 
enrichment results to do not specify whether these results are associated with increased or 
decreased gene expression. This accounts for the presence of the first result, visual perception, 
and also the 5
th
 result, retinal degeneration. As might be expected, genes involved in visual 
perception are highly expressed in normal retinal tissue [140]; therefore in a GRN inferred 
from normal tissue using the positive Z score method, enrichment results relating to visual 
perception are present. These results are also a reminder of the nature of the work in the thesis; 
it is intended to be able to guide clinicians and biologists with specialist and specific medical 
and biological knowledge that can use this knowledge to interpret the results.     
7.4 RB Blue Category GRN Inferred using Positive Z Score Method 
Having investigated the network level metrics, and the largest unique cliques in the networks, 
the focus now is using node level metrics to identify genes of interest. As before, a combined 
metric comprised of weighted degree, weighted betweenness and weighted closeness, is used 
to infer a list of top 20 ranked genes for this disease category, and all subsequent categories. 
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Enrichment and the presence of previously identified retinoblastoma genes will be 
investigated for the combined list. Correlations will be calculated for the metrics, and the 
metrics will be scored using the 500 top ranked genes for retinoblastoma returned by Génie.  
Table 7.4 shows the top 20 ranked genes for the combined metric  in the RB Blue category 
GRN inferred using the positive Z score method. Four of these genes in the table appear in the 
list of 500 retinoblastoma genes generated by Génie; EYA1, MYC, HMGA2, and CD24. This 
represents quite a high proportion of genes having been previously identified as interest for 
retinoblastoma. None of the genes that appear in the top 20 ranked list appear in any of the top 
20 ranked for the other categories. As was the case with the largest unique cliques, this 
suggests clearly distinguishable differences between the retinoblastoma categories in terms of 
the genes that are playing important roles in cellular processes.  
Despite 4 genes out of the 20 appearing on the Génie retinoblastoma list, no enrichment 
results are returned for the 20 genes in the table below. This suggests that despite a number of 
these genes being associated with retinoblastoma, they have not been identified as being 
involved together in biological processes. 
TABLE 7.4 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB BLUE GRN INFERRED USING 
POSITIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
EYA1 1 HMGA2 11 
MYC 2 IGHD 12 
DSC2 3 TRPC5 13 
DPP10 4 SOX4 14 
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KCNQ5 5 RSPO1 15 
ZNF193 6 NEUROG1 16 
IGLJ3 7 OR4C16 17 
RPS24 8 MED20 18 
RPS27A 9 TFF1 19 
TUBB2B 10 CD24 20 
 
Table 7.5 below shows the Spearman Rank correlation scores for  the rankings assigned to the 
genes by each metric in the RB Blue GRN inferred using the positive Z score method.  
TABLE 7.5 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB BLUE GRN INFERRED USING POSITIVE Z SCORE METHOD  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.415 0.687 0.572 
Weighted 
Degree 0.999 1 0.430 0.699 0.575 
Eigenvector 
Centrality 0.415 0.430 1 0.562 0.176 
Closeness 
Centrality 0.687 0.699 0.562 1 0.732 
Betweenness 
Centrality 0.572 0.575 0.176 0.732 1 
 
From table 7.5 above, it can be seen that for this category, and unlike most of the previous 
categories in this work to date, there are a number of weak correlations. In particular, the 
weak correlation of 0.177 between the eigenvector centrality and the weighted betweenness 
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centrality stands out. There are also a number of other correlations with scores less than 0.5.   
These weak correlations imply that there is not as substantial an overlap in the genes that the 
metrics rank highly as was the case with the other categories, and that the genes that the  
metrics identify will be quite different. 
The list of genes generated by Génie for retinoblastoma will be used to score the metrics, 
limited to the top 500 ranking genes. This is due to a great deal of genes returned, and some 
specificity of results is desired. Starting with the top 20 ranked genes by each metric, table 7.6 
below shows the scores that are obtained.  
TABLE 7.6 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB BLUE GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 4 1581 1
st
 
Combined Metric 4 1403 2
nd
 
Weighted Closeness 2 646 3
rd
 
Degree Centrality 1 150 4
th
 
Weighted Degree 1 150 4
th
 
Eigenvector Centrality 1 150 4
th
 
 
The weighted betweenness centrality is the best performing metric, followed by the combined 
metric. Both the weighted betweenness centrality and the combined metric identify four 
genes, although the weighted betweenness identifies higher scoring genes. Applying the 
scoring system to the top 100 ranked genes for each metric, the results in table 7.7 below are 
given. 
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TABLE 7.7 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB BLUE GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 7 2546 1
st
 
Weighted Closeness 7 2327 2
nd
 
Weighted Betweenness 5 1631 3
rd
 
Weighted Degree 5 1592 4
th
 
Degree Centrality 4 1122 5
th
 
Eigenvector Centrality 3 946 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the combined 
metric is the best performing metrics, followed by the weighted closeness centrality. Both 
these metrics identify 7 genes, with the genes identified by the combined metric being higher 
scoring. The eigenvector centrality metrics perform relatively poorly, only identifying 3 
genes. Finally, extending the scoring system to the top 500 genes, the following results shown 
in table 7.8 below are given. 
TABLE 7.8 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB BLUE GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 25 7062 1
st
 
Degree Centrality 17 5192 2
nd
 
Weighted Degree 17 5192 2
nd
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Weighted Closeness 17 4846 4
th
 
Combined Metric 14 4078 5
th
 
Weighted Betweenness 12 3408 6
th
 
 
Despite performing badly in the two previous categories, this time the eigenvector centrality  
performs best, clearly outperforming the other metrics. The weighted degree and degree 
centrality are the next best performing metrics. Three of the top 25 ranked genes by Génie for 
retinoblastoma are identified by these metrics; TP53 ranked 3
rd
, MYCN ranked 6
th
, and KIT 
ranked 25
th
. This implies that these metrics are able to identify biologically relevant genes of 
interest in the network inferred from the RB Blue samples in the retinoblastoma dataset.  
Across the whole network, 48 out of the 500 retinoblastoma genes generated by Génie are 
present, with 25 of these present in the top 500 based on eigenvector centrality. However, 
only 4 out of the top 50 Génie ranked retinoblastoma genes are present in the top 500 ranked 
retinoblastoma genes for any of the metrics. This shows that many of the genes that Génie 
highlights as being important for retinoblastoma are not identified by the network metrics in 
this category. This could be due to three reasons. Firstly, that the network inference method 
and metrics are not accurate in re-constructing and identifying the gene regulatory processes 
that take place; secondly, that the modified version of the Z score method that has been 
applied only identifies a small number of retinoblastoma genes of interest; thirdly, that the  
genes that are present on the list generated by Génie do not in fact play an important role in 
this retinoblastoma category. It should again be noted that as well as no information 
concerning under and over-expressed genes, there is also no stage specific information present 
with the genes identified by Génie, i.e. specific genes are not associated with specific 
retinoblastoma stages. One possible reason for this is that the only retinoblastoma tissue 
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available for investigation is from high stage tumours , as these are the only ones which are 
removed surgically. As a result, there is very little genetic information about low stage 
tumours, except in the very few cases where these are detected in eyes simultaneously with a 
higher stage tumour.  
7.5 RB Red Category GRN Inferred using Positive Z Score Method 
Table 7.9 shows the top 20 ranked genes for the combined metric in the RB Red category 
GRN inferred using the positive Z score method. None of the genes in the table appear in the 
list of 500 retinoblastoma genes generated by Génie. Also, none of the genes that appear in 
the top 20 ranked list for the combined metric appear in any of the top 20 combined metric  
ranked lists for the other categories. As was the case with the previous category, this suggests 
that different genes are playing important roles in the different retinoblastoma stages.   
In contrast to the last category, where a number of the top 20 combined metric ranked genes 
appeared on the Génie list but no enrichment results were returned, a number of enrichment 
results are returned for this list of genes.  The top ten results are shown in table A.38 of the 
appendix. However, none of these enrichment results directly relate to retinal biology or 
retinoblastoma.   
TABLE 7.9 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB RED GRN INFERRED USING 
POSITIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
PGM3 1 SNUPN 11 
ACAT1 2 EXOSC8 12 
C20ORF72 3 AKR1A1 13 
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TRPM7 4 GPRASP2 14 
SESN1 5 TBC1D5 15 
YARS 6 TRIM32 16 
C6ORF204 7 NEDD4 17 
CARS2 8 TEX9 18 
ZNF702P 9 PDHB 19 
FBLN5 10 SGPL1 20 
 
Table 7.10 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the RB Red GRN inferred using the positive Z score method.  
TABLE 7.10 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB RED GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.953 0.903 0.899 
Weighted 
Degree 0.999 1 0.949 0.897 0.900 
Eigenvector 
Centrality 0.953 0.949 1 0.980 0.799 
Closeness 
Centrality 0.903 0.897 0.980 1 0.751 
Betweenness 
Centrality 0.899 0.900 0.799 0.751 1 
 
Unlike the previous category, where there were a number of weak correlations, in the table 
above it can be seen that for this category all of metrics have a positive correlation greater 
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than 0.75. These strong correlations imply that there is a substantial overlap in the genes that 
the metrics rank highly and we would expect that there will be quite a lot of overlap in the 
genes that these metrics identify.  
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 7.11 below. 
TABLE 7.11 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB RED GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 1 454 1
st
 
Degree Centrality 0 0 2
nd
 
Weighted Degree 0 0 2
nd
 
Weighted Closeness 0 0 2
nd
 
Eigenvector Centrality 0 0 2
nd
 
Combined Metric 0 0 2
nd
 
 
As noted previously, no genes on the Génie top 500 ranked list are identified by the combined 
rank, and this is also the case for all of the metrics apart from the weighted betweenness 
centrality, which only identifies one gene despite being the best performing metric. Applying 
the scoring system to the top 100 ranked genes for each metric, the results in table 7.12 below 
are given. 
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TABLE 7.12 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB RED GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Eigenvector Centrality 3 961 1
st
 
Degree Centrality 3 925 2
nd
 
Weighted Degree 3 925 2
nd
 
Weighted Closeness 3 925 2
nd
 
Combined Metric 3 925 2
nd
 
Weighted Betweenness 2 572 6
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the eigenvector 
centrality is the best performing metric, identifying three genes. All of the other metrics apart 
from the weighted betweenness also identify three genes, but these are lower scoring.  One of 
the three genes identified by the eigenvector centrality, RBL2, is the 11
th
 ranked gene for 
retinoblastoma. Fewer genes are identified by the metrics than for the last retinoblastoma 
stage. Finally, extending the scoring system to the top 500 genes, the following results shown 
in table 7.13 below are given.  
TABLE 7.13 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB RED GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 18 5481 1
st
 
Weighted Degree 18 5481 1
st
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Combined Metric 18 5481 1
st
 
Eigenvector Centrality 18 5465 4
th
 
Weighted Betweenness 17 5016 5
th
 
Weighted Closeness 17 5003 6
th
 
 
The combined metric , weighted degree and degree centrality are the joint best performing 
metrics, identifying the same 18 genes.  Eigenvector centrality also identifies 18 genes, but 
these are lower scoring. Five of the top 25 ranked genes for retinoblastoma are identified by 
the joint best performing metrics, compared to 3 of the top 25 by the best performing metric 
for the previous retinoblastoma stage. Extending this, 6 of the top 50 ranked genes are 
identified, again better than the best performing metric for the last category.  Across the whole 
network, 53 out of the 500 retinoblastoma genes generated by Génie are present, slightly more 
than were identified in the last category.  
7.6 RB Green Category GRN Inferred using Positive Z Score Method  
Table 7.14 shows the top 20 ranked genes for the combined metric in the RB Green category 
GRN inferred using the positive Z score method. As was the case with the previous category, 
none of the genes in the table appear in the list of 500 retinoblastoma genes generated by 
Génie. Also, none of the genes that appear in the top 20 combined metric ranked list appear in 
any of the top 20 combined metric ranked lists for the other categories. This again suggests 
that different genes are playing important roles in the different retinoblastoma stages.   
Also in keeping with the last category, a number of enrichment results are returned for this list 
of genes.  The top ten results are shown in table A.39 of the appendix. However, unlike the 
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last category, amongst these enrichment results there is one biological process that involves 
the retina. Rods, named in the first enrichment result, are photoreceptor cells in the retina.  
TABLE 7.14 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB GREEN GRN INFERRED 
USING POSITIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
GNAT1 1 CLUL1 11 
RHO 2 ANK3 12 
PDE6G 3 PDE8B 13 
CALB2 4 UNC13C 14 
NFIA 5 PVALB 15 
WIF1 6 MAPK10 16 
LSAMP 7 
SNORD115-
32 17 
GPR37 8 C1ORF61 18 
GABRA1 9 TANC1 19 
SEMA3A 10 NT5E 20 
 
Table 7.15 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the RB Green GRN inferred using the positive Z score method.  
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TABLE 7.15 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB GREEN GRN INFERRED USING POSITIVE Z SCORE METHOD  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.998 0.993 0.991 0.428 
Weighted 
Degree 0.998 1 0.996 0.984 0.424 
Eigenvector 
Centrality 0.993 0.996 1 0.974 0.394 
Closeness 
Centrality 0.991 0.984 0.974 1 0.446 
Betweenness 
Centrality 0.428 0.424 0.394 0.446 1 
 
The correlation scores for this category make for interesting reading. It is a mix of extremely 
strong correlations between almost all of the metrics apart from the weighted betweenness 
centrality, and weak correlations between the weighted betweenness centrality and the other 
metrics. As such, four of the five metrics would be expected to identify almost identical genes 
as being highly ranked. The genes identified by the weighted betweenness would be expected 
to be somewhat different though.  
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 7.16 below. 
 
 
216 
 
TABLE 7.16 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB GREEN GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Degree 2 680 1
st
 
Eigenvector Centrality 2 680 1
st
 
Degree Centrality 1 432 3
rd
 
Weighted Closeness 1 432 3
rd
 
Weighted Betweenness 1 125 5
th
 
Combined Metric 0 0 6
th
 
 
The weighted degree and eigenvector centrality are the best performing metrics, identifying 
the same two genes, followed by the degree and weighted closeness that both identify the 
same gene. Applying the scoring system to the top 100 ranked genes for each metric, the 
results in table 7.17 below are given.  
TABLE 7.17 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB GREEN GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 6 1841 1
st
 
Combined Metric 6 1841 1
st
 
Weighted Degree 6 1794 3
rd
 
Eigenvector Centrality 6 1794 3
rd
 
Degree Centrality 5 1537 5
th
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Weighted Betweenness 5 1073 6
th
 
 
The weighted closeness and combined metric are the joint best performing, identifying the 
same six genes. The weighted degree and eigenvector centrality also identify six genes, but 
these are lower scoring. Finally, extending the scoring system to the top 500 genes, the 
following results shown table 7.18 below are given. 
TABLE 7.18 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB GREEN GRN INFERRED USING POSITIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 27 7541 1
st
 
Weighted Degree 27 7541 1
st
 
Weighted Betweenness 27 7541 1
st
 
Weighted Closeness 27 7541 1
st
 
Eigenvector Centrality 27 7541 1
st
 
Combined Metric 27 7541 1
st
 
 
The metrics perform better at identifying genes in the Génie list of ranked retinoblastoma 
genes from their respective top 500 ranked genes for this category than for the two previous 
retinoblastoma categories. This is borne out by all 27 of the Génie ranked genes present in the 
network being identified. Previously, it was suggested that due to the extremely strong 
correlation scores between some of the metrics, we would expect to see the metrics 
identifying similar genes. This is the case here, although it was not expected that the weighted 
betweenness would also identify exactly the same genes as the other metrics. The lower 
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number of retinoblastoma genes on the Génie list in the network is perhaps also expected, 
considering that this network has been inferred from what have been taken to be samples from 
normal retinal tissue.  
7.7 Metric Performance in the GRNs Inferred from the Retinoblastoma Microarray 
using the Positive Z Score Method 
Previously, each metric was ranked based on the top 20, top 100 and top 500 genes they 
identified from each retinoblastoma category GRN inferred using the positive Z score method. 
This ranking is based on the score of the identified genes in the Génie retinoblastoma gene 
list.  
The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 7.19 below are given.  
TABLE 7.19 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING POSITIVE Z SCORE APPROACH 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Weighted 
Degree 3rd 1st 1st 5 1st 
Combined 
Metric 1st 1st 4th 6 2nd 
Weighted 
Closeness 2nd 5th 1st 8 3rd 
Eigenvector 
Centrality 5th 4th 1st 10 4th 
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Degree 
Centrality 5th 1st 5th 11 5th 
Weighted 
Betweenness 3rd 6th 6th 15 6th 
 
Weighted degree is the best performing metric overall, followed by the combined metric and 
the weighted closeness centrality.  As pointed out previously, the number of connections a 
node has in a network is the most often applied property for determining its importance in a 
network. It should perhaps not be surprising then to see a degree based metric perform well, 
although the poor performance of the degree centrality itself compared to the weighted degree 
perhaps is. If the rankings for just the top 20 genes in each category are taken into 
consideration, the following scores shown in table 7.20 are obtained. 
TABLE 7.20 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING POSITIVE Z SCORE APPROACH BASED ON 
THE TOP 20 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Weighted 
Degree 4th 2nd 1st 7 1st 
Weighted 
Betweenness 1st 1st 5th 7 1st 
Eigenvector 
Centrality 4th 2nd 1st 7 1st 
Weighted 
Closeness 3rd 2nd 3rd 8 4th 
Degree 
Centrality 4th 2nd 3rd 9 5th 
Combined 
Metric 2nd 2nd 6th 10 6th 
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Weighted betweenness, eigenvector centrality, and the weighted degree are the joint best 
performing metrics. The degree centrality again performs poorly. Taking the rankings for the 
top 100 genes into account, the following results shown in table 7.21 are obtained.  
TABLE 7.21 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING POSITIVE Z SCORE APPROACH BASED ON 
THE TOP 100 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Combined 
Metric 1st 
 
2nd 
 
1st 4 1st 
Weighted 
Closeness 2nd 
 
2nd 
 
1st 5 2nd 
Weighted 
Degree 4th 
 
2nd 
 
3rd 9 3rd 
Eigenvector 
Centrality 6th 
 
1st 
 
3rd 10 4th 
Degree 
Centrality 5th 
 
2nd 
 
5th 12 5th 
Weighted 
Betweenness 3rd 
 
6th 
 
6th 15 6th 
 
This time, the combined metric is the best performing metric, followed by weighted closeness 
centrality and weighted degree. Finally, taking the top 500 gene into account, the following 
results in table 7.22 are obtained.  
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TABLE 7.22 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING POSITIVE Z SCORE APPROACH BASED ON 
THE TOP 500 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Degree 
Centrality 2nd 
 
1st 
 
1st 4 1st 
Weighted 
Degree 2nd 
 
1st 
 
1st 4 1st 
Eigenvector 
Centrality 1st 
 
4th 
 
1st 6 3rd 
Combined 
Metric 5th 
 
1st 
 
1st 7 4th 
Weighted 
Closeness 4th 
 
6th 
 
1st 11 5th 
Weighted 
Betweenness 6th 
 
5th 
 
1st 12 6th 
 
Weighted degree and degree centrality are the joint best performing metric , performing 
slightly better than the eigenvector centrality. The combined metric is the 4
th
 best performing 
metric. Weighted closeness centrality, the 5
th
 ranked metric, and weighted betweenness 
centrality, the 6
th
 ranked metric, perform poorly compared to the other metrics. 
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7.8 Distribution of Genes in the Combined Metric Ranking Lists in the GRNs Inferred 
from the Retinoblastoma Microarray using the Positive Z Score Method 
As noted in the retinoblastoma GRN category sections, none of the genes that appear in the 
top 20 ranked genes for the combined metric for any of the retinoblastoma categories appear 
in any other. This can be seen on the Venn diagram in figure B.21 in the appendix showing 
the distribution of genes in the top 20 combined metric rankings list in the categories. 
Furthermore, extending this to look at the top 100 combined metric rankings lists, shown in 
figure B.22 of the appendix, this is still the case, suggesting that this approach is suited to 
identifying specific genes associated with the different survival time  
7.9 Network Level Metrics in the Retinoblastoma GRNs Inferred using the Negative Z 
Score Method 
Having inferred networks for the three retinoblastoma categories using the positive z score 
method, the negative z score method can now be implemented to infer networks. As before, 
prior to looking at the individual genes in the networks, the network level metrics will be 
calculated and analysed. The same metrics will be used again; weighted degree assortativity, 
degree asssortativity, diameter, and network clustering.  The scores for these are shown in 
table 7.23 below. The largest unique cliques will again be calculated for each of the networks 
for the two different datasets, and the genes that comprise these cliques will be investigated 
for both enrichment and the presence of retinoblastoma genes of interest using Génie.  
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TABLE 7.23 NETWORK LEVEL SCORES ACROSS THE CATEGORIES FOR THE RETINOBLASTOMA 
GRNS INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric RB Blue RB Red RB Green 
Weighted Degree 
Assortativity 
-0.242 -0.490 -0.579 
Degree Assortativity -0.242 -0.497 -0.600 
Diameter 6.091 2.775 1.898 
Network Clustering 0.424 0.621 0.599 
Largest Clique Size 105 125 155 
 
Looking at the network level scores, the value of the diameter once again is  of interest. For 
both the datasets in the last chapter, and the networks constructed using the Z score positive – 
positive variant, the value of the diameter was greatest in the most advanced neuroblastoma 
category. This is also the case here. This again is an indication that the diameter is a network 
level property that is associated with disease stage, and more specifically, one could 
hypothesise that this could be due to genes involved in certain cellular processes not being 
able to easily communicate with each other, thereby contributing to the more advanced stage 
of disease.  There is also a perfect correlation between the diameter ranking across the 
categories in the networks inferred using both the positive and negative variants of the Z score 
approach. In the next section, the size and composition of the largest unique cliques in the 
different categories will be looked at as this can be informative. 
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7.10 Largest Clique Calculation and Analysis  in Retinoblastoma GRNs Inferred using 
Negative Z Score Method 
The size and composition of the largest unique cliques in the different categories can be 
informative. It is also of interest to compare the largest unique cliques for the categories in the 
networks inferred from both datasets. A large number of common genes in the same category 
cliques across both datasets would be indicative of the same genes being involved in 
important cellular processes for specific retinoblastoma stages.  
As well as identifying common and unique genes in the cliques for the different categories, it 
is informative to see whether these genes have been previously identified as being 
retinoblastoma genes of interest and appear on the list of Génie retinoblastoma genes. The list 
of genes that comprise the largest unique c lique in each network category can also be checked 
for enrichment using the GenesetDB website. Table 7.24 below shows the size of the cliques 
in each category, whether any of the genes that comprise this clique are present in any other 
cliques, and finally whether any of the genes in the clique appear on the Génie retinoblastoma 
gene list.   
TABLE 7.24 RETINOBLASTOMA GENES OF INTEREST IN THE LARGEST UNIQUE CLIQUES IN THE 
RETINOBLASTOMA GRNS INFERRED USING NEGATIVE Z SCORE METHOD 
 
 Clique 
Size 
Genes 
present in 
other RB 
cliques 
Number of 
Génie genes 
and score 
RB Blue 105 0 5, score of 
1535 
RB Red 125 0 1, score of 
68 
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RB Green 155 0 16, score of 
5005 
 
Across the cliques, a number of retinoblastoma genes that appear on the list generated by 
Génie are present. As was the case with the largest unique cliques in the networks constructed 
using the positive Z score method, the RB Green category has both the highest number of 
Génie genes, and also the highest score of genes identified. As noted before, this might appear 
to be a surprising result, considering that the RB Green category network has been inferred 
from normal retinal samples.  The sizes of the cliques in the three categories are more similar 
in size than was the case with the cliques for the categories in the networks inferred using the 
positive Z score method, with a range of 50, compared to a range of 142.  It should also be 
noted that the RB Green clique is also the largest again. The RB Red category  has the lowest 
number of genes identified, and the lowest score. A similar number of genes, 22 compared to 
21, to the positive Z score method are present in the cliques, representing just 4.4 % of the 
complete list used. This lower proportion can be attributed to the more specific network 
inference method used; if both network construction variants are included, then 43 of the 500 
genes are present in the cliques. The Venn diagram in figure B.23 of the appendix shows the 
distribution of the genes in the largest unique cliques in the networks inferred using the 
negative Z score method.   
There are 385 genes in total across the three cliques. There are no genes common to either two 
or three cliques, with each gene only appearing in one clique.  This result is indicative that the 
cellular processes are very different in the cliques in the different retinoblastoma categories. It 
would be expected that different genes are over-expressed in different retinoblastoma stages 
and healthy cellular processes; the distribution of genes in the cliques corresponds with this. 
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There are also no genes that are common between the largest unique cliques in the networks 
constructed using the positive Z score and negative Z score methods. 
Having investigated the distribution of genes in the cliques, the next step is to investigate the 
enrichment of these genes using GenesetDB. For the genes that comprise the largest unique 
clique in the RB Blue category, 22 results are returned by GenesetDB. The top ten results 
returned are shown in table A.40 of the appendix. There are a number of results of interest 
here; sets relating to translation and mRNA splicing/processing may have relevance to 
retinoblastoma. Retinal photoreceptor cells are one of the most metabolically active cells in 
the body [141], and are reliant on high levels of gene transcription and translation for normal 
function. This characteristic may also facilitate tumour growth.  
For the genes that comprise the largest unique clique in the RB Red category, only three 
results are returned from GenesetDB. This would imply that this combination of genes has not 
been identified as being involved in biological processes. The three results returned are shown 
in table A.41 of the appendix.  
Unlike the previous two categories, that returned a small amount of enrichment results, the 
genes that comprise the largest unique clique in the RB Green category return a number of 
enrichment results. The top ten results returned are shown in table A.42 of the appendix. 
However, unlike with the enrichment results returned from the largest unique clique in the 
network inferred using the positive Z score method; none of these results are of interest. 
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7.11 RB Blue Category GRN Inferred using Negative Z Score  Method 
Table 7.25 shows the top 20 ranked genes for the combined metric in the RB Blue category 
GRN inferred using the negative Z score method. Two of these genes in the table appear in 
the list of 500 retinoblastoma genes generated by Génie; SP1, and SPAST. None of the genes 
that appear in the top 20 combine metric ranked list appear in any of the top 20 combined 
metric ranked lists for the other categories. As was the case with the largest unique cliques, 
this suggests clearly distinguishable differences between the retinoblastoma categories in 
terms of the genes that are playing important roles in cellular processes.  
Despite 2 genes out of the 20 appearing on the Génie retinoblastoma list, and as was the case 
with the RB Blue network inferred using the positive Z score method, no enrichment results 
are returned for the 20 genes in the table below. This suggests that despite some of these 
genes being associated with retinoblastoma, they have not been identified as being involved 
together in biological processes. 
TABLE 7.25 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB BLUE GRN INFERRED USING 
NEGATIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
SON 1 ZFR 11 
SNAPC3 2 MRPL3 12 
ACTR3 3 WAC 13 
SP1 4 KIF5B 14 
CSDE1 5 PPP1CB 15 
KCMF1 6 ZNF532 16 
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MRPL50 7 HELZ 17 
CNOT7 8 SPAST 18 
TMEM33 9 ZNF138 19 
MTMR4 10 MYST3 20 
 
Table 7.26 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the RB Blue GRN inferred using the negative Z score method.  
TABLE 7.26 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB BLUE GRN INFERRED USING THE NEGATIVE Z SCORE METHOD  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.930 0.926 0.833 
Weighted 
Degree 0.999 1 0.928 0.923 0.834 
Eigenvector 
Centrality 0.930 0.928 1 0.967 0.659 
Closeness 
Centrality 0.926 0.923 0.967 1 0.704 
Betweenness 
Centrality 0.833 0.834 0.659 0.704 1 
 
From the table above, it can be seen that all of metrics have a positive correlation greater than 
0.65, and that a number of metrics have very strong correlations with other metrics.  These 
strong correlations imply that there is a substantial overlap in the genes that the metrics rank 
highly, as was the case for a lot of the metrics in the last chapters. Therefore, we would expect 
that there will be quite a lot of overlap in the genes that these metrics identify.  
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Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 7.27 below. 
TABLE 7.27 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB BLUE GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 2 677 1
st
 
Degree Centrality 1 428 2
nd
 
Weighted Degree 1 428 2
nd
 
Weighted Betweenness 1 428 2
nd
 
Weighted Closeness 1 428 2
nd
 
Eigenvector Centrality 0 0 6
th
 
 
The combined metric performs best, identifying two genes, including the gene ranked 73
rd
 for 
retinoblastoma by Génie, SP1. All of the other metrics apart from the eigenvector centrality 
also identify Génie; SP1.  Applying the scoring system to the top 100 ranked genes for each 
metric, the results in table 7.28 below are given.  
TABLE 7.28 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB BLUE GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 5 1644 1
st
 
230 
 
Weighted Closeness 4 1425 2
nd
 
Combined Metric 3 1156 3
rd
 
Degree Centrality 2 677 4
th
 
Weighted Degree 2 677 4
th
 
Eigenvector Centrality 2 677 4
th
 
 
Applying the scoring system to the top 100 genes identified by the metrics, the weighted 
betweenness centrality is the best performing metric, identifying 5 genes. Finally, extending 
the scoring system to the top 500 genes, the following results shown in table 7.29 below are 
given. 
TABLE 7.29 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB BLUE GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Combined Metric 25 5968 1
st
 
Weighted Closeness 21 5358 2
nd
 
Degree Centrality 22 5252 3
rd
 
Weighted Degree 22 5252 3
rd
 
Eigenvector Centrality 22 5161 5
th
 
Weighted Betweenness 22 4807 6
th
 
 
The combined metric performs best, followed by weighted closeness and then degree and 
weighted degree centrality. Three of the top 25 ranked genes by Génie for retinoblastoma are 
identified by the combined metric; CDK4 ranked 15
th
, BRAF ranked 22
nd
, and CDKN1B 
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ranked 23
rd
.  Extending this, 5 of the top 50 ranked genes are identified. Across the whole 
network, 76 out of the 500 retinoblastoma genes generated by Génie are present; compared to 
53 that are present in the RB Blue network inferred using the positive Z score method. This 
result might indicate that under-expression of genes is more informative in the RB Blue 
category than gene amplification; based on more Génie retinoblastoma genes of interest being 
present in the network inferred using the negative Z score method. 
7.12 RB Red Category GRN Inferred using Negative Z Score Method 
Table 7.30 shows the top 20 ranked genes for the combined metric in the RB Red category 
GRN inferred using the negative Z score method. None of the genes in the table appear in the 
list of 500 retinoblastoma genes generated by Génie. Also, none of the genes that appear in 
the top 20 combined metric ranked list appear in any of the top 20 combined metric ranked 
lists for the other categories. As was the case with the previous category, this suggests that 
different genes are playing important roles in the different retinoblastoma stages.   
No enrichment results are returned for the list of top 20 ranked genes, implying that this 
particular combination of genes has not been ident ified as being involved in any significant 
biological processes. None of the genes being present in the top 500 list returned by Génie 
also suggests that this list of genes might not be as biologically relevant as the list of 20 genes 
returned by the previous retinoblastoma category.  
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TABLE 7.30 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB RED GRN INFERRED USING 
NEGATIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
FXYD7 1 LEFTY1 11 
RBMS1 2 C6ORF15 12 
GPR37L1 3 MADCAM1 13 
IL28B 4 GPR149 14 
BARHL2 5 CTF1 15 
DNM1P35 6 C9ORF141 16 
OR6C76 7 MCCD1 17 
DRD5 8 IGFBP1 18 
FAM115C 9 ADAMTS7 19 
PLA2G2D 10 DKFZP779M0652 20 
 
Table 7.31 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the RB Red GRN inferred using the negative Z score method.  
 
TABLE 7.31 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB RED GRN INFERRED USING NEGATIVE Z SCORE METHOD  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.998 0.998 0.912 
Weighted 
Degree 0.999 1 0.997 0.997 0.913 
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Eigenvector 
Centrality 0.998 0.997 1 0.996 0.899 
Closeness 
Centrality 0.998 0.997 0.996 1 0.913 
Betweenness 
Centrality 0.912 0.913 0.899 0.913 1 
 
There are extremely strong correlation scores between the metrics in this category, as can be 
seen in table above, with the weakest correlation of 0.899.  These extremely strong 
correlations imply that there will be a great deal of overlap in the genes that the metrics rank 
highly, as was the case for a lot of the metrics in the last chapters. 
Applying the scoring system to the top 20, top 100, and top 500 genes identified by each of 
metrics, the metrics can be ranked. The scores for the top 20 genes identified by each metric 
are shown in table 7.32 below. 
TABLE 7.32 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB RED GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 0 0 1st 
Weighted Degree 0 0 1st 
Weighted Betweenness 0 0 1st 
Weighted Closeness 0 0 1st 
Eigenvector Centrality 0 0 1st 
Combined Metric 0 0 1st 
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None of the metrics identify a single Génie retinoblastoma gene of interest.  Applying the 
scoring system to the top 100 ranked genes for each metric, the results in table 7.33 below are 
given. 
TABLE 7.33 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB RED GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 2 217 1
st
 
Combined Metric 2 217 1
st
 
Degree Centrality 1 68 3
rd
 
Weighted Degree 1 68 3
rd
 
Weighted Closeness 1 68 3
rd
 
Eigenvector Centrality 1 68 3
rd
 
 
The weighted betweenness and the combined metric are the joint best performing metrics, 
both identifying the same two genes. All of the other metrics identify one of these two genes. 
All of the metrics perform badly at identifying genes, although the performance is similar to 
that of the metrics in the RB Red category in the network inferred using the positive Z score 
method. Finally, extending the scoring system to the top 500 genes, the following results 
shown in table 7.34 below are given.  
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TABLE 7.34 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB RED GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 8 1172 1st 
Weighted Degree 8 1172 1st 
Weighted Betweenness 8 1172 1st 
Weighted Closeness 8 1172 1st 
Eigenvector Centrality 8 1172 1st 
Combined Metric 8 1172 1st 
 
All of the metrics identify the same eight genes, which are also all of the Génie 
retinoblastoma genes of interest that are present in the whole network.  There are no genes in 
either the top 25 or top 50 ranking by Génie of retinoblastoma genes. Compared to the RB 
Red network inferred using the positive Z score method, there are 45 fewer Génie 
retinoblastoma genes present. In contrast to the RB Blue category, this could indicate that 
over-expression of genes is more informative in the RB Red category than gene under-
expression; based on more Génie retinoblastoma genes of interest being present in the 
network inferred using the positive Z score method.  
7.13 RB Green Category GRN Inferred using Negative  Z Score Method 
Table 7.35 shows the top 20 ranked genes for the combined metric in the RB Green category 
GRN inferred using the negative Z score method. Three of the genes in the table, E2F1 ranked 
5
th
 by Génie, PLK1 ranked 220
th
 by Génie, and TP73 ranked 41
st
 by Génie, appear in the list 
of retinoblastoma genes of interest. None of the genes that appear in the top 20 combined 
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metric ranked list appear in any of the top 20 combined metric ranked lists for the other 
categories. This again suggests that different genes are playing important roles in the different 
retinoblastoma stages.   
Table A.43 of the appendix shows the top twenty enrichment results for this list of genes. The 
top twenty results are shown this time as whilst none of the top ten results are directly 
involved in retinal or retinoblastoma biology, the 16
th
 result returned concerns the regulation 
of the previously mentioned E2F1. The 17
th
 result returns also details increased incidence of  
tumours. The genes PLK1, POLA2, and TP73 that are in the list of top 20 ranked genes, have 
been identified as being involved in the regulation of the gene E2F1.  
TABLE 7.35 TOP 20 RANKED GENES FOR COMBINED METRIC IN RB GREEN GRN INFERRED 
USING NEGATIVE Z SCORE METHOD 
 
Gene Combined 
Metric 
Rank 
Gene Combined 
Metric 
Rank 
CHAF1A 1 TROAP 11 
WDR34 2 CPXM1 12 
ZWINT 3 POLA2 13 
E2F1 4 KIF18B 14 
REC8 5 DKFZP434L187 15 
LRDD 6 MCM2 16 
GLT25D1 7 FEN1 17 
CENPM 8 PLK1 18 
RCC2 9 CDCA2 19 
STMN1 10 TP73 20 
 
237 
 
Table 7.36 below shows the Spearman Rank correlation scores for the rankings assigned to 
the genes by each metric in the RB Green GRN inferred using the negative Z score method.  
TABLE 7.36 SPEARMAN RANK CORRELATION SCORES OF RANKINGS ASSIGNED BY THE 
METRICS TO THE GENES IN RB GREEN GRN INFERRED USING NEGATIVE Z SCORE METHOD  
 
 Degree 
Centrality 
Weighted 
Degree 
Eigenvector 
Centrality 
Closeness 
Centrality 
Betweenness 
Centrality 
Degree 
Centrality 1 0.999 0.999 0.992 0.806 
Weighted 
Degree 0.999 1 0.999 0.992 0.805 
Eigenvector 
Centrality 0.999 0.999 1 0.991 0.804 
Closeness 
Centrality 0.992 0.992 0.991 1 0.804 
Betweenness 
Centrality 0.806 0.805 0.804 0.804 1 
 
Once again, there are strong correlation scores between the metrics, with the minimum 
correlation score being 0.80. Again, this implies significant overlap in the genes ranked highly 
by the different metrics.  Applying the scoring system to the top 20, top 100, and top 500 
genes identified by each of metrics, the metrics can be ranked. The scores for the top 20 genes 
identified by each metric are shown in table 7.37 below. 
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TABLE 7.37 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 20 RANKED GENES FOR EACH 
METRIC IN RB GREEN GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Betweenness 3 1237 1
st
 
Combined Metric 3 1237 1
st
 
Degree Centrality 2 777 3
rd
 
Weighted Degree 2 777 3
rd
 
Weighted Closeness 2 777 3
rd
 
Eigenvector Centrality 2 777 3
rd
 
 
The weighted betweenness and the combined metric are the joint best performing metrics, 
both identifying the same three genes, including TP73. The other metrics all identify the 
genes E2F1 and PLK1 that the weighted betweenness and combined metric also identify. 
Applying the scoring system to the top 100 ranked genes for each metric, the results in table 
7.38 below are given.  
TABLE 7.38 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 100 RANKED GENES FOR 
EACH METRIC IN RB GREEN GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Degree Centrality 14 4520 1
st
 
Weighted Degree 14 4520 1
st
 
Weighted Closeness 14 4520 1
st
 
Eigenvector Centrality 14 4520 1
st
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Combined Metric 13 4028 5
th
 
Weighted Betweenness 10 2644 6
th
 
 
The degree, weighted degree, weighted closeness and eigenvector centrality all identify the 
same 14 genes. As noted, the strong correlation scores between the metrics means that we 
might expect the metrics to identify the same genes.  Three of the top 50 ranked genes for 
retinoblastoma; E2F1, BRCA1, and TP73, are present amongst these 14 genes.  Finally, 
extending the scoring system to the top 500 genes, the following results shown in table  7.39 
below are given.  
TABLE 7.39 GÉNIE  SCORES AND METRIC RANKING FOR THE TOP 500 RANKED GENES FOR 
EACH METRIC IN RB GREEN GRN INFERRED USING THE NEGATIVE Z SCORE METHOD 
 
Metric Number of Génie 
retinoblastoma genes 
identified 
Génie  Score Metric Rank 
Weighted Closeness 45 12866 1
st
 
Combined Metric 45 12866 1
st
 
Degree Centrality 44 12731 3
rd
 
Weighted Degree 44 12731 3
rd
 
Weighted Betweenness 44 12731 3
rd
 
Eigenvector Centrality 44 12731 3
rd
 
 
The combined metric and weighted closeness are the best performing metrics, identifying the 
same 45 genes. These two just outperform the other metrics that identify 44 genes. 7 of the 45  
genes that the combined metric and weighted closeness identify are in the top 50 Génie 
ranked genes for retinoblastoma. There are 49 retinoblastoma genes of interest present in this 
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network. Again, it might be surprising for so many retinoblastoma genes to be identified in 
the network inferred from healthy samples, as before, there are a variety of reasons as to why 
this is the case, and again highlights the role of clinicians and biologists to infer biological 
meaning from these results. 27 Génie retinoblastoma genes of interest are present in the RB 
Green network inferred using the positive Z score method, indicating that under-expression of 
genes is more informative in the RB Green category than gene amplification; based on more 
Génie retinoblastoma genes of interest being present in the network inferred using the 
negative Z score method. Another interpretation of this is that these genes might be involved 
in retinoblastoma cellular processes when they are significantly over-expressed, thereby 
explaining their presence in the network inferred from healthy retinal samples using the 
negative Z score method. 
7.14 Metric Performance in the GRNs Inferred from the Retinoblastoma Microarray 
using the Negative Z Score Method 
Previously, each metric was ranked based on the top 20, top 100 and top 500 genes they 
identified from each retinoblastoma category GRN inferred using the negative Z score 
method. This ranking is based on the score of the identified genes in the Génie retinoblastoma 
gene list.  
The results of these metric rankings can now be presented together, allowing an analysis of 
which metric is the best performing overall. Assigning an equal weighting to the scores of the  
top 20, top 100, and top 500 ranked genes for each metric in each category, the following 
ranks shown in table 7.40 below are given.  
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TABLE 7.40 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING NEGATIVE Z SCORE APPROACH 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Combined 
Metric 1st 1st 2nd 4 1st 
Weighted 
Closeness 2nd 3rd 1st 6 2nd 
Degree 
Centrality 3rd 3rd 2nd 8 3rd 
Weighted 
Degree 3rd 3rd 2nd 8 3rd 
Weighted 
Betweenness 3rd 1st 6th 10 5th 
Eigenvector 
Centrality 6th 3rd 2nd 11 6th 
 
The combined metric is the best performing metric overall, followed by weighted closeness. If 
the rankings for just the top 20 genes in each category are taken into consideration, the 
following scores shown in table 7.41 are obtained.  
TABLE 7.41 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING NEGATIVE Z SCORE APPROACH BASED 
ON THE TOP 20 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Combined 
Metric 1st 1st 1st 3 1st 
Weighted 
Betweenness 2nd 1st 1st 4 2nd 
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Degree 
Centrality 2nd 1st 3rd 6 3rd 
Weighted 
Degree 2nd 1st 3rd 6 3rd 
Weighted 
Closeness 2nd 1st 3rd 6 3rd 
Eigenvector 
Centrality 6th 1st 3rd 10 6th 
 
The combined metric is again the best performing metric, followed by weighted betweenness. 
The eigenvector centrality is the worst performing metric again. If we take the ranking for the 
top 100 genes into account, the following results shown in table 7.42 are obtained.  
 
TABLE 7.42 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING NEGATIVE Z SCORE APPROACH BASED 
ON THE TOP 100 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Weighted 
Closeness 2nd 
 
3rd 
 
1st 6 1st 
Degree 
Centrality 4th 
 
3rd 
 
1st 8 2nd 
Weighted 
Degree 4th 
 
3rd 
 
1st 8 2nd 
Weighted 
Betweenness 1st 
 
1st 
 
6th 8 2nd 
Eigenvector 
Centrality 4th 
 
3rd 
 
1st 8 2nd 
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Combined 
Metric 3rd 
 
1st 
 
5th 9 6th 
 
Weighted closeness is the Degree centrality is the best performing metric, followed by four of 
the other metrics that all exhibit the same performance. The combined metric, which was the 
best performing metric the previous two times, is the worst performing metric this time. 
Finally, taking the top 500 gene into account, the following results in table 7.43 are obtained.  
TABLE 7.43 OVERALL METRIC RANKS IN THE DIFFERENT RETINOBLASTOMA CATEGORY GRNS 
INFERRED FROM RETINOBLASTOMA MICROARRAY USING NEGATIVE Z SCORE APPROACH BASED 
ON THE TOP 500 GENES IDENTIFIED BY EACH METRIC 
 
  
RB Blue 
Category 
Rank 
RB Red 
Category 
Rank 
RB Green 
Category 
Rank 
Ranking 
Totals 
Overall 
Rank 
Combined 
Metric 1st 
 
1st 
 
1st 3 1st 
Weighted 
Closeness 2nd 
 
1st 
 
1st 4 2nd 
Degree 
Centrality 3rd 
 
1st 
 
3rd 7 3rd 
Weighted 
Degree 3rd 
 
1st 
 
3rd 7 3rd 
Eigenvector 
Centrality 5th 
 
1st 
 
3rd 9 5th 
Weighted 
Betweenness 6th 
 
1st 
 
3rd 10 6th 
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This time the combined metric just out-performs weighted closeness centrality, with these two 
metrics showing similar performance. Eigenvector centrality, the 5
th
 ranked metric, and 
weighted betweenness centrality, the 6
th
 ranked metric, perform poorly compared to the other 
metrics. 
7.15 Distribution of Genes in the Combined Metric Ranking Lists in the GRNs Inferred 
from the Retinoblastoma Microarray using the Negative Z Score Method 
As noted in the retinoblastoma category sections for the networks inferred using the positive  
Z score method, none of the genes that appear in the top 20 ranked list for the combined 
metric for any category appear in any other, shown in figure B.21 of the appendix.  This is 
also the case for the networks inferred using the negative Z score method, shown in figure 
B.24 of the appendix. As well as this, no top 20 ranked genes for the combined metric for any 
category in the network inferred using the positive Z score method are present in any of the 
top 20 combined metric ranking genes for the GRNs inferred using the negative Z score 
method, and vice-versa. This demonstrates that clearly distinguishable genes are involved in 
the different networks constructed using the two different methods; it is not a case of certain 
genes that are identified as being high ranking in the network for one category using one of 
the methods, is then identified as being high ranking in the network for a different category 
using the other method. This would suggest that implementing the two different methods 
based on the nature of the correlations allows identification of very specific genes, which may 
be beneficial to clinicians and biologists looking to identify particular genes being important 
in particular diseases categories. Extending this to look at the top 100 ranked genes in the 
combined metric rankings list, shown in figure B.25 of the appendix, this is also the case.  
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7.16 Discussion 
In this chapter, a modified version of the Z score network inference method used in the 
previous two chapters was introduced. The principal reason for this was to enable a specific 
means to infer separate networks involving gene over expression and gene under expression, 
as oppose to the absolute correlation approach adopted before. As a result of implementing 
this approach, unique and specific genes were identified as being important in different 
categories of a proprietary retinoblastoma dataset based on both gene over expression, and 
gene under expression. This can be seen by the fact that there are no common genes either 
between the top 100 combined metric ranked genes for each category, either between the 
categories inferred using the same network inference method, and also between the categories 
of the networks inferred using the two different network inference methods. This is also the 
case with the genes that comprise the largest unique cliques of the networks inferred.  
In the networks inferred using the positive Z score method, there are a number of perhaps 
unexpected findings. These mostly concern the genes that comprise the largest unique cliques  
in the GRNs, and the enrichment results these yield. As noted, it might be surprising to find 
more genes identified as being amongst the 500 most important for retinoblastoma by Génie 
in the largest unique clique for the RB Green category, than in the largest unique cliques for 
the other two categories. The perhaps paradoxical enrichment results yielded for this clique; 
results pertaining to both healthy retinal cell processes and diseased retinal processes might 
also be a result that at first has little sense, although, can be attributed to the enrichment 
results not distinguishing between gene over expression and under expression.  However, 
looking at the top ranked genes in each of the three networks and the genes that make up these 
networks, there are a number of expected results. The RB Blue Category, the most advanced 
retinoblastoma stage, has a greater number of genes identified by Génie in the top 20 ranked 
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genes than the other two networks. Furthermore, both the RB Blue, 48 genes, and the RB 
Red, 53 genes, have more of these top 500 retinoblastoma genes of interest in their networks, 
than the RB Green network has, 27 genes. We would expect that more genes previously 
identified as being important for retinoblastoma would be present in the networks inferred 
from the retinoblastoma samples than the network inferred from healthy retinal samples.  
A similar result with the composition of the largest unique cliques occurs in the networks 
inferred using the negative Z score method. There are again more genes identified as being 
amongst the 500 most important for retinoblastoma by Génie in the largest unique clique for 
the RB Green category, than in the largest unique cliques for the other two categories. No 
enrichment results are yielded this time that relate either to retinoblastoma or the retina in 
general for any of the cliques. In the GRNs, there is one particular enrichment result that is 
yielded for the RB Green category, relating to the regulation of the gene E2F1, ranked 5
th
 by 
Génie for retinoblastoma. pRB, the protein that is encoded by the RB1 gene, is directly 
responsible for blocking the expression of E2F1[142]. Therefore, the expression of E2F1 is 
lower in the RB Green samples that have a normal RB1 gene, than in the RB Red and RB 
Blue samples. E2F1 is one of the top 20 ranked genes in the RB Green network, suggesting 
therefore that the gene regulatory processes responsible for under expressing E2F1 might be a 
property that distinguishes healthy retina from retinoblastoma. There are also more 
retinoblastoma genes of interest in the top 20 ranked genes for the RB Green network, than 
for the RB Blue network, 2, and the RB Red network, 0.  Clear differences can be seen 
between the two networks inferred from the retinoblastoma samples; there are 76 
retinoblastoma genes of interest in the RB Blue network, whilst only 8 in the RB Red 
network.  There are 49 retinoblastoma genes of interest in the RB Green network.  
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The use of the modified implementation of the Z score network inference method is 
promising; unique genes in all categories of the retinoblastoma dataset were identified, despite 
the small number of samples. A number of previously identified retinoblastoma genes of 
interest were present amongst these genes, although the need for expert interpretation from 
specialists such as biologists and clinicians was shown by the network inferred from the 
healthy retinal samples containing a number of genes identified by Génie. This shows that 
despite the promising results obtained, there is still a need for manual verification from 
experts. 
7.17 Conclusions 
To conclude, in this chapter a ref inement of the novel inference method was introduced, to 
specifically distinguish between genes whose expression is amplified together, and genes 
whose expression is under expressed together. This method was applied to a retinoblastoma 
microarray dataset from samples collected at BCH to infer three categories of GRN. Unlike 
the previous microarray datasets used in the work, a normal reference GRN was amongst the 
categories of network inferred, due to the presence of what appeared to be normal tissues 
amongst the samples in the dataset. This allowed comparisons to be made against this normal 
GRN. Again, graph theory metrics were used to identify high ranking genes, and the metrics 
were scored and compared based on their ability to identify genes identified by the text-
mining tool Génie as being important for retinoblastoma. The next chapter details approaches 
for making the GRN inference methods and tools for calculating the metrics used in this work 
available to clinicians and biologists, as well as the wider scientific community. This is done 
to improve the accessibility and usability of the methods.   
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Chapter 8 
Improving the Accessibility of GRN Inference and 
Analysis Tools 
8.1 Introduction 
In this chapter, a number of options for making the network inference methods used in this 
work more accessible are presented. The work in this chapter addresses the accessibility and 
usability outlined in the first objective. Having specifically seen in chapters 5, 6, and 7 how 
the application of the novel network inference method identifies unique genes of interest 
specifically associated with disease stages, one important area to consider is how easily it can 
be adopted by clinicians and biologists to interrogate microarray data. To date, the approach 
adopted in this work has been to infer and then analyse GRNs using R from microarray 
datasets that have been flagged as being of interest by clinicians and biologists. Following 
feedback from clinicians and biologists, they would like to be able to use the network 
inference method themselves on microarray datasets, but without having to learn a 
programming language.  
Specialist programming skills required for network inference methods in languages such as R, 
Matlab, and Python, are proving a barrier to widespread use of network inference approaches 
to microarray data by biologists and clinicians [9]. There is also great variation in the 
programming languages that different research groups involved in microarray analysis use, 
posing potential problems to collaborative research. One drawback of this is that the potential 
benefit of greater use of network inference techniques to analyse microarray data is not being 
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fully harnessed, especially considering that biologists and clinicians are those with the expert 
knowledge that are the best-equipped to interpret the results. To counter this, the Z score 
network inference method should be accessible to users that do not possess these specialist  
programming skills. Therefore, the implementation of the Z score network inference method, 
along with other GRN inference and analysis tools for microarray data, on a web based 
interface is one of the options presented. This was originally going to be presented as one of 
the recommendations for the future for building upon this work, however following 
discussions with biologists and clinicians, the immediate need for an easy means to access 
network inference tools for microarray analysis became apparent. 
Despite there being a number of web based platforms that host bioinformatics tools, there is a 
lack of network inference and analysis tools available on these platforms. A number of these 
web based platforms, such as GenePattern [143] and Genevestigator [144], host gene 
expression analysis tools but these fall mainly into the different ial analysis category. There 
are no tools to infer GRNs from gene expression data. Therefore, following advice from 
researchers at the Bioinformatics Institute at the University of Auckland, including Director of 
the New Zealand Bioinformatics Institute Associate Professor Cristin Print, a number of GRN 
inference and analysis tools  have been developed using the Galaxy framework [10]; an open, 
web-based platform for data intensive biomedical research. The package RGalaxy [145] was 
used to enable the R based scripts that the Z score network inference was coded in to be 
accessed via the Galaxy interface, as well as the other network inference and analysis tools. 
For the purposed of this project, a personalised local host version of Galaxy running on a 
dedicated Ubuntu machine that can be remotely accessed has been set up. This has been done 
for two reasons; firstly to evaluate the feasibility of such a tool before a publically accessible 
version is made available, and secondly due to the confidential nature of a number of 
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unpublished datasets that the biologists and clinicians would not feel comfortable analysing 
using a publically accessible tool. It is envisioned that this local host version will be retained 
in the future alongside any publicly accessible version, specifically for use with confidential 
data. As well as the novel network inference method used in chapters 5 and 6 in this work, a 
number of other network inference and analysis tools have also been made available. These 
include the WGCNA network inference method used in chapter 4, network metric calculation 
tools for analysing existing networks, enrichment analysis tools, and tools to export subnets of 
interest to the network visualisation software Cytoscape [146]. There are a number of tools on 
the public Galaxy server that are not of use, and have been removed to make the interface a 
lot simpler. On the screenshot below, these tools can be seen on the left-hand side, as well as 
the welcome screen. 
FIGURE 8.1 PUBLIC GALAXY SERVER WELCOME SCREEN 
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In order to facilitate use of the network inference and analysis tools using Galaxy, as well as 
removing the non-required tools, the welcome screen has also been simplified. The screenshot 
below shows the welcome screen of the local personalised Galaxy version.  
FIGURE 8.2 PERSONALISED LOCAL HOST  VERSION OF GALAXY WELCOME SCREEN 
 
As can be seen, there is a much cleaner and simpler interface, with only three categories of 
tools.  The Get Data and Text Manipulation tool sections have been maintained, and the 
network inference and analysis tools are found under the custom section. A number of 
additional screenshots are included in appendix C.  
The flowchart on the next page shows an overview of the process for the biologists and 
clinicians to analyse microarray datasets using the local host version of Galaxy. All that is 
required is for the end user to categorise the datasets based on their own criteria, and upload 
them to the platform. The all-in-one tool then carries out all the processes seen in the 
flowchart in figure 3.2 that required specialist programming skills, and presents the output for 
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the end user to download for their own further analysis and interpretation. Two main benefits 
have been achieved; the need for an end user with specialist programming skills has been 
removed; and the need for this end user to go back and forth to the clinicians and biologists 
for guidance on the classification criteria and expert interpretation of the results has also been 
removed.  Figure 8.3 below shows the new simplified process. 
FIGURE 8.3 OVERVIEW OF PROCESS FOR NETWORK INFERENCE AND ANALYSIS USING 
PERSONALISED GALAXY LOCAL HOST SERVER  
 
8.2 Making Tools Accessible  to the Wider Scientific Community 
As well as the local host implementation of Galaxy aimed at clinicians and biologists , there 
are alternative options that can make the tools implemented available to the wider scientific 
community. These fall into two categories; without hosting, and with hosting. The first of 
these is to publish the Galaxy tools developed directly to the Galaxy Tool Shed, found at 
http://toolshed.g2.bx.psu.edu/. This allows other users with personalised Galaxy installations 
253 
 
to directly implement these, thus allowing all users of their respective installation to access 
these tools. This option is aimed at users responsible for installing and maintaining Galaxy 
installations, rather than at clinicians and biologists. In addition, an R package can be created 
and contributed to CRAN, http://cran.r-project.org/, allowing users with knowledge of R to 
access and use the tools, and R scripts can be made available online, at sites such as 
http://sourceforge.net/.  
The second means by which to make the tools accessible to the wider scientific community is 
to host a publically accessible version of Galaxy on a dedicated separate server.  The main 
benefit of this is that a publically accessible server specifically tailored to microarray analysis 
can be deployed. Additionally, access will not be limited to biologists and clinicians affiliated 
to a particular research group with a local version of Galaxy. However , in order to provide 
this an extensive validation and verification process will be required to ensure the robustness 
of both the tools implemented and the infrastructure used, and extensive hardware resources 
will be required. To illustrate this, one instance of a publically accessible Galaxy server 
consists of a Dell blade/m1000e chassis, with 128 cores, 1TB RAM, and 72TB raw array 
storage. 
8.3 Summary 
The first section of this chapter detailed the implementation of GRN inference and analysis 
tools on a local host of the Galaxy biomedical analysis server. This has been presented as a 
means to improve the accessibility and usability of GRN inference and analysis tools to end 
users without specialist programming skills, and will require extensive evaluation and testing 
before they can be made available on a publically available web-based server. Initial feedback 
from researchers who have used the local version based at the Bioinformatics Institute at the 
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University of Auckland has been promising, suggesting that this is potential means by which 
to improve the accessibility and usability of GRN inference and analysis tools for microarray 
datasets. The second section provided an overview of ways that the tools can be made 
available to the wider scientific community, which includes making the tools available on the 
Galaxy Tool Shed. In the next chapter, the overall conclusions for the thesis are presented, 
along with limitations and areas for future development. 
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Chapter 9 
Conclusions 
The aim of this thesis was to investigate the progression and evolution of tumours, by 
inferring and analysing GRNs for different evolutionary and clinical stages of cancer 
microarray datasets.  It has been shown in this thesis that applying graph theory metrics to 
GRNs inferred using a novel inference method achieved this aim, and identified a number of 
genes with specific clinical or evolutionary stages. 
Inferring GRNs from microarray datasets to investigate the progression and evolution of 
tumours is a complex process. Three specific objectives were set out at the beginning of work 
in order to achieve the aim of the work; contributions towards these three objectives are 
outlined below. 
9.1 Contributions 
9.1.1 Development of a Novel Network Inference Method 
The first objective of the work was to develop a network inference method specifically 
designed to infer a number of GRNs for a number of different evolutionary or disease stage 
categories from a single microarray dataset. Following feedback from biologists and 
clinicians, a novel network inference method was developed.  Comparing the scores of the top 
ranked genes identified by the node level metrics in the five glioblastoma survival category 
GRNs inferred using this method, to the top ranked genes in the equivalent networks inferred 
using WGCNA, this method consistently identified higher scoring glioblastoma genes across 
all of the survival stage networks.  
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The application of this network inference method to other microarray datasets, such as 
neuroblastoma and retinoblastoma, also identified unique genes with significantly varying 
gene expression in each disease stage. This was something that was not the case when the 
WGCNA method was used to infer GRNs for the different survival categories within the 
glioblastoma dataset, and was something that the biologists felt went against biological 
principles. The identification of unique genes with varying gene expression levels by the 
novel method is both in concordance with the underlying biology, and also gave greater 
confidence to the biologists that this approach was something that could provide useful results 
for them. A further refined version of the novel inference method was applied to a 
retinoblastoma microarray dataset, with a number of promising results.  
9.1.2 Calculation of Network Level and Node Level Metrics in the Networks Inferred 
In previous studies, such as those by Allen et al [94], and Hurley et al [9], the performance of 
a number of network inference methods for microarray data was compared. However, the 
validation of these results did not employ a gene ranking system for the particular disease of 
the microarray dataset. The second objective addresses this; for each of the GRNs inferred in 
this work, high ranking genes for a number of graph theory metrics are identified, and these 
genes are scored based on a ranked gene list for the disease returned by a text-mining tool. 
This is done with the aim of further developing the approach to network inference method 
comparison, by introducing a quantitat ive approach to biological validation. To our 
knowledge, this is the first attempt to quantitatively score network metrics applied to GRNs 
based on the genes that they identify. Weighted degree centrality is shown to the best metric 
at identifying scoring genes across all of the networks, followed by degree centrality. 
Weighted betweenness is the worst performing. Table 9.1 shows the overall ranks of the 
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metrics across all of the GRNs in this work, based on the Génie scoring genes identified by 
the metrics for their top 20, top100, and top 500 ranking genes. 
TABLE 9.1 OVERALL METRIC RANKS IN THE DIFFERENT CATEGORIES OF GRNS ACROSS ALL 
OF THE MICROARRAY DATASETS 
 
 
WGCNA 
GBM 
GRNs 
Novel 
Method 
GBM 
GRNs 
Wang 
Dataset 
GRNs 
Molenaar 
Dataset 
GRNs 
Positive       
Z score 
RB 
GRNs 
Negative        
Z score 
RB GRNs 
Ranking 
totals 
Overall 
rank 
Weighted 
Degree 4th 1st 2nd 1st 1st 3rd 12 1st 
Degree 
Centrality 5th 1st 1st 1st 5th 3rd 16 2nd 
Combined 
Metric 6th 3rd 3rd 4th 2nd 1st 19 3rd 
Weighted 
Closeness 2nd 5th 6th 6th 3rd 2nd 24 4th 
Eigenvector 
Centrality 3rd 6th 5th 1st 4th 6th 25 5th 
Weighted 
Betweenness 1st 4th 4th 5th 6th 5th 25 5th 
 
Furthermore, network level metrics were calculated in all of the networks inferred, and an 
interesting phenomenon was observed with the value of the diameter in the networks inferred 
using all variants of the Z score method. The network inferred from the most advanced stage 
of the disease for the glioblastoma, both neuroblastoma, and the retinoblastoma microarray 
datasets had the greatest diameter value compared to the networks inferred for the other 
disease stages in the respective datasets. In section 2.5, low diameter in a GRN was proposed 
as an indicator of genes being able to communicate with each other easily. One hypothesis is 
that the high diameter value observed is a contributing factor to the most advanced stage of 
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the disease; certain genes, such as tumour suppressor genes, are not able to easily 
communicate with other genes involved in regulating tumour progression.  
9.1.3 Comparison of GRNs inferred from Two Neuroblastoma Microarray Datasets  and 
Comparison of Disease Stage GRNs to a Healthy GRN inferred from Retinoblastoma 
Microarray Dataset 
As well as the inference and analysis of GRNs for different stages in a microarray dataset, 
GRNs were also inferred for the same disease categories across different microarray datasets 
for the same disease, namely neuroblastoma. This was set out as the third objective of the 
work. Although three out of the four disease stages common to both neuroblastoma datasets 
did not show any notable correlation, the 4M disease stage did. 7 out of the top 20 ranked 
genes for the combined metric were common to both GRNs. Previous network inference 
studies for disease have shown little concordance with other network inference approaches for 
the same disease microarray dataset, so this represents a promising finding. Another 
promising result was MYCN as the top ranked gene, based on the combined metric, for the 
GRNs inferred from the stage 4M samples in both datasets, something specifically 
commented on by the biologists.  
Extending both the first and third objectives of the work, a refined version of the novel 
network inference method was used to infer GRNs from a retinoblastoma microarray dataset 
containing a small number of both previously categorised retinoblastoma subtype and normal 
retinal samples. This extended the work in the thesis, by comparing disease stage GRNs to a 
normal GRN. A number of significant results were returned, specifically the identification of 
the gene E2F1 as a highly ranked gene in the normal GRN inferred using the negative Z score 
approach. Furthermore, the small number of samples in this microarray dataset had previously 
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prevented the use of GRN inference and analysis using existing methods. The use of the novel 
network inference method made it possible to compare two retinoblastoma subtypes to normal 
retinal samples using a GRN inference and analysis approach. This potentially allows 
biologists and clinicians to infer and analyse GRNs for microarray data they had previously 
been unable to analyse, as a number of microarray datasets contain very few samples per 
disease stage. This specific example highlights one of the main advantages of the novel 
network inference method, namely that it does not require a large number of samples to infer 
a GRN. 
9.2 Limitations 
Whilst this work has provided a number of contributions, it does have certain limitations. The 
first limitation concerns the underlying assumption of inferring networks that have a power 
law degree distribution. Whilst this property has been observed in a number of other 
networks, including biological networks, it is an assumption of this work that all GRNs 
display this property. As with any model, it is likely that assumptions used do not always hold 
true, and that as such GRNs do not always display this property.  
The second limitation of the work is that directionality is not defined for the GRNs that are 
inferred. Directionality has the potential to further identify genes of interest, as genes with a 
high out-degree are likely to be important genes in the network as this is suggestive of 
controlling the expression level of a number of other genes. It should however be remembered 
that a number of other methods for network inference that assign directionality have been 
shown to be inaccurate, as noted by Hurley et al [9].  
The third limitation is the lack of overlap in the top scoring genes between the common 
disease stage GRNs inferred for neuroblastoma. The best overlap in results is observed for the 
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common stage 4M GRNs, classified using the expression level of MYCN. This is an obvious 
limitation of the work, as it does suggest that there are some issues with comparing disease 
stage networks from different datasets using the method presented in this thesis.  This could be 
due to a number of factors. The first is that an additional process might be required in order to 
normalise microarray datasets from different sources for comparison before networks are 
inferred. Considering that the two microarray platforms for the neuroblastoma datasets are 
somewhat different from each other, especially in the number of probes, this is a pertinent 
issue. The second is the implication that using expression based criteria is better suited to 
classifying microarray data, rather than using either clinical stage or other evolutionary 
information. This would again require an additional step to classify the samples in the 
microarray dataset, and would require the identification and implication of suitable gene 
signatures for classification. There is also the poss ibility that this might not be of use to 
biologists and clinicians, who are more interested in the networks of disease stage, rather than 
networks based on a different classification criteria. 
9.3 Future Work 
Whilst a number of contributions to the field have been outlined in this work, there are a 
number of areas that should be taken into consideration for future work. The first point to note 
is the availability of samples across all disease stages for certain tumours. For certain 
tumours, such as retinoblastoma, there is very low availability of low disease stage samples. 
In the absence of low stage samples, it is not possible to infer GRNs for these low stages. 
Whilst in this work this has been overcome to an extent by comparing the high stage GRNs 
inferred to a reference normal GRN, it is something to be aware, and also a restriction 
meaning that the approach adopted in this work may not be feasible for all tumours due to the 
absence of low stage samples. 
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The second point to note concerns the method by which the genes identified by the metrics, 
and also in the largest cliques in the GRNs, have been scored. The text-mining tool Génie was 
used as a disease-agnostic approach for quantitatively scoring the genes identified. However, 
this tool does not provide any evolutionary or disease stage detail to the results. For example; 
a gene may have been identified in a number of studies as being associated with stage 4 of a 
disease, but the identification of this gene in a GRN inferred for stage 1 of that disease by a 
metric will still result in that metric being highly scored. As such, a tool that is able to provide 
additional disease and evolutionary specific detail to the genes identified would greatly aid in 
the quantitative scoring of the metrics, and would result in greater biological accuracy for the 
second objective of this work. 
Linked to this is the use of enrichment databases, specifically GeneSetDB. Whilst GeneSetDB 
has not been used to quantitatively score the genes identified by the metrics, it has been used 
to interpret results. One possible approach could be to use enrichment databases as a disease-
agnostic means by which to score the genes identified, although this will require the 
subjective interpretation of experts, namely clinicians and biologists. It should also be noted 
that enrichment databases do not detail all biological processes. In this work, a number of 
genes either identified as being in the largest cliques or highly ranked did not return any 
enrichment results. Whilst it was suggested that this could be due to these genes not being 
involved in any significant biological processes, another reason could be that the biological 
processes that these genes are involved in are not detailed in the enrichment results. As such, 
the use of more enrichment databases could counter this issue. For this work, GeneSetDB was 
chosen as the choice of enrichment database as it offers greater coverage than other 
enrichment databases; however it could well be that using additional enrichment databases, 
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such as DAVID and GATHER, alongside GeneSetDB would result in additional enrichment 
results being returned. 
During the initial stages of the work, interaction databases, such as BioGRID [147] and IntAct 
[148], were consulted in an attempt to verify whether interactions in the inferred GRNs were 
accurate. This is also another potential approach by which to score the genes identified in the 
networks inferred from the various algorithms. However, this approach was abandoned, as 
only a small number of interactions have been experimentally validated. As such, even in the 
case that interactions in inferred networks are completely accurate, there is no way to validate 
this using the interaction databases. Verification of results is potentially the greatest challenge 
to bioinformaticians working in the area of network inference from microarray data. 
The underlying nature of the microarray dataset that is used to infer the GRNs from should 
also be taken into account; the data preparation and the platform are greatly influential. In 
chapter 6, it was noted that there were only 4829 genes in common between the two 
neuroblastoma microarray datasets. This is a major problem concerning the analysis of 
microarrays for the same disease across different studies, as newer microarray technology is 
introduced and utilised, it creates problems for comparisons with older studies that used older 
microarray platforms. Whilst microarray technology has been available for a number of years, 
issues of backward compatibility suggest the technology is still immature, and that a flexible 
protocol is needed. An attempt has been made at incorporating flexibility into the approach 
used in this work, but even then, a very low number of common genes were identified as 
being highly ranked across the GRNs for three out of the four disease stages common to both 
neuroblastoma datasets. Whilst the stage 4M GRNs across both neuroblastoma datasets 
showed a promising overlap, this categorisation was based on a genomic property, the 
amplification of the gene MYCN, suggesting that for future work across multiple microarray 
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datasets categorisation based on genomic properties, such as gene amplification or under-
expression, might be a better choice of classification criteria than disease stage  information 
already present in the dataset. 
Despite one of the objectives of the work specifically concerning the quantitative comparison 
of the metrics, no single metric was shown to perform better than the others in all of the 
microarray datasets.  Weighted degree and degree centrality, the top two performing metrics, 
were both the best performing metrics in the GRNs for three out of the six microarray 
categories, as shown in table 9.1. Additionally, these results do not provide any novel 
findings; despite adopting what is believed to be a novel approach at identifying appropriate 
metrics to use for identifying genes of interest across different evolutionary and disease stages 
of GRNs, the degree centrality is the most commonly studied and used graph theory metric. 
Perhaps more surprising is that weighted betweenness centrality is the joint worst performing 
metric overall, considering that it is arguably the second most widely used metric after degree 
centrality. The finding that the diameter value is greatest in the GRN for the most advanced 
disease stage in the GRNs inferred from the glioblastoma, both neuroblastoma, and 
retinoblastoma microarray datasets is believed to be a novel finding, and warrants further 
investigation.  
Finally, in this work it has been shown that adopting a GRN inference and analysis approach 
for investigating the evolution and progression of tumours has yielded a number of promising 
results, and has identified specific genes as being associated with specific disease or 
evolutionary stages. One explicit recommendation for future work is the implementation of 
the GRN inference and analysis tools used in this work on a personalised publically accessible 
Galaxy server. Whilst further testing and evaluation of the local host detailed in chapter 8 will 
be required, providing biologists and clinicians with the means to directly analyse microarray 
264 
 
data through the inference and analysis of GRNs for the different stages within the microarray 
dataset is beneficial, as they are better suited to determine whether the genes that the metrics 
mark out are biologically of interest. The overall ethos of this work is that the biologists and 
clinicians are those with the expert knowledge to properly analyse and interpret the results, 
and as such, should be provided with a tool to provide them with these results.  
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APPENDIX A  
GÉNIE GENE LISTS AND GENESETDB ENRICHMENT 
RESULTS 
The following appendix contains the list of ranked genes returned by the text-mining tool 
Génie for glioblastoma, neuroblastoma, and retinoblastoma. Additionally, this appendix 
contains all the enrichment results returned by the enrichment tool GeneSetDB referred to in 
the main body of the thesis.  
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TABLE A.1 RANKED GLIOBLASTOMA GENES GENERATED BY GÉNIE 
Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
IDH1 1 299 SMARCB1 48 252 GRIA1 95 205 
MGMT 2 298 BCL2 49 251 ANGPT2 96 204 
EGFR 3 297 MYC 50 250 BCAN 97 203 
IDH2 4 296 NOTCH1 51 249 EGF 98 202 
PTEN 5 295 ERCC1 52 248 EZH2 99 201 
TP53 6 294 WT1 53 247 SHH 100 200 
PROM1 7 293 PMS2 54 246 MAGEC2 101 199 
CHI3L1 8 292 MMP9 55 245 CD248 102 198 
VEGFA 9 291 NRP1 56 244 KLF6 103 197 
ERBB2 10 290 ERCC2 57 243 MET 104 196 
OLIG2 11 289 DCX 58 242 TOP2A 105 195 
PDGFRA 12 288 BAI1 59 241 RB1 106 194 
BIRC5 13 287 LRRC4 60 240 FOXM1 107 193 
TERT 14 286 NF1 61 239 NANOG 108 192 
CDKN2A 15 285 GSTP1 62 238 MELK 109 191 
AKT1 16 284 NDRG2 63 237 TNFSF10 110 190 
IL13RA2 17 283 RTEL1 64 236 LGALS3 111 189 
TNC 18 282 MIR221 65 235 PTK2 112 188 
MKI67 19 281 GLIPR1 66 234 PARP1 113 187 
PTGS2 20 280 CXCL12 67 233 YEATS4 114 186 
BRAF 21 279 SPARC 68 232 CYR61 115 185 
NES 22 278 ATM 69 231 XRCC3 116 184 
GLI1 23 277 EPAS1 70 230 KCNMA1 117 183 
IGFBP2 24 276 MIF 71 229 NBN 118 182 
GFAP 25 275 MSH2 72 228 MMP19 119 181 
CA9 26 274 GSTT1 73 227 MSI1 120 180 
PLAUR 27 273 PDGFA 74 226 PRKCI 121 179 
HIF1A 28 272 TYMS 75 225 MAPK3 122 178 
MDM2 29 271 PLAU 76 224 PRND 123 177 
SOX2 30 270 MIIP 77 223 AURKA 124 176 
AQP4 31 269 CDK4 78 222 TLR9 125 175 
CXCR4 32 268 MIR222 79 221 ABCB1 126 174 
EPHA2 33 267 SOX10 80 220 CA12 127 173 
FABP7 34 266 CDK6 81 219 SOX6 128 172 
KDR 35 265 IGF2BP3 82 218 PIK3CG 129 171 
SPP1 36 264 AKT2 83 217 ROS1 130 170 
PIK3CA 37 263 MTDH 84 216 BAX 131 169 
STAT3 38 262 APEX1 85 215 CDKN1B 132 168 
CCND1 39 261 NF2 86 214 PTPRM 133 167 
KIT 40 260 MMP1 87 213 RAD51 134 166 
BMI1 41 259 PHF3 88 212 LGI1 135 165 
DMBT1 42 258 SLC7A5 89 211 ASIC1 136 164 
CTNNB1 43 257 PHF20 90 210 ABCG2 137 163 
IL24 44 256 GSTM1 91 209 TNFRSF12A 138 162 
RAC1 45 255 TP73 92 208 DKK1 139 161 
PTN 46 254 S100B 93 207 ASPM 140 160 
PGR 47 253 NTRK1 94 206 IGF1 141 159 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
NUMB 142 158 WNT1 191 109 EIF4E 240 60 
PTPRZ1 143 157 LRIG3 192 108 LRIG1 241 59 
TNFRSF10B 144 156 SOD3 193 107 STAT6 242 58 
MIR21 145 155 XRCC1 194 106 SOD2 243 57 
RECK 146 154 NQO1 195 105 RHOA 244 56 
CTSB 147 153 CD24 196 104 RET 245 55 
AURKB 148 152 AXIN1 197 103 LGALS1 246 54 
EFNA1 149 151 PHLDB1 198 102 APC 247 53 
CTNNBIP1 150 150 BRCA1 199 101 CD34 248 52 
DPP4 151 149 GDF15 200 100 PTK2B 249 51 
HGF 152 148 ITGB1 201 99 CSF2 250 50 
ROBO1 153 147 SLC9A3R1 202 98 PHLPP1 251 49 
ERBB3 154 146 L2HGDH 203 97 H2AFX 252 48 
SOCS3 155 145 PYGO2 204 96 FHIT 253 47 
DKK3 156 144 MIR196A1 205 95 CDH11 254 46 
TSC2 157 143 CSF3 206 94 MIA 255 45 
XPC 158 142 MAPK1 207 93 MIB1 256 44 
CFLAR 159 141 CCR7 208 92 PRKCA 257 43 
ING1 160 140 PTCH1 209 91 AQP9 258 42 
NFKB1 161 139 BECN1 210 90 CLCN3 259 41 
IGF1R 162 138 MIR181A1 211 89 MSH6 260 40 
CASP8 163 137 LPO 212 88 MXI1 261 39 
RAC2 164 136 PEG3 213 87 BCCIP 262 38 
AKT3 165 135 MIR451A 214 86 ID4 263 37 
CDKN2B 166 134 IL8 215 85 ITGA7 264 36 
TGFB1 167 133 ALKBH2 216 84 MUC6 265 35 
FPR1 168 132 ERCC5 217 83 QKI 266 34 
RASSF1 169 131 ERBB4 218 82 IMP3 267 33 
CD44 170 130 SLC22A18 219 81 VIM 268 32 
EZR 171 129 NR2E1 220 80 DCT 269 31 
KIAA1549 172 128 TGFB2 221 79 HDGF 270 30 
MMP2 173 127 NFIX 222 78 PFKFB3 271 29 
MTHFR 174 126 EPOR 223 77 WHSC1 272 28 
SLC2A1 175 125 YBX1 224 76 NODAL 273 27 
GPR26 176 124 FGF2 225 75 BSG 274 26 
GLTSCR1 177 123 BCL2L12 226 74 PDGFRB 275 25 
PCDHGA11 178 122 MIR10B 227 73 XRCC5 276 24 
HSPA5 179 121 ESR1 228 72 MLH1 277 23 
CDKN1A 180 120 CX3CR1 229 71 FLT3LG 278 22 
ALDH1A1 181 119 CAV1 230 70 GRPR 279 21 
ALAD 182 118 GLTSCR2 231 69 RAD51B 280 20 
CDH1 183 117 ALOX5 232 68 CSPG4 281 19 
PTENP1 184 116 PAX6 233 67 PDE4A 282 18 
BRCA2 185 115 SERPINE1 234 66 TPX2 283 17 
YAP1 186 114 RAC3 235 65 NOS1 284 16 
PRKDC 187 113 MAML2 236 64 CLU 285 15 
LIG4 188 112 ALK 237 63 MMP7 286 14 
VCAN 189 111 NGFR 238 62 MTOR 287 13 
EMP3 190 110 MYCN 239 61 RECQL4 288 12 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
MMP14 289 11 MPG 293 7 MTR 297 3 
DOCK1 290 10 CTGF 294 6 LAMC1 298 2 
GLUL 291 9 SOX4 295 5 ESR2 299 1 
PEA15 292 8 ING4 296 4    
 
TABLE A.2 ENRICHMENT RESULTS LARGEST CLIQUE 200 OR LESS  GLIOBLASTOMA 
CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB Annotated genes Non-annotated p.value 
GO 
synaptic 
transmission 
(GO:0007268) GO_BP  30 359 1.20E-22 
Pathway 
Transmission 
across Chemical 
Synapses Reactome 21 169 3.10E-19 
Pathway Neuronal System Reactome 23 260 5.70E-18 
Pathway 
Glutamate 
Neurotransmitter 
Release Cycle  Reactome 9 7 4.20E-16 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 11 25 8.90E-16 
GO 
glutamate 
secretion 
(GO:0014047) GO_BP  9 8 9.00E-16 
Pathway 
Dopamine 
Neurotransmitter 
Release Cycle  Reactome 8 4 2.80E-15 
Pathway 
Serotonin 
Neurotransmitter 
Release Cycle  Reactome 8 4 2.80E-15 
GO 
neurotransmitter 
secretion 
(GO:0007269) GO_BP  11 38 4.00E-14 
GO 
cell junction 
(GO:0030054) GO_CC 24 461 7.40E-14 
 
TABLE A.3 ENRICHMENT RESULTS LARGEST CLIQUE 201 – 400 GLIOBLASTOMA CATEGORY 
INFERRED USING WGCNA  
Class Set Name Source_DB 
Annotated 
genes Non-annotated p.value 
GO 
synaptic transmission 
(GO:0007268) GO_BP  30 359 2.40E-20 
Pathway 
Transmission across 
Chemical Synapses Reactome 21 169 1.20E-17 
Pathway Neuronal System Reactome 24 259 2.30E-17 
GO 
neurotransmitter 
secretion 
(GO:0007269) GO_BP  11 38 2.70E-13 
Pathway 
Glutamate 
Neurotransmitter 
Release Cycle  Reactome 8 8 2.80E-13 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 10 26 3.20E-13 
GO glutamate secretion GO_BP  8 9 5.30E-13 
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(GO:0014047) 
Disease/Phenotype convulsive seizures MPO 10 29 7.80E-13 
Pathway 
Dopamine 
Neurotransmitter 
Release Cycle  Reactome 7 5 2.20E-12 
Pathway 
Serotonin 
Neurotransmitter 
Release Cycle  Reactome 7 5 2.20E-12 
 
 
TABLE A.4 ENRICHMENT RESULTS LARGEST CLIQUE 401 – 600 GLIOBLASTOMA CATEGORY 
INFERRED USING WGCNA  
Class Set Name Source_DB Annotated genes Non-annotated p.value 
GO 
synaptic transmission 
(GO:0007268) GO_BP  26 363 1.90E-18 
Pathway 
Transmission across 
Chemical Synapses Reactome 18 172 1.20E-15 
GO 
synapse 
(GO:0045202) GO_CC 20 264 8.50E-15 
Pathway Neuronal System Reactome 19 264 1.00E-13 
GO 
cell junction 
(GO:0030054) GO_CC 23 462 3.20E-13 
Pathway 
Dopamine 
Neurotransmitter 
Release Cycle  Reactome 7 5 5.20E-13 
Pathway 
Serotonin 
Neurotransmitter 
Release Cycle  Reactome 7 5 5.20E-13 
GO 
neurotransmitter 
secretion 
(GO:0007269) GO_BP  10 39 1.20E-12 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 9 27 2.30E-12 
Pathway 
Glutamate 
Neurotransmitter 
Release Cycle  Reactome 7 9 7.40E-12 
 
 
TABLE A.5 ENRICHMENT RESULTS LARGEST CLIQUE 601 – 800 GLIOBLASTOMA CATEGORY 
INFERRED USING WGCNA  
Class Set Name Source_DB Annotated genes Non-annotated p.value 
GO 
synaptic 
transmission 
(GO:0007268) GO_BP  37 352 2.00E-26 
Pathway 
Transmission 
across Chemical 
Synapses Reactome 24 166 3.00E-20 
Pathway Neuronal System Reactome 27 256 1.90E-19 
GO 
synapse 
(GO:0045202) GO_CC 24 260 3.60E-16 
Disease/ 
Phenotype 
abnormal CNS 
synaptic 
transmission MPO 16 86 2.20E-15 
GO 
neurotransmitter 
secretion GO_BP  12 37 2.70E-14 
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(GO:0007269) 
Pathway 
Glutamate 
Neurotransmitter 
Release Cycle  Reactome 8 8 7.10E-13 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 10 26 9.90E-13 
GO 
glutamate 
secretion 
(GO:0014047) GO_BP  8 9 1.30E-12 
Pathway 
Dopamine 
Neurotransmitter 
Release Cycle  Reactome 7 5 4.90E-12 
 
TABLE A.6 ENRICHMENT RESULTS LARGEST CLIQUE MORE THAN 800 GLIOBLASTOMA 
CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB Annotated genes Non-annotated p.value 
GO 
synaptic 
transmission 
(GO:0007268) GO_BP  21 368 5.30E-20 
Pathway Neuronal System Reactome 14 269 6.00E-13 
Pathway 
Transmission across 
Chemical Synapses Reactome 12 178 1.80E-12 
Drug/         
Chemical 
gamma-
aminobutyric 
acid(CID000000119) STITCH 10 199 2.20E-09 
GO 
neurotransmitter 
secretion 
(GO:0007269) GO_BP  6 43 1.60E-08 
Drug/         
Chemical 
gamma-
aminobutyric 
acid(CID100000119) STITCH 9 199 3.60E-08 
Disease/  
Phenotype 
abnormal CNS 
synaptic 
transmission MPO 7 95 5.70E-08 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 5 31 1.40E-07 
GO 
synaptic vesicle 
membrane 
(GO:0030672) GO_CC 5 38 3.50E-07 
Pathway 
Neurotransmitter 
Receptor Binding 
And Downstream 
Transmission In The  
Postsynaptic Cell Reactome 7 129 4.10E-07 
 
TABLE A.7 TOP TEN GENESETDB ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES 
IN  LESS THAN 200 GRN CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway 
Neurotransmitter 
Release Cycle  Reactome 5 31 1.70E-10 
Pathway 
Dopamine 
Neurotransmitter 
Release Cycle  Reactome 4 8 3.00E-10 
Pathway 
Serotonin 
Neurotransmitter Reactome 4 8 3.00E-10 
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Release Cycle  
GO 
neurotransmitter 
secretion (GO:0007269) GO_BP  5 44 8.50E-10 
Pathway 
Glutamate 
Neurotransmitter 
Release Cycle  Reactome 4 12 1.10E-09 
GO 
glutamate secretion 
(GO:0014047) GO_BP  4 13 1.40E-09 
Disease/ Phenotype 
abnormal 
neurotransmitter 
secretion MPO 4 17 3.60E-09 
Pathway 
Transmission across 
Chemical Synapses Reactome 6 184 1.70E-08 
GO 
synaptic vesicle 
membrane 
(GO:0030672) GO_CC 4 39 7.30E-08 
Pathway 
Acetylcholine 
Neurotransmitter 
Release Cycle  Reactome 3 8 1.20E-07 
 
 
TABLE A.8 TOP TEN GENESETDB ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES 
IN  201-400 SURVIVAL DAYS GRN CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype 
Syndromic X-linked 
mental retardation with 
epilepsy or seizures, 
including:  KEGG(Disease)  2 18 1.10E-04 
GO 
cellular response to drug 
(GO:0035690) GO_BP  2 23 1.80E-04 
GO 
cellular response to 
transforming growth 
factor beta stimulus 
(GO:0071560) GO_BP  2 24 1.90E-04 
GO 
antiporter activity 
(GO:0015297) GO_MF 2 37 4.40E-04 
Disease/ Phenotype 
Intellectual disability, 
progressive  HPO 2 54 9.10E-04 
Pathway Platelet homeostasis Reactome 2 80 1.90E-03 
Pathway 
Transport of inorganic 
cations/anions and 
amino 
acids/oligopeptides Reactome 2 93 2.60E-03 
Pathway 
ErbB1 do wnstream 
signaling PID 2 104 3.20E-03 
GO 
sodium ion transport 
(GO:0006814) GO_BP  2 117 4.00E-03 
GO 
perinuclear region of 
cytoplasm 
(GO:0048471) GO_CC 3 427 4.50E-03 
 
 
 
 
A-9 
 
TABLE A.9 TOP TEN GENESETDB ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES 
IN  401-600 SURVIVAL DAYS GRN CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p. value 
Pathway 
Neurotransmitter Release 
Cycle Reactome 3 33 7.40E-06 
GO 
neurotransmitter secretion 
(GO:0007269) GO_BP  3 46 1.90E-05 
Drug/Chemical 
aminooxyacetic 
acid(CID100000285) STITCH 2 8 4.90E-05 
Disease/ Phenotype 
decreased aggression  
towards males MPO 2 12 9.90E-05 
Drug/Chemical 
aminooxyacetic 
acid(CID000000285) STITCH 2 12 9.90E-05 
GeneRegulation ATF4 TFactS 2 16 1.70E-04 
GO synapse (GO:0045202) GO_CC 4 280 2.10E-04 
Pathway Glutamate_Glutamine_ metabolism INOH 2 24 3.50E-04 
GO 
synaptic transmission 
(GO:0007268) GO_BP  4 385 6.90E-04 
Disease/ Phenotype impaired glucose tolerance MPO 3 180 9.40E-04 
 
 
TABLE A.10 TOP TEN GENESETDB ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES 
IN  601-800 SURVIVAL DAYS GRN CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
calcium ion-dependent 
exocytosis 
(GO:0017156) GO_BP  2 10 7.20E-05 
GO 
regulation of synaptic 
plasticity (GO:0048167) GO_BP  2 18 2.10E-04 
GO 
cellular response to drug 
(GO:0035690) GO_BP  2 23 3.20E-04 
Pathway 
Insulin-mediated 
glucose transport PID 2 27 4.40E-04 
Pathway 
Calcium Regulation in 
the Cardiac 
Cell(WP536) WikiPathways 3 148 5.40E-04 
GO 
calcium ion 
transmembrane transport 
(GO:0070588) GO_BP  2 32 6.00E-04 
GO 
calmodulin binding 
(GO:0005516) GO_MF 3 156 6.20E-04 
GO 
synaptic vesicle 
membrane 
(GO:0030672) GO_CC 2 41 9.60E-04 
GO 
hydrolase activity, 
acting on acid 
anhydrides, catalyzing 
transmembrane 
movement of substances 
(GO:0016820) GO_MF 2 43 1.10E-03 
GO 
protein complex 
(GO:0043234) GO_CC 3 193 1.10E-03 
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TABLE A.11 TOP TEN GENESETDB ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES 
IN  MORE THAN 800 SURVIVAL DAYS GRN CATEGORY INFERRED USING WGCNA 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
synaptic transmission 
(GO:0007268) GO_BP  9 380 9.30E-11 
Pathway 
Transmission across 
Chemical Synapses Reactome 6 184 3.50E-08 
Pathway Neuronal System Reactome 6 277 3.70E-07 
Drug/          
Chemical 
gamma-aminobutyric 
acid(CID100000119) STITCH 5 203 2.20E-06 
Drug/       
Chemical 
gamma-aminobutyric 
acid(CID000000119) STITCH 5 204 2.30E-06 
Pathway 
Neurotransmitter Release 
Cycle Reactome 3 33 7.40E-06 
GO 
cell junction 
(GO:0030054) GO_CC 6 479 8.50E-06 
Disease/ Phenotype convulsive seizures MPO 3 36 9.40E-06 
GO synapse (GO:0045202) GO_CC 5 279 1.00E-05 
Drug/     
Chemical muscimol(CID100004266) STITCH 3 40 1.30E-05 
 
 
TABLE A.12 ENRICHMENT RESULTS LARGEST CLIQUE 200 OR LESS GLIOBLASTOMA CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
extracellular matrix 
(GO:0031012) GO_CC 21 132 4.00E-25 
Pathway 
Beta1 integrin cell surface 
interactions PID 10 55 5.90E-13 
GO 
extracellular matrix 
structural constituent 
(GO:0005201) GO_MF 10 56 6.90E-13 
Disease/ Phenotype 
abnormal cutaneous 
collagen fibril morphology MPO 7 13 3.50E-12 
Pathway 
Syndecan-1-mediated 
signaling events PID 8 38 4.80E-11 
Gene Regulation SMAD7 TFactS 6 9 5.10E-11 
Disease/ Phenotype Dermal atrophy  HPO 7 30 4.40E-10 
Disease/ Phenotype Mitral valve prolapse  HPO 6 16 7.50E-10 
Disease/ Phenotype Osteoarthritis  HPO 6 16 7.50E-10 
Disease/ Phenotype 
abnormal tendon 
morphology MPO 6 17 1.00E-09 
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TABLE A.13 ENRICHMENT RESULTS LARGEST CLIQUE 201-400 GLIOBLASTOMA CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway EPHB forward signalling PID 6 30 1.90E-07 
Pathway Internalization of ErbB1 PID 6 34 3.70E-07 
Drug/Chemical 
inositol 1,4,5-trisphosphate 
(CID000439456) STITCH 9 121 3.80E-07 
Pathway 
CXCR3-mediated signaling 
events PID 6 36 5.00E-07 
Drug/Chemical 
inositol 1,4,5-trisphosphate 
(CID100000806) STITCH 9 130 6.80E-07 
Pathway 
Dopamine Neurotransmitter 
Release Cycle  Reactome 4 8 1.20E-06 
Pathway 
Serotonin Neurotransmitter 
Release Cycle  Reactome 4 8 1.20E-06 
GO 
neurotransmitter secretion 
(GO:0007269) GO_BP  6 43 1.30E-06 
Pathway 
Role of ?-arrestins in the 
activation and targeting of 
MAP kinases Biocarta 4 10 2.30E-06 
Pathway Purine metabolism EHMN 11 255 3.30E-06 
 
 
TABLE A.14 ENRICHMENT RESULTS LARGEST CLIQUE 401-600 GLIOBLASTOMA CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype 
increased susceptibility to 
bacterial infection MPO 15 193 4.10E-12 
GO 
interferon-gamma-mediated 
signaling pathway 
(GO:0060333) GO_BP  10 59 1.70E-11 
Disease/ Phenotype 
abnormal macrophage 
physiology MPO 14 191 4.60E-11 
Gene Regulation SPI1 TFactS 10 77 1.80E-10 
Disease/ Phenotype 
abnormal antigen presenting 
cell physiology MPO 6 10 4.30E-10 
Disease/ Phenotype increased IgG level MPO 9 62 6.40E-10 
Pathway Interferon gamma signaling Reactome 9 64 8.20E-10 
Drug/Chemical 
N-acetylglucosamine 
(CID100000899) STITCH 16 363 2.20E-09 
Disease/ Phenotype 
decreased susceptibility to 
bacterial infection MPO 8 61 1.20E-08 
Disease/ Phenotype 
increased lymphocyte cell 
number MPO 8 62 1.40E-08 
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TABLE A.15 ENRICHMENT RESULTS LARGEST CLIQUE 601-800 GLIOBLASTOMA CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
synaptic transmission 
(GO:0007268) GO_BP  32 357 1.20E-18 
Pathway 
Transmission across 
Chemical Synapses Reactome 22 168 3.20E-16 
Pathway Neuronal System Reactome 23 260 1.50E-13 
GO synapse (GO:0045202) GO_CC 22 262 1.40E-12 
GO cell junction (GO:0030054) GO_CC 28 457 1.40E-12 
GO 
postsynaptic membrane 
(GO:0045211) GO_CC 17 152 8.60E-12 
Drug/Chemical glutamate(CID100000611) STITCH 21 287 5.10E-11 
GO 
postsynaptic density 
(GO:0014069) GO_CC 13 87 1.00E-10 
Drug/Chemical glutamate(CID000033032) STITCH 21 306 1.50E-10 
Pathway 
Neurotransmitter Receptor 
Binding And Do wnstream 
Transmission In The  
Postsynaptic Cell Reactome 14 122 4.60E-10 
 
TABLE A.16 ENRICHMENT RESULTS LARGEST CLIQUE MORE THAN 800 GLIOBLASTOMA 
CATEGORY INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype anophthalmia MPO 6 58 3.10E-06 
Drug/Chemical MT19c compound CTD 13 486 1.70E-05 
Drug/Chemical N-acetylsphingosine CTD 4 22 2.00E-05 
 
TABLE A.17 ENRICHMENT RESULTS  COMBINED RANK TOP 20 GENES IN  LESS THAN 200 GRN 
CATEGORY INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype partial neonatal lethality MPO 5 310 1.70E-05 
 
TABLE A.18 ENRICHMENT RESULTS  COMBINED RANK TOP 20 GENES IN 201 -400 GRN CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway 
GMCSF-mediated 
signaling events PID 3 32 6.70E-06 
Pathway 
Angiopoietin receptor 
T ie2-mediated signaling PID 3 45 1.80E-05 
Pathway 
IL-4 signaling 
pathway(WP395) WikiPathways 3 48 2.10E-05 
Pathway 
Fc-epsilon receptor I 
signaling in mast cells PID 3 55 3.10E-05 
Pathway 
Leptin signaling 
pathway(WP2034) WikiPathways 3 58 3.60E-05 
A-13 
 
Pathway BCR signalin g pathway PID 3 63 4.60E-05 
Drug/Chemical 
di-arsenic-
trioxide(CID100518740) STITCH 2 9 6.00E-05 
Drug/Chemical 
di-arsenic-
trioxide(CID000518740) STITCH 2 9 6.00E-05 
Pathway 
Osteopontin 
Signaling(WP1434) WikiPathways 2 9 6.00E-05 
Pathway IL4 Signaling Pathway NetPath 3 72 6.80E-05 
 
 
TABLE A.19 ENRICHMENT RESULTS  COMBINED RANK TOP 20 GENES IN  401 -600 GRN CATEGORY 
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype rib bifurcation MPO 2 26 4.10E-04 
Disease/ Phenotype 
squamous cell 
carcinoma MPO 2 33 6.40E-04 
GeneRegulation TP53 TFactS 3 142 4.80E-04 
GO 
response to morphine 
(GO:0043278) GO_BP  2 18 2.10E-04 
GO 
response to UV 
(GO:0009411) GO_BP  2 34 6.70E-04 
Pathway 
DNA damage 
response(WP707) WikiPathways 3 66 5.30E-05 
Pathway Direct p53 effectors PID 3 133 3.90E-04 
 
TABLE A.20 ENRICHMENT RESULTS  COMBINED RANK TOP 20 GENES IN  MORE THAN 800 GRN 
CATEGORY INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway 
Benzo(a)pyrene 
metabolism(WP696) WikiPathways 2 8 Pathway 
GO 
tight junction 
(GO:0005923) GO_CC 3 88 GO 
Disease/ Phenotype prolonged diestrus MPO 2 17 Disease/Phenotype 
Disease/ Phenotype prolonged estrous cycle MPO 2 29 Disease/Phenotype 
Disease/ Phenotype 
disorganized em bryonic 
tissue MPO 2 31 Disease/Phenotype 
Pathway 
Regulation of RAC1 
activity PID 2 36 Pathway 
Pathway 
E-cadherin signaling in 
the nascent adherens 
junction PID 2 36 Pathway 
GO 
cytoskeletal protein 
binding (GO:0008092) GO_MF 2 42 GO 
GO 
cell cycle 
(GO:0007049) GO_BP  4 430 GO 
GO 
negative regulation of 
neuron differentiation 
(GO:0045665) GO_BP  2 45 GO 
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TABLE A.21 RANKED NEUROBLASTOMA GENES GENERATED BY GÉNIE 
Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
MYCN 1 500 NME1 48 453 RET 95 406 
EGFR 2 499 IGF1 49 452 GSK3B 96 405 
AKT1 3 498 ID1 50 451 ADAM10 97 404 
VEGFA 4 497 BCL2 51 450 TP73 98 403 
PTGS2 5 496 CCND1 52 449 SHH 99 402 
TP53 6 495 ITGB1 53 448 UBC 100 401 
TGFB1 7 494 IL8 54 447 ABCB1 101 400 
MMP2 8 493 PTN 55 446 TGFA 102 399 
APP 9 492 DKK1 56 445 FAS 103 398 
MMP9 10 491 MMP1 57 444 MDM2 104 397 
ALK 11 490 IL24 58 443 HYAL1 105 396 
CD44 12 489 BSG 59 442 RUNX2 106 395 
MMP14 13 488 PLAUR 60 441 SPARC 107 394 
NFKB1 14 487 CDH1 61 440 RB1 108 393 
TNF 15 486 CD4 62 439 MDK 109 392 
CXCR4 16 485 IL6 63 438 BAX 110 391 
STAT3 17 484 PIK3CG 64 437 AR 111 390 
NTRK1 18 483 CTGF 65 436 MMP7 112 389 
HIF1A 19 482 PTHLH 66 435 MAPK8 113 388 
BMP2 20 481 L1CAM 67 434 SOD1 114 387 
PLAU 21 480 KDR 68 433 CCL2 115 386 
ERBB2 22 479 SP1 69 432 IGFBP7 116 385 
HGF 23 478 TGM2 70 431 CTSB 117 384 
TERT 24 477 ITGAV 71 430 BMP7 118 383 
MAPK1 25 476 PTK2 72 429 RAC1 119 382 
IGF1R 26 475 ID2 73 428 PIK3CA 120 381 
HPSE 27 474 BIRC5 74 427 CDKN1B 121 380 
PTEN 28 473 CDKN2A 75 426 ALOX12 122 379 
MYC 29 472 VEGFC 76 425 PRNP 123 378 
FGF2 30 471 SNCA 77 424 TNFRSF11B 124 377 
TNFSF10 31 470 CASP8 78 423 HMOX1 125 376 
MAPK3 32 469 SERPINB5 79 422 PSEN1 126 375 
NOTCH1 33 468 PPARG 80 421 THBS1 127 374 
CDKN1A 34 467 PDGFB 81 420 PRKCD 128 373 
PROM1 35 466 BMP4 82 419 MCAM 129 372 
ADAM17 36 465 MAPT 83 418 NANOG 130 371 
MTOR 37 464 BRAF 84 417 PRKCA 131 370 
NCAM1 38 463 KIT 85 416 NF2 132 369 
CAV1 39 462 SPP1 86 415 FASN 133 368 
SRC 40 461 CSF1 87 414 NT5E 134 367 
TNFSF11 41 460 INHBA 88 413 ALOX5 135 366 
NTRK2 42 459 PHOX2B 89 412 AREG 136 365 
CXCL12 43 458 TIMP1 90 411 DKK3 137 364 
MET 44 457 CADM1 91 410 GDNF 138 363 
FN1 45 456 EGR1 92 409 KITLG 139 362 
CTNNB1 46 455 MAPK14 93 408 CYR61 140 361 
MUC1 47 454 HBEGF 94 407 SERPINE1 141 360 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
TNFRSF10B 142 359 ADM 191 310 ABCG2 240 261 
F3 143 358 FGFR2 192 309 MIR34A 241 260 
SLC7A5 144 357 BDNF 193 308 SHC1 242 259 
EDN1 145 356 IFNG 194 307 NOS1 243 258 
CASP3 146 355 SLC3A2 195 306 FYN 244 257 
TH 147 354 CTSD 196 305 HRAS 245 256 
FGFR1 148 353 SMAD3 197 304 ICAM1 246 255 
NF1 149 352 TWIST1 198 303 CDH2 247 254 
ESR1 150 351 PLA2G4A 199 302 LOX 248 253 
EGF 151 350 EPAS1 200 301 KRAS 249 252 
SDC1 152 349 GPC3 201 300 IDH1 250 251 
CA9 153 348 CXCL1 202 299 LIF 251 250 
TNC 154 347 RELA 203 298 ILK 252 249 
ITGA5 155 346 FIGF 204 297 ANXA2 253 248 
CD40 156 345 DLK1 205 296 NOV 254 247 
SMAD4 157 344 IL1B 206 295 EIF2AK2 255 246 
POU5F1 158 343 LAMC2 207 294 RARA 256 245 
NGFR 159 342 TFPI2 208 293 THY1 257 244 
CYP19A1 160 341 PDGFRB 209 292 NES 258 243 
PARK2 161 340 LAMA1 210 291 CNTN1 259 242 
RHOA 162 339 HLA-G 211 290 GDF15 260 241 
CD24 163 338 CEACAM5 212 289 XIAP 261 240 
S100A4 164 337 ITGB3 213 288 NID1 262 239 
BMI1 165 336 RASSF1 214 287 PDPN 263 238 
CD9 166 335 ERBB4 215 286 KLF4 264 237 
FLT1 167 334 EZR 216 285 IGF2 265 236 
MFI2 168 333 JUN 217 284 EWSR1 266 235 
PTK2B 169 332 SEMA3F 218 283 NDRG1 267 234 
NEU3 170 331 ALOX15 219 282 AGER 268 233 
EPCAM 171 330 CSF2 220 281 LAMA3 269 232 
GJA1 172 329 NRG1 221 280 CD40LG 270 231 
PTP4A3 173 328 BACE1 222 279 KLK3 271 230 
FOLH1 174 327 PDGFRA 223 278 COL4A2 272 229 
IDO1 175 326 MCL1 224 277 PRKCZ 273 228 
HDAC1 176 325 TFAP2A 225 276 EPHB2 274 227 
MIF 177 324 VIM 226 275 CSPG4 275 226 
HSPG2 178 323 SPINT1 227 274 E2F1 276 225 
ID3 179 322 PDGFA 228 273 LAMA5 277 224 
SERPINF1 180 321 BCL2L1 229 272 FOXO3 278 223 
MME 181 320 TIMP2 230 271 IL10 279 222 
COL4A1 182 319 ENPP2 231 270 WT1 280 221 
HSP90AA1 183 318 COL1A1 232 269 MTAP 281 220 
DPP4 184 317 CD82 233 268 ST8SIA1 282 219 
CEACAM1 185 316 CDK2 234 267 BCL2L11 283 218 
JAK2 186 315 IL2 235 266 MGMT 284 217 
LGALS3 187 314 CSF1R 236 265 IGFBP5 285 216 
ERBB3 188 313 SP3 237 264 PTPRZ1 286 215 
CLU 189 312 CD34 238 263 NOS2 287 214 
GLI1 190 311 SLIT2 239 262 HLA-A 288 213 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
STAT5B 289 212 FLT4 338 163 ANGPT1 387 114 
ANPEP 290 211 TNFSF12 339 162 DNMT1 388 113 
RECK 291 210 PTPN11 340 161 DPYSL3 389 112 
F2R 292 209 ACHE 341 160 COL4A6 390 111 
IGFBP2 293 208 GRB2 342 159 GAPDH 391 110 
HMGB1 294 207 KLRK1 343 158 TNFRSF11A 392 109 
EPO 295 206 HPN 344 157 PTTG1 393 108 
DSG3 296 205 KRT8 345 156 ITGB5 394 107 
COL4A3 297 204 ALDH1A1 346 155 IL15 395 106 
PTGS1 298 203 IL13RA2 347 154 ACTB 396 105 
NBL1 299 202 GNRHR 348 153 CX3CL1 397 104 
TOP2A 300 201 NTRK3 349 152 NRP1 398 103 
ODC1 301 200 STAR 350 151 FAP 399 102 
MIA 302 199 CD38 351 150 HAS3 400 101 
PLD2 303 198 CPM 352 149 LGALS3BP 401 100 
PLCG1 304 197 FASLG 353 148 CEBPB 402 99 
PARK7 305 196 PCNA 354 147 STAT1 403 98 
VIP 306 195 REST 355 146 RHOC 404 97 
FOXM1 307 194 JAG1 356 145 WNT5A 405 96 
PLD1 308 193 POLA1 357 144 LGALS1 406 95 
EBAG9 309 192 IGFBP3 358 143 CSF3 407 94 
NFKBIA 310 191 CTAG1B 359 142 CTSL1 408 93 
RARB 311 190 SFRP1 360 141 TNFSF13B 409 92 
HAS2 312 189 RTN4 361 140 CDK4 410 91 
OPRM1 313 188 NEWENTRY 362 139 LCN2 411 90 
CDX2 314 187 LRRC4 363 138 DGAT1 412 89 
FHIT 315 186 VCAN 364 137 PTGER2 413 88 
STMN1 316 185 FABP7 365 136 CRABP2 414 87 
KIF1B 317 184 WWOX 366 135 CD63 415 86 
HSPA5 318 183 NDN 367 134 OGFR 416 85 
FGFR3 319 182 MSLN 368 133 PTPRJ 417 84 
WNT1 320 181 CASZ1 369 132 ITGA3 418 83 
HPGD 321 180 AKR1B1 370 131 PRKACA 419 82 
SERPINA5 322 179 FOLR1 371 130 LAMC1 420 81 
ST14 323 178 TP63 372 129 SOX9 421 80 
PRKCE 324 177 CFLAR 373 128 COL1A2 422 79 
TYMP 325 176 GPI 374 127 FURIN 423 78 
MAP2K1 326 175 ING1 375 126 F2RL1 424 77 
PIK3R1 327 174 SCD 376 125 TGFBI 425 76 
PHB 328 173 HYAL2 377 124 TNFRSF1B 426 75 
GAS1 329 172 SOD2 378 123 PTGES 427 74 
ADCYAP1 330 171 PODXL 379 122 GCNT1 428 73 
RUNX3 331 170 CASP9 380 121 FGF7 429 72 
SLC9A1 332 169 TXN 381 120 PEBP1 430 71 
HSPB1 333 168 DLC1 382 119 CXCR7 431 70 
PTP4A2 334 167 PFKFB3 383 118 ANGPT2 432 69 
FGFR4 335 166 NFE2L2 384 117 FGF1 433 68 
PLK1 336 165 MMP13 385 116 ABCC1 434 67 
CEACAM6 337 164 PAPPA 386 115 ITGA6 435 66 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
CHKA 436 65 SKP2 458 43 HES1 480 21 
PLA2G10 437 64 ALCAM 459 42 PRKCI 481 20 
TLR4 438 63 NTF3 460 41 LDHA 482 19 
DPYSL2 439 62 SIRT1 461 40 LEF1 483 18 
SERPINE2 440 61 CAV2 462 39 ASPH 484 17 
CAMK2G 441 60 PTPRB 463 38 PTGER1 485 16 
CHRM3 442 59 NGF 464 37 SDC3 486 15 
NRP2 443 58 KRT19 465 36 RPSA 487 14 
AKT2 444 57 ELAVL4 466 35 TGFB3 488 13 
LAMB1 445 56 NBAS 467 34 SNAI2 489 12 
MTDH 446 55 KISS1 468 33 DCN 490 11 
ZEB1 447 54 SPHK1 469 32 HDAC6 491 10 
INSR 448 53 ABL1 470 31 HOXB7 492 9 
ACTN1 449 52 CHAT 471 30 IL6R 493 8 
CREB1 450 51 IGFBP1 472 29 TGFBR1 494 7 
CEBPA 451 50 CDCP1 473 28 FHL2 495 6 
EP300 452 49 ANG 474 27 PTPRD 496 5 
RARG 453 48 DDIT3 475 26 DCD 497 4 
NDRG2 454 47 GRN 476 25 IL17A 498 3 
IL3 455 46 CXCR2 477 24 TM4SF1 499 2 
SSTR2 456 45 ROCK1 478 23 CHD5 500 1 
EPHB4 457 44 FUT4 479 22    
 
TABLE A.22 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 1 GRN MOLENAAR DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype 
abnormal humoral immune 
response MPO 13 97 2.20E-15 
Disease/ Phenotype 
abnormal macrophage 
physiology MPO 14 191 3.90E-13 
Disease/ Phenotype 
decreased CD8-positive T 
cell number MPO 13 155 5.80E-13 
Disease/ Phenotype 
decreased CD4-positive T 
cell number MPO 13 165 1.20E-12 
Disease/ Phenotype decreased B cell number  MPO 14 215 1.80E-12 
Pathway 
Cytokine Signaling in 
Immune system Reactome 15 270 2.30E-12 
Disease/ Phenotype 
decreased T  cell 
proliferation MPO 13 175 2.40E-12 
Pathway TCR signalling Reactome 9 58 1.70E-11 
Disease/ Phenotype abnormal T  cell physiology MPO 11 122 1.90E-11 
GO 
cytokine-mediated signaling 
pathway (GO:0019221) GO_BP  13 210 2.10E-11 
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TABLE A.23 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 3 GRN MOLENAAR DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Drug/     
Chemical methylselenic acid CTD 19 383 7.20E-11 
Drug/   
Chemical Etoposide CTD 17 328 4.10E-10 
Drug/    
Chemical Plant Extracts CTD 12 204 4.80E-08 
Drug/    
Chemical Thiophenes CTD 6 35 4.30E-07 
Disease/  
Phenotype 
Arthrogryposis multiplex 
congenita  HPO 5 20 8.10E-07 
Drug/    
Chemical Mitoxantrone CTD 10 189 1.60E-06 
Disease/  
Phenotype Congenital contractures  HPO 5 24 1.80E-06 
Disease/  
Phenotype 
Abnormality of the 
esophagus  HPO 8 114 2.60E-06 
Disease/  
Phenotype 
abnormal cornea 
morphology MPO 6 53 3.90E-06 
Pathway 
Interferon alpha/beta 
signaling Reactome 6 58 6.30E-06 
 
TABLE A.24 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 4 GRN MOLENAAR DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
extracellular matrix 
(GO:0031012) GO_CC 20 133 3.10E-22 
Pathway 
Beta1 integrin cell surface 
interactions PID 13 52 2.60E-17 
Pathway 
Syndecan-1-mediated 
signaling events PID 10 36 5.80E-14 
Disease/  
Phenotype 
Abnormality of connective 
tissue  HPO 16 259 2.30E-12 
GO 
basement membrane 
(GO:0005604) GO_CC 10 58 3.80E-12 
Disease/ Phenotype Joint hypermobility  HPO 10 66 1.20E-11 
Disease/ Phenotype Abnormality of the hip  HPO 11 101 2.80E-11 
Disease/ Phenotype Joint dislocation  HPO 9 50 3.30E-11 
Disease/ Phenotype Abnormality of the joints  HPO 17 382 6.30E-11 
Disease/ Phenotype Herniae  HPO 10 80 6.70E-11 
 
TABLE A.25 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 4 GRN MOLENAAR DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO actin binding (GO:0003779) GO_MF 10 273 1.30E-07 
GO stress fiber (GO:0001725) GO_CC 5 40 8.10E-07 
Pathway Smooth Muscle Contraction Reactome 4 18 1.40E-06 
Drug/ Chemical paricalcitol CTD 5 49 2.00E-06 
GO 
extracellular matrix 
(GO:0031012) GO_CC 7 146 2.00E-06 
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Drug/ Chemical methylselenic acid CTD 10 392 3.10E-06 
GO 
actin cytoskeleton 
(GO:0015629) GO_CC 7 169 5.20E-06 
GO 
focal adhesion 
(GO:0005925) GO_CC 6 114 6.90E-06 
Drug/ Chemical Phosphorus CTD 5 66 7.90E-06 
GO 
negative regulation of 
transforming growth factor 
beta receptor signaling 
pathway (GO:0030512) GO_BP  4 35 1.50E-05 
 
TABLE A.26  ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 1 GRN WANG DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
RNA processing 
(GO:0006396) GO_BP  5 78 7.50E-06 
 
TABLE A.27 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 3 GRN WANG DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Disease/ Phenotype 
abnormal macrophage 
physiology MPO 14 191 7.20E-11 
Gene Regulation SP1 TFactS 18 400 2.50E-10 
Drug/Chemical Dexamethasone CTD 16 321 6.60E-10 
Drug/Chemical Lipopolysaccharides CTD 13 191 8.40E-10 
Drug/Chemical Paclitaxel CTD 18 458 2.00E-09 
Disease/ Phenotype necrosis MPO 8 49 3.40E-09 
GO 
blood coagulation 
(GO:0007596) GO_BP  17 439 7.20E-09 
Drug/Chemical rosiglitazone CTD 13 231 7.40E-09 
Pathway 
Beta1 integrin cell surface 
interactions PID 8 57 9.80E-09 
GO 
platelet activation 
(GO:0030168) GO_BP  12 193 1.00E-08 
 
 
TABLE A.28 ENRICHMENT RESULTS LARGEST UNIQUE CLIQUE STAGE 4M GRN WANG DATASET  
INFERRED USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway 
Eukaryotic Translation 
Elongation Reactome 43 44 7.90E-75 
Pathway 
Nonsense Mediated Decay 
Independent of the Exon 
Junction Complex Reactome 43 46 3.00E-74 
GO 
viral transcription 
(GO:0019083) GO_BP  42 40 6.50E-74 
GO 
viral infectious cycle 
(GO:0019058) GO_BP  43 48 1.10E-73 
Pathway Eukaryotic Translation Reactome 42 42 2.60E-73 
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Termination 
Pathway Peptide chain elongation Reactome 42 42 2.60E-73 
Pathway Viral mRNA Translation Reactome 42 43 5.20E-73 
GO 
translational elongation 
(GO:0006414) GO_BP  43 51 6.80E-73 
GO 
translational termination 
(GO:0006415) GO_BP  42 44 1.00E-72 
Pathway 
Influenza Viral RNA 
Transcription and 
Replication Reactome 43 58 3.80E-71 
 
TABLE A.29 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 1 GRN 
INFERRED FROM MOLENAAR DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Drug/Chemical Mercury CTD 5 297 1.40E-05 
Drug/Chemical Choline CTD 3 42 1.50E-05 
Drug/Chemical Vitamin A CTD 3 66 5.30E-05 
Disease/Phenotype abnormal joint mobility MPO 2 9 6.00E-05 
GeneRegulation SP1 TFactS 5 413 6.50E-05 
Drug/Chemical 
3-(2-hydroxy-4-(1,1-
dimethylheptyl)phenyl)-4-
(3-
hydroxypropyl)cyclohexanol CTD 2 10 7.20E-05 
Pathway CD40L Signaling Pathway Biocarta 2 12 9.90E-05 
Pathway TNFR2 Signaling Pathway Biocarta 2 15 1.50E-04 
Drug/Chemical Cycloheximide CTD 4 256 1.50E-04 
Disease/Phenotype 
decreased susceptibility to 
induced colitis MPO 2 18 2.10E-04 
 
TABLE A.30 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 4 GRN 
INFERRED FROM MOLENAAR DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_ DB Annotated genes Non-annotated p.value 
Disease/ Phenotype hypertension MPO 3 39 1.20E-05 
Disease/ Phenotype abnormal adrenaline level MPO 2 8 4.90E-05 
 
TABLE A.31 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 4M GRN 
INFERRED FROM MOLENAAR DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_ DB Annotated genes Non-annotated p. value 
Disease/ Phenotype Malaise  SIDER 6 458 6.60E-06 
Disease/ Phenotype Rigors SIDER 5 413 6.50E-05 
Drug / Chemical  7MP (CID110062694) STITCH 2 11 8.50E-05 
Drug/ Chemical 7MP (CID010062694) STITCH 2 11 8.50E-05 
GO 
chromatin DNA binding 
(GO:0031490) GO_MF 2 13 1.10E-04 
Disease/ Phenotype Mental disorder SIDER 4 258 1.50E-04 
Disease/ Phenotype Hemorrhage MPO 4 260 1.60E-04 
GO 
embryonic cranial skeleton 
morphogenesis (GO:0048701) GO_BP  2 18 2.10E-04 
Disease/ Phenotype Vogelstein and Kinzler 2004 Cancer Genes 3 109 2.20E-04 
Disease/ Phenotype Hypoplasia of the toes  HPO 2 19 2.30E-04 
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TABLE A.32 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 1 GRN 
INFERRED FROM WANG DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB Annotated genes Non-annotated p.value 
GO 
microtubule plus-end 
binding (GO:0051010) GO_MF 2 9 6.00E-05 
Disease/ Phenotype 
abnormal depression-related 
behaviour MPO 2 15 1.50E-04 
GO 
negative regulation of 
microtubule 
depolymerization 
(GO:0007026) GO_BP  2 15 1.50E-04 
Disease/ Phenotype small stomach MPO 2 17 1.80E-04 
GO 
establishment or 
maintenance of cell polarity 
(GO:0007163) GO_BP  2 18 2.10E-04 
Disease/ Phenotype blepharoptosis MPO 2 18 2.10E-04 
 
TABLE A.33 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 4 GRN 
INFERRED FROM WANG DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_DB 
Annotated 
genes Non-annotated p.value 
Pathway Insulin Signalling SMPDB 3 35 7.40E-06 
Pathway 
TNFalpha Signalin g 
Pathway NetPath 5 334 1.80E-05 
Disease/ Phenotype 
decreased percent body 
fat MPO 3 54 2.50E-05 
Pathway mTOR signaling pathway PID 3 64 4.10E-05 
Pathway IL1 Signaling Pathway NetPath 3 65 4.30E-05 
Pathway IL 4 signaling pathway Biocarta 2 9 5.40E-05 
GO 
insulin-like growth factor 
receptor signaling 
pathway (GO:0048009) GO_BP  2 10 6.40E-05 
Disease/ Phenotype 
decreased white adipose 
tissue amount MPO 3 77 7.00E-05 
GO 
positive regulation of 
glycogen biosynthetic 
process (GO:0045725) GO_BP  2 11 7.60E-05 
GO 
positive regulation of 
blood vessel endothelial 
cell migration 
(GO:0043536) GO_BP  2 12 8.90E-05 
 
TABLE A.34 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  STAGE 4M GRN 
INFERRED FROM WANG DATASET  USING THE NOVEL Z-SCORE INFERENCE METHOD 
Class Set Name Source_ DB Annotated genes Non-annotated p. value 
Pathway 
Purine ribonucleoside monophosphate 
biosynthesis Reactome 4 7 3.20E-10 
Pathway 
purine nucleotides de novo 
biosynthesis II HumanCyc 4 7 3.20E-10 
GO 
purine ribonucleoside monophosphate 
biosynthetic process (GO:0009168) GO_BP  4 10 9.50E-10 
GO 
purine nucleotide biosynthetic 
process (GO:0006164) GO_BP  4 14 2.90E-09 
Pathway Purine metabolism Reactome 4 28 3.40E-08 
GO 
purine base metabolic process 
(GO:0006144) GO_BP  4 30 4.40E-08 
GO nucleobase-containing small molecule GO_BP  4 66 8.40E-07 
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metabolic process (GO:0055086) 
Pathway Metabolism of nucleotides Reactome 4 66 8.40E-07 
Drug/ 
Chemical glutamin(CID000000738) STITCH 3 23 2.70E-06 
Pathway 
Purine_nucleotides_nucleosides_ 
metabolism INOH 4 101 4.30E-06 
 
TABLE A.35 RANKED RETINOBLASTOMA GENES GENERATED BY GÉNIE 
Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
RB1 1 500 TP73 41 460 IGF2 81 420 
CDKN2A 2 499 CDH1 42 459 EWSR1 82 419 
TP53 3 498 SMAD4 43 458 HIF1A 83 418 
PTEN 4 497 E2F4 44 457 TFDP1 84 417 
E2F1 5 496 MGMT 45 456 MIR34A 85 416 
MYCN 6 495 RET 46 455 GSTM1 86 415 
EGFR 7 494 HDAC1 47 454 BCL6 87 414 
CCND1 8 493 NF2 48 453 ETV6 88 413 
BRCA1 9 492 PTCH1 49 452 CDKN2C 89 412 
MSH2 10 491 BIRC5 50 451 RAD51 90 411 
RBL2 11 490 CDK2 51 450 GSTP1 91 410 
MLH1 12 489 CDK6 52 449 MLL 92 409 
KRAS 13 488 AKT1 53 448 GSTT1 93 408 
ATM 14 487 PMS2 54 447 NDP 94 407 
CDK4 15 486 SDHD 55 446 CCND2 95 406 
BRCA2 16 485 E2F3 56 445 TSC2 96 405 
RBL1 17 484 FGFR3 57 444 IDH1 97 404 
RASSF1 18 483 CCNE1 58 443 SRY 98 403 
FHIT 19 482 STK11 59 442 PHOX2B 99 402 
MDM2 20 481 MSH6 60 441 MECP2 100 401 
VHL 21 480 AURKA 61 440 TET2 101 400 
BRAF 22 479 HRAS 62 439 ID1 102 399 
CDKN1B 23 478 TP63 63 438 CCNA2 103 398 
APC 24 477 HMGA2 64 437 RUNX3 104 397 
KIT 25 476 FLCN 65 436 MKI67 105 396 
WT1 26 475 GJB2 66 435 CHEK2 106 395 
SMARCB1 27 474 WWOX 67 434 ING1 107 394 
MEN1 28 473 PROM1 68 433 CD44 108 393 
CDKN1A 29 472 PAX6 69 432 ID2 109 392 
ERBB2 30 471 BCL2 70 431 DMBT1 110 391 
MYC 31 470 FGFR2 71 430 MYBL2 111 390 
NF1 32 469 RUNX1 72 429 DLC1 112 389 
TERT 33 468 SP1 73 428 KLF6 113 388 
CTNNB1 34 467 CCND3 74 427 NOTCH1 114 387 
ALK 35 466 AR 75 426 RBBP4 115 386 
PIK3CA 36 465 E2F5 76 425 TFE3 116 385 
PDGFRA 37 464 TOP2A 77 424 BAX 117 384 
NBN 38 463 E2F2 78 423 BMI1 118 383 
PRDM2 39 462 FGFR4 79 422 XRCC1 119 382 
CDKN2B 40 461 MTAP 80 421 VEGFA 120 381 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
EXT1 121 380 PRAME 170 331 DNMT1 219 282 
SMARCA4 122 379 CADM1 171 330 PLK1 220 281 
ERG 123 378 TGFBI 172 329 PTGS2 221 280 
H2AFX 124 377 DCC 173 328 FGFR1 222 279 
JAK2 125 376 DAZ1 174 327 AURKB 223 278 
CHM 126 375 ZEB2 175 326 EP300 224 277 
CYLD 127 374 LGALS3 176 325 PTPRD 225 276 
EZH2 128 373 RPGR 177 324 EZR 226 275 
TYMS 129 372 FBXW7 178 323 FAM123B 227 274 
NME1 130 371 TPD52 179 322 GJB6 228 273 
SOX2 131 370 HIC1 180 321 TMPRSS2 229 272 
EXT2 132 369 CD24 181 320 ABCB1 230 271 
ABCC6 133 368 PTTG1 182 319 DAZ4 231 270 
MUTYH 134 367 HPRT1 183 318 UBE3A 232 269 
TFAP2A 135 366 PLAGL1 184 317 CYP1B1 233 268 
PRPF31 136 365 PAX8 185 316 DBC1 234 267 
FAS 137 364 NKX3-1 186 315 XRCC3 235 266 
SHOX 138 363 DMD 187 314 DLK1 236 265 
PAX5 139 362 FOXO1 188 313 LZTS1 237 264 
PARK2 140 361 AZF1 189 312 POU5F1 238 263 
PAX2 141 360 NQO1 190 311 CYP21A2 239 262 
LMNA 142 359 HDAC2 191 310 MAPK1 240 261 
SMN1 143 358 PRKAR1A 192 309 FH 241 260 
CAV1 144 357 NRAS 193 308 RPE65 242 259 
SDHB 145 356 CASP8 194 307 PML 243 258 
FOXC1 146 355 SRPX 195 306 NGFR 244 257 
ARID4A 147 354 NPM1 196 305 BEST1 245 256 
MTOR 148 353 STAT3 197 304 SKP2 246 255 
PCNA 149 352 USP9Y 198 303 NTRK3 247 254 
TNF 150 351 CDKN1C 199 302 CASZ1 248 253 
ABCA4 151 350 GPC3 200 301 NDRG1 249 252 
OPA1 152 349 TIMP3 201 300 JAK3 250 251 
ST7 153 348 ATR 202 299 CACNA1F 251 250 
TGFB1 154 347 ERCC2 203 298 SPAST 252 249 
NPHP1 155 346 MDM4 204 297 DKK3 253 248 
PHB 156 345 IL24 205 296 CDKN2D 254 247 
NFKB1 157 344 PMP22 206 295 MAGEC2 255 246 
TSPY1 158 343 IKZF1 207 294 TGFBR2 256 245 
NSD1 159 342 XPC 208 293 SMARCA2 257 244 
RBBP7 160 341 SHH 209 292 TFDP2 258 243 
PAX3 161 340 SFN 210 291 GNAS 259 242 
NTRK1 162 339 CTAG1B 211 290 FGF2 260 241 
MET 163 338 PDPN 212 289 TNFSF10 261 240 
TSC1 164 337 NTRK2 213 288 MRE11A 262 239 
NKX2-1 165 336 CEBPA 214 287 CTDSPL 263 238 
ESR1 166 335 AXIN2 215 286 PRDM1 264 237 
AIP 167 334 ABL1 216 285 OCA2 265 236 
ERCC1 168 333 XRCC5 217 284 PRKDC 266 235 
RS1 169 332 CA9 218 283 MAGEA1 267 234 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
RECQL4 268 233 BLM 317 184 SSX4 366 135 
ABCD1 269 232 DEK 318 183 SNCG 367 134 
TWIST1 270 231 CTCF 319 182 CBL 368 133 
DAZ3 271 230 NES 320 181 TMPO 369 132 
MAD2L1 272 229 NRG1 321 180 APAF1 370 131 
IGF1R 273 228 ATP7B 322 179 RAF1 371 130 
EPAS1 274 227 SLC26A4 323 178 LTA 372 129 
DAPK1 275 226 RCVRN 324 177 ESR2 373 128 
SERPINB5 276 225 EYA1 325 176 MMP1 374 127 
CYP1A1 277 224 KLF4 326 175 KRT19 375 126 
MAGEA3 278 223 SSX2 327 174 IGFBP5 376 125 
DAZ2 279 222 EID1 328 173 RPS19 377 124 
FOXL2 280 221 BNIP3 329 172 FOXP1 378 123 
MIR21 281 220 TSG101 330 171 ZFHX3 379 122 
HNF1B 282 219 LPAR6 331 170 MAGEA4 380 121 
AHR 283 218 OTX2 332 169 MIR15A 381 120 
TCF4 284 217 PITX2 333 168 CEBPB 382 119 
MCL1 285 216 TNFRSF10A 334 167 TNFRSF10B 383 118 
GJA1 286 215 CXCR4 335 166 BUB1 384 117 
USH2A 287 214 CASP3 336 165 PARK7 385 116 
MITF 288 213 EPB41L3 337 164 MXI1 386 115 
JAG1 289 212 DLEU2 338 163 NDN 387 114 
POLH 290 211 TNFRSF1A 339 162 PKHD1 388 113 
OGG1 291 210 DUSP6 340 161 PDGFB 389 112 
TUSC2 292 209 MUC1 341 160 GLI1 390 111 
TES 293 208 SERPINF1 342 159 ID4 391 110 
KDM5A 294 207 GATA3 343 158 FZD4 392 109 
XIAP 295 206 XPA 344 157 FANCA 393 108 
IKBKG 296 205 FBN1 345 156 TGFBR1 394 107 
RBM5 297 204 SOX11 346 155 COL2A1 395 106 
ABCC1 298 203 MDK 347 154 KIF1B 396 105 
S100A4 299 202 PKD1 348 153 LIMD1 397 104 
GPR143 300 201 DCLRE1C 349 152 FOXO3 398 103 
NPRL2 301 200 COL4A5 350 151 PTPN11 399 102 
DACH1 302 199 EBF3 351 150 THBS1 400 101 
EBAG9 303 198 NANOG 352 149 IGH@ 401 100 
MAGEC1 304 197 ELOVL4 353 148 EGF 402 99 
TRIM13 305 196 EPHB2 354 147 ZMYND10 403 98 
PLAG1 306 195 PROX1 355 146 SOX9 404 97 
PSMD10 307 194 MTHFR 356 145 ABCC8 405 96 
RRM2B 308 193 MYOC 357 144 HMGA1 406 95 
NCAM1 309 192 RBBP9 358 143 MIR16-1 407 94 
CHD5 310 191 MLL5 359 142 ASPSCR1 408 93 
CDC73 311 190 FLT3 360 141 SP3 409 92 
CLN3 312 189 RBBP8 361 140 NFE2L2 410 91 
BSG 313 188 CHFR 362 139 MYB 411 90 
KISS1 314 187 CREBBP 363 138 NOTCH3 412 89 
KLK10 315 186 FANCD2 364 137 HDAC3 413 88 
GDAP1 316 185 GAGE1 365 136 BIN1 414 87 
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Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score Gene Génie 
Rank 
Score 
CKS1B 415 86 WNT1 444 57 HLA-G 473 28 
PPP2R1B 416 85 SLC2A1 445 56 SMAD5 474 27 
RUNX2 417 84 SOD2 446 55 TYR 475 26 
SSX1 418 83 HBP1 447 54 DICER1 476 25 
CAMTA1 419 82 ASCL1 448 53 PYCARD 477 24 
EGR1 420 81 MTDH 449 52 HGF 478 23 
TERC 421 80 MTA1 450 51 NEUROD1 479 22 
YAP1 422 79 ZIC2 451 50 TP53BP1 480 21 
ILK 423 78 FRMD7 452 49 MMP2 481 20 
CCNDBP1 424 77 MERTK 453 48 EPHA2 482 19 
PRPH2 425 76 HSPA5 454 47 FGF14 483 18 
FOXM1 426 75 CYR61 455 46 PPARG 484 17 
GADD45A 427 74 COL18A1 456 45 MSH3 485 16 
SFRP1 428 73 ARNT 457 44 UMOD 486 15 
CDK1 429 72 CDC25A 458 43 USH1C 487 14 
PURA 430 71 MYOD1 459 42 REG4 488 13 
L3MBTL1 431 70 JUN 460 41 CLDN4 489 12 
PTK2 432 69 MAPK3 461 40 PIK3CG 490 11 
BCR 433 68 SIX3 462 39 SCN1A 491 10 
SPARC 434 67 SSX4B 463 38 AAAS 492 9 
NOD2 435 66 RASSF2 464 37 BACH2 493 8 
CD82 436 65 KCNQ1OT1 465 36 TAL1 494 7 
LMO1 437 64 FIP1L1 466 35 BRIP1 495 6 
UVRAG 438 63 AMACR 467 34 XAF1 496 5 
LIN9 439 62 BARD1 468 33 CTTN 497 4 
NR0B1 440 61 WRN 469 32 RP2 498 3 
IGF2BP3 441 60 ESD 470 31 MAX 499 2 
C9orf72 442 59 OTC 471 30 PARP1 500 1 
SET 443 58 DCN 472 29    
 
TABLE A.36 ENRICHMENT RESULTS FOR GENES IN THE LARGEST UNIQUE CLIQUE  IN THE RB 
BLUE GRN INFERRED USING POSITIVE Z SCORE METHOD  
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO axon guidance (GO:0007411) GO_BP  11 294 5.70E-06 
Disease/ Phenotype decreased cell proliferation MPO 10 272 1.80E-05 
Disease/ Phenotype 
abnormal nervous system 
development MPO 5 53 4.00E-05 
Pathway 
Transport of vitamins, nucleosides, 
and related molecules Reactome 4 27 4.90E-05 
Pathway Axon guidance Reactome 9 257 6.80E-05 
Disease/ Phenotype abnormal spinal nerve morphology MPO 4 30 7.20E-05 
Disease/ Phenotype complete perinatal lethality MPO 9 265 8.50E-05 
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TABLE A.37 ENRICHMENT RESULTS FOR GENES IN THE LARGEST UNIQUE CLIQUE  IN THE RB 
GREEN GRN INFERRED USING POSITIVE Z SCORE METHOD  
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
visual perception 
(GO:0007601) GO_BP  21 157 1.20E-15 
Pathway 
Transmission across 
Chemical Synapses Reactome 18 172 6.10E-12 
Disease/ Phenotype 
abnormal eye 
electrophysiology MPO 14 104 7.20E-11 
GO 
synaptic transmission 
(GO:0007268) GO_BP  23 366 1.10E-10 
Disease/ Phenotype retinal degeneration MPO 12 72 1.90E-10 
Pathway 
Neurotransmitter Receptor 
Binding And Do wnstream 
Transmission In The  
Postsynaptic Cell Reactome 14 122 4.90E-10 
Pathway Neuronal System Reactome 19 264 6.20E-10 
Pathway 
Visual signal transduction: 
Rods PID 7 16 4.70E-09 
Drug/Chemical Kainite (CID000010255) STITCH 11 97 4.10E-08 
GO 
nervous system 
development (GO:0007399) GO_BP  20 389 4.80E-08 
 
 
TABLE A.38 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  RB RED GRN 
INFERRED USING THE POSITIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Drug/     Chemical 
acetyl coenzyme-
A(CID000000181) STITCH 3 53 2.00E-05 
Drug/     Chemical 
potassium 
hydride(CID000082127) STITCH 3 64 3.50E-05 
Pathway 
Glycolysis and 
Gluconeogenesis EHMN 3 77 5.90E-05 
Pathway 
2-Hydroxyglutric 
Aciduria (D And L 
Form) SMPDB 2 13 9.20E-05 
Drug/     Chemical 
acetyl-
CoA(CID000006302) STITCH 3 90 9.30E-05 
GO 
myosin binding 
(GO:0017022) GO_MF 2 14 1.00E-04 
Pathway Pyruvate Metabolism SMPDB 2 18 1.70E-04 
Pathway Leigh Syndrome SMPDB 2 18 1.70E-04 
Drug/    Chemical  
acetyl-
CoA(CID100000181) STITCH 3 121 2.20E-04 
GO 
positive regulation of 
protein catabolic process 
(GO:0045732) GO_BP  2 21 2.20E-04 
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TABLE A.39 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  RB GREEN GRN 
INFERRED USING THE POSITIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Pathway 
Visual signal transduction: 
Rods PID 3 20 1.60E-06 
Drug/Chemical alprazolam(CID000002118) STITCH 3 34 6.80E-06 
Drug/ Chemical alprazolam(CID100002118) STITCH 3 35 7.40E-06 
Disease/ Phenotype Memory impairment SIDER 4 155 1.80E-05 
Disease/ 
Phenotype Difficulty in micturition SIDER 3 50 2.00E-05 
Disease/ 
Phenotype Movements involuntary SIDER 3 50 2.00E-05 
Disease/ 
Phenotype Abdominal distress SIDER 3 50 2.00E-05 
Disease/ 
Phenotype Dysarthria SIDER 3 50 2.00E-05 
Disease/ 
Phenotype 
Abnormal involuntary 
movements SIDER 3 50 2.00E-05 
Disease/ 
Phenotype Cognitive disorder SIDER 3 50 2.00E-05 
 
TABLE A.40 ENRICHMENT RESULTS FOR THE GENES IN LARGEST UNIQUE CLIQUE IN THE RB 
BLUE GRN INFERRED USING NEGATIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
helicase activity 
(GO:0004386) GO_MF 7 112 2.20E-06 
Drug/Chemical fulvestrant CTD 9 242 4.50E-06 
GO translation (GO:0006412) GO_BP  9 258 7.40E-06 
GO 
nuclear mRNA splicing, via 
spliceosome (GO:0000398) GO_BP  7 160 2.00E-05 
Disease/ Phenotype 
complete embryonic 
lethality before implantation MPO 6 118 3.60E-05 
Pathway 
Processing of Capped 
Intron-Containing Pre-
mRNA Reactome 6 131 6.30E-05 
Pathway 
Translation 
Factors(WP107) WikiPathways 4 46 1.10E-04 
Pathway mRNA Processing Reactome 6 150 1.30E-04 
Disease/ Phenotype 
Classification of acute 
myeloid leukemias MethyCancer 5 93 1.30E-04 
GO 
translation initiation factor 
activity (GO:0003743) GO_MF 4 50 1.50E-04 
 
TABLE A.41 ENRICHMENT RESULTS FOR THE GENES IN LARGEST UNIQUE CLIQUE IN THE RB 
RED GRN INFERRED USING NEGATIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
keratinization 
(GO:0031424) GO_BP  10 33 2.50E-14 
GO 
keratin filament 
(GO:0045095) GO_CC 10 83 8.40E-11 
GO 
cytokine activity 
(GO:0005125) GO_MF 7 156 3.10E-05 
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TABLE A.42 ENRICHMENT RESULTS FOR THE GENES IN LARGEST UNIQUE CLIQUE IN THE RB 
GREEN GRN INFERRED USING NEGATIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
Drug/Chemical Lucanthone CTD 54 159 1.60E-69 
Drug/Chemical dasatinib CTD 59 406 2.90E-57 
Drug/Chemical Polychlorinated Biphenyls CTD 38 155 1.20E-43 
Pathway Cell Cycle  Reactome 42 367 5.20E-36 
GO 
mitotic cell cycle 
(GO:0000278) GO_BP  38 280 5.20E-35 
Pathway Cell Cycle, Mitotic Reactome 37 293 5.00E-33 
Drug/Chemical 
trans-10,cis-12-conjugated 
linoleic acid CTD 28 116 6.10E-32 
Pathway DNA Replication Reactome 30 170 1.30E-30 
GO cell cycle (GO:0007049) GO_BP  35 399 2.90E-26 
GO 
DNA replication 
(GO:0006260) GO_BP  23 127 8.20E-24 
 
TABLE A.43 ENRICHMENT RESULTS FOR COMBINED RANK TOP 20 GENES IN  RB GREEN GRN 
INFERRED USING THE NEGATIVE Z SCORE METHOD 
Class Set Name Source_DB 
Annotated 
genes 
Non-
annotated p.value 
GO 
mitotic cell cycle 
(GO:0000278) GO_BP  9 309 2.30E-12 
Pathway DNA Replication Reactome 8 192 3.40E-12 
Pathway Cell Cycle  Reactome 9 400 2.20E-11 
Pathway Mitotic M-M/G1 phases Reactome 7 171 1.10E-10 
Pathway Cell Cycle, Mitotic Reactome 8 322 1.90E-10 
GO 
mitotic prometaphase 
(GO:0000236) GO_BP  4 80 8.70E-07 
GO 
M phase of mitotic cell 
cycle (GO:0000087) GO_BP  4 88 1.30E-06 
Pathway Mitotic Prometaphase Reactome 4 88 1.30E-06 
Pathway M Phase Reactome 4 92 1.50E-06 
Drug/Chemical dasatinib CTD 6 459 2.30E-06 
GO 
DNA strand elongation 
involved in DNA 
replication (GO:0006271) GO_BP  3 28 2.80E-06 
Pathway DNA strand elongation Reactome 3 28 2.80E-06 
Disease/ Phenotype abnormal cell cycle MPO 4 116 3.60E-06 
Drug/Chemical 
trans-10,cis-12-conjugated 
linoleic acid CTD 4 140 7.50E-06 
GO 
DNA replication 
(GO:0006260) GO_BP  4 146 8.80E-06 
GeneRegulation E2F1 TFactS 4 158 1.20E-05 
Disease/ Phenotype increased tumor incidence MPO 4 159 1.20E-05 
Drug/  Chemical  Polychlorinated Biphenyls CTD 4 189 2.40E-05 
GO 
condensed chromosome 
kinetochore (GO:0000777) GO_CC 3 60 2.40E-05 
Disease/ Phenotype sarcoma MPO 3 64 2.90E-05 
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APPENDIX B  
VENN DIAGRAMS OF GENE DISTRIBUTION FOR THE VARIOUS GRNS INFERRED 
FROM THE DIFFERENT MICROARRAY DATASETS 
 
The following appendix contains Venn diagrams of the distribution of genes in both the largest cliques, and also the top 20 ranked genes 
for the combined metric for the various GRNs in the work.  
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FIGURE B.1 VENN DIAGRAM OF UNIQUE AND COMMON GENES IN THE CLIQUES IN THE GLIOBLASTOMA CATEGORY GRNS 
INFERRED USING WGCNA 
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FIGURE B.2 VENN DIAGRAM OF UNIQUE AND COMMON GENES IN THE TOP 20 RANKING GENES FOR EACH METRIC IN THE 0-200 
GLIOBLASTOMA GRN INFERRED USING WGCNA 
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FIGURE B.3 VENN DIAGRAM OF UNIQUE AND COMMON GENES IN THE LARGEST UNIQUE CLIQUES IN THE DIFFERENT CATEGORIES OF 
GLIOBLASTOMA GRN INFERRED USING THE NOVEL INFERENCE METHOD 
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FIGURE B.4 VENN DIAGRAM OF GENE DISTRIBUTION IN THE TOP 20 COMBINED METRIC RANKINGS OF THE GLIOBLASTOMA CATEGORY GRNS 
INFERRED USING NOVEL INFERENCE METHOD 
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FIGURE B.5 VENN DIAGRAM OF GENE DISTRIBUTION IN THE TOP 100 COMBINED METRIC RANKINGS OF THE GLIOBLASTOMA CATEGORY GRNS 
INFERRED USING NOVEL INFERENCE METHOD 
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FIGURE B.6 VENN DIAGRAM OF GENE DISTRIBUTION IN THE LARGEST UNIQUE CLIQUES IN THE GRNS INFERRED FROM THE MOLENAAR 
DATASET USING NOVEL INFERENCE METHOD 
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FIGURE B.7 VENN DIAGRAM OF GENE DISTRIBUTION IN THE LARGEST UNIQUE CLIQUES IN THE GRNS INFERRED FROM THE WANG DATASET 
USING NOVEL INFERENCE METHOD 
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FIGURE B.8 GENE DISTRIBUTION OF TOP 20 COMBINED METRIC RANKINGS IN THE GRNS INFERRED FROM THE MOLENAAR DATASET 
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FIGURE B.9 GENE DISTRIBUTION OF TOP 100 COMBINED METRIC RANKINGS IN THE GRNS INFERRED FROM THE MOLENAAR DATASET 
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FIGURE B.10 GENE DISTRIBUTION OF TOP 20 COMBINED METRIC RANKINGS IN THE GRNS INFERRED FROM THE WANG DATASET 
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FIGURE B.11 GENE DISTRIBUTION OF TOP 100 COMBINED METRIC RANKINGS IN THE GRNS INFERRED FROM THE WANG DATASET 
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FIGURE B.12 VENN DIAGRAM STAGE1 TOP 20 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
 
A = MOLENAAR STAGE 1 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
B = WANG STAGE 1 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
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FIGURE B.13 VENN DIAGRAM STAGE3 TOP 20 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
 
A = MOLENAAR STAGE 3 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
B = WANG STAGE 3 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
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FIGURE B.14 VENN DIAGRAM STAGE4 TOP 20 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
A = MOLENAAR STAGE 4 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
B = WANG STAGE 4 GRN TOP 20 RANKED GENES FOR COMBINED METRIC 
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FIGURE B.15 VENN DIAGRAM STAGE4M TOP 20 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
A = MOLENAAR STAGE 4M GRN TOP 20 RANKED GENES FOR COM BINED METRIC 
B = WANG STAGE 4M GRN TOP 20 RANKED GENES FOR COM BINED METRIC 
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FIGURE B.16 VENN DIAGRAM STAGE1 TOP 100 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
 
A = MOLENAAR STAGE 1 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
B = WANG STAGE 1 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
 
 
B-18 
 
FIGURE B.17 VENN DIAGRAM STAGE3 TOP 100 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
A = MOLENAAR STAGE 3 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
B = WANG STAGE 3 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
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FIGURE B.18 VENN DIAGRAM STAGE4 TOP 100 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
A = MOLENAAR STAGE 4 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
B = WANG STAGE 4 GRN TOP 100 RANKED GENES FOR COM BINED METRIC 
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FIGURE B.19 VENN DIAGRAM STAGE4M TOP 100 RANKED GENES MOLENAAR AND WANG DATASETS 
 
 
A = MOLENAAR STAGE 4M GRN TOP 100 RANKED GENES FOR COMBINED METRIC 
B = WANG STAGE 4M GRN TOP 100 RANKED GENES FOR COMBINED METRIC 
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FIGURE B.20 VENN DIAGRAM OF GENE DISTRIBUTION IN THE LARGEST UNIQUE CLIQUES IN THE GLIOBLASTOMA GRNS INFERRED USING THE 
POSITIVE Z SCORE METHOD 
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FIGURE B.21 GENE DISTRIBUTION OF TOP 20 COMBINED METRIC RANKINGS IN THE DIFFERENT CATEGORIES OF RETINOBLASTOMA GRN 
INFERRED USING THE POSITIVE Z SCORE METHOD 
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FIGURE B.22 GENE DISTRIBUTION OF TOP 100 COMBINED METRIC RANKINGS IN THE DIFFERENT CATEGORIES OF RETINOBLASTOMA GRN 
INFERRED USING THE POSITIVE Z SCORE METHOD 
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FIGURE B.23 VENN DIAGRAM OF GENE DISTRIBUTION IN THE LARGEST UNIQUE CLIQUES IN THE RETINOBLASTOMA GRNS INFERRED USING THE 
NEGATIVE Z SCORE METHOD 
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FIGURE B.24 GENE DISTRIBUTION OF TOP 20 COMBINED METRIC RANKINGS IN THE DIFFERENT CATEGORIES OF RETINOBLASTOMA GRN 
INFERRED USING THE NEGATIVE Z SCORE METHOD 
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FIGURE B.25 GENE DISTRIBUTION OF TOP 100 COMBINED METRIC RANKINGS IN THE DIFFERENT CATEGORIES OF RETINOBLASTOMA GRN 
INFERRED USING THE NEGATIVE Z SCORE METHOD 
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APPENDIX C  
SCREENSHOTS OF GENE REGULATORY NETWORK INFERENCE AND ANALYSIS 
TOOLS ON GALAXY LOCAL HOST 
The following appendix contains additional screenshots of various GRN inference and analysis tools implemented on a local host version 
of Galaxy introduced in chapter 8 of the work. One screenshot of both the all-in-one tool using the novel Z score GRN inference method, 
and the all-in-one tool using the WGCNA GRN inference method are provided. As the end user is presented with the same options for the 
all-in-one tools using the positive and negative Z score methods, these screenshots are not shown in order to avoid repetition.  
A number of output files are provided to the end user; an adjacency matrix of the GRN inferred, a table with all the metric ranks for the 
genes in the network, the correlation scores between the rankings of the metrics calculated, enrichment results for the top ten ranked genes 
in the GRN based on the combined metric, and additionally edge lists of the whole network and the subnets of the top ten rank ing genes 
that can be imported straight into Cytoscape for visualisation. 
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FIGURE C.1 SCREENSHOT OF TOOLS AVAILABLE TO THE END USER IN THE LOCAL HOST VERSION OF GALAXY 
 
As can be seen from the screenshot above, there are four all-in-one tools available to the end user. These are shown in more detail in the 
following screenshots.  
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FIGURE C.2 SCREENSHOT OF ALL-IN-ONE TOOL USING THE NOVEL Z SCORE GRN INFERENCE METHOD 
 
The above screenshot is for the all-in-one tool using the novel Z score GRN inference method. The end user has three options; the input file 
location of the microarray dataset, the percentage of edges to retain in the network, and also the threshold of edge size to use for 
visualisation.  
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FIGURE C.3 SCREENSHOT OF ALL-IN-ONE TOOL USING THE WGCNA GRN INFERENCE METHOD 
                
The above screenshot is for the all-in-one tool using the WGCNA GRN inference method. The end user has the same three options; the 
input file location of the microarray dataset, the percentage of edges to retain in the network, and also the threshold of edge size to use for 
visualisation.  
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FIGURE C.4 SCREENSHOT OF ALL-IN-ONE TOOL USING THE WGCNA GRN INFERENCE M ETHOD 
 
The above screenshot shows input to the three options in all-one-tool using WGCNA. Finally, the screenshot below shows the output that is 
generated. 
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FIGURE C.5 SCREENSHOT OF OUTPUT OF ALL-IN-ONE TOOL USING THE WGCNA GRN INFERENCE M ETHOD 
 
As can be seen in the above screenshot, output files are generated to the end user without having to carry out any programming using 
specialist programming languages.
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Selected Personal Communication with Experts 
[PC1] Email from Dr Carmel McConville, Senior Lecturer in the School of Cancer Sciences 
at the University of Birmingham, sent on 21
st
 November 2012 at 08:01. This email is 
regarding the use of the WGCNA network inference method for the inference of 
multiple categories of gene regulatory network from one microarray dataset. This 
email specifically details the application to a neuroblastoma dataset, but the issues are 
the same regardless of the dataset applied to.  
Theo, 
I've had a look at Alex's data and have put a few comments below which we could discuss. 
 
Best wishes, 
Carmel.  
 
I assume that the purpose of the analysis is to find gene networks (with genes within the 
network showing similar patterns of expression) which might account for the different clinical 
characteristics of categories 1, 4 and 4M.  If a gene shows a change in expression in for 
example, category 1 compared to category 4, then the whole network might be expected to 
change in the same direction. 
The first thing I did was to look at the lists of genes in the degree distribution, weighted 
degree distribution and combined distribution for the 3 groups (category 1, category 4, 
category 4M).  Biologically I would expect cat 1 to be very different to the other two, and cat 
4 to be somewhat different from cat 4M.  Surprisingly there was quite a lot of overlap 
 
 
between categories especially in the combined distribution, where 7 genes in cat 1 were also 
in either cat 4 or cat 4m. 
I next looked at the raw data to try to understand how the analysis was working. From this it 
was obvious that although the analysis was selecting genes which were highly correlated in 
their expression, actually expression wasn't differing at all across the 3 categories and this is 
why the same genes were appearing in different categories. At least some of these genes may 
have functions which aren't relevant to tumorigenesis.  
In addition  lots of the selected genes had very low expression (close to background noise) - 
this is a problem  because it's always difficult to know how relevant these are - a two-fold 
difference in expression might just be 'noise' and likewise apparent correlated expression 
patterns might be because the genes aren't expressed .  We might need to think about doing 
some additional filtering of the data before the main analysis. 
 
[PC2] Email from Dr Andrew Peet, Reader in Paediatric Oncology in the School of Cancer 
Sciences at the University of Birmingham and Honorary Consultant at Birmingham 
Children’s Hospital, sent on 21st November 2012 at 08:09. This email is also regarding 
the use of the WGCNA network inference method for the inference of multiple 
categories of gene regulatory network from one microarray dataset. This email 
specifically mentions taking into account the relative expression levels of the genes.  
Hi, 
I agree that concentrating on the highly expressed genes is a good one, however you probably 
then loose the closely connected ones which you will need to building networks. How about 
weighting the genes according to their relative expression levels?  
Best wishes, 
Andrew 
 
 
 
